Unnamed: 0
stringlengths 3
8
| Date
stringlengths 23
23
| Article_title
stringlengths 1
250
| Stock_symbol
stringlengths 1
5
| Url
stringlengths 44
135
| Publisher
stringclasses 1
value | Author
stringclasses 1
value | Article
stringlengths 1
343k
| Lsa_summary
stringlengths 3
53.9k
| Luhn_summary
stringlengths 1
53.9k
| Textrank_summary
stringlengths 1
53.9k
| Lexrank_summary
stringlengths 1
53.9k
| uuid
stringlengths 36
36
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
715400.0
|
2023-10-30 00:00:00 UTC
|
Deciphera Pharma Spikes On Improved Q3 Revenue, Positive Results From Motion Study
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharma-spikes-on-improved-q3-revenue-positive-results-from-motion-study
|
nan
|
nan
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) shares are surging more than 23 percent on Monday morning trade after the company announced improved revenue for the third quarter and positive results from its MOTION phase 3 study of Vimseltinib in patients with Tenosynovial giant cell tumor. The company said the study met the primary endpoint and met all key secondary endpoints with statistically meaningful improvements in comparison to placebo.
Deciphera is planning to submit a new drug application or NDA in the second quarter of 2024 and a marketing authorization application in the third quarter.
Further, the third quarter loss came in below estimates. The company reported quarterly revenue of $43.3 million, up 20.4 percent compared to $35.97 million last year.
Currently, shares are at $12.55, up 23.65 percent from the previous close of $10.15 on a volume of 1,964,407.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) shares are surging more than 23 percent on Monday morning trade after the company announced improved revenue for the third quarter and positive results from its MOTION phase 3 study of Vimseltinib in patients with Tenosynovial giant cell tumor. The company said the study met the primary endpoint and met all key secondary endpoints with statistically meaningful improvements in comparison to placebo. Currently, shares are at $12.55, up 23.65 percent from the previous close of $10.15 on a volume of 1,964,407.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) shares are surging more than 23 percent on Monday morning trade after the company announced improved revenue for the third quarter and positive results from its MOTION phase 3 study of Vimseltinib in patients with Tenosynovial giant cell tumor. The company said the study met the primary endpoint and met all key secondary endpoints with statistically meaningful improvements in comparison to placebo. The company reported quarterly revenue of $43.3 million, up 20.4 percent compared to $35.97 million last year.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) shares are surging more than 23 percent on Monday morning trade after the company announced improved revenue for the third quarter and positive results from its MOTION phase 3 study of Vimseltinib in patients with Tenosynovial giant cell tumor. Deciphera is planning to submit a new drug application or NDA in the second quarter of 2024 and a marketing authorization application in the third quarter. The company reported quarterly revenue of $43.3 million, up 20.4 percent compared to $35.97 million last year.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) shares are surging more than 23 percent on Monday morning trade after the company announced improved revenue for the third quarter and positive results from its MOTION phase 3 study of Vimseltinib in patients with Tenosynovial giant cell tumor. The company said the study met the primary endpoint and met all key secondary endpoints with statistically meaningful improvements in comparison to placebo. Deciphera is planning to submit a new drug application or NDA in the second quarter of 2024 and a marketing authorization application in the third quarter.
|
58b25422-91c4-402d-a625-c3c4b7ac67cb
|
715401.0
|
2023-10-30 00:00:00 UTC
|
Monday Sector Leaders: Drugs, Education & Training Services
|
DCPH
|
https://www.nasdaq.com/articles/monday-sector-leaders%3A-drugs-education-training-services
|
nan
|
nan
|
In trading on Monday, drugs shares were relative leaders, up on the day by about 2.5%. Leading the group were shares of Reviva Pharmaceuticals Holdings, up about 64.9% and shares of Deciphera Pharmaceuticals up about 22.3% on the day.
Also showing relative strength are education & training services shares, up on the day by about 2.3% as a group, led by Vitru, trading higher by about 14.3% and 2U, trading higher by about 4.1% on Monday.
VIDEO: Monday Sector Leaders: Drugs, Education & Training Services
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Monday, drugs shares were relative leaders, up on the day by about 2.5%. Also showing relative strength are education & training services shares, up on the day by about 2.3% as a group, led by Vitru, trading higher by about 14.3% and 2U, trading higher by about 4.1% on Monday. VIDEO: Monday Sector Leaders: Drugs, Education & Training Services The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Monday, drugs shares were relative leaders, up on the day by about 2.5%. Also showing relative strength are education & training services shares, up on the day by about 2.3% as a group, led by Vitru, trading higher by about 14.3% and 2U, trading higher by about 4.1% on Monday. VIDEO: Monday Sector Leaders: Drugs, Education & Training Services The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Leading the group were shares of Reviva Pharmaceuticals Holdings, up about 64.9% and shares of Deciphera Pharmaceuticals up about 22.3% on the day. Also showing relative strength are education & training services shares, up on the day by about 2.3% as a group, led by Vitru, trading higher by about 14.3% and 2U, trading higher by about 4.1% on Monday. VIDEO: Monday Sector Leaders: Drugs, Education & Training Services The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Monday, drugs shares were relative leaders, up on the day by about 2.5%. Leading the group were shares of Reviva Pharmaceuticals Holdings, up about 64.9% and shares of Deciphera Pharmaceuticals up about 22.3% on the day. Also showing relative strength are education & training services shares, up on the day by about 2.3% as a group, led by Vitru, trading higher by about 14.3% and 2U, trading higher by about 4.1% on Monday.
|
f33e9258-bb28-47c4-b075-0f11389f4b0d
|
715402.0
|
2023-10-30 00:00:00 UTC
|
Monday's ETF Movers: XBI, QCLN
|
DCPH
|
https://www.nasdaq.com/articles/mondays-etf-movers%3A-xbi-qcln
|
nan
|
nan
|
In trading on Monday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 2% on the day. Components of that ETF showing particular strength include shares of Deciphera Pharmaceuticals, up about 22.3% and shares of Day One Biopharmaceuticals, up about 21.9% on the day.
And underperforming other ETFs today is the First Trust NASDAQ Clean Edge Green Energy Index Fund ETF, down about 4.1% in Monday afternoon trading. Among components of that ETF with the weakest showing on Monday were shares of ON Semiconductor, lower by about 19%, and shares of Lanzatech Global, lower by about 8.6% on the day.
VIDEO: Monday's ETF Movers: XBI, QCLN
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
And underperforming other ETFs today is the First Trust NASDAQ Clean Edge Green Energy Index Fund ETF, down about 4.1% in Monday afternoon trading. Among components of that ETF with the weakest showing on Monday were shares of ON Semiconductor, lower by about 19%, and shares of Lanzatech Global, lower by about 8.6% on the day. VIDEO: Monday's ETF Movers: XBI, QCLN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Components of that ETF showing particular strength include shares of Deciphera Pharmaceuticals, up about 22.3% and shares of Day One Biopharmaceuticals, up about 21.9% on the day. Among components of that ETF with the weakest showing on Monday were shares of ON Semiconductor, lower by about 19%, and shares of Lanzatech Global, lower by about 8.6% on the day. VIDEO: Monday's ETF Movers: XBI, QCLN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Components of that ETF showing particular strength include shares of Deciphera Pharmaceuticals, up about 22.3% and shares of Day One Biopharmaceuticals, up about 21.9% on the day. And underperforming other ETFs today is the First Trust NASDAQ Clean Edge Green Energy Index Fund ETF, down about 4.1% in Monday afternoon trading. Among components of that ETF with the weakest showing on Monday were shares of ON Semiconductor, lower by about 19%, and shares of Lanzatech Global, lower by about 8.6% on the day.
|
In trading on Monday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 2% on the day. Components of that ETF showing particular strength include shares of Deciphera Pharmaceuticals, up about 22.3% and shares of Day One Biopharmaceuticals, up about 21.9% on the day. And underperforming other ETFs today is the First Trust NASDAQ Clean Edge Green Energy Index Fund ETF, down about 4.1% in Monday afternoon trading.
|
231550f1-74a2-46cb-99bf-057149d51038
|
715403.0
|
2023-10-30 00:00:00 UTC
|
Deciphera Reports Positive Results From MOTION Phase 3 Study Of Vimseltinib In TGCT
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-reports-positive-results-from-motion-phase-3-study-of-vimseltinib-in-tgct
|
nan
|
nan
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) Monday announced positive top-line results from the pivotal Phase 3 MOTION study of its investigational drug Vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT). The study met its primary goal.
TGCT is typically benign growths that form around joints.
The MOTION Phase 3 trial, a two-part study, was to evaluate the efficacy and safety of Vimseltinib in patients with TGCT not amenable to surgery.
In part 1, patients were randomized two-to-one to receive either Vimseltinib or placebo. The study met its primary endpoint of Objective Response Rate (ORR) at Week 25 of 40% Compared to 0% for Placebo.
Part 2 portion of the study, in which patients from both the Vimseltinib and placebo arms receive treatment with Vimseltinib, is going on.
The company also announced updated results from the Phase 1/2 study of Vimseltinib in TGCT, in which Vimseltinib showed ORR of 72% in Phase 1 and 64% in Phase 2 studies.
Deciphera expects to submit a New Drug Application (NDA) to the FDA for vimseltinib for the treatment of patients with TGCT in the second quarter of 2024 and a Marketing Authorisation Application (MAA) to the European Medicines Agency in the third quarter of 2024.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) Monday announced positive top-line results from the pivotal Phase 3 MOTION study of its investigational drug Vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT). The MOTION Phase 3 trial, a two-part study, was to evaluate the efficacy and safety of Vimseltinib in patients with TGCT not amenable to surgery. The study met its primary endpoint of Objective Response Rate (ORR) at Week 25 of 40% Compared to 0% for Placebo.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) Monday announced positive top-line results from the pivotal Phase 3 MOTION study of its investigational drug Vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT). Part 2 portion of the study, in which patients from both the Vimseltinib and placebo arms receive treatment with Vimseltinib, is going on. The company also announced updated results from the Phase 1/2 study of Vimseltinib in TGCT, in which Vimseltinib showed ORR of 72% in Phase 1 and 64% in Phase 2 studies.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) Monday announced positive top-line results from the pivotal Phase 3 MOTION study of its investigational drug Vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT). Part 2 portion of the study, in which patients from both the Vimseltinib and placebo arms receive treatment with Vimseltinib, is going on. The company also announced updated results from the Phase 1/2 study of Vimseltinib in TGCT, in which Vimseltinib showed ORR of 72% in Phase 1 and 64% in Phase 2 studies.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) Monday announced positive top-line results from the pivotal Phase 3 MOTION study of its investigational drug Vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT). The study met its primary goal. TGCT is typically benign growths that form around joints.
|
8e4f4e44-9b26-4e1c-9fe0-0904f7e40a9e
|
715404.0
|
2023-10-30 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-reports-q3-loss-tops-revenue-estimates-0
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 3.33%. A quarter ago, it was expected that this company would post a loss of $0.62 per share when it actually produced a loss of $0.57, delivering a surprise of 8.06%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $43.31 million for the quarter ended September 2023, surpassing the Zacks Consensus Estimate by 9.21%. This compares to year-ago revenues of $35.97 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Deciphera Pharmaceuticals, Inc. Shares have lost about 38.1% since the beginning of the year versus the S&P 500's gain of 7.2%.
What's Next for Deciphera Pharmaceuticals, Inc.
While Deciphera Pharmaceuticals, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Deciphera Pharmaceuticals, Inc. Unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.58 on $41.5 million in revenues for the coming quarter and -$2.36 on $152.93 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Denali Therapeutics Inc. (DNLI), is yet to report results for the quarter ended September 2023.
This company is expected to post quarterly loss of $0.83 per share in its upcoming report, which represents a year-over-year change of +1.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Denali Therapeutics Inc.'s revenues are expected to be $10.86 million, up 205.1% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
Denali Therapeutics Inc. (DNLI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.60. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Denali Therapeutics Inc. (DNLI) : Free Stock Analysis Report To read this article on Zacks.com click here. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock.
|
Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Denali Therapeutics Inc. (DNLI) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.60. Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $43.31 million for the quarter ended September 2023, surpassing the Zacks Consensus Estimate by 9.21%.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.60. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Denali Therapeutics Inc. (DNLI) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $43.31 million for the quarter ended September 2023, surpassing the Zacks Consensus Estimate by 9.21%.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.60. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Denali Therapeutics Inc. (DNLI) : Free Stock Analysis Report To read this article on Zacks.com click here. The company has topped consensus revenue estimates three times over the last four quarters.
|
cca7ae29-7bc1-4a2e-839e-b86950c0e450
|
715405.0
|
2023-10-30 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. Q3 Loss increases, but beats estimates
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-q3-loss-increases-but-beats-estimates
|
nan
|
nan
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) revealed Loss for its third quarter that increased from the same period last year but beat the Street estimates.
The company's bottom line totaled -$49.581 million, or -$0.58 per share. This compares with -$43.043 million, or -$0.55 per share, in last year's third quarter.
Analysts on average had expected the company to earn -$0.61 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 20.4% to $43.313 million from $35.974 million last year.
Deciphera Pharmaceuticals, Inc. earnings at a glance (GAAP) :
-Earnings (Q3): -$49.581 Mln. vs. -$43.043 Mln. last year. -EPS (Q3): -$0.58 vs. -$0.55 last year. -Analyst Estimate: -$0.61 -Revenue (Q3): $43.313 Mln vs. $35.974 Mln last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) revealed Loss for its third quarter that increased from the same period last year but beat the Street estimates. Analysts on average had expected the company to earn -$0.61 per share, according to figures compiled by Thomson Reuters. Deciphera Pharmaceuticals, Inc. earnings at a glance (GAAP) : -Earnings (Q3): -$49.581 Mln.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) revealed Loss for its third quarter that increased from the same period last year but beat the Street estimates. The company's revenue for the quarter rose 20.4% to $43.313 million from $35.974 million last year. Deciphera Pharmaceuticals, Inc. earnings at a glance (GAAP) : -Earnings (Q3): -$49.581 Mln.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) revealed Loss for its third quarter that increased from the same period last year but beat the Street estimates. This compares with -$43.043 million, or -$0.55 per share, in last year's third quarter. The company's revenue for the quarter rose 20.4% to $43.313 million from $35.974 million last year.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) revealed Loss for its third quarter that increased from the same period last year but beat the Street estimates. This compares with -$43.043 million, or -$0.55 per share, in last year's third quarter. Deciphera Pharmaceuticals, Inc. earnings at a glance (GAAP) : -Earnings (Q3): -$49.581 Mln.
|
a183fdd1-e0bb-4093-9aec-e9e904e301c4
|
715406.0
|
2023-10-19 00:00:00 UTC
|
Sage's (SAGE) Huntington's Disease Drug Gets FDA's Orphan Tag
|
DCPH
|
https://www.nasdaq.com/articles/sages-sage-huntingtons-disease-drug-gets-fdas-orphan-tag
|
nan
|
nan
|
Sage Therapeutics SAGE announced that the FDA has granted orphan drug designation to its lead neuropsychiatric candidate, SAGE-718, for treating Huntington’s disease (“HD”), a rare neurodegenerative disease.
An orphan drug designation is granted by the FDA to the candidates developed to treat, diagnose or prevent a rare disease or condition. This FDA designation makes the sponsor eligible for seven years of market exclusivity, following the potential approval and tax credit for qualified clinical studies.
An inherited disorder, HD causes nerve cells (neurons) in brain parts to gradually break down and die. Cognitive impairment is one of the most under-recognized aspects of HD.An estimated one in 40,000 people across the United States is affected by this disorder each year.
In the year so far, shares of Sage have plunged 49.6% compared to the industry’s 11.0% fall.
Image Source: Zacks Investment Research
Currently, no treatment options are available to improve HD's cognitive effects. An investigational oral therapy, SAGE-718, is being developed for cognitive disorders associated with NMDA receptor dysfunction. The candidate has already been granted fast-track designation by the FDA and orphan drug designation by the EMA as a potential treatment for HD.
SAGE-718 is being evaluated as a potential treatment for patients with HD-related cognition dysfunction across three ongoing clinical studies – two phase II studies (DIMENSION and SURVEYOR) and a phase III study (PURVIEW). The candidate is also being evaluated in separate mid-stage studies for treating cognitive issues associated with Parkinson’s and Alzheimer’s diseases.
The above news comes a couple of months after the FDA decided on zuranolone in postpartum depression (“PPD”) and major depressive disorder (“MDD”) indications. While the agency approved the drug for treating PPD, it issued a complete response letter (“CRL”) in the MDD indication. The drug will be marketed in PPD indication under the trade name Zurzuvae.
Per the CRL, the FDA stated that the NDA filing did not provide substantial evidence of effectiveness to support the approval of zuranolone. Hence, an additional study or studies will be needed.
Sage Therapeutics has developed Zurzuvae in collaboration with Biogen BIIB. Currently, Sage and Biogen are evaluating the further course of action.
Following the above setbacks and to support Zurzuvae’s commercial launch, Sage Therapeutics implemented a strategic reorganization plan. Based on this plan, the company will reduce its workforce by around 40%, focus on the pipeline development of SAGE-718 and lead the neurology program, SAGE-324. Like Zurzuvae, SAGE-324 is also being developed in collaboration with Biogen.
The restructuring plan is designed to help Sage Therapeutics save around $240 million a year, allowing it to extend its cash runway into 2026.
Sage Therapeutics, Inc. Price
Sage Therapeutics, Inc. price | Sage Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Sage currently carries a Zacks Rank #3 (Hold).A couple of better-ranked stocks include Deciphera Pharmaceuticals DCPH and Jazz Pharmaceuticals JAZZ, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Deciphera Pharmaceuticals’ 2023 loss per share have narrowed from $2.38 to $2.36. Year to date, Deciphera’s stock has plunged 35.5%.
Deciphera’s earnings surpassed estimates in two of the last four quarters, met the mark on one occasion and missed on another. The company witnessed an earnings surprise of 1.58% on average. In the last reported quarter, Deciphera’s earnings beat estimates by 8.06%.
In the past 60 days, estimates for Jazz Pharmaceuticals’ 2023 and 2024 earnings per share have increased from $18.49 to $18.64 and $20.31 to $20.59, respectively. Year to date, JAZZ’s stock has dipped 16.7%.
Jazz Pharmaceuticals’ earnings outpaced estimates in two of the trailing four quarters while missing the mark on the other two occasions, witnessing a negative surprise of 27.59%, on average. In the last reported quarter, Jazz Pharmaceuticals’ earnings beat estimates by 1.12%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Biogen Inc. (BIIB) : Free Stock Analysis Report
Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report
Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Sage Therapeutics, Inc. Price Sage Therapeutics, Inc. price | Sage Therapeutics, Inc. Quote Zacks Rank & Stocks to Consider Sage currently carries a Zacks Rank #3 (Hold).A couple of better-ranked stocks include Deciphera Pharmaceuticals DCPH and Jazz Pharmaceuticals JAZZ, each carrying a Zacks Rank #2 (Buy). Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. This FDA designation makes the sponsor eligible for seven years of market exclusivity, following the potential approval and tax credit for qualified clinical studies.
|
Sage Therapeutics, Inc. Price Sage Therapeutics, Inc. price | Sage Therapeutics, Inc. Quote Zacks Rank & Stocks to Consider Sage currently carries a Zacks Rank #3 (Hold).A couple of better-ranked stocks include Deciphera Pharmaceuticals DCPH and Jazz Pharmaceuticals JAZZ, each carrying a Zacks Rank #2 (Buy). Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Sage Therapeutics SAGE announced that the FDA has granted orphan drug designation to its lead neuropsychiatric candidate, SAGE-718, for treating Huntington’s disease (“HD”), a rare neurodegenerative disease.
|
Sage Therapeutics, Inc. Price Sage Therapeutics, Inc. price | Sage Therapeutics, Inc. Quote Zacks Rank & Stocks to Consider Sage currently carries a Zacks Rank #3 (Hold).A couple of better-ranked stocks include Deciphera Pharmaceuticals DCPH and Jazz Pharmaceuticals JAZZ, each carrying a Zacks Rank #2 (Buy). Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Sage Therapeutics SAGE announced that the FDA has granted orphan drug designation to its lead neuropsychiatric candidate, SAGE-718, for treating Huntington’s disease (“HD”), a rare neurodegenerative disease.
|
Sage Therapeutics, Inc. Price Sage Therapeutics, Inc. price | Sage Therapeutics, Inc. Quote Zacks Rank & Stocks to Consider Sage currently carries a Zacks Rank #3 (Hold).A couple of better-ranked stocks include Deciphera Pharmaceuticals DCPH and Jazz Pharmaceuticals JAZZ, each carrying a Zacks Rank #2 (Buy). Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. While the agency approved the drug for treating PPD, it issued a complete response letter (“CRL”) in the MDD indication.
|
0aafa4bd-e6ec-4308-9828-135371034ddf
|
715407.0
|
2023-10-17 00:00:00 UTC
|
Merck's (MRK) Keytruda Gets FDA Nod in Sixth NSCLC Indication
|
DCPH
|
https://www.nasdaq.com/articles/mercks-mrk-keytruda-gets-fda-nod-in-sixth-nsclc-indication
|
nan
|
nan
|
Merck MRK announced that the FDA has approved its blockbuster drug Keytruda for another new indication in non-small cell lung cancer (“NSCLC”).
Following the FDA’s decision, Keytruda is now approved for treating patients with resectable NSCLC, who can get their tumors removed surgically. The drug can be used in combination with chemotherapy as a neoadjuvant treatment given before surgery and then continued as a single agent as part of an adjuvant treatment given after surgery.
The approval is based on data from the phase III KEYNOTE-671 study which showed that continued treatment with Keytruda demonstrated statistically significant improvements in event-free survival and overall survival, which are the study’s dual primary endpoints.
Following the approval, Merck’s Keytruda is now approved for six indications in NSCLC, spanning across both metastatic and earlier stages of the disease.
In a separate press release, Merck also announced that the European Commission granted label expansion to Keytruda for a fifth indication in NSCLC. Keytruda, as a single agent, is approved as an adjuvant treatment for adult patients with NSCLC who are at high risk of recurrence following complete resection and platinum-based chemotherapy. This approval marks the first immunotherapy option approved in the European Union for such patients.
Merck’s shares have lost 6.1% year to date against the industry’s 8.5% growth.
Image Source: Zacks Investment Research
Apart from NSCLC, Keytruda is approved for treatment of many cancers globally. Keytruda sales are gaining from continued strong momentum in metastatic indications and rapid uptake across recent earlier-stage launches. In the first half of 2023, the drug’s sales alone accounted for over 40% of Merck’s total revenues. Keytruda is presently approved to treat at least seven indications in earlier-stage cancers in the United States.
Keytruda is continuously growing and expanding into new indications and markets globally. Numerous recent approvals and the expected launch of many additional indications including in earlier lines of therapy can further boost sales. In the United States, MRK expects over half of Keytruda’s growth to come from indications in early-stage (neoadjuvant/adjuvant) treatment settings through 2025 and to represent roughly 25% of total global Keytruda sales by that time.
Management is evaluating Keytruda across many indications that are progressing well. Keytruda is being studied for more than 30 types of cancer indications in more than 1600 studies including combination studies. If approved, label expansions for new cancer indications will aid sales.
Zacks Rank & Stocks to Consider
Merck currently carries a Zacks Rank #3 (Hold).
Merck & Co., Inc. Price
Merck & Co., Inc. price | Merck & Co., Inc. Quote
Some better-ranked stocks are Allogene Therapeutics ALLO, Deciphera Pharmaceuticals DCPH and Jazz Pharmaceuticals JAZZ, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimate for Allogene Therapeutics’ 2024 earnings per share narrowed from $2.23 to $2.21. Year to date, the stock has lost 48.5%.
ALLO’s earnings beat estimates in three of the trailing four quarters while meeting the mark on one occasion, witnessing an average earnings surprise of 3.93%. In the last reported quarter, Allogene’s earnings beat estimates by 10.17%.
In the past 60 days, estimates for Deciphera Pharmaceuticals’ 2023 loss per share have narrowed from $2.38 to $2.36. Year to date, the stock has plunged 33.9%.
DCPH’s earnings surpassed estimates in two of the last four quarters, met the mark on one occasion while missing it on another. The company witnessed an earnings surprise of 1.58% on average. In the last reported quarter, Deciphera’s earnings beat estimates by 8.06%.
In the past 60 days, estimates for Jazz Pharmaceuticals’ 2023 and 2024 earnings per share have increased from $18.49 to $18.64 and $20.31 to $20.40, respectively. Year to date, JAZZ’s stock has dipped 14.6%.
JAZZ’s earnings outpaced estimates in two of the trailing four quarters while missing the mark on the other two occasions, witnessing a negative surprise of 27.59%, on average. In the last reported quarter, Jazz Pharmaceuticals’ earnings beat estimates by 1.12%.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Merck & Co., Inc. Price Merck & Co., Inc. price | Merck & Co., Inc. Quote Some better-ranked stocks are Allogene Therapeutics ALLO, Deciphera Pharmaceuticals DCPH and Jazz Pharmaceuticals JAZZ, each carrying a Zacks Rank #2 (Buy). DCPH’s earnings surpassed estimates in two of the last four quarters, met the mark on one occasion while missing it on another. Click to get this free report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Merck & Co., Inc. Price Merck & Co., Inc. price | Merck & Co., Inc. Quote Some better-ranked stocks are Allogene Therapeutics ALLO, Deciphera Pharmaceuticals DCPH and Jazz Pharmaceuticals JAZZ, each carrying a Zacks Rank #2 (Buy). Click to get this free report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. DCPH’s earnings surpassed estimates in two of the last four quarters, met the mark on one occasion while missing it on another.
|
Merck & Co., Inc. Price Merck & Co., Inc. price | Merck & Co., Inc. Quote Some better-ranked stocks are Allogene Therapeutics ALLO, Deciphera Pharmaceuticals DCPH and Jazz Pharmaceuticals JAZZ, each carrying a Zacks Rank #2 (Buy). Click to get this free report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. DCPH’s earnings surpassed estimates in two of the last four quarters, met the mark on one occasion while missing it on another.
|
Merck & Co., Inc. Price Merck & Co., Inc. price | Merck & Co., Inc. Quote Some better-ranked stocks are Allogene Therapeutics ALLO, Deciphera Pharmaceuticals DCPH and Jazz Pharmaceuticals JAZZ, each carrying a Zacks Rank #2 (Buy). DCPH’s earnings surpassed estimates in two of the last four quarters, met the mark on one occasion while missing it on another. Click to get this free report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
15f05f90-9f5b-454c-99fb-d199f25feba3
|
715408.0
|
2023-10-16 00:00:00 UTC
|
Intellia's (NTLA) HAE Candidate Gets EMA's PRIME Designation
|
DCPH
|
https://www.nasdaq.com/articles/intellias-ntla-hae-candidate-gets-emas-prime-designation
|
nan
|
nan
|
Intellia Therapeutics, Inc. NTLA announced that the European Medicines Agency (“EMA”) has granted Priority Medicines (“PRIME”) designation to its pipeline candidate, NTLA-2002, for the treatment of hereditary angioedema (HAE).
HAE is a rare genetic disorder characterized by recurring attacks of severe swelling, which can be painful and even life-threatening at times. NTLA-2002 aims to prevent HAE attacks by suppressing the plasma kallikrein activity.
The EMA grants PRIME designation to support the development of medicines, which target an unmet need. Treatments and therapies that are granted this designation are offered early and proactive support by the regulatory body, including being eligible for an accelerated assessment at the time of applying for marketing authorization.
NTLA-2002 is Intellia’s in vivo CRISPR-based investigational therapy candidate, which is currently being evaluated in a phase I/II study for treating HAE.
In June 2023, Intellia announced updated interim data from the phase I portion of the phase I/II study on NTLA-2002. With a cut-off date of Feb 17, 2023, the interim data indicated that patients suffering from HAE experienced a reduction in attacks following the administration of a single dose of NTLA-2002. Also, an average decrease of 95% in monthly attack rates was observed in all 10 patients after receiving a single dose of NTLA-2002.
The above mentioned PRIME status granted to NTLA-2002 was based on this positive data.
The FDA has already granted Orphan Drug designation and Regenerative Medicine Advanced Therapy designation to NTLA-2002 for the treatment of HAE.
NTLA-2002 also received the Innovation Passport from the United Kingdom Medicines and Healthcare products Regulatory Agency.
Shares of Intellia have declined 14.5% compared with the industry’s decrease of 20%.
Image Source: Zacks Investment Research
Intellia is engaged in developing CRISPR/Cas9-based therapies for multiple indications. The company’s other candidate, NTLA-2001, is being evaluated for the treatment of transthyretin amyloidosis.
NTLA-2001 is part of the company’s co-development and co-promotion agreement with Regeneron Pharmaceuticals REGN.
While NTLA is the lead party in the deal, REGN shares some of the development costs and commercial profits. Intellia’s collaboration with Regeneron has given a boost to the former to develop its pipeline.
In the absence of a marketed product, successful development of the pipeline candidates remains the key focus for Intellia.
Zacks Rank & Stocks to Consider
Intellia currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector include CRISPR Therapeutics AG CRSP and Deciphera Pharmaceuticals, Inc. DCPH, carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, estimates for CRISPR Therapeutics’ 2023 loss per share have improved from $4.97 to $4.83. During the same period, loss estimates per share for 2024 have narrowed from $6.62 to $6.45. Year to date, shares of CRSP have risen 9%.
Earnings of CRISPR Therapeutics beat estimates in each of the trailing four quarters, the average surprise being 39.19%.
In the past 30 days, estimates for Deciphera’s 2023 loss per share have remained stable at $2.36. During the same period, the loss estimate per share for 2024 has also remained stable at $2.17. Year to date, shares of DCPH have declined 33.2%.
Earnings of Deciphera beat estimates in two of the trailing four quarters, met the same once, and missed the mark on the other occasion. On average, DCPH delivered an earnings surprise of 1.58%.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
Intellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked stocks in the biotech sector include CRISPR Therapeutics AG CRSP and Deciphera Pharmaceuticals, Inc. DCPH, carrying a Zacks Rank #2 (Buy) each. Year to date, shares of DCPH have declined 33.2%. On average, DCPH delivered an earnings surprise of 1.58%.
|
Some better-ranked stocks in the biotech sector include CRISPR Therapeutics AG CRSP and Deciphera Pharmaceuticals, Inc. DCPH, carrying a Zacks Rank #2 (Buy) each. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Intellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Year to date, shares of DCPH have declined 33.2%.
|
Some better-ranked stocks in the biotech sector include CRISPR Therapeutics AG CRSP and Deciphera Pharmaceuticals, Inc. DCPH, carrying a Zacks Rank #2 (Buy) each. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Intellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Year to date, shares of DCPH have declined 33.2%.
|
Some better-ranked stocks in the biotech sector include CRISPR Therapeutics AG CRSP and Deciphera Pharmaceuticals, Inc. DCPH, carrying a Zacks Rank #2 (Buy) each. Year to date, shares of DCPH have declined 33.2%. On average, DCPH delivered an earnings surprise of 1.58%.
|
d109795d-576d-4081-8a48-77e1d59d6e6e
|
715409.0
|
2023-10-13 00:00:00 UTC
|
Here's Why You May Invest in CRISPR Therapeutics (CRSP) Stock
|
DCPH
|
https://www.nasdaq.com/articles/heres-why-you-may-invest-in-crispr-therapeutics-crsp-stock
|
nan
|
nan
|
CRISPR Therapeutics AG CRSP is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases. Currently, this Switzerland-based company has no marketed drug in its portfolio.
CRISPR Therapeutics, in partnership with large biotech Vertex Pharmaceuticals VRTX, has developed its lead pipeline candidate, exa-cel — an investigational ex-vivo CRISPR gene-edited therapy for treating sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).
Here are some reasons why investors should consider betting on CRISPR Therapeutics stock.
Good Rank, Rising Share Price and Estimates: CRISPR Therapeutics currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The bottom line estimate for CRISPR Therapeutics has narrowed from a loss of $5.11 per share to a loss of $4.83 per share for 2023 over the past 60 days. For 2024, the estimate has narrowed from a loss of $6.64 per share to a loss of $6.45 per share over the past 60 days.
The stock has risen 5.9% so far this year against the industry’s decline of 18.9%.
Image Source: Zacks Investment Research
Exa-cel Nearing Potential Approval: In June 2023, the FDA accepted the biologics license application seeking approval for exa-cel in SCD and TDT indications. A final decision from the regulatory body for the SCD and the TDT indications is expected by Dec 8, 2023 and Mar 30, 2024, respectively.
Both SCD and TDT diseases have significant unmet medical needs. If approved and successfully commercialized, the candidate can give a huge boost to CRISPR Therapeutics’ prospects and drive the stock in the days ahead.
CRSP, along with VRTX, filed similar regulatory submissions for exa-cel in Europe, which were validated in the fourth quarter of 2022.
Immuno-Oncology & Other Pipeline Holds Promise: Apart from exa-cel, CRISPR Therapeutics is developing two chimeric antigen receptor T cell (CAR-T) therapy candidates — CTX110 and CTX130 — for hematological and solid-tumor cancers.
The company is enrolling patients in the phase II study evaluating CTX110 in relapsed/refractory B-cell malignancies. A phase I COBALT-LYM study is ongoing, evaluating CTX130 targeting CD70 for treating relapsed or refractory T cell malignancies.
These candidates hold great potential and target a lucrative market, which can help CRSP drive growth upon successful development.
Other Pipeline Progressing Well: Apart from hemoglobinopathies and immuno-oncology, CRISPR Therapeutics is also exploring the field of regenerative medicines.
Along with partner ViaCyte (now acquired by Vertex), the company has advanced the first program incorporating stem-cell therapy in diabetes. Several early-stage studies evaluating various stem-derived candidates are currently underway for treating type I diabetes.
Other Stocks to Consider
Some other top-ranked stocks in the biotech sector are Anixa Biosciences ANIX and Deciphera Pharmaceuticals DCPH, carrying a Zacks Rank #2 each.
In the past 30 days, 2023 estimates for Anixa Biosciences have narrowed from a loss of 33 cents per share to a loss of 32 cents per share. During the same period, loss estimates per share for 2024 have narrowed from 38 cents to 37 cents. Year to date, shares of ANIX have lost 22.1%.
Earnings of Anixa Biosciences beat estimates in each of the last four quarters, delivering an earnings surprise of 26.29% on average.
In the past 30 days, estimates for Deciphera’s 2023 loss per share have remained stable at $2.36. During the same period, the loss per share estimates for 2024 have also remained stable at $2.17. Year to date, shares of DCPH have declined 34.2%.
Earnings of Deciphera beat estimates in two of the trailing four quarters, met the same once and missed the mark on the other occasion. On average, DCPH delivered an earnings surprise of 1.58%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other Stocks to Consider Some other top-ranked stocks in the biotech sector are Anixa Biosciences ANIX and Deciphera Pharmaceuticals DCPH, carrying a Zacks Rank #2 each. Year to date, shares of DCPH have declined 34.2%. On average, DCPH delivered an earnings surprise of 1.58%.
|
Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Stocks to Consider Some other top-ranked stocks in the biotech sector are Anixa Biosciences ANIX and Deciphera Pharmaceuticals DCPH, carrying a Zacks Rank #2 each. Year to date, shares of DCPH have declined 34.2%.
|
Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Stocks to Consider Some other top-ranked stocks in the biotech sector are Anixa Biosciences ANIX and Deciphera Pharmaceuticals DCPH, carrying a Zacks Rank #2 each. Year to date, shares of DCPH have declined 34.2%.
|
Other Stocks to Consider Some other top-ranked stocks in the biotech sector are Anixa Biosciences ANIX and Deciphera Pharmaceuticals DCPH, carrying a Zacks Rank #2 each. Year to date, shares of DCPH have declined 34.2%. On average, DCPH delivered an earnings surprise of 1.58%.
|
55c7590e-6334-48fb-937b-626730aceaa9
|
715410.0
|
2023-10-12 00:00:00 UTC
|
BioCardia (BCDA) Up on Plans for Second Heart Failure Study
|
DCPH
|
https://www.nasdaq.com/articles/biocardia-bcda-up-on-plans-for-second-heart-failure-study
|
nan
|
nan
|
Shares of BioCardia, Inc. BCDA were up 28.2% on Wednesday after the company completed enrollment in the ongoing pivotal phase III CardiAMP HF study. The study is evaluating its CardiAMP cell therapy for the treatment of heart failure.
BCDA also announced that it is looking to initiate a second pivotal study to evaluate patients who responded well to CardiAMP cell therapy in the initial study.
CardiAMP cell therapy uses a patient's bone marrow cells delivered to the heart via a catheter-based procedure to stimulate the body’s natural healing response.
Last month, BCDA announced interim data from the first phase III study investigating CardiAMP cell therapy for heart failure. Data from the interim analysis showed that the study is unlikely to meet its primary efficacy endpoint based on the three-tiered Finkelstein-Schoenfeld hierarchical analysis of 12-month data.
This announcement also confirmed the validity of the statement made by an independent data safety monitoring board in July 2023. The board said that the study was not likely to meet its primary efficacy endpoint based on an initial analysis of data.
Shares of BioCardia have plunged 76.1% so far this year compared with the industry’s decline of 19.3%.
Image Source: Zacks Investment Research
However, it was observed in the initial study that CardiAMP cell therapy treatment greatly benefited a certain group of patients with high levels of NT-proBNP.
In the study, in patients with NT-pro BNP levels greater than 500 pg/ml at baseline, treatment with CardiAMP cell therapy led to a 59% relative risk reduction in mortality and 54% relative risk reduction of major adverse cardiac events compared with the control group.
NTproBNP is a known biological indicator of increased heart failure and stress to the heart.
Per the company, the new Heart Failure II study will only enroll patients who have an NTproBNP at baseline greater than 500 pg/ml. It will also have a new modified primary endpoint.
Per the latest press release, the company believes that if it had focused on the subset of patients (elevated NT-proBNP at baseline) with the updated composite endpoint, the study would have eventually met the primary endpoint.
BioCardia, Inc. Price
BioCardia, Inc. price | BioCardia, Inc. Quote
Zacks Rank & Stocks to Consider
BioCardia currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector include Anixa Biosciences, Inc. ANIX, CRISPR Therapeutics AG CRSP, and Deciphera Pharmaceuticals, Inc. DCPH, carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, loss per share estimates for Anixa Biosciences’ 2023 have narrowed from 33 cents to 32 cents. During the same period, the loss estimates per share for 2024 have narrowed from 38 cents to 37 cents. Year to date, shares of ANIX have lost 22.8%.
Earnings of Anixa Biosciences beat estimates in each of the last four quarters, delivering an earnings surprise of 26.29% on average.
In the past 30 days, estimates for CRISPR Therapeutics’ 2023 loss per share have improved from $4.97 to $4.83. During the same period, loss estimates per share for 2024 have narrowed from $6.62 to $6.45. Year to date, shares of CRSP have risen 10.1%.
Earnings of CRISPR Therapeutics beat estimates in each of the trailing four quarters, the average surprise being 39.19%.
In the past 30 days, estimates for Deciphera’s 2023 loss per share have remained stable at $2.36. During the same period, the loss estimates per share for 2024 have also remained stable at $2.17. Year to date, shares of DCPH have declined 33.5%.
Earnings of Deciphera beat estimates in three of the trailing four quarters and missed the mark on the other occasion. On average, DCPH delivered an earnings surprise of 1.58%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2023. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
BioCardia, Inc. (BCDA) : Free Stock Analysis Report
ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked stocks in the biotech sector include Anixa Biosciences, Inc. ANIX, CRISPR Therapeutics AG CRSP, and Deciphera Pharmaceuticals, Inc. DCPH, carrying a Zacks Rank #2 (Buy) each. Year to date, shares of DCPH have declined 33.5%. On average, DCPH delivered an earnings surprise of 1.58%.
|
Some better-ranked stocks in the biotech sector include Anixa Biosciences, Inc. ANIX, CRISPR Therapeutics AG CRSP, and Deciphera Pharmaceuticals, Inc. DCPH, carrying a Zacks Rank #2 (Buy) each. Click to get this free report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report BioCardia, Inc. (BCDA) : Free Stock Analysis Report ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report To read this article on Zacks.com click here. Year to date, shares of DCPH have declined 33.5%.
|
Click to get this free report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report BioCardia, Inc. (BCDA) : Free Stock Analysis Report ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the biotech sector include Anixa Biosciences, Inc. ANIX, CRISPR Therapeutics AG CRSP, and Deciphera Pharmaceuticals, Inc. DCPH, carrying a Zacks Rank #2 (Buy) each. Year to date, shares of DCPH have declined 33.5%.
|
Some better-ranked stocks in the biotech sector include Anixa Biosciences, Inc. ANIX, CRISPR Therapeutics AG CRSP, and Deciphera Pharmaceuticals, Inc. DCPH, carrying a Zacks Rank #2 (Buy) each. Year to date, shares of DCPH have declined 33.5%. On average, DCPH delivered an earnings surprise of 1.58%.
|
9ce279e2-a27e-427c-a64f-bb9b61035084
|
715411.0
|
2023-09-08 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Down 9.7% Since Last Earnings Report: Can It Rebound?
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-down-9.7-since-last-earnings-report%3A-can-it-rebound
|
nan
|
nan
|
It has been about a month since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). Shares have lost about 9.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Deciphera Pharmaceuticals, Inc. due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Deciphera Q2 Earnings Beat, Qinlock Drives Revenues
Deciphera Pharmaceuticals, Inc. reported second-quarter 2023 loss of 57 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents. In the year-ago quarter, DCPH had incurred a loss of 60 cents per share.
Net revenues were $38.3 million, which beat the Zacks Consensus Estimate of $36 million. The figure rose almost 18.8% year over year.
Quarter in Detail
Total revenues comprise net product revenues and collaboration revenues for Qinlock (ripretinib).
Deciphera’s sole marketed drug, Qinlock, was approved by the FDA in 2020 to treat adult patients with advanced GIST, who received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib). Qinlock was approved in Europe in late 2021. Apart from Qinlock, there is no marketed drug in Deciphera’s portfolio.
Net product revenues from Qinlock sales were $37.3 million, up 18.4% year over year. The drug generated sales of $28.9 million and $8.4 million in the United States and the ex-U.S. markets, respectively.
Qinlock’s net product revenues beat both the Zacks Consensus Estimate of $35.09 million and our model estimate of $35 million.
Collaboration revenues totaled $1 million, which was in line with the year-ago quarter’s figure. The top line missed the Zacks Consensus Estimate of $1.26 million but beat our model estimate of $0.3 million.
Research and development expenses (including stock-based compensation) amounted to $58.3 million, up 30% year over year owing to costs related to clinical studies on vimseltinib and Qinlock.
Selling, general and administrative expenses (including stock-based compensation) totaled $32.6 million, up 10.1% year over year owing to increased professional fees, personnel-related costs and consultant fees.
Deciphera had cash, cash equivalents and investments worth $389.4 million as of Jun 30, 2023 compared with $426.3 million as of Mar 31, 2023. The company expects its current cash balance, together with the anticipated product, royalty and supply revenues, excluding any potential future milestone payments under its collaboration or license agreements, to fund its operating and capital expenditures into 2026.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision flatlined during the past month.
VGM Scores
Currently, Deciphera Pharmaceuticals, Inc. has an average Growth Score of C, a grade with the same score on the momentum front. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Deciphera Pharmaceuticals, Inc. has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Deciphera Pharmaceuticals, Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Blueprint Medicines (BPMC), has gained 2.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2023.
Blueprint Medicines reported revenues of $57.57 million in the last reported quarter, representing a year-over-year change of +57.5%. EPS of -$2.19 for the same period compares with -$2.68 a year ago.
For the current quarter, Blueprint Medicines is expected to post a loss of $2.39 per share, indicating a change of -7.2% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.7% over the last 30 days.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Blueprint Medicines. Also, the stock has a VGM Score of F.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
It has been about a month since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). In the year-ago quarter, DCPH had incurred a loss of 60 cents per share. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report To read this article on Zacks.com click here. It has been about a month since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). In the year-ago quarter, DCPH had incurred a loss of 60 cents per share.
|
Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report To read this article on Zacks.com click here. It has been about a month since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). In the year-ago quarter, DCPH had incurred a loss of 60 cents per share.
|
It has been about a month since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). In the year-ago quarter, DCPH had incurred a loss of 60 cents per share. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
62646daf-90e3-474d-b0b4-1e6e07a79f67
|
715412.0
|
2023-09-01 00:00:00 UTC
|
Commit To Purchase Deciphera Pharmaceuticals At $12.50, Earn 10.1% Annualized Using Options
|
DCPH
|
https://www.nasdaq.com/articles/commit-to-purchase-deciphera-pharmaceuticals-at-%2412.50-earn-10.1-annualized-using-options
|
nan
|
nan
|
Investors considering a purchase of Deciphera Pharmaceuticals Inc (Symbol: DCPH) shares, but tentative about paying the going market price of $14.39/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2024 put at the $12.50 strike, which has a bid at the time of this writing of 80 cents. Collecting that bid as the premium represents a 6.4% return against the $12.50 commitment, or a 10.1% annualized rate of return (at Stock Options Channel we call this the YieldBoost).
Selling a put does not give an investor access to DCPH's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $12.50 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Deciphera Pharmaceuticals Inc sees its shares fall 12.9% and the contract is exercised (resulting in a cost basis of $11.70 per share before broker commissions, subtracting the 80 cents from $12.50), the only upside to the put seller is from collecting that premium for the 10.1% annualized rate of return.
Below is a chart showing the trailing twelve month trading history for Deciphera Pharmaceuticals Inc, and highlighting in green where the $12.50 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the April 2024 put at the $12.50 strike for the 10.1% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Deciphera Pharmaceuticals Inc (considering the last 251 trading day closing values as well as today's price of $14.39) to be 53%. For other put options contract ideas at the various different available expirations, visit the DCPH Stock Options page of StockOptionsChannel.com.
In mid-afternoon trading on Friday, the put volume among S&P 500 components was 2.43M contracts, with call volume at 2.92M, for a put:call ratio of 0.83 so far for the day, which is unusually high compared to the long-term median put:call ratio of .65. In other words, there are lots more put buyers out there in options trading so far today than would normally be seen, as compared to call buyers. Find out which 15 call and put options traders are talking about today.
Top YieldBoost Puts of the S&P 500 »
Also see:
Future Dividend Aristocrats
AZTA Insider Buying
UVE Dividend History
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Investors considering a purchase of Deciphera Pharmaceuticals Inc (Symbol: DCPH) shares, but tentative about paying the going market price of $14.39/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to DCPH's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. For other put options contract ideas at the various different available expirations, visit the DCPH Stock Options page of StockOptionsChannel.com.
|
Selling a put does not give an investor access to DCPH's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. Investors considering a purchase of Deciphera Pharmaceuticals Inc (Symbol: DCPH) shares, but tentative about paying the going market price of $14.39/share, might benefit from considering selling puts among the alternative strategies at their disposal. For other put options contract ideas at the various different available expirations, visit the DCPH Stock Options page of StockOptionsChannel.com.
|
Selling a put does not give an investor access to DCPH's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. Investors considering a purchase of Deciphera Pharmaceuticals Inc (Symbol: DCPH) shares, but tentative about paying the going market price of $14.39/share, might benefit from considering selling puts among the alternative strategies at their disposal. For other put options contract ideas at the various different available expirations, visit the DCPH Stock Options page of StockOptionsChannel.com.
|
Investors considering a purchase of Deciphera Pharmaceuticals Inc (Symbol: DCPH) shares, but tentative about paying the going market price of $14.39/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to DCPH's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. For other put options contract ideas at the various different available expirations, visit the DCPH Stock Options page of StockOptionsChannel.com.
|
977db4e2-a7d7-4f29-b8cb-f6b51edb1b98
|
715413.0
|
2023-08-21 00:00:00 UTC
|
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
|
DCPH
|
https://www.nasdaq.com/articles/want-to-get-rich-3-game-changing-biotech-stocks-to-buy-right-now
|
nan
|
nan
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Biotech stocks may offer some of the most explosive opportunities on the market. For one, we have millions of baby boomers demanding better care. Two, there’s substantial demand for new innovative therapies, especially with gene editing. Three, multiple heavyweight companies are hunting for new drugs to keep their pipelines fresh with patent expirations nearing.
Even better, according to The Wall Street Journal, biotech M&A is gaining big momentum. All because drug makers are facing a patent cliff. Plus, biotech stock valuations are exceptionally low, making many of them attractive.
We also have to consider biotech stocks are relatively recession resistant. All because millions of people will always need care. That being said, investors may want to focus on biotech stocks, including these potential game-changers with strong catalysts.
Apellis Pharmaceuticals (APLS)
Source: Shutterstock
Weakness may be an opportunity for Apellis Pharmaceuticals (NASDAQ:APLS), whose eye-disease drug, Syfovre is the first US FDA-approved treatment for geographic atrophy. Granted, the stock was recently halved after six recipients of Syfovre said they experienced inflammation in their eyes. However, most of the negativity has been priced into the stock.
Plus, analysts have been coming out in support of the company. For example, Plus, according to STATNews.com, “the passing of more ‘clean’ days and weeks while the total number of eye injections continues to add up makes it more likely the scare will dissipate and strong demand for Syfovre will return.” Even better, with recent weakness – and a potential game-changing eye drug – APLS could be a potential acquisition target – especially for companies with patent cliffs nearing.
Recursion Pharmaceuticals (RXRX)
Source: Piotr Swat / Shutterstock.com
The last time I mentioned Recursion Pharmaceuticals (NASDAQ:RXRX), it traded around $10.75 on Aug. 8. While the stock dipped to about $8.58 following that note, there’s still a lot to like here. Remember, Nvidia (NASDAQ:NVDA) recently invested $50 million in the company to work on drug development using artificial intelligence.
With Nvidia’s help, Recursion can accelerate AI software that can identify relationships between trillions of genes and compounds. All in an effort to treat issues we never thought could be treated.
In addition, Recursion is also working on potential treatments for cerebral cavernous malformations, neurofibromatosis, familial adenomatous polyposis, mutant cancers, ovarian cancers, and cancer immunotherapy. If RXRX AI efforts can create treatments for issues such as cancer, the stock may never be as cheap as it is now.
Deciphera Pharmaceuticals (DCPH)
Source: Dmitry Kalinovsky / Shutterstock.com
Also, take a look at Deciphera Pharmaceuticals (NASDAQ:DCPH), which could see higher highs. For one, the company just reported second-quarter earnings per share (EPS) loss of $48.6 million, or 57 cents a share. That was an earnings beat by five cents. It also posted revenues of $38.3 million, which beat expectations by $1.98 million.
Two, its lead therapy Qinlock (ripretinib), which was approved for gastrointestinal stromal tumors (GISTs), just saw $37.3 million in product revenue, an 18% jump year over year. Three, DCPH just began another Phase 3 study for patients with advanced GIST.
It also expects to post Phase 3 trial results on its vimseltinib treatment for tenosynovial giant cell tumor (TGCT) in the last quarter of the year. Another treatment in trials is DC-3116 for several types of cancer. At the moment, DC-3116 is in Phase 1 trials. Analysts at Stifel just upgraded the DCPH stock to a buy rating with a $20 price target. “Despite a significant ~40% drop from its 2023 peak, the continuous expansion of Qinlock’s core business, the prospective commercial roll-out of vimseltinib, and potential long-term gains from Qinlock label enhancements are encouraging signs,” said the firm, as quoted by WeBull.com.
On the date of publication, Ian Cooper did not hold (either directly or indirectly) any positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.
More From InvestorPlace
Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
ChatGPT IPO Could Shock the World, Make This Move Before the Announcement
It doesn’t matter if you have $500 or $5 million. Do this now.
The post Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals (DCPH) Source: Dmitry Kalinovsky / Shutterstock.com Also, take a look at Deciphera Pharmaceuticals (NASDAQ:DCPH), which could see higher highs. Three, DCPH just began another Phase 3 study for patients with advanced GIST. Analysts at Stifel just upgraded the DCPH stock to a buy rating with a $20 price target.
|
Deciphera Pharmaceuticals (DCPH) Source: Dmitry Kalinovsky / Shutterstock.com Also, take a look at Deciphera Pharmaceuticals (NASDAQ:DCPH), which could see higher highs. Three, DCPH just began another Phase 3 study for patients with advanced GIST. Analysts at Stifel just upgraded the DCPH stock to a buy rating with a $20 price target.
|
Deciphera Pharmaceuticals (DCPH) Source: Dmitry Kalinovsky / Shutterstock.com Also, take a look at Deciphera Pharmaceuticals (NASDAQ:DCPH), which could see higher highs. Three, DCPH just began another Phase 3 study for patients with advanced GIST. Analysts at Stifel just upgraded the DCPH stock to a buy rating with a $20 price target.
|
Deciphera Pharmaceuticals (DCPH) Source: Dmitry Kalinovsky / Shutterstock.com Also, take a look at Deciphera Pharmaceuticals (NASDAQ:DCPH), which could see higher highs. Three, DCPH just began another Phase 3 study for patients with advanced GIST. Analysts at Stifel just upgraded the DCPH stock to a buy rating with a $20 price target.
|
d11bfb1f-417d-4868-ae3c-94853f305fa4
|
715414.0
|
2023-08-11 00:00:00 UTC
|
Why Shares of Deciphera Pharmaceuticals Rose This Week
|
DCPH
|
https://www.nasdaq.com/articles/why-shares-of-deciphera-pharmaceuticals-rose-this-week
|
nan
|
nan
|
What happened
Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) were up more than 17% for the week as of Friday at 2 p.m. ET, according to data provided by S&P Global Market Intelligence. The biotech company's stock closed last week at $13.08, then rose to a high of $16.43 on Friday. The stock is still down more than 7% so far this year.
So what
The company, which focuses on therapies to treat various cancers, reported second-quarter earnings on Wednesday before the markets opened. Its sole marketed therapy, Qinlock (ripretinib), led a surge in growth in revenue and earnings per share (EPS).
Deciphera reported revenue of $38.3 million, up 17.4% year over year. All but $1 million of the revenue came from sales of gastrointestinal stromal tumor (GIST) therapy Qinlock.
The company reported cash of $389.4 million, enough, it said, to fund operations into 2026, not counting any future milestone payments.
The company had an EPS loss of $0.57, compared to an EPS loss of $0.60 in the same period a year ago.
Now what
Qinlock is approved as a fourth-line treatment for GIST, a type of stomach cancer. The company is working to broaden its label. The therapy is in a phase 3 trial versus sunitnib to treat second-line GIST patients with mutations in the KIT exon 11 and 17/18 genes.
The company has a pipeline with 16 programs. It also reported that it expects phase 1/2 trial results for vimseltinib in patients with tenosynovial giant cell tumor (TGCT), which is a rare, typically nonmalignant tumor of the joints. Deciphera sees vimseltinib as having the potential to be its second approved drug.
Earlier this week, HC Wainwright reiterated its buy rating for the stock, and Stifel Nicolaus upgraded its rating from hold to buy and boosted its price target from $14 to $20.
10 stocks we like better than Deciphera Pharmaceuticals
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 1, 2023
Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) were up more than 17% for the week as of Friday at 2 p.m. So what The company, which focuses on therapies to treat various cancers, reported second-quarter earnings on Wednesday before the markets opened. Its sole marketed therapy, Qinlock (ripretinib), led a surge in growth in revenue and earnings per share (EPS).
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) were up more than 17% for the week as of Friday at 2 p.m. Deciphera reported revenue of $38.3 million, up 17.4% year over year. All but $1 million of the revenue came from sales of gastrointestinal stromal tumor (GIST) therapy Qinlock.
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) were up more than 17% for the week as of Friday at 2 p.m. So what The company, which focuses on therapies to treat various cancers, reported second-quarter earnings on Wednesday before the markets opened. 10 stocks we like better than Deciphera Pharmaceuticals When our analyst team has a stock tip, it can pay to listen.
|
What happened Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) were up more than 17% for the week as of Friday at 2 p.m. All but $1 million of the revenue came from sales of gastrointestinal stromal tumor (GIST) therapy Qinlock. That's right -- they think these 10 stocks are even better buys.
|
2155be96-95e0-4635-a41a-c86036f13723
|
715415.0
|
2023-08-11 00:00:00 UTC
|
HC Wainwright & Co. Reiterates Deciphera Pharmaceuticals (DCPH) Buy Recommendation
|
DCPH
|
https://www.nasdaq.com/articles/hc-wainwright-co.-reiterates-deciphera-pharmaceuticals-dcph-buy-recommendation
|
nan
|
nan
|
Fintel reports that on August 10, 2023, HC Wainwright & Co. reiterated coverage of Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy recommendation.
Analyst Price Forecast Suggests 42.04% Upside
As of August 2, 2023, the average one-year price target for Deciphera Pharmaceuticals is 21.76. The forecasts range from a low of 9.09 to a high of $31.50. The average price target represents an increase of 42.04% from its latest reported closing price of 15.32.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Deciphera Pharmaceuticals is 157MM, an increase of 8.87%. The projected annual non-GAAP EPS is -2.26.
What is the Fund Sentiment?
There are 363 funds or institutions reporting positions in Deciphera Pharmaceuticals. This is an increase of 11 owner(s) or 3.12% in the last quarter. Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 66.35%. Total shares owned by institutions increased in the last three months by 12.15% to 61,582K shares.
The put/call ratio of DCPH is 0.26, indicating a bullish outlook.
What are Other Shareholders Doing?
Redmile Group holds 5,582K shares representing 7.11% ownership of the company. In it's prior filing, the firm reported owning 3,593K shares, representing an increase of 35.63%. The firm increased its portfolio allocation in DCPH by 55.33% over the last quarter.
Deerfield Management Company, L.p. holds 5,219K shares representing 6.65% ownership of the company. In it's prior filing, the firm reported owning 2,349K shares, representing an increase of 54.98%. The firm increased its portfolio allocation in DCPH by 125.52% over the last quarter.
Armistice Capital holds 4,100K shares representing 5.22% ownership of the company. In it's prior filing, the firm reported owning 5,172K shares, representing a decrease of 26.15%. The firm decreased its portfolio allocation in DCPH by 38.32% over the last quarter.
Braidwell holds 3,241K shares representing 4.13% ownership of the company. In it's prior filing, the firm reported owning 3,272K shares, representing a decrease of 0.93%. The firm decreased its portfolio allocation in DCPH by 8.08% over the last quarter.
Goldman Sachs Group holds 3,058K shares representing 3.89% ownership of the company. In it's prior filing, the firm reported owning 2,200K shares, representing an increase of 28.04%. The firm increased its portfolio allocation in DCPH by 24.93% over the last quarter.
Deciphera Pharmaceuticals Background Information
(This description is provided by the company.)
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.
Additional reading:
Press Release issued by Deciphera Pharmaceuticals, Inc. on August 9, 2023
, dated May 3, 2023, by and between Deciphera Pharmaceuticals, LLC and Jefferies LLC
Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer — Director Ron Squarer Appointed Chairperson of the Board; James A. Bristol,
Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results – First Quarter 2023 Total Revenue of $33.4 Million; Net Product Revenue for QINLOCK® Increased 15% to $33.2 Million Compared to First Quarter 2022 – – Enrollment Complete in th
Form of indenture for senior debt securities and the related form of senior debt security.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Fintel reports that on August 10, 2023, HC Wainwright & Co. reiterated coverage of Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 66.35%. The put/call ratio of DCPH is 0.26, indicating a bullish outlook.
|
Fintel reports that on August 10, 2023, HC Wainwright & Co. reiterated coverage of Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 66.35%. The put/call ratio of DCPH is 0.26, indicating a bullish outlook.
|
Fintel reports that on August 10, 2023, HC Wainwright & Co. reiterated coverage of Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 66.35%. The put/call ratio of DCPH is 0.26, indicating a bullish outlook.
|
Fintel reports that on August 10, 2023, HC Wainwright & Co. reiterated coverage of Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy recommendation. Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 66.35%. The put/call ratio of DCPH is 0.26, indicating a bullish outlook.
|
94171cf6-2505-4d15-80a4-93bc5cca560a
|
715416.0
|
2023-08-11 00:00:00 UTC
|
Stifel Upgrades Deciphera Pharmaceuticals (DCPH)
|
DCPH
|
https://www.nasdaq.com/articles/stifel-upgrades-deciphera-pharmaceuticals-dcph
|
nan
|
nan
|
Fintel reports that on August 10, 2023, Stifel upgraded their outlook for Deciphera Pharmaceuticals (NASDAQ:DCPH) from Hold to Buy .
Analyst Price Forecast Suggests 42.04% Upside
As of August 2, 2023, the average one-year price target for Deciphera Pharmaceuticals is 21.76. The forecasts range from a low of 9.09 to a high of $31.50. The average price target represents an increase of 42.04% from its latest reported closing price of 15.32.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Deciphera Pharmaceuticals is 157MM, an increase of 8.87%. The projected annual non-GAAP EPS is -2.26.
What is the Fund Sentiment?
There are 363 funds or institutions reporting positions in Deciphera Pharmaceuticals. This is an increase of 11 owner(s) or 3.12% in the last quarter. Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 66.35%. Total shares owned by institutions increased in the last three months by 12.15% to 61,582K shares.
The put/call ratio of DCPH is 0.26, indicating a bullish outlook.
What are Other Shareholders Doing?
Redmile Group holds 5,582K shares representing 7.11% ownership of the company. In it's prior filing, the firm reported owning 3,593K shares, representing an increase of 35.63%. The firm increased its portfolio allocation in DCPH by 55.33% over the last quarter.
Deerfield Management Company, L.p. holds 5,219K shares representing 6.65% ownership of the company. In it's prior filing, the firm reported owning 2,349K shares, representing an increase of 54.98%. The firm increased its portfolio allocation in DCPH by 125.52% over the last quarter.
Armistice Capital holds 4,100K shares representing 5.22% ownership of the company. In it's prior filing, the firm reported owning 5,172K shares, representing a decrease of 26.15%. The firm decreased its portfolio allocation in DCPH by 38.32% over the last quarter.
Braidwell holds 3,241K shares representing 4.13% ownership of the company. In it's prior filing, the firm reported owning 3,272K shares, representing a decrease of 0.93%. The firm decreased its portfolio allocation in DCPH by 8.08% over the last quarter.
Goldman Sachs Group holds 3,058K shares representing 3.89% ownership of the company. In it's prior filing, the firm reported owning 2,200K shares, representing an increase of 28.04%. The firm increased its portfolio allocation in DCPH by 24.93% over the last quarter.
Deciphera Pharmaceuticals Background Information
(This description is provided by the company.)
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.
Additional reading:
Press Release issued by Deciphera Pharmaceuticals, Inc. on August 9, 2023
, dated May 3, 2023, by and between Deciphera Pharmaceuticals, LLC and Jefferies LLC
Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer — Director Ron Squarer Appointed Chairperson of the Board; James A. Bristol,
Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results – First Quarter 2023 Total Revenue of $33.4 Million; Net Product Revenue for QINLOCK® Increased 15% to $33.2 Million Compared to First Quarter 2022 – – Enrollment Complete in th
Form of indenture for senior debt securities and the related form of senior debt security.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Fintel reports that on August 10, 2023, Stifel upgraded their outlook for Deciphera Pharmaceuticals (NASDAQ:DCPH) from Hold to Buy . Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 66.35%. The put/call ratio of DCPH is 0.26, indicating a bullish outlook.
|
Fintel reports that on August 10, 2023, Stifel upgraded their outlook for Deciphera Pharmaceuticals (NASDAQ:DCPH) from Hold to Buy . Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 66.35%. The put/call ratio of DCPH is 0.26, indicating a bullish outlook.
|
Fintel reports that on August 10, 2023, Stifel upgraded their outlook for Deciphera Pharmaceuticals (NASDAQ:DCPH) from Hold to Buy . Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 66.35%. The put/call ratio of DCPH is 0.26, indicating a bullish outlook.
|
Fintel reports that on August 10, 2023, Stifel upgraded their outlook for Deciphera Pharmaceuticals (NASDAQ:DCPH) from Hold to Buy . Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 66.35%. The put/call ratio of DCPH is 0.26, indicating a bullish outlook.
|
c53294b3-6ba9-4084-8867-6caaa2d0f55d
|
715417.0
|
2023-08-10 00:00:00 UTC
|
Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-dcph-q2-earnings-beat-qinlock-drives-revenues
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. DCPH reported second-quarter 2023 loss of 57 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents. In the year-ago quarter, DCPH had reported a loss of 60 cents per share.
Net revenues were $38.3 million, which beat the Zacks Consensus Estimate of $36 million. The figure rose almost 18.8% year over year.
Shares of Deciphera rallied 6.18% on Aug 9, as the company reported better-than-expected results. The stock has nosedived 16.2% year to date compared with the industry’s decline of 12.2%.
Image Source: Zacks Investment Research
Quarter in Detail
Total revenues comprise of net product revenues and collaboration revenues for Qinlock (ripretinib).
Deciphera’s sole marketed drug, Qinlock, was approved by the FDA in 2020 to treat adult patients with advanced gastrointestinal stromal tumors (GIST), who received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib). Qinlock was approved in Europe in late 2021. Apart from Qinlock, there is no marketed drug in Deciphera’s portfolio.
Net product revenues from Qinlock sales were $37.3 million, up 18.4% year over year. The drug generated sales of $28.9 million and $8.4 million in the United States and the ex-U.S. markets, respectively.
Qinlock’s net product revenues beat both the Zacks Consensus Estimate of $35.09 million and our model estimate of $35 million.
Collaboration revenues totaled $1 million, which was in line with the year-ago quarter’s figure. The top line missed the Zacks Consensus Estimate of $1.26 million but beat our model estimate of $0.3 million.
Research and development expenses (including stock-based compensation) amounted to $58.3 million, up 30% year over year owing to costs related to clinical studies on vimseltinib and Qinlock.
Selling, general and administrative expenses (including stock-based compensation) totaled $32.6 million, up 10.1% year over year owing to increased professional fees, personnel-related costs and consultant fees.
Deciphera had cash, cash equivalents and investments worth $389.4 million as of Jun 30, 2023, compared with $426.3 million as of Mar 31, 2023. The company expects its current cash balance, together with the anticipated product, royalty and supply revenues, excluding any potential future milestone payments under its collaboration or license agreements, to fund its operating and capital expenditures into 2026.
Other Updates
Deciphera is also working to expand the label of Qinlock for the larger commercial opportunity in GIST.
In the reported quarter, the company initiated a phase III INSIGHT study to evaluate Qinlock versus sunitinib for the treatment of second-line GIST patients with mutations in KIT exon 11 and 17/18.
DCPH is evaluating another candidate, vimseltinib, in the phase III MOTION study to treat patients with tenosynovial giant-cell tumors, who are not amenable to surgery. It expects to report results from the study in the fourth quarter of 2023.
This apart, DCPH, in collaboration with Pfizer, Inc. PFE, initiated new combination escalation studies evaluating DCC-3116 in combination with ripretinib in patients with GIST, and in combination with encorafenib and cetuximab in patients with colorectal cancer. Per the terms of the agreement with Pfizer, Deciphera will bear the cost of the study while Pfizer will supply encorafenib free of cost.
Additionally, DCPH also initiated three expansion cohorts in the ongoing phase I/II study of DCC-3116 in combination with trametinib, binimetinib and sotorasib in patients with advanced solid tumors.
Deciphera Pharmaceuticals, Inc. Price and Consensus
Deciphera Pharmaceuticals, Inc. price-consensus-chart | Deciphera Pharmaceuticals, Inc. Quote
Zacks Rank and Other Stocks to Consider
Deciphera currently carries a Zacks Rank #2 (Buy).
A couple of other top-ranked stocks in the same industry are ADC Therapeutics ADCT and ImmunoGen IMGN, both carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for ADC Therapeutics has narrowed from a loss of $2.84 per share to a loss of $2.61 for 2023. The consensus estimate has narrowed from a loss of $2.56 per share to a loss of $2.55 for 2024 during the same time frame. Shares of the company have lost 60.9% year to date.
ADCT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average negative surprise of 3.25%.
In the past 90 days, the Zacks Consensus Estimate for ImmunoGen has narrowed from a loss of 55 cents per share to a loss of 21 cents for 2023. The consensus estimate has improved from a loss of 31 cents per share to a profit of 3 cents for 2024 during the same time frame. Shares of the company have rallied 189.9% year to date.
IMGN’s earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 31.24%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
ADC Therapeutics SA (ADCT) : Free Stock Analysis Report
ImmunoGen, Inc. (IMGN) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. DCPH reported second-quarter 2023 loss of 57 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents. In the year-ago quarter, DCPH had reported a loss of 60 cents per share. DCPH is evaluating another candidate, vimseltinib, in the phase III MOTION study to treat patients with tenosynovial giant-cell tumors, who are not amenable to surgery.
|
Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ImmunoGen, Inc. (IMGN) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. DCPH reported second-quarter 2023 loss of 57 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents. In the year-ago quarter, DCPH had reported a loss of 60 cents per share.
|
Deciphera Pharmaceuticals, Inc. DCPH reported second-quarter 2023 loss of 57 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents. Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ImmunoGen, Inc. (IMGN) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. In the year-ago quarter, DCPH had reported a loss of 60 cents per share.
|
Deciphera Pharmaceuticals, Inc. DCPH reported second-quarter 2023 loss of 57 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents. In the year-ago quarter, DCPH had reported a loss of 60 cents per share. DCPH is evaluating another candidate, vimseltinib, in the phase III MOTION study to treat patients with tenosynovial giant-cell tumors, who are not amenable to surgery.
|
84fdd088-449b-49e4-a9c9-1941c9c17b32
|
715418.0
|
2023-08-09 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-reports-q2-loss-tops-revenue-estimates-0
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.60 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 8.06%. A quarter ago, it was expected that this company would post a loss of $0.60 per share when it actually produced a loss of $0.60, delivering no surprise.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $38.3 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 5.42%. This compares to year-ago revenues of $32.49 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Deciphera Pharmaceuticals, Inc. Shares have lost about 21.1% since the beginning of the year versus the S&P 500's gain of 17.2%.
What's Next for Deciphera Pharmaceuticals, Inc.
While Deciphera Pharmaceuticals, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Deciphera Pharmaceuticals, Inc. Favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.61 on $37.79 million in revenues for the coming quarter and -$2.47 on $147.73 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Lineage Cell (LCTX), another stock in the same industry, has yet to report results for the quarter ended June 2023. The results are expected to be released on August 10.
This biotechnology company is expected to post quarterly loss of $0.04 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Lineage Cell's revenues are expected to be $2.65 million, down 41.8% from the year-ago quarter.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
Lineage Cell Therapeutics, Inc. (LCTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.62. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Lineage Cell Therapeutics, Inc. (LCTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Lineage Cell Therapeutics, Inc. (LCTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.62. Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $38.3 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 5.42%.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.62. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Lineage Cell Therapeutics, Inc. (LCTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $38.3 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 5.42%.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.62. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Lineage Cell Therapeutics, Inc. (LCTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
|
68a6683a-b5a1-46ca-a404-a5a968714610
|
715419.0
|
2023-06-24 00:00:00 UTC
|
DCPH Quantitative Stock Analysis - Benjamin Graham
|
DCPH
|
https://www.nasdaq.com/articles/dcph-quantitative-stock-analysis-benjamin-graham
|
nan
|
nan
|
Below is Validea's guru fundamental report for DECIPHERA PHARMACEUTICALS INC (DCPH). Of the 22 guru strategies we follow, DCPH rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have low P/B and P/E ratios, along with low debt and solid long-term earnings growth.
DECIPHERA PHARMACEUTICALS INC (DCPH) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 43% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: FAIL
CURRENT RATIO: PASS
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: PASS
LONG-TERM EPS GROWTH: FAIL
P/E RATIO: FAIL
PRICE/BOOK RATIO: FAIL
Detailed Analysis of DECIPHERA PHARMACEUTICALS INC
DCPH Guru Analysis
DCPH Fundamental Analysis
More Information on Benjamin Graham
Benjamin Graham Portfolio
Top Benjamin Graham Stocks
About Benjamin Graham: The late Benjamin Graham may be the oldest of the gurus we follow, but his impact on the investing world has lasted for decades after his death in 1976. Known as both the "Father of Value Investing" and the founder of the entire field of security analysis, Graham mentored several of history's greatest investors -- including Warren Buffett -- and inspired a slew of others, including John Templeton, Mario Gabelli, and another of Validea's gurus, John Neff. Graham built his fortune and reputation after living through some extremely difficult times, including both the Great Depression and his own family's financial woes following his father's death when Benjamin was a young man. His investment firm posted per annum returns of about 20 percent from 1936 to 1956, far outpacing the 12.2 percent average return for the market during that time.
Additional Research Links
Top NASDAQ 100 Stocks
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
High Shareholder Yield Stocks
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Below is Validea's guru fundamental report for DECIPHERA PHARMACEUTICALS INC (DCPH). Of the 22 guru strategies we follow, DCPH rates highest using our Value Investor model based on the published strategy of Benjamin Graham. DECIPHERA PHARMACEUTICALS INC (DCPH) is a small-cap growth stock in the Biotechnology & Drugs industry.
|
Detailed Analysis of DECIPHERA PHARMACEUTICALS INC DCPH Guru Analysis DCPH Fundamental Analysis More Information on Benjamin Graham Benjamin Graham Portfolio Top Benjamin Graham Stocks About Benjamin Graham: The late Benjamin Graham may be the oldest of the gurus we follow, but his impact on the investing world has lasted for decades after his death in 1976. Below is Validea's guru fundamental report for DECIPHERA PHARMACEUTICALS INC (DCPH). Of the 22 guru strategies we follow, DCPH rates highest using our Value Investor model based on the published strategy of Benjamin Graham.
|
Detailed Analysis of DECIPHERA PHARMACEUTICALS INC DCPH Guru Analysis DCPH Fundamental Analysis More Information on Benjamin Graham Benjamin Graham Portfolio Top Benjamin Graham Stocks About Benjamin Graham: The late Benjamin Graham may be the oldest of the gurus we follow, but his impact on the investing world has lasted for decades after his death in 1976. Below is Validea's guru fundamental report for DECIPHERA PHARMACEUTICALS INC (DCPH). Of the 22 guru strategies we follow, DCPH rates highest using our Value Investor model based on the published strategy of Benjamin Graham.
|
Below is Validea's guru fundamental report for DECIPHERA PHARMACEUTICALS INC (DCPH). Detailed Analysis of DECIPHERA PHARMACEUTICALS INC DCPH Guru Analysis DCPH Fundamental Analysis More Information on Benjamin Graham Benjamin Graham Portfolio Top Benjamin Graham Stocks About Benjamin Graham: The late Benjamin Graham may be the oldest of the gurus we follow, but his impact on the investing world has lasted for decades after his death in 1976. Of the 22 guru strategies we follow, DCPH rates highest using our Value Investor model based on the published strategy of Benjamin Graham.
|
3f6d37da-5cf4-4dd3-bf59-d549ab64def9
|
715420.0
|
2023-06-05 00:00:00 UTC
|
JMP Securities Reiterates Deciphera Pharmaceuticals (DCPH) Market Outperform Recommendation
|
DCPH
|
https://www.nasdaq.com/articles/jmp-securities-reiterates-deciphera-pharmaceuticals-dcph-market-outperform-0
|
nan
|
nan
|
Fintel reports that on June 5, 2023, JMP Securities reiterated coverage of Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Market Outperform recommendation.
Analyst Price Forecast Suggests 54.55% Upside
As of June 2, 2023, the average one-year price target for Deciphera Pharmaceuticals is 21.76. The forecasts range from a low of 9.09 to a high of $31.50. The average price target represents an increase of 54.55% from its latest reported closing price of 14.08.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Deciphera Pharmaceuticals is 157MM, an increase of 13.44%. The projected annual non-GAAP EPS is -2.26.
What is the Fund Sentiment?
There are 358 funds or institutions reporting positions in Deciphera Pharmaceuticals. This is an increase of 9 owner(s) or 2.58% in the last quarter. Average portfolio weight of all funds dedicated to DCPH is 0.13%, a decrease of 8.49%. Total shares owned by institutions increased in the last three months by 9.73% to 60,669K shares.
The put/call ratio of DCPH is 0.48, indicating a bullish outlook.
What are Other Shareholders Doing?
Redmile Group holds 5,582K shares representing 7.11% ownership of the company. In it's prior filing, the firm reported owning 3,593K shares, representing an increase of 35.63%. The firm increased its portfolio allocation in DCPH by 55.33% over the last quarter.
Deerfield Management Company, L.p. holds 5,219K shares representing 6.65% ownership of the company. In it's prior filing, the firm reported owning 2,349K shares, representing an increase of 54.98%. The firm increased its portfolio allocation in DCPH by 125.52% over the last quarter.
Armistice Capital holds 4,100K shares representing 5.22% ownership of the company. In it's prior filing, the firm reported owning 5,172K shares, representing a decrease of 26.15%. The firm decreased its portfolio allocation in DCPH by 38.32% over the last quarter.
Braidwell holds 3,241K shares representing 4.13% ownership of the company. In it's prior filing, the firm reported owning 3,272K shares, representing a decrease of 0.93%. The firm decreased its portfolio allocation in DCPH by 8.08% over the last quarter.
Goldman Sachs Group holds 3,058K shares representing 3.89% ownership of the company. In it's prior filing, the firm reported owning 2,200K shares, representing an increase of 28.04%. The firm increased its portfolio allocation in DCPH by 24.93% over the last quarter.
Deciphera Pharmaceuticals Background Information
(This description is provided by the company.)
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.
Key filings for this company:
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Fintel reports that on June 5, 2023, JMP Securities reiterated coverage of Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Market Outperform recommendation. Average portfolio weight of all funds dedicated to DCPH is 0.13%, a decrease of 8.49%. The put/call ratio of DCPH is 0.48, indicating a bullish outlook.
|
Fintel reports that on June 5, 2023, JMP Securities reiterated coverage of Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Market Outperform recommendation. Average portfolio weight of all funds dedicated to DCPH is 0.13%, a decrease of 8.49%. The put/call ratio of DCPH is 0.48, indicating a bullish outlook.
|
Fintel reports that on June 5, 2023, JMP Securities reiterated coverage of Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Market Outperform recommendation. Average portfolio weight of all funds dedicated to DCPH is 0.13%, a decrease of 8.49%. The put/call ratio of DCPH is 0.48, indicating a bullish outlook.
|
Fintel reports that on June 5, 2023, JMP Securities reiterated coverage of Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Market Outperform recommendation. Average portfolio weight of all funds dedicated to DCPH is 0.13%, a decrease of 8.49%. The put/call ratio of DCPH is 0.48, indicating a bullish outlook.
|
69e72f56-2656-4dd0-b1f9-4059a8d3a44c
|
715421.0
|
2023-05-04 00:00:00 UTC
|
JMP Securities Reiterates Deciphera Pharmaceuticals (DCPH) Market Outperform Recommendation
|
DCPH
|
https://www.nasdaq.com/articles/jmp-securities-reiterates-deciphera-pharmaceuticals-dcph-market-outperform-recommendation
|
nan
|
nan
|
Fintel reports that on May 4, 2023, JMP Securities reiterated coverage of Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Market Outperform recommendation.
Analyst Price Forecast Suggests 58.65% Upside
As of April 24, 2023, the average one-year price target for Deciphera Pharmaceuticals is 22.10. The forecasts range from a low of 9.09 to a high of $31.50. The average price target represents an increase of 58.65% from its latest reported closing price of 13.93.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Deciphera Pharmaceuticals is 157MM, an increase of 13.44%. The projected annual non-GAAP EPS is -2.26.
What is the Fund Sentiment?
There are 349 funds or institutions reporting positions in Deciphera Pharmaceuticals. This is a decrease of 8 owner(s) or 2.24% in the last quarter. Average portfolio weight of all funds dedicated to DCPH is 0.08%, a decrease of 34.86%. Total shares owned by institutions increased in the last three months by 6.88% to 55,186K shares.
The put/call ratio of DCPH is 0.48, indicating a bullish outlook.
What are Other Shareholders Doing?
Armistice Capital holds 5,172K shares representing 6.59% ownership of the company. In it's prior filing, the firm reported owning 4,768K shares, representing an increase of 7.81%. The firm decreased its portfolio allocation in DCPH by 3.35% over the last quarter.
Redmile Group holds 3,593K shares representing 4.58% ownership of the company. In it's prior filing, the firm reported owning 2,973K shares, representing an increase of 17.26%. The firm increased its portfolio allocation in DCPH by 12.92% over the last quarter.
Braidwell holds 3,272K shares representing 4.17% ownership of the company.
XBI - SPDR(R) S&P(R) Biotech ETF holds 2,440K shares representing 3.11% ownership of the company. In it's prior filing, the firm reported owning 2,206K shares, representing an increase of 9.58%. The firm decreased its portfolio allocation in DCPH by 16.61% over the last quarter.
Deerfield Management Company, L.p. holds 2,349K shares representing 2.99% ownership of the company. In it's prior filing, the firm reported owning 2,491K shares, representing a decrease of 6.06%. The firm decreased its portfolio allocation in DCPH by 13.13% over the last quarter.
Deciphera Pharmaceuticals Background Information
(This description is provided by the company.)
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.
See all Deciphera Pharmaceuticals regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Fintel reports that on May 4, 2023, JMP Securities reiterated coverage of Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Market Outperform recommendation. Average portfolio weight of all funds dedicated to DCPH is 0.08%, a decrease of 34.86%. The put/call ratio of DCPH is 0.48, indicating a bullish outlook.
|
Fintel reports that on May 4, 2023, JMP Securities reiterated coverage of Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Market Outperform recommendation. Average portfolio weight of all funds dedicated to DCPH is 0.08%, a decrease of 34.86%. The put/call ratio of DCPH is 0.48, indicating a bullish outlook.
|
Fintel reports that on May 4, 2023, JMP Securities reiterated coverage of Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Market Outperform recommendation. Average portfolio weight of all funds dedicated to DCPH is 0.08%, a decrease of 34.86%. The put/call ratio of DCPH is 0.48, indicating a bullish outlook.
|
Fintel reports that on May 4, 2023, JMP Securities reiterated coverage of Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Market Outperform recommendation. Average portfolio weight of all funds dedicated to DCPH is 0.08%, a decrease of 34.86%. The put/call ratio of DCPH is 0.48, indicating a bullish outlook.
|
bb61fc8c-5c50-4750-8481-003dedda0fc6
|
715422.0
|
2023-05-04 00:00:00 UTC
|
Deciphera (DCPH) Q1 Earnings Match Estimates, Sales Miss
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-dcph-q1-earnings-match-estimates-sales-miss
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. DCPH reported a first-quarter 2023 loss of 60 cents per share, which was in line with the Zacks Consensus Estimate. In the year-ago quarter, DCPH had reported a loss of 80 cents per share.
Total net revenues were $33.4 million in the quarter, missing the Zacks Consensus Estimate of $35 million. Revenues rose 15% year over year.
Shares of Deciphera have rallied 31% in the year so far against the industry’s decline of 6.2%.
Image Source: Zacks Investment Research
Deciphera’s sole marketed drug is Qinlock (ripretinib), which was approved by the FDA in 2020 to treat adult patients with advanced gastrointestinal stromal tumors (GIST). These patients received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib). Qinlock was approved in Europe in late 2021. Apart from Qinlock, there is no marketed drug in Deciphera’s portfolio.
Quarter in Detail
Total revenues comprised net product revenues and collaboration revenues. Net product revenues from Qinlock sales were $33.2 million, up 15.3% year over year. Qinlock generated $24.6 million in sales in the United States and $8.6 million in sales in the ex-U.S. markets.
Collaboration revenues in the reported quarter were $0.2 million compared with $0.4 million recorded in the year-ago quarter.
Research and development expenses were $54.8 million, up 15.5% year over year owing to costs related to clinical studies on vimseltinib and Qinlock.
Selling, general and administrative expenses were $31.4 million, up 11% year over year owing to increased professional and consultant feespartially offset by a decrease in personnel-related costs.
Deciphera had cash, cash equivalents and investments worth $426.3 million as of Mar 31, 2023, compared with $339.0 million as of Dec 31, 2022. Deciphera expects its current cash balance together with the anticipated product, royalty and supply revenues, excluding any potential future milestone payments under its collaboration or license agreements, to fund its operating and capital expenditures into 2026.
Other Updates
Deciphera is also working to expand the label of Qinlock for the larger commercial opportunity in GIST.
In March 2023, Deciphera announced that the FDA has granted Breakthrough Therapy Designationfor its drug Qinlock for treating second-line GIST patients with mutations in KIT Exon 11 and 17/18. The breakthrough therapy designation is based on data from the ctDNA analysis of the INTRIGUE phase III study which demonstrated Qinlock’s clinical benefit for the above-mentioned patient population. Management claims that Qinlock could become the standard of care for second-line GIST patients globally subject to its approval.
Based on the results from the ctDNA analysis of phase III INTRIGUE study data, the company is also planning to initiate the pivotal phase III INSIGHT study to evaluate Qinlock versus sunitinib for the treatment of second-line GIST patients with mutations in KIT exon 11 and 17/18, later in 2023.
In the same press release, the company also announced that Qinlock has been included in the latest National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a preferred treatment therapy for second-line GIST patients intolerant to sunitinib.
Deciphera is evaluating another candidate, vimseltinib in the phase III MOTION study to treat patients with tenosynovial giant-cell tumors, who are not amenable to surgery. Enrollment in the study stands completed, expecting to report results from the study in the fourth quarter of 2023.
This apart, DCPH, in collaboration with Pfizer, Inc. PFE expects to initiate new combination escalation studies evaluating DCC-3116 in combination withripretinib in patients with GIST and incombination with encorafenib and cetuximab in patients with colorectal cancer, in the second half of 2023. Per the terms of the agreement with Pfizer, Deciphera will bear the cost of the study while Pfizer will supply encorafenib free of cost.
Additionally, Deciphera also expects to initiate one or more expansion cohorts in the ongoing phase I/II study of DCC-3116 in the second half of 2023, in combination with either trametinib, binimetinib, or sotorasib. The study is currently evaluating the safety and tolerability of DCC-3116 as a single agent and in combination with trametinib to treat patients with advanced or metastatic tumors with a RAS or RAF mutation. Trametinib is an FDA-approved MEK inhibitor.
Deciphera Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Deciphera Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Deciphera Pharmaceuticals, Inc. Quote
Zacks Rank and Stocks to Consider
Deciphera currently has a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Aptinyx APTX and ADMA Biologics ADMA, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate for Aptinyx’s 2023 loss per share has narrowed from 77 cents to 47 cents. In the past year, shares of Aptinyx have fallen by 86.9%.
APTX beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 6.56%.
In the past 90 days, the consensus estimate for ADMA Biologics’ 2023 loss per share has narrowed from 19 cents to 14 cents. In the past year, shares of ADMA Biologics have increased by 85.1%.
ADMA beat estimates in three out of the trailing four quarters, missing the mark on one occasion, delivering an average earnings surprise of 2.88%.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
Aptinyx Inc. (APTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. DCPH reported a first-quarter 2023 loss of 60 cents per share, which was in line with the Zacks Consensus Estimate. In the year-ago quarter, DCPH had reported a loss of 80 cents per share. This apart, DCPH, in collaboration with Pfizer, Inc. PFE expects to initiate new combination escalation studies evaluating DCC-3116 in combination withripretinib in patients with GIST and incombination with encorafenib and cetuximab in patients with colorectal cancer, in the second half of 2023.
|
Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. DCPH reported a first-quarter 2023 loss of 60 cents per share, which was in line with the Zacks Consensus Estimate. In the year-ago quarter, DCPH had reported a loss of 80 cents per share.
|
Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. DCPH reported a first-quarter 2023 loss of 60 cents per share, which was in line with the Zacks Consensus Estimate. In the year-ago quarter, DCPH had reported a loss of 80 cents per share.
|
Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. DCPH reported a first-quarter 2023 loss of 60 cents per share, which was in line with the Zacks Consensus Estimate. In the year-ago quarter, DCPH had reported a loss of 80 cents per share.
|
96317600-5ec9-43f5-8882-9ec82f6cef93
|
715423.0
|
2023-05-03 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Lags Revenue Estimates
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-reports-q1-loss-lags-revenue-estimates
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.80 per share a year ago. These figures are adjusted for non-recurring items.
A quarter ago, it was expected that this company would post a loss of $0.57 per share when it actually produced a loss of $0.60, delivering a surprise of -5.26%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $33.45 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 5.10%. This compares to year-ago revenues of $29.22 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Deciphera Pharmaceuticals, Inc. Shares have lost about 12.8% since the beginning of the year versus the S&P 500's gain of 7.3%.
What's Next for Deciphera Pharmaceuticals, Inc.
While Deciphera Pharmaceuticals, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Deciphera Pharmaceuticals, Inc. Unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.59 on $36.74 million in revenues for the coming quarter and -$2.42 on $150.21 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Curis (CRIS), has yet to report results for the quarter ended March 2023. The results are expected to be released on May 4.
This drug developer is expected to post quarterly loss of $0.11 per share in its upcoming report, which represents a year-over-year change of +38.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Curis' revenues are expected to be $2.49 million, up 20.6% from the year-ago quarter.
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%.
Download the brand-new FREE report revealing 5 EV battery stocks set to soar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
Curis, Inc. (CRIS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share in line with the Zacks Consensus Estimate. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Curis, Inc. (CRIS) : Free Stock Analysis Report To read this article on Zacks.com click here. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock.
|
Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Curis, Inc. (CRIS) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share in line with the Zacks Consensus Estimate. Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $33.45 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 5.10%.
|
Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Curis, Inc. (CRIS) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share in line with the Zacks Consensus Estimate. Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $33.45 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 5.10%.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share in line with the Zacks Consensus Estimate. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Curis, Inc. (CRIS) : Free Stock Analysis Report To read this article on Zacks.com click here. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
|
f97e95ad-d798-45ba-b65a-cb81c52185f8
|
715424.0
|
2023-04-27 00:00:00 UTC
|
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
|
DCPH
|
https://www.nasdaq.com/articles/ultragenyx-rare-may-report-negative-earnings%3A-know-the-trend-ahead-of-q1-release
|
nan
|
nan
|
The market expects Ultragenyx (RARE) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This biotechnology company is expected to post quarterly loss of $1.97 per share in its upcoming report, which represents a year-over-year change of +10.1%.
Revenues are expected to be $104.75 million, up 31% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 4.28% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Ultragenyx?
For Ultragenyx, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.69%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Ultragenyx will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Ultragenyx would post a loss of $2.03 per share when it actually produced a loss of $2.16, delivering a surprise of -6.40%.
The company has not been able to beat consensus EPS estimates in any of the last four quarters.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Ultragenyx doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected Results
Deciphera Pharmaceuticals, Inc. (DCPH), another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $0.60 for the quarter ended March 2023. This estimate points to a year-over-year change of +25%. Revenues for the quarter are expected to be $35.38 million, up 21.1% from the year-ago quarter.
The consensus EPS estimate for Deciphera Pharmaceuticals, Inc. has been revised 1.2% lower over the last 30 days to the current level. However, a higher Most Accurate Estimate has resulted in an Earnings ESP of 2.50%.
When combined with a Zacks Rank of #4 (Sell), this Earnings ESP makes it difficult to conclusively predict that Deciphera Pharmaceuticals, Inc. will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ultragenyx Pharmaceutical Inc. (RARE) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
An Industry Player's Expected Results Deciphera Pharmaceuticals, Inc. (DCPH), another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $0.60 for the quarter ended March 2023. Click to get this free report Ultragenyx Pharmaceutical Inc. (RARE) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
|
Click to get this free report Ultragenyx Pharmaceutical Inc. (RARE) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. An Industry Player's Expected Results Deciphera Pharmaceuticals, Inc. (DCPH), another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $0.60 for the quarter ended March 2023. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate.
|
An Industry Player's Expected Results Deciphera Pharmaceuticals, Inc. (DCPH), another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $0.60 for the quarter ended March 2023. Click to get this free report Ultragenyx Pharmaceutical Inc. (RARE) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate.
|
An Industry Player's Expected Results Deciphera Pharmaceuticals, Inc. (DCPH), another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $0.60 for the quarter ended March 2023. Click to get this free report Ultragenyx Pharmaceutical Inc. (RARE) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. The stock might move higher if these key numbers top expectations in the upcoming earnings report.
|
dc00996e-f2d7-430d-a6f0-0cdcb3a5f540
|
715425.0
|
2023-04-26 00:00:00 UTC
|
Will Deciphera Pharmaceuticals, Inc. (DCPH) Report Negative Q1 Earnings? What You Should Know
|
DCPH
|
https://www.nasdaq.com/articles/will-deciphera-pharmaceuticals-inc.-dcph-report-negative-q1-earnings-what-you-should-know
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This company is expected to post quarterly loss of $0.59 per share in its upcoming report, which represents a year-over-year change of +26.3%.
Revenues are expected to be $35.46 million, up 21.4% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0.62% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Deciphera Pharmaceuticals, Inc.
For Deciphera Pharmaceuticals, Inc.The Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -2.95%.
On the other hand, the stock currently carries a Zacks Rank of #4.
So, this combination makes it difficult to conclusively predict that Deciphera Pharmaceuticals, Inc. Will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Deciphera Pharmaceuticals, Inc. Would post a loss of $0.57 per share when it actually produced a loss of $0.60, delivering a surprise of -5.26%.
Over the last four quarters, the company has beaten consensus EPS estimates three times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Deciphera Pharmaceuticals, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2023. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2023. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2023. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2023. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. The earnings report might help the stock move higher if these key numbers are better than expectations.
|
5eaddefe-fe48-436e-832c-2a56859aaa7d
|
715426.0
|
2023-03-23 00:00:00 UTC
|
Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 7% Since Last Earnings Report?
|
DCPH
|
https://www.nasdaq.com/articles/why-is-apellis-pharmaceuticals-inc.-apls-down-7-since-last-earnings-report
|
nan
|
nan
|
It has been about a month since the last earnings report for Apellis Pharmaceuticals, Inc. (APLS). Shares have lost about 7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Apellis Pharmaceuticals, Inc. due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Apellis' Q4 Earnings Top, Empaveli Sales Boost Revenues
Apellis Pharmaceuticals reported a loss per share of $1.50 for fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $1.65. The loss was also narrower than our estimates of a loss of $1.82 per share. The company had reported a loss of $1.61 per share in the year-ago quarter.
Total revenues were $22.7 million, surpassing the Zacks Consensus Estimate of $21 million. Total revenues were also higher than our model estimates of $21.2 million in the reported quarter. In the year-ago quarter, the company reported revenues of $60.3 million. The drastic difference is due to the $51.1 million milestone and additional licensing revenues received from the Swedish Orphan Biovitrum (Sobi) collaboration in the year-ago quarter.
Revenues in the reported quarter included product sales of the marketed drug Empaveli (pegcetacoplan), which stood at $19.7 million, and licensing and other revenues of $3 million under the Sobi collaboration.
Quarter in Detail
Research and development expenses were $99.4 million in the fourth quarter of 2022, down 8.13% from $108.2 million in the year-ago quarter.
General and administrative expenses were $84.4 million in the fourth quarter of 2022, up 103.4% from $41.5 million in the year-ago quarter. This increase was driven by higher employee-related costs and an increase in professional and consulting fees.
As of Dec 31, 2022, Apellis had cash, cash equivalents and marketable securities worth $551.8 million compared with $708.6 million as of Sep 30, 2022.
Full-Year 2022 Results
The company recorded a loss per share of $6.15 for full-year 2022, narrower than the previous year’s loss per share of $8.84.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month.
VGM Scores
Currently, Apellis Pharmaceuticals, Inc. has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Apellis Pharmaceuticals, Inc. has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Apellis Pharmaceuticals, Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 1.4% over the past month. More than a month has passed since the company reported results for the quarter ended December 2022.
Deciphera Pharmaceuticals, Inc. reported revenues of $36.35 million in the last reported quarter, representing a year-over-year change of +50.2%. EPS of -$0.60 for the same period compares with -$1.51 a year ago.
Deciphera Pharmaceuticals, Inc. is expected to post a loss of $0.59 per share for the current quarter, representing a year-over-year change of +26.3%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.2%.
Deciphera Pharmaceuticals, Inc. has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.
Is THIS the Ultimate New Clean Energy Source? (4 Ways to Profit)
The world is increasingly focused on eliminating fossil fuels and ramping up use of renewable, clean energy sources. Hydrogen fuel cells, powered by the most abundant substance in the universe, could provide an unlimited amount of ultra-clean energy for multiple industries.
Our urgent special report reveals 4 hydrogen stocks primed for big gains - plus our other top clean energy stocks.
See Stocks Now
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Apellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 1.4% over the past month. Click to get this free report Apellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
|
Click to get this free report Apellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 1.4% over the past month. Apellis' Q4 Earnings Top, Empaveli Sales Boost Revenues Apellis Pharmaceuticals reported a loss per share of $1.50 for fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $1.65.
|
Click to get this free report Apellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 1.4% over the past month. Apellis' Q4 Earnings Top, Empaveli Sales Boost Revenues Apellis Pharmaceuticals reported a loss per share of $1.50 for fourth-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $1.65.
|
Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 1.4% over the past month. Click to get this free report Apellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. It has been about a month since the last earnings report for Apellis Pharmaceuticals, Inc. (APLS).
|
7c67b8e3-b55b-4dcd-87bf-b8038e9d1b94
|
715427.0
|
2023-03-19 00:00:00 UTC
|
Validea's Top Ten Healthcare Stocks Based On Motley Fool - 3/19/2023
|
DCPH
|
https://www.nasdaq.com/articles/valideas-top-ten-healthcare-stocks-based-on-motley-fool-3-19-2023
|
nan
|
nan
|
The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.
LEMAITRE VASCULAR INC (LMAT) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 73% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: LeMaitre Vascular, Inc. is a provider of medical devices and human tissue cryopreservation services, which are used in the treatment of peripheral vascular disease, end-stage renal disease and to a lesser extent cardiovascular disease. The Company develops, manufactures and markets vascular devices to address the needs of vascular surgeons, and to a lesser degree, other specialties, such as cardiac surgeons, general surgeons and neurosurgeons. It sold its principal product in the United States, Europe, the United Kingdom, Canada and Asia Pacific. The Company sales its products and services primarily through a direct sales force. Its products and services offering includes Allografts, Angioscopes, Balloon Catheters for Embolectomy and Thrombectomy, Balloon Catheters for Occlusion and Perfusion, Bovine Grafts, Vascular and Cardiac Patches, Carotid Shunts, Closure Systems, Ovine Vascular Grafts, Polyester Vascular Grafts, ePTFE Vascular Grafts, Radiopaque Tape, and Valvulotomes.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PROFIT MARGIN: PASS
RELATIVE STRENGTH: FAIL
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL
INSIDER HOLDINGS: PASS
CASH FLOW FROM OPERATIONS: PASS
PROFIT MARGIN CONSISTENCY: FAIL
R&D AS A PERCENTAGE OF SALES: NEUTRAL
CASH AND CASH EQUIVALENTS: PASS
INVENTORY TO SALES: PASS
ACCOUNTS RECEIVABLE TO SALES: PASS
LONG TERM DEBT/EQUITY RATIO: PASS
"THE FOOL RATIO" (P/E TO GROWTH): FAIL
AVERAGE SHARES OUTSTANDING: PASS
SALES: PASS
DAILY DOLLAR VOLUME: PASS
PRICE: PASS
INCOME TAX PERCENTAGE: PASS
Detailed Analysis of LEMAITRE VASCULAR INC
LMAT Guru Analysis
LMAT Fundamental Analysis
CATALYST PHARMACEUTICALS INC (CPRX) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 65% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With the patient focus, the Company is engaged in developing a robust pipeline of cutting-edge, medicines for rare diseases. The Company's New Drug Application for FIRDAPSE (amifampridine) tablets 10 milligrams (mg) for the treatment of adults with Lambert-Eaton myasthenic syndrome (LEMS). The Company's FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. The FIRDAPSE is also used for the treatment of adult patients in Canada with LEMS. The Company is also focused on initiating clinical trials of amifampridine in other ultra-rare neuromuscular conditions.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PROFIT MARGIN: PASS
RELATIVE STRENGTH: PASS
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS
INSIDER HOLDINGS: FAIL
CASH FLOW FROM OPERATIONS: PASS
PROFIT MARGIN CONSISTENCY: FAIL
R&D AS A PERCENTAGE OF SALES: FAIL
CASH AND CASH EQUIVALENTS: PASS
INVENTORY TO SALES: PASS
ACCOUNTS RECEIVABLE TO SALES: PASS
LONG TERM DEBT/EQUITY RATIO: PASS
"THE FOOL RATIO" (P/E TO GROWTH): FAIL
AVERAGE SHARES OUTSTANDING: PASS
SALES: PASS
DAILY DOLLAR VOLUME: FAIL
PRICE: PASS
INCOME TAX PERCENTAGE: FAIL
Detailed Analysis of CATALYST PHARMACEUTICALS INC
CPRX Guru Analysis
CPRX Fundamental Analysis
AMRYT PHARMA PLC - ADR (AMYT) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 63% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Amryt Pharma plc is a commercial-stage biopharmaceutical company. It is focused on acquiring, developing, and commercializing novel treatments for rare diseases. Its commercial business comprises three orphan disease products, such as metreleptin (Myalept/ Myalepta); lomitapide (Juxtapid/ Lojuxta), and oral octreotide (Mycapssa). Myalept is approved in the United States as an adjunct to diet as replacement therapy to treat leptin deficiency in patients with congenital or acquired generalised lipodystrophy (GL). Juxtapid is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, homozygous familial hypercholesterolaemia (HoFH). Mycapssa is a combination of octreotide acetate and excipients, collectively called Transient Permeability Enhancer (TPE). Its development candidate, Oleogel-S10 (Filsuvez) is a treatment for the cutaneous manifestations of junctional and dystrophic (JEB and DEB) epidermolysis bullosa.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PROFIT MARGIN: FAIL
RELATIVE STRENGTH: PASS
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL
INSIDER HOLDINGS: FAIL
CASH FLOW FROM OPERATIONS: PASS
PROFIT MARGIN CONSISTENCY: PASS
R&D AS A PERCENTAGE OF SALES: PASS
CASH AND CASH EQUIVALENTS: PASS
INVENTORY TO SALES: PASS
ACCOUNTS RECEIVABLE TO SALES: PASS
LONG TERM DEBT/EQUITY RATIO: FAIL
"THE FOOL RATIO" (P/E TO GROWTH): FAIL
AVERAGE SHARES OUTSTANDING: PASS
SALES: PASS
DAILY DOLLAR VOLUME: PASS
PRICE: PASS
INCOME TAX PERCENTAGE: FAIL
Detailed Analysis of AMRYT PHARMA PLC - ADR
AMYT Guru Analysis
AMYT Fundamental Analysis
ALPHATEC HOLDINGS INC (ATEC) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 63% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Alphatec Holdings, Inc. is a medical technology company. The Company is focused on the design, development, and advancement of technology for surgical treatment of spinal disorders. The Company, through its wholly owned subsidiaries, Alphatec Spine, Inc., SafeOp Surgical, Inc. and EOS imaging S.A. is focused on developing approaches that integrate with its Alpha InformatiX product platform. It has a range of product portfolios designed to address the spine's various pathologies. Its product portfolio includes Alpha InformatiX, which include SafeOp Neural InformatiX System; Access Systems, which include Sigma-TLIF Pedicle-based Access System, PTP Patient Positioning System, and Squadron Lateral Retractor; Fixation Systems, which include InVictus Spinal Fixation Systems (Open and MIS), InVictus MIS SingleStep System, and InVictus Modular Fixation Systems (Open and MIS) and Interbody Systems, which include IdentiTi Porous Ti Interbody Implants and Transcend Lateral Interbody Implants.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PROFIT MARGIN: FAIL
RELATIVE STRENGTH: PASS
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL
INSIDER HOLDINGS: PASS
CASH FLOW FROM OPERATIONS: FAIL
PROFIT MARGIN CONSISTENCY: FAIL
R&D AS A PERCENTAGE OF SALES: NEUTRAL
CASH AND CASH EQUIVALENTS: PASS
INVENTORY TO SALES: PASS
ACCOUNTS RECEIVABLE TO SALES: PASS
LONG TERM DEBT/EQUITY RATIO: PASS
"THE FOOL RATIO" (P/E TO GROWTH): FAIL
AVERAGE SHARES OUTSTANDING: FAIL
SALES: PASS
DAILY DOLLAR VOLUME: PASS
PRICE: PASS
INCOME TAX PERCENTAGE: FAIL
Detailed Analysis of ALPHATEC HOLDINGS INC
ATEC Guru Analysis
ATEC Fundamental Analysis
CELLDEX THERAPEUTICS, INC. (CLDX) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 63% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Company is using the technologies to develop targeted immunotherapeutics consisting of protein-based molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. It operates in development, manufacturing of therapeutics. Company's CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity. Its CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, being studied in a Phase II study. The Company's CDX-527, a bispecific antibody that uses active anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, for which it initiated a Phase II study in advanced solid tumors.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PROFIT MARGIN: FAIL
RELATIVE STRENGTH: PASS
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS
INSIDER HOLDINGS: FAIL
CASH FLOW FROM OPERATIONS: FAIL
PROFIT MARGIN CONSISTENCY: FAIL
R&D AS A PERCENTAGE OF SALES: PASS
CASH AND CASH EQUIVALENTS: PASS
ACCOUNTS RECEIVABLE TO SALES: PASS
LONG TERM DEBT/EQUITY RATIO: PASS
"THE FOOL RATIO" (P/E TO GROWTH): FAIL
AVERAGE SHARES OUTSTANDING: PASS
SALES: PASS
DAILY DOLLAR VOLUME: PASS
PRICE: PASS
INCOME TAX PERCENTAGE: FAIL
Detailed Analysis of CELLDEX THERAPEUTICS, INC.
CLDX Guru Analysis
CLDX Fundamental Analysis
DECIPHERA PHARMACEUTICALS INC (DCPH) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 63% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer. The Company has developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a broad portfolio of medicines. The Company has one approved drug, QINLOCK, which is a switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition, the Company is developing three clinical-stage drug candidates, which includes Vimseltinib (DCC-3014) - colony stimulating factor 1 receptor (CSF1R) Kinase Inhibition for Tenosynovial Giant Cell Tumor (TGCT), Rebastinib - TEK tyrosine kinase (TIE2) Kinase Inhibition for advanced or Metastatic Solid Tumors, and DCC-3116 - ULK Kinase Inhibition for Mutant RAS/RAF Cancers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PROFIT MARGIN: FAIL
RELATIVE STRENGTH: PASS
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL
INSIDER HOLDINGS: PASS
CASH FLOW FROM OPERATIONS: FAIL
PROFIT MARGIN CONSISTENCY: PASS
R&D AS A PERCENTAGE OF SALES: FAIL
CASH AND CASH EQUIVALENTS: PASS
INVENTORY TO SALES: PASS
ACCOUNTS RECEIVABLE TO SALES: PASS
LONG TERM DEBT/EQUITY RATIO: PASS
"THE FOOL RATIO" (P/E TO GROWTH): FAIL
AVERAGE SHARES OUTSTANDING: PASS
SALES: PASS
DAILY DOLLAR VOLUME: PASS
PRICE: PASS
INCOME TAX PERCENTAGE: FAIL
Detailed Analysis of DECIPHERA PHARMACEUTICALS INC
DCPH Guru Analysis
DCPH Fundamental Analysis
ESTABLISHMENT LABS HOLDINGS INC (ESTA) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 63% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PROFIT MARGIN: FAIL
RELATIVE STRENGTH: FAIL
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL
INSIDER HOLDINGS: PASS
CASH FLOW FROM OPERATIONS: FAIL
PROFIT MARGIN CONSISTENCY: PASS
R&D AS A PERCENTAGE OF SALES: NEUTRAL
CASH AND CASH EQUIVALENTS: PASS
INVENTORY TO SALES: PASS
ACCOUNTS RECEIVABLE TO SALES: PASS
LONG TERM DEBT/EQUITY RATIO: PASS
"THE FOOL RATIO" (P/E TO GROWTH): FAIL
AVERAGE SHARES OUTSTANDING: PASS
SALES: PASS
DAILY DOLLAR VOLUME: PASS
PRICE: PASS
INCOME TAX PERCENTAGE: FAIL
Detailed Analysis of ESTABLISHMENT LABS HOLDINGS INC
ESTA Guru Analysis
ESTA Fundamental Analysis
CHINOOK THERAPEUTICS INC (KDNY) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 63% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing medicines for kidney diseases. Its lead product candidate is atrasentan, which is a selective endothelin A receptor antagonist that is developed for the treatment of proteinuric glomerular diseases. The Company's second product candidate, BION-1301, is an investigational humanized IgG4 monoclonal antibody that blocks APRIL, a soluble factor that is implicated in IgAN and other indications, from binding to its receptors. Its third clinical development candidate is CHK-336, a liver-targeted oral small molecule lactate dehydrogenase (LDHA), inhibitor, which is developed for the treatment of primary hyperoxaluria (PH), as well as secondary hyperoxaluria and idiopathic kidney stone formation. It is conducting a Phase I/II clinical trial of BION-1301.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PROFIT MARGIN: FAIL
RELATIVE STRENGTH: PASS
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL
INSIDER HOLDINGS: FAIL
CASH FLOW FROM OPERATIONS: FAIL
PROFIT MARGIN CONSISTENCY: PASS
R&D AS A PERCENTAGE OF SALES: PASS
CASH AND CASH EQUIVALENTS: PASS
ACCOUNTS RECEIVABLE TO SALES: PASS
LONG TERM DEBT/EQUITY RATIO: PASS
"THE FOOL RATIO" (P/E TO GROWTH): FAIL
AVERAGE SHARES OUTSTANDING: PASS
SALES: PASS
DAILY DOLLAR VOLUME: PASS
PRICE: PASS
INCOME TAX PERCENTAGE: FAIL
Detailed Analysis of CHINOOK THERAPEUTICS INC
KDNY Guru Analysis
KDNY Fundamental Analysis
PROTHENA CORPORATION PLC (PRTA) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 63% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Prothena Corporation Public Limited Company is a late-stage clinical company engaged in the protein dysregulation and a pipeline of investigational therapies for rare peripheral amyloid and neurodegenerative diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company is also advancing several discovery and preclinical-stage programs for neurological diseases with unmet medical needs such as AD and amyotrophic lateral sclerosis (ALS). The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis. The Company's pipeline includes AL Amyloidosis & Birtamimab, Parkinson's Disease & Prasinezumab, Transthyretin amyloidosis (ATTR) & PRX004, Alzheimer's Disease and Pioneering Neuroscience.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PROFIT MARGIN: FAIL
RELATIVE STRENGTH: PASS
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL
INSIDER HOLDINGS: FAIL
CASH FLOW FROM OPERATIONS: FAIL
PROFIT MARGIN CONSISTENCY: PASS
R&D AS A PERCENTAGE OF SALES: PASS
CASH AND CASH EQUIVALENTS: PASS
ACCOUNTS RECEIVABLE TO SALES: PASS
LONG TERM DEBT/EQUITY RATIO: PASS
"THE FOOL RATIO" (P/E TO GROWTH): FAIL
AVERAGE SHARES OUTSTANDING: PASS
SALES: PASS
DAILY DOLLAR VOLUME: PASS
PRICE: PASS
INCOME TAX PERCENTAGE: FAIL
Detailed Analysis of PROTHENA CORPORATION PLC
PRTA Guru Analysis
PRTA Fundamental Analysis
VIRIDIAN THERAPEUTICS INC (VRDN) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 63% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Viridian Therapeutics, Inc. is a biotechnology company that is focused on advancing treatments for patients suffering from serious diseases. The Company is engaged in developing two product candidates, VRDN-001 and VRDN-002, to treat patients who suffer from thyroid eye disease (TED). TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye, which can cause double vision, pain, and potential blindness. Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. It has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PROFIT MARGIN: FAIL
RELATIVE STRENGTH: PASS
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL
INSIDER HOLDINGS: FAIL
CASH FLOW FROM OPERATIONS: FAIL
PROFIT MARGIN CONSISTENCY: PASS
R&D AS A PERCENTAGE OF SALES: PASS
CASH AND CASH EQUIVALENTS: PASS
ACCOUNTS RECEIVABLE TO SALES: PASS
LONG TERM DEBT/EQUITY RATIO: PASS
"THE FOOL RATIO" (P/E TO GROWTH): FAIL
AVERAGE SHARES OUTSTANDING: PASS
SALES: PASS
DAILY DOLLAR VOLUME: PASS
PRICE: PASS
INCOME TAX PERCENTAGE: FAIL
Detailed Analysis of VIRIDIAN THERAPEUTICS INC
VRDN Guru Analysis
VRDN Fundamental Analysis
Motley Fool Portfolio
About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' "Fool" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Detailed Analysis of CELLDEX THERAPEUTICS, INC. CLDX Guru Analysis CLDX Fundamental Analysis DECIPHERA PHARMACEUTICALS INC (DCPH) is a small-cap growth stock in the Biotechnology & Drugs industry. Detailed Analysis of DECIPHERA PHARMACEUTICALS INC DCPH Guru Analysis DCPH Fundamental Analysis ESTABLISHMENT LABS HOLDINGS INC (ESTA) is a small-cap growth stock in the Medical Equipment & Supplies industry. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.
|
Detailed Analysis of CELLDEX THERAPEUTICS, INC. CLDX Guru Analysis CLDX Fundamental Analysis DECIPHERA PHARMACEUTICALS INC (DCPH) is a small-cap growth stock in the Biotechnology & Drugs industry. Detailed Analysis of DECIPHERA PHARMACEUTICALS INC DCPH Guru Analysis DCPH Fundamental Analysis ESTABLISHMENT LABS HOLDINGS INC (ESTA) is a small-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of CATALYST PHARMACEUTICALS INC CPRX Guru Analysis CPRX Fundamental Analysis AMRYT PHARMA PLC - ADR (AMYT) is a small-cap growth stock in the Biotechnology & Drugs industry.
|
Detailed Analysis of CELLDEX THERAPEUTICS, INC. CLDX Guru Analysis CLDX Fundamental Analysis DECIPHERA PHARMACEUTICALS INC (DCPH) is a small-cap growth stock in the Biotechnology & Drugs industry. Detailed Analysis of DECIPHERA PHARMACEUTICALS INC DCPH Guru Analysis DCPH Fundamental Analysis ESTABLISHMENT LABS HOLDINGS INC (ESTA) is a small-cap growth stock in the Medical Equipment & Supplies industry. Company Description: Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer.
|
Detailed Analysis of CELLDEX THERAPEUTICS, INC. CLDX Guru Analysis CLDX Fundamental Analysis DECIPHERA PHARMACEUTICALS INC (DCPH) is a small-cap growth stock in the Biotechnology & Drugs industry. Detailed Analysis of DECIPHERA PHARMACEUTICALS INC DCPH Guru Analysis DCPH Fundamental Analysis ESTABLISHMENT LABS HOLDINGS INC (ESTA) is a small-cap growth stock in the Medical Equipment & Supplies industry. Company Description: Viridian Therapeutics, Inc. is a biotechnology company that is focused on advancing treatments for patients suffering from serious diseases.
|
20cb1d7b-a4a0-4f1a-ba0e-d85b9e78201a
|
715428.0
|
2023-03-15 00:00:00 UTC
|
Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded Use
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-dcph-gets-breakthrough-tag-for-qinlock-expanded-use
|
nan
|
nan
|
Deciphera Pharmaceuticals DCPH announced that the FDA has granted Breakthrough Therapy Designation for its drug Qinlock for treating second-line gastrointestinal stromal tumor (GIST) patients with mutations in KIT Exon 11 and 17/18. Qinlock was first approved on May 15, 2020 for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib). Qinlock is approved in 12 countries across the world, including the major markets of the United States, Europe, the United Kingdom and China, for treating fourth-line GIST.
Deciphera’s stock was up 4.7% on Tuesday in response to the positive news. In the past year, the shares of the company have gained 103.3% against the industry’s decline of 13.2%.
Image Source: Zacks Investment Research
The breakthrough therapy designation by the FDA shows Qinlock’s substantial potential to treat second-line GIST patients with mutations in KIT exon 11 and 17/18. The breakthrough therapy designation is based on data from the ctDNA analysis of the INTRIGUE phase III study, which demonstrated Qinlock’s clinical benefit for the abovementioned patient population. Management claims that Qinlock could become the standard of care for second-line GIST patients globally subject to its approval.
Based on the results from the ctDNA analysis of phase III INTRIGUE study data, the company is also planning to initiate the pivotal phase III INSIGHT study to evaluate Qinlock versus sunitinib for the treatment of second-line GIST patients with mutations in KIT exon 11 and 17/18, later in 2023.
In this context, we would like to remind investors that in November 2021, Deciphera announced top-line data from the phase III INTRIGUE study, which failed to meet its primary endpoint of improved progression-free survival (PFS). In the intention-to-treat population comprising 453 patients, Qinlock demonstrated a median PFS of 8.0 months compared with 8.3 months for the patients treated with sunitinib which was not statistically significant.
In the same press release, the company also announced that its sole marketed product Qinlock (ripretinib) has been included in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred treatment therapy for second-line GIST patients intolerant to sunitinib.
The inclusion of Qinlock to NCCN guideline was based on the primary analysis of the phase III INTRIGUE study, anopen-label study to evaluate the efficacy and safety of QINLOCK compared with sunitinib in patients with GIST previously treated with imatinib. Per management, the inclusion of Qinlock, as a preferred treatment therapy for second-line GIST, in the latest NCCN clinical practice guidelines in oncology, contributes to the unmet medical need for additional treatment options for GIST patients in the post-imatinib setting. This inclusion also supports the results from the company’s phase III INTRIGUE study, where Qinlock was established as an active and well-tolerated agent.
It is to be noted that there is substantial competition in the market for the treatment of GIST. Deciphera faces stiff competition from other players in this field, one of them being, Blueprint Medicines BPMC. In January 2020, Blueprint Medicines received FDA approval for Ayvakit as a treatment for unresectable or metastatic GIST, harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations in adults. In September 2020, the European Commission granted conditional marketing authorization to Ayvakyt as a monotherapy for the treatment of adults with unresectable or metastatic GIST, harboring the PDGFRA D842V mutation. However, Blueprint received a complete response letter from the FDA for its new drug application which sought approval for Ayvakit to treat adult patients with unresectable or metastatic fourth-line GIST. In April 2020, Blueprint’s phase III VOYAGER study, evaluating the safety and efficacy of Ayvakit compared with Stivarga (regorafenib) in patients with third- and fourth-line GIST, did not meet the primary endpoint. Following this, the company discontinued further development of Ayvakit for GIST beyond PDGFRA exon 18 mutant GIST.
Deciphera Pharmaceuticals, Inc. Price and Consensus
Deciphera Pharmaceuticals, Inc. price-consensus-chart | Deciphera Pharmaceuticals, Inc. Quote
Zacks Rank and Stocks to Consider
Deciphera currently has a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the same industry are Aptinyx APTX and Annovis Bio ANVS, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the estimate for Aptinyx’s 2023 loss per share has narrowed from 77 cents to 56 cents. In the past year, the shares of Aptinyx have fallen by 95.4%.
APTX’s earnings witnessed an average earnings surprise of 9.53%, beating all four estimates in the trailing four reported quarters.
In the past 90 days, the consensus estimate for Annovis’ 2023 loss per share has widened from $2.94 to $3.87. In the past year, the shares of Annovis have increased by 22.7%.
ANVS incurred a narrower-than-expected loss per share in the last reported quarter, delivering an earnings surprise of 20.51%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
Aptinyx Inc. (APTX) : Free Stock Analysis Report
Annovis Bio, Inc. (ANVS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals DCPH announced that the FDA has granted Breakthrough Therapy Designation for its drug Qinlock for treating second-line gastrointestinal stromal tumor (GIST) patients with mutations in KIT Exon 11 and 17/18. Click to get this free report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report Annovis Bio, Inc. (ANVS) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research The breakthrough therapy designation by the FDA shows Qinlock’s substantial potential to treat second-line GIST patients with mutations in KIT exon 11 and 17/18.
|
Click to get this free report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report Annovis Bio, Inc. (ANVS) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals DCPH announced that the FDA has granted Breakthrough Therapy Designation for its drug Qinlock for treating second-line gastrointestinal stromal tumor (GIST) patients with mutations in KIT Exon 11 and 17/18. The inclusion of Qinlock to NCCN guideline was based on the primary analysis of the phase III INTRIGUE study, anopen-label study to evaluate the efficacy and safety of QINLOCK compared with sunitinib in patients with GIST previously treated with imatinib.
|
Click to get this free report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report Annovis Bio, Inc. (ANVS) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals DCPH announced that the FDA has granted Breakthrough Therapy Designation for its drug Qinlock for treating second-line gastrointestinal stromal tumor (GIST) patients with mutations in KIT Exon 11 and 17/18. Based on the results from the ctDNA analysis of phase III INTRIGUE study data, the company is also planning to initiate the pivotal phase III INSIGHT study to evaluate Qinlock versus sunitinib for the treatment of second-line GIST patients with mutations in KIT exon 11 and 17/18, later in 2023.
|
Click to get this free report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report Annovis Bio, Inc. (ANVS) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals DCPH announced that the FDA has granted Breakthrough Therapy Designation for its drug Qinlock for treating second-line gastrointestinal stromal tumor (GIST) patients with mutations in KIT Exon 11 and 17/18. The inclusion of Qinlock to NCCN guideline was based on the primary analysis of the phase III INTRIGUE study, anopen-label study to evaluate the efficacy and safety of QINLOCK compared with sunitinib in patients with GIST previously treated with imatinib.
|
0c846408-ff98-45a6-839e-b5b739cd683d
|
715429.0
|
2023-03-14 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Soars 10.3%: Is Further Upside Left in the Stock?
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-soars-10.3%3A-is-further-upside-left-in-the-stock
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. (DCPH) shares soared 10.3% in the last trading session to close at $16. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.4% loss over the past four weeks.
The soar in the stock price is attributable to the pipeline progress of Deciphera and the positive momentum built around it. Earlier this month, the company reported the completion of enrollment in its phase III MOTION study of vimseltinib in patients with tenosynovial giant cell tumor (TGCT) who are not amenable to surgery. Top-line data from the study is expected in the fourth quarter of 2023. The company also plans to initiate the pivotal phase III INSIGHT study evaluating its sole marketed drug, Qinlock (ripretinib) compared with sunitinib for treating patients with gastrointestinal stromal tumor (GIST) who were previously treated with Novartis’ Gleevec (imatinib) in the second half of 2023.
This company is expected to post quarterly loss of $0.59 per share in its upcoming report, which represents a year-over-year change of +26.3%. Revenues are expected to be $35.46 million, up 21.3% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Deciphera Pharmaceuticals, Inc., the consensus EPS estimate for the quarter has been revised marginally higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on DCPH going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Deciphera Pharmaceuticals, Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, BioNTech SE Sponsored ADR (BNTX), closed the last trading session 1.8% higher at $129.77. Over the past month, BNTX has returned -9.9%.
For BioNTech SE Sponsored ADR, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $8.93. This represents a change of -35.9% from what the company reported a year ago. BioNTech SE Sponsored ADR currently has a Zacks Rank of #4 (Sell).
Free Report: Must-See Hydrogen Stocks
Hydrogen fuel cells are already used to provide efficient, ultra-clean energy to buses, ships and even hospitals. This technology is on the verge of a massive breakthrough, one that could make hydrogen a major source of America's power. It could even totally revolutionize the EV industry.
Zacks has released a special report revealing the 4 stocks experts believe will deliver the biggest gains.
Download Cashing In on Cleaner Energy today, absolutely free.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) shares soared 10.3% in the last trading session to close at $16. So, make sure to keep an eye on DCPH going forward to see if this recent jump can turn into more strength down the road. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. (DCPH) shares soared 10.3% in the last trading session to close at $16. So, make sure to keep an eye on DCPH going forward to see if this recent jump can turn into more strength down the road.
|
Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. (DCPH) shares soared 10.3% in the last trading session to close at $16. So, make sure to keep an eye on DCPH going forward to see if this recent jump can turn into more strength down the road.
|
Deciphera Pharmaceuticals, Inc. (DCPH) shares soared 10.3% in the last trading session to close at $16. So, make sure to keep an eye on DCPH going forward to see if this recent jump can turn into more strength down the road. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
160f9e67-6920-4dde-a68a-257957deb294
|
715430.0
|
2023-03-09 00:00:00 UTC
|
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Down 7.1% Since Last Earnings Report?
|
DCPH
|
https://www.nasdaq.com/articles/why-is-deciphera-pharmaceuticals-inc.-dcph-down-7.1-since-last-earnings-report
|
nan
|
nan
|
A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). Shares have lost about 7.1% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Deciphera Pharmaceuticals, Inc. due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Deciphera's Q4 Earnings Miss, Qinlock Drives Revenues
Deciphera reported a fourth-quarter 2022 loss of 60 cents per share, wider than the Zacks Consensus Estimate of a loss of 57 cents. In the year-ago quarter, DCPH had reported a loss of $1.51.
Total net revenues were $36.35 million in the quarter, surpassing the Zacks Consensus Estimate of $35.52 million. Revenues rose 50.2% year over year.
In May 2020, the FDA approved Deciphera’s sole marketed drug Qinlock (ripretinib) to treat adult patients with advanced GIST, who received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib).
Full-Year Results
For 2022, Deciphera generated total revenues of $134 million compared with $96.1 million recorded in 2021, witnessing year-over-year growth of 39.41%.
For the full-year 2022, the company reported a loss of $2.37 per share compared with a net loss of $5.16 per share in 2021.
Quarter in Detail
Apart from Qinlock, there is no marketable drug in Deciphera’s portfolio. Total revenues comprised net product revenues and collaboration revenues. Net product revenues from Qinlock sales were $32.9 million, up 39% year over year. Qinlock generated $25.6 million in sales in the United States and $7.3 million in sales in the ex-U.S. markets.
Collaboration revenues in the reported quarter were $3.5 million compared with $0.5 million recorded in the year-ago quarter.
Research and development expenses were $48 million, down 35.9% year over year, owing to lower costs related to clinical studies on Qinlock and the discontinuation of the rebastinib program after corporate restructuring implemented in the fourth quarter of 2021.
Selling, general and administrative expenses were $32.2 million, down 13.3% year over year owing to lower professional and consultant fees.
Deciphera had cash, cash equivalents and investments worth $339 million as of Dec 31, 2022, compared with $327.6 million as of Dec 31, 2021. Deciphera expects its current cash balance together with the anticipated product, royalty, supply revenues and the net proceeds from its underwritten public offering completed in January 2023 to fund its operating and capital expenditures into 2026.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month.
VGM Scores
Currently, Deciphera Pharmaceuticals, Inc. has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Deciphera Pharmaceuticals, Inc. has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Just Released: Zacks Top 10 Stocks for 2023
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for 2023?
From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%. Our Director of Research has now combed through 4,000 companies covered by the Zacks Rank and handpicked the best 10 tickers to buy and hold in 2023. Don’t miss your chance to still be among the first to get in on these just-released stocks.
See New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). In the year-ago quarter, DCPH had reported a loss of $1.51. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). In the year-ago quarter, DCPH had reported a loss of $1.51.
|
A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). In the year-ago quarter, DCPH had reported a loss of $1.51. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). In the year-ago quarter, DCPH had reported a loss of $1.51. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
cb8b558b-bdb4-4120-b439-bf162180324f
|
715431.0
|
2023-02-16 00:00:00 UTC
|
DCPH Makes Notable Cross Below Critical Moving Average
|
DCPH
|
https://www.nasdaq.com/articles/dcph-makes-notable-cross-below-critical-moving-average
|
nan
|
nan
|
In trading on Thursday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $15.37, changing hands as low as $14.88 per share. Deciphera Pharmaceuticals Inc shares are currently trading off about 2.3% on the day. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average:
Looking at the chart above, DCPH's low point in its 52 week range is $6.51 per share, with $22.76 as the 52 week high point — that compares with a last trade of $15.12.
Click here to find out which 9 other stocks recently crossed below their 200 day moving average »
Also see:
Mergers and Acquisitions
Funds Holding IXC
CADE Options Chain
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Thursday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $15.37, changing hands as low as $14.88 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $6.51 per share, with $22.76 as the 52 week high point — that compares with a last trade of $15.12. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » Also see: Mergers and Acquisitions Funds Holding IXC CADE Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Thursday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $15.37, changing hands as low as $14.88 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $6.51 per share, with $22.76 as the 52 week high point — that compares with a last trade of $15.12. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » Also see: Mergers and Acquisitions Funds Holding IXC CADE Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Thursday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $15.37, changing hands as low as $14.88 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $6.51 per share, with $22.76 as the 52 week high point — that compares with a last trade of $15.12. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » Also see: Mergers and Acquisitions Funds Holding IXC CADE Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In trading on Thursday, shares of Deciphera Pharmaceuticals Inc (Symbol: DCPH) crossed below their 200 day moving average of $15.37, changing hands as low as $14.88 per share. The chart below shows the one year performance of DCPH shares, versus its 200 day moving average: Looking at the chart above, DCPH's low point in its 52 week range is $6.51 per share, with $22.76 as the 52 week high point — that compares with a last trade of $15.12. Deciphera Pharmaceuticals Inc shares are currently trading off about 2.3% on the day.
|
b9fb08d7-39fa-4ed6-8e57-47eca546a74f
|
715432.0
|
2023-02-14 00:00:00 UTC
|
Bank Of America Now Owns 0.40% of Deciphera Pharmaceuticals (DCPH)
|
DCPH
|
https://www.nasdaq.com/articles/bank-of-america-now-owns-0.40-of-deciphera-pharmaceuticals-dcph
|
nan
|
nan
|
Fintel reports that Bank Of America has filed a 13G/A form with the SEC disclosing ownership of 0.30MM shares of Deciphera Pharmaceuticals Inc (DCPH). This represents 0.4% of the company.
In their previous filing dated January 31, 2022 they reported 3.03MM shares and 5.20% of the company, a decrease in shares of 90.00% and a decrease in total ownership of 4.80% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 37.01% Upside
As of February 10, 2023, the average one-year price target for Deciphera Pharmaceuticals is $22.10. The forecasts range from a low of $9.09 to a high of $31.50. The average price target represents an increase of 37.01% from its latest reported closing price of $16.13.
The projected annual revenue for Deciphera Pharmaceuticals is $157MM, an increase of 17.01%. The projected annual EPS is -$2.26.
What is the Fund Sentiment?
There are 356 funds or institutions reporting positions in Deciphera Pharmaceuticals. This is an increase of 40 owner(s) or 12.66% in the last quarter. Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 14.08%. Total shares owned by institutions decreased in the last three months by 2.07% to 50,549K shares. The put/call ratio of DCPH is 0.57, indicating a bullish outlook.
What are large shareholders doing?
Armistice Capital holds 4,768K shares representing 6.28% ownership of the company. In it's prior filing, the firm reported owning 5,400K shares, representing a decrease of 13.26%. The firm increased its portfolio allocation in DCPH by 23.51% over the last quarter.
Redmile Group holds 2,973K shares representing 3.91% ownership of the company. In it's prior filing, the firm reported owning 1,431K shares, representing an increase of 51.87%. The firm increased its portfolio allocation in DCPH by 196.92% over the last quarter.
Deerfield Management Company, L.p. holds 2,491K shares representing 3.28% ownership of the company. In it's prior filing, the firm reported owning 6,251K shares, representing a decrease of 150.89%. The firm decreased its portfolio allocation in DCPH by 45.88% over the last quarter.
XBI - SPDR Biotech ETF holds 2,206K shares representing 2.90% ownership of the company. In it's prior filing, the firm reported owning 2,949K shares, representing a decrease of 33.67%. The firm increased its portfolio allocation in DCPH by 5.37% over the last quarter.
Goldman Sachs Group holds 2,200K shares representing 2.90% ownership of the company. In it's prior filing, the firm reported owning 3,767K shares, representing a decrease of 71.19%. The firm decreased its portfolio allocation in DCPH by 49.89% over the last quarter.
Deciphera Pharmaceuticals Background Information
(This description is provided by the company.)
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Fintel reports that Bank Of America has filed a 13G/A form with the SEC disclosing ownership of 0.30MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 14.08%. The put/call ratio of DCPH is 0.57, indicating a bullish outlook.
|
Fintel reports that Bank Of America has filed a 13G/A form with the SEC disclosing ownership of 0.30MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 14.08%. The put/call ratio of DCPH is 0.57, indicating a bullish outlook.
|
Fintel reports that Bank Of America has filed a 13G/A form with the SEC disclosing ownership of 0.30MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 14.08%. The put/call ratio of DCPH is 0.57, indicating a bullish outlook.
|
Fintel reports that Bank Of America has filed a 13G/A form with the SEC disclosing ownership of 0.30MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 14.08%. The put/call ratio of DCPH is 0.57, indicating a bullish outlook.
|
55e16f97-4ce7-477f-9051-1e8a7dc32aa2
|
715433.0
|
2023-02-13 00:00:00 UTC
|
Blueprint's (BPMC) Cancer Study Put on Partial Hold by FDA
|
DCPH
|
https://www.nasdaq.com/articles/blueprints-bpmc-cancer-study-put-on-partial-hold-by-fda
|
nan
|
nan
|
Blueprint Medicines Corporation BPMC announced that the FDA placed a partial clinical hold on the phase I/II study of pipeline candidate BLU-222.
The company is developing investigational inhibitor, BLU-222, targeting CDK2 for the treatment of patients with CDK2-vulnerable cancers. The company initiated the phase I/II study, VELA, of BLU-222 in the first quarter of 2022. BLU-222 is being evaluated in the phase I dose escalation portion of the VELA trial.
The regulatory body informed the company about the hold in a verbal communication. The partial clinical hold was placed due to visual adverse events (AEs) observed in a limited number of patients. Patients currently enrolled in the trial are continuing to take the study drug at this time, but additional patients will not be enrolled until the partial clinical hold is resolved.
The reported visual AEs consisted of transient, reversible episodes of light sensitivity and blurred vision. All events were Grade 1, except one Grade 3 event involving light sensitivity and blurred vision in a patient treated at 600 mg BID. The company claims to have resolved all events involving dose interruption or reduction.
The company has stated that patients have been treated with BLU-222 at doses ranging from 50 mg BID to 800 mg BID to date, with evidence of clinical benefit observed and no discontinuations due to AEs.
Blueprint Medicines will look to amend the VELA trial protocol to provide specific guidance to investigators on how to monitor for and manage these events, should they occur. The company targets to present its initial dose escalation data from the VELA trial of BLU-222 in the first half of 2023.
In the past year, shares of Blueprint have lost 47.1% compared with the industry’s decline of 8.6%.
Image Source: Zacks Investment Research
Blueprint Medicines’ lead drug, Ayvakit (avapritinib), is a kinase inhibitor approved by the FDA for the treatment of adults with advanced systemic mastocytosis (SM), including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL), and adults with an unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.
The FDA recently accepted the company's supplemental new drug application for Ayvakit for the treatment of adults with indolent SM. The FDA granted the application priority review with an action date of May 22, 2023.
The company’s other drug, Gavreto (pralsetinib), is approved for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC).
Ayvakit faces competition for the GIST indication from Deciphera Pharmaceutical’s DCPH Qinlock, which is approved for advanced GIST.
Deciphera received FDA approval for Qinlock for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors back in May 2020.
Blueprint Medicines currently has a Zacks Rank #3 (Hold). A couple of better-ranked stocks are Alkermes ALKS and Dynavax Technologies DVAX, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Over the past 60 days, earnings estimates for Alkermes for 2022 have increased by 2 cents to 25 cents. Alkermes surpassed estimates in three of the trailing four quarters and met the same in the remaining one, the average surprise being 306.73%.
Over the past 60 days, earnings estimates for Dynavax for 2022 have increased by 11 cents to $1.95. Dynavax surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 73.15%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report
Alkermes plc (ALKS) : Free Stock Analysis Report
Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Ayvakit faces competition for the GIST indication from Deciphera Pharmaceutical’s DCPH Qinlock, which is approved for advanced GIST. Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Alkermes plc (ALKS) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Blueprint Medicines Corporation BPMC announced that the FDA placed a partial clinical hold on the phase I/II study of pipeline candidate BLU-222.
|
Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Alkermes plc (ALKS) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Ayvakit faces competition for the GIST indication from Deciphera Pharmaceutical’s DCPH Qinlock, which is approved for advanced GIST. All events were Grade 1, except one Grade 3 event involving light sensitivity and blurred vision in a patient treated at 600 mg BID.
|
Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Alkermes plc (ALKS) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Ayvakit faces competition for the GIST indication from Deciphera Pharmaceutical’s DCPH Qinlock, which is approved for advanced GIST. Image Source: Zacks Investment Research Blueprint Medicines’ lead drug, Ayvakit (avapritinib), is a kinase inhibitor approved by the FDA for the treatment of adults with advanced systemic mastocytosis (SM), including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL), and adults with an unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.
|
Ayvakit faces competition for the GIST indication from Deciphera Pharmaceutical’s DCPH Qinlock, which is approved for advanced GIST. Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Alkermes plc (ALKS) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. The FDA recently accepted the company's supplemental new drug application for Ayvakit for the treatment of adults with indolent SM.
|
f188fe1b-7bc7-416d-a525-7cb4f906fbb7
|
715434.0
|
2023-02-09 00:00:00 UTC
|
Vanguard Group Increases Position in Deciphera Pharmaceuticals (DCPH)
|
DCPH
|
https://www.nasdaq.com/articles/vanguard-group-increases-position-in-deciphera-pharmaceuticals-dcph
|
nan
|
nan
|
Fintel reports that Vanguard Group has filed a 13G/A form with the SEC disclosing ownership of 4.75MM shares of Deciphera Pharmaceuticals Inc (DCPH). This represents 7.02% of the company.
In their previous filing dated February 9, 2022 they reported 3.47MM shares and 5.93% of the company, an increase in shares of 36.78% and an increase in total ownership of 1.09% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 40.59% Upside
As of February 9, 2023, the average one-year price target for Deciphera Pharmaceuticals is $22.10. The forecasts range from a low of $9.09 to a high of $31.50. The average price target represents an increase of 40.59% from its latest reported closing price of $15.72.
The projected annual revenue for Deciphera Pharmaceuticals is $157MM, an increase of 17.01%. The projected annual EPS is -$2.26.
What is the Fund Sentiment?
There are 356 funds or institutions reporting positions in Deciphera Pharmaceuticals. This is an increase of 43 owner(s) or 13.74% in the last quarter. Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 27.27%. Total shares owned by institutions increased in the last three months by 1.87% to 51,671K shares. The put/call ratio of DCPH is 0.56, indicating a bullish outlook.
What are large shareholders doing?
Armistice Capital holds 4,768K shares representing 6.32% ownership of the company. In it's prior filing, the firm reported owning 5,400K shares, representing a decrease of 13.26%. The firm increased its portfolio allocation in DCPH by 23.51% over the last quarter.
Goldman Sachs Group holds 3,767K shares representing 4.99% ownership of the company. In it's prior filing, the firm reported owning 3,664K shares, representing an increase of 2.74%. The firm increased its portfolio allocation in DCPH by 47.99% over the last quarter.
Redmile Group holds 2,973K shares representing 3.94% ownership of the company. In it's prior filing, the firm reported owning 1,431K shares, representing an increase of 51.87%. The firm increased its portfolio allocation in DCPH by 196.92% over the last quarter.
Deerfield Management Company, L.p. holds 2,491K shares representing 3.30% ownership of the company. In it's prior filing, the firm reported owning 6,251K shares, representing a decrease of 150.89%. The firm decreased its portfolio allocation in DCPH by 45.88% over the last quarter.
XBI - SPDR Biotech ETF holds 2,206K shares representing 2.93% ownership of the company. In it's prior filing, the firm reported owning 2,949K shares, representing a decrease of 33.67%. The firm increased its portfolio allocation in DCPH by 5.37% over the last quarter.
Deciphera Pharmaceuticals Background Information
(This description is provided by the company.)
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Fintel reports that Vanguard Group has filed a 13G/A form with the SEC disclosing ownership of 4.75MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 27.27%. The put/call ratio of DCPH is 0.56, indicating a bullish outlook.
|
Fintel reports that Vanguard Group has filed a 13G/A form with the SEC disclosing ownership of 4.75MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 27.27%. The put/call ratio of DCPH is 0.56, indicating a bullish outlook.
|
Fintel reports that Vanguard Group has filed a 13G/A form with the SEC disclosing ownership of 4.75MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 27.27%. The put/call ratio of DCPH is 0.56, indicating a bullish outlook.
|
Fintel reports that Vanguard Group has filed a 13G/A form with the SEC disclosing ownership of 4.75MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to DCPH is 0.12%, an increase of 27.27%. The put/call ratio of DCPH is 0.56, indicating a bullish outlook.
|
2596f4cb-1158-4ecb-900c-3a2263c5a033
|
715435.0
|
2023-02-08 00:00:00 UTC
|
Deciphera's (DCPH) Q4 Earnings Miss, Qinlock Drives Revenues
|
DCPH
|
https://www.nasdaq.com/articles/decipheras-dcph-q4-earnings-miss-qinlock-drives-revenues
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. DCPH reported a fourth-quarter 2022 loss of 60 cents per share, wider than the Zacks Consensus Estimate of a loss of 57 cents. In the year-ago quarter, DCPH had reported a loss of $1.51.
Total net revenues were $36.35 million in the quarter, surpassing the Zacks Consensus Estimate of $35.52 million. Revenues rose 50.2% year over year.
Shares of Deciphera have rallied 76.2% in the past year against the industry’s decline of 11.4%.
Image Source: Zacks Investment Research
In May 2020, the FDA approved Deciphera’s sole marketed drug Qinlock (ripretinib) to treat adult patients with advanced gastrointestinal stromal tumors (GIST), who received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib).
Full-Year Results
For 2022, Deciphera generated total revenues of $134 million compared with $96.1 million recorded in 2021, witnessing year-over-year growth of 39.41%.
For the full-year 2022, the company reported a loss of $2.37 per share compared with a net loss of $5.16 per share in 2021.
Quarter in Detail
Apart from Qinlock, there is no marketable drug in Deciphera’s portfolio. Total revenues comprised net product revenues and collaboration revenues. Net product revenues from Qinlock sales were $32.9 million, up 39% year over year. Qinlock generated $25.6 million in sales in the United States and $7.3 million in sales in the ex-U.S. markets.
Collaboration revenues in the reported quarter were $3.5 million compared with $0.5 million recorded in the year-ago quarter.
Research and development expenses were $48 million, down 35.9% year over year owing to lower costs related to clinical studies on Qinlock and the discontinuation of the rebastinib program after corporate restructuring implemented in the fourth quarter of 2021.
Selling, general and administrative expenses were $32.2 million, down 13.3% year over year owing to lower professional and consultant fees.
Deciphera had cash, cash equivalents and investments worth $339 million as of Dec 31, 2022 compared with $327.6 million as of Dec 31, 2021. Deciphera expects its current cash balance together with the anticipated product, royalty, supply revenues and the net proceeds from its underwritten public offering completed in January 2023 to fund its operating and capital expenditures into 2026.
Other Updates
In November 2021, the European Commission approved Qinlock for treating adult patients with advanced GIST, who already received treatment with three or more kinase inhibitors, including Gleevec. The nod in Europe is already generating incremental sales. Qinlock got included in the National Reimbursement Drug List in China for patients with GIST as well as receiving approval in New Zealand in December 2022.
Deciphera expects to initiate the pivotal phase III INSIGHT study to evaluate Qinlock versus sunitinib for the treatment of second-line GIST patients with mutations in KIT exon 11 and 17/18, later in 2023.
Deciphera is evaluating vimseltinib in the phase III MOTION study to treat patients with tenosynovial giant-cell tumors, who are not amenable to surgery. Enrollment in the study is currently ongoing and expected to be completed in the first quarter of 2023 and report results from the study in the fourth quarter of 2023.
This apart, DCPH, in collaboration with Pfizer, Inc. PFE expects to initiate a new study evaluating DCC-3116 in combination with encorafenib and cetuximab in patients with colorectal cancer. Per the terms of the agreement with Pfizer, Deciphera will bear the cost of the study while Pfizer will supply encorafenib free of cost.
Additionally, Deciphera initiated enrollment in three phase Ib dose escalation studies of DCC-3116 in the fourth quarter of 2022, expecting to report data from the study in the second half of 2023.
Deciphera Pharmaceuticals, Inc. Price and Consensus
Deciphera Pharmaceuticals, Inc. price-consensus-chart | Deciphera Pharmaceuticals, Inc. Quote
Zacks Rank & Other Stocks to Consider
Deciphera currently carries a Zacks Rank #3 (Hold).
Other stocks worth considering in the biotech sector are 89BIO, Inc. ETNB and ADMA Biologics, Inc. ADMA both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the estimate for 89BIO’s 2022 loss per share has narrowed from $3.81 to $2.99. During the same period, the loss estimate per share for 2023 has narrowed from $3.59 to $2.59. In the past year, the shares of 89BIO have risen by 170%.
ETNB’s earnings witnessed an average earnings surprise of 10.08%, beating three out of four estimates in the trailing four reported quarters.
In the past 90 days, the consensus estimate for ADMA Biologics’ 2022 loss per share has narrowed from 34 cents to 33 cents. During the same period, the loss estimate per share for 2023 has narrowed from 20 cents to 19 cents. In the past year, the shares of ADMA Biologics have increased by 131.1%.
ADMA’s earnings beat estimates in three of the trailing four quarters, delivering an average earnings surprise of 1.81%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.8% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
89BIO (ETNB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. DCPH reported a fourth-quarter 2022 loss of 60 cents per share, wider than the Zacks Consensus Estimate of a loss of 57 cents. In the year-ago quarter, DCPH had reported a loss of $1.51. This apart, DCPH, in collaboration with Pfizer, Inc. PFE expects to initiate a new study evaluating DCC-3116 in combination with encorafenib and cetuximab in patients with colorectal cancer.
|
Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report 89BIO (ETNB) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. DCPH reported a fourth-quarter 2022 loss of 60 cents per share, wider than the Zacks Consensus Estimate of a loss of 57 cents. In the year-ago quarter, DCPH had reported a loss of $1.51.
|
Deciphera Pharmaceuticals, Inc. DCPH reported a fourth-quarter 2022 loss of 60 cents per share, wider than the Zacks Consensus Estimate of a loss of 57 cents. Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report 89BIO (ETNB) : Free Stock Analysis Report To read this article on Zacks.com click here. In the year-ago quarter, DCPH had reported a loss of $1.51.
|
Deciphera Pharmaceuticals, Inc. DCPH reported a fourth-quarter 2022 loss of 60 cents per share, wider than the Zacks Consensus Estimate of a loss of 57 cents. In the year-ago quarter, DCPH had reported a loss of $1.51. This apart, DCPH, in collaboration with Pfizer, Inc. PFE expects to initiate a new study evaluating DCC-3116 in combination with encorafenib and cetuximab in patients with colorectal cancer.
|
849d12c2-055b-47be-8dd2-667424d8017c
|
715436.0
|
2023-02-07 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-reports-q4-loss-tops-revenue-estimates-0
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $1.51 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -5.26%. A quarter ago, it was expected that this company would post a loss of $0.57 per share when it actually produced a loss of $0.55, delivering a surprise of 3.51%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $36.35 million for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 2.59%. This compares to year-ago revenues of $24.2 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Deciphera Pharmaceuticals, Inc. Shares have added about 2% since the beginning of the year versus the S&P 500's gain of 7.1%.
What's Next for Deciphera Pharmaceuticals, Inc.
While Deciphera Pharmaceuticals, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Deciphera Pharmaceuticals, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.58 on $34.83 million in revenues for the coming quarter and -$2.32 on $152.12 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Albireo Pharma (ALBO), has yet to report results for the quarter ended December 2022.
This company is expected to post quarterly loss of $1.80 per share in its upcoming report, which represents a year-over-year change of -215.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Albireo Pharma's revenues are expected to be $9.82 million, down 69.8% from the year-ago quarter.
Free Report: Must-See Hydrogen Stocks
Hydrogen fuel cells are already used to provide efficient, ultra-clean energy to buses, ships and even hospitals. This technology is on the verge of a massive breakthrough, one that could make hydrogen a major source of America's power. It could even totally revolutionize the EV industry.
Zacks has released a special report revealing the 4 stocks experts believe will deliver the biggest gains.
Download Cashing In on Cleaner Energy today, absolutely free.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
Albireo Pharma (ALBO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.57. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Albireo Pharma (ALBO) : Free Stock Analysis Report To read this article on Zacks.com click here. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook.
|
Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Albireo Pharma (ALBO) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.57. Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $36.35 million for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 2.59%.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.57. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Albireo Pharma (ALBO) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $36.35 million for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 2.59%.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.57. Click to get this free report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report Albireo Pharma (ALBO) : Free Stock Analysis Report To read this article on Zacks.com click here. The company has topped consensus revenue estimates four times over the last four quarters.
|
c96cea52-1604-450f-afb2-bc61abbfc207
|
715437.0
|
2023-02-03 00:00:00 UTC
|
BlackRock Increases Position in Deciphera Pharmaceuticals (DCPH)
|
DCPH
|
https://www.nasdaq.com/articles/blackrock-increases-position-in-deciphera-pharmaceuticals-dcph
|
nan
|
nan
|
Fintel reports that BlackRock has filed a 13G/A form with the SEC disclosing ownership of 5.42MM shares of Deciphera Pharmaceuticals Inc (DCPH). This represents 8.0% of the company.
In their previous filing dated February 3, 2022 they reported 3.80MM shares and 6.50% of the company, an increase in shares of 42.72% and an increase in total ownership of 1.50% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 19.73% Upside
As of February 2, 2023, the average one-year price target for Deciphera Pharmaceuticals is $21.01. The forecasts range from a low of $9.09 to a high of $29.40. The average price target represents an increase of 19.73% from its latest reported closing price of $17.55.
The projected annual revenue for Deciphera Pharmaceuticals is $157MM, an increase of 28.67%. The projected annual EPS is $-2.26.
Fund Sentiment
There are 357 funds or institutions reporting positions in Deciphera Pharmaceuticals. This is an increase of 48 owner(s) or 15.53%.
Average portfolio weight of all funds dedicated to US:DCPH is 0.1182%, an increase of 22.8783%. Total shares owned by institutions increased in the last three months by 2.43% to 51,633K shares.
What are large shareholders doing?
Armistice Capital holds 4,768,000 shares representing 6.32% ownership of the company. In it's prior filing, the firm reported owning 5,400,000 shares, representing a decrease of 13.26%. The firm increased its portfolio allocation in DCPH by 23.51% over the last quarter.
Goldman Sachs Group holds 3,766,853 shares representing 4.99% ownership of the company. In it's prior filing, the firm reported owning 3,663,819 shares, representing an increase of 2.74%. The firm increased its portfolio allocation in DCPH by 47.99% over the last quarter.
Redmile Group holds 2,973,029 shares representing 3.94% ownership of the company. In it's prior filing, the firm reported owning 1,430,917 shares, representing an increase of 51.87%. The firm increased its portfolio allocation in DCPH by 196.92% over the last quarter.
Deerfield Management Company, L.p. holds 2,491,490 shares representing 3.30% ownership of the company. In it's prior filing, the firm reported owning 6,250,964 shares, representing a decrease of 150.89%. The firm decreased its portfolio allocation in DCPH by 45.88% over the last quarter.
XBI - SPDR Biotech ETF holds 2,206,033 shares representing 2.93% ownership of the company. In it's prior filing, the firm reported owning 2,948,810 shares, representing a decrease of 33.67%. The firm increased its portfolio allocation in DCPH by 5.37% over the last quarter.
Deciphera Pharmaceuticals Background Information
(This description is provided by the company.)
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Fintel reports that BlackRock has filed a 13G/A form with the SEC disclosing ownership of 5.42MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to US:DCPH is 0.1182%, an increase of 22.8783%. The firm increased its portfolio allocation in DCPH by 23.51% over the last quarter.
|
Fintel reports that BlackRock has filed a 13G/A form with the SEC disclosing ownership of 5.42MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to US:DCPH is 0.1182%, an increase of 22.8783%. The firm increased its portfolio allocation in DCPH by 23.51% over the last quarter.
|
Fintel reports that BlackRock has filed a 13G/A form with the SEC disclosing ownership of 5.42MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to US:DCPH is 0.1182%, an increase of 22.8783%. The firm increased its portfolio allocation in DCPH by 23.51% over the last quarter.
|
Fintel reports that BlackRock has filed a 13G/A form with the SEC disclosing ownership of 5.42MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to US:DCPH is 0.1182%, an increase of 22.8783%. The firm increased its portfolio allocation in DCPH by 23.51% over the last quarter.
|
613bfa06-6402-4d1a-a196-f552bc9900a3
|
715438.0
|
2023-02-03 00:00:00 UTC
|
State Street Cuts Stake in Deciphera Pharmaceuticals (DCPH)
|
DCPH
|
https://www.nasdaq.com/articles/state-street-cuts-stake-in-deciphera-pharmaceuticals-dcph
|
nan
|
nan
|
Fintel reports that State Street has filed a 13G/A form with the SEC disclosing ownership of 3.45MM shares of Deciphera Pharmaceuticals Inc (DCPH). This represents 5.1% of the company.
In their previous filing dated July 11, 2022 they reported 3.93MM shares and 5.94% of the company, a decrease in shares of 12.28% and a decrease in total ownership of 0.84% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 19.73% Upside
As of February 2, 2023, the average one-year price target for Deciphera Pharmaceuticals is $21.01. The forecasts range from a low of $9.09 to a high of $29.40. The average price target represents an increase of 19.73% from its latest reported closing price of $17.55.
The projected annual revenue for Deciphera Pharmaceuticals is $157MM, an increase of 28.67%. The projected annual EPS is $-2.26.
Fund Sentiment
There are 357 funds or institutions reporting positions in Deciphera Pharmaceuticals. This is an increase of 48 owner(s) or 15.53%.
Average portfolio weight of all funds dedicated to US:DCPH is 0.1182%, an increase of 22.8783%. Total shares owned by institutions increased in the last three months by 2.43% to 51,633K shares.
What are large shareholders doing?
Armistice Capital holds 4,768,000 shares representing 6.32% ownership of the company. In it's prior filing, the firm reported owning 5,400,000 shares, representing a decrease of 13.26%. The firm increased its portfolio allocation in DCPH by 23.51% over the last quarter.
Goldman Sachs Group holds 3,766,853 shares representing 4.99% ownership of the company. In it's prior filing, the firm reported owning 3,663,819 shares, representing an increase of 2.74%. The firm increased its portfolio allocation in DCPH by 47.99% over the last quarter.
Redmile Group holds 2,973,029 shares representing 3.94% ownership of the company. In it's prior filing, the firm reported owning 1,430,917 shares, representing an increase of 51.87%. The firm increased its portfolio allocation in DCPH by 196.92% over the last quarter.
Deerfield Management Company, L.p. holds 2,491,490 shares representing 3.30% ownership of the company. In it's prior filing, the firm reported owning 6,250,964 shares, representing a decrease of 150.89%. The firm decreased its portfolio allocation in DCPH by 45.88% over the last quarter.
XBI - SPDR Biotech ETF holds 2,206,033 shares representing 2.93% ownership of the company. In it's prior filing, the firm reported owning 2,948,810 shares, representing a decrease of 33.67%. The firm increased its portfolio allocation in DCPH by 5.37% over the last quarter.
Deciphera Pharmaceuticals Background Information
(This description is provided by the company.)
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Fintel reports that State Street has filed a 13G/A form with the SEC disclosing ownership of 3.45MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to US:DCPH is 0.1182%, an increase of 22.8783%. The firm increased its portfolio allocation in DCPH by 23.51% over the last quarter.
|
Fintel reports that State Street has filed a 13G/A form with the SEC disclosing ownership of 3.45MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to US:DCPH is 0.1182%, an increase of 22.8783%. The firm increased its portfolio allocation in DCPH by 23.51% over the last quarter.
|
Fintel reports that State Street has filed a 13G/A form with the SEC disclosing ownership of 3.45MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to US:DCPH is 0.1182%, an increase of 22.8783%. The firm increased its portfolio allocation in DCPH by 23.51% over the last quarter.
|
Fintel reports that State Street has filed a 13G/A form with the SEC disclosing ownership of 3.45MM shares of Deciphera Pharmaceuticals Inc (DCPH). Average portfolio weight of all funds dedicated to US:DCPH is 0.1182%, an increase of 22.8783%. The firm increased its portfolio allocation in DCPH by 23.51% over the last quarter.
|
8210a4b9-acb2-4b2c-af2e-4bc47af54c38
|
715439.0
|
2023-01-24 00:00:00 UTC
|
Blueprint Medicines' (BPMC) Aykavit sNDA Gets FDA Priority Tag
|
DCPH
|
https://www.nasdaq.com/articles/blueprint-medicines-bpmc-aykavit-snda-gets-fda-priority-tag
|
nan
|
nan
|
Blueprint Medicines Corporation BPMC announced that the FDA has accepted its supplemental new drug application (sNDA) seeking label expansion for Ayvakit, Blueprint’s only marketed drug to treat adults’ indolent Systemic Mastocytosis (SM). The FDA has granted priority review to the sNDA with a Prescription Drug User Fee Act (PDUFA) date of May 22, 2023.
Aykavit, a kinase inhibitor, is already approved in the United States for the treatment of adults with advanced SM, which includes patients with aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). Indolent SM is a form of non-advanced SM. Aykavit is also approved to treat adults with unresectable or metastatic gastrointestinal stromal tumors (GIST). Aykavit is also approved in Europe for the treatment of adults with ASM, SM-AHN, or MCL and metastatic GIST.
The sNDA for indolent SM was based on positive top-line results from the global PIONEER study conducted by Blueprint. Management reported that Aykavit achieved the primary as well as all key secondary endpoints in the PIONEER study. The study showed that Ayvakit led to statistically significant reductions in patient-reported symptoms and all measures of mast cell burden studies. The drug was generally well tolerated and met a safety profile supporting chronic treatment. If the company receives approval for expanded use in indolent SM, Blueprint will become the first company with approved therapies for patients which will provide a major boost to the company’s revenues.
In the past year, the shares of Blueprint have declined 35.7% compared with the industry’s decline of 6.9%.
Image Source: Zacks Investment Research
SM is a rare disease that is caused by KIT D816V mutation in most cases. It is a result of abnormal growth of mast cells in the human body resulting in chronic, severe, and often unprecedented symptoms in multiple organs. According to demographics, most patients suffer from non-advanced (indolent or smoldering) SM. Popular symptoms for such non-advanced SM include anaphylaxis, maculopapular rash, pruritis, diarrhea, brain fog, fatigue, and bone pain despite treatment being treated with multiple symptom-driven therapies. This significantly degrades the quality of life of patients and with no approved therapies for the treatment of non-advanced SM, there remains a huge unmet medical need.
We remind investors that Ayvakit faces competition for the GIST indication from Deciphera Pharmaceutical’s DCPH Qinlock, which is approved for advanced GIST. Deciphera received FDA approval for Qinlock (ripretinib), for the treatment of adult patients with advanced GIST, who have received prior treatment with three or more kinase inhibitors back in May 2020.
DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in second-line GIST in its phase III Intrigue study and reported statistically significant data, recently.
Zacks Rank and Stocks to Consider
Blueprint Medicines currently has a Zacks Rank #4 (Sell).
Some better-ranked stocks in the same industry are 89BIO, Inc. ETNB and Adicet Bio, Inc. ACET, both carrying a Zacks Ranks #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the estimate for 89BIO’s 2022 loss per share has narrowed from $3.34 to $2.65. During the same period, the loss estimate per share for 2023 has narrowed from $3.59 to $2.59. In the past year, the shares of 89BIO have risen by 28.1%.
ETNB delivered an average earnings surprise of 10.08%, beating estimates in three out of the trailing four reported quarters.
In the past 90 days, the estimate for Adicet Bio’s 2022 loss per share has narrowed from $1.63 to $1.54. During the same period, the loss estimate per share for 2023 has narrowed from $2.25 to $2.09. In the past year, the shares of Adicet have decreased by 31.9%.
ACET delivered an average earnings surprise of 54.24% for the trailing four quarters, having beaten estimates twice and missing the same twice.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Adicet Bio, Inc. (ACET) : Free Stock Analysis Report
Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
89BIO (ETNB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in second-line GIST in its phase III Intrigue study and reported statistically significant data, recently. We remind investors that Ayvakit faces competition for the GIST indication from Deciphera Pharmaceutical’s DCPH Qinlock, which is approved for advanced GIST. Click to get this free report Adicet Bio, Inc. (ACET) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report 89BIO (ETNB) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
Click to get this free report Adicet Bio, Inc. (ACET) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report 89BIO (ETNB) : Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Ayvakit faces competition for the GIST indication from Deciphera Pharmaceutical’s DCPH Qinlock, which is approved for advanced GIST. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in second-line GIST in its phase III Intrigue study and reported statistically significant data, recently.
|
Click to get this free report Adicet Bio, Inc. (ACET) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report 89BIO (ETNB) : Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Ayvakit faces competition for the GIST indication from Deciphera Pharmaceutical’s DCPH Qinlock, which is approved for advanced GIST. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in second-line GIST in its phase III Intrigue study and reported statistically significant data, recently.
|
We remind investors that Ayvakit faces competition for the GIST indication from Deciphera Pharmaceutical’s DCPH Qinlock, which is approved for advanced GIST. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in second-line GIST in its phase III Intrigue study and reported statistically significant data, recently. Click to get this free report Adicet Bio, Inc. (ACET) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report 89BIO (ETNB) : Free Stock Analysis Report To read this article on Zacks.com click here.
|
74ea354d-c4a9-4895-bd12-d8b4212042d5
|
715440.0
|
2023-01-19 00:00:00 UTC
|
Deciphera Pharma Prices Public Offering Of 6.94 Mln Shares At $18/shr
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharma-prices-public-offering-of-6.94-mln-shares-at-%2418-shr
|
nan
|
nan
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that it has priced an underwritten public offering of 6.94 million shares of its common stock at a public offering price of $18.00 per share.
The company expects aggregate gross proceeds to Deciphera from the offering to be about $125 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
In addition, Deciphera has granted the underwriters a 30-day option to purchase up to an additional 1.04 million shares of common stock at the public offering price of $18.00 per share, less underwriting discounts and commissions. The offering is expected to close on January 24, 2023.
Deciphera plans to use the net proceeds from the offering to fund its planned Phase 3 INSIGHT study of QINLOCK versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18 only; to fund the development of vimseltinib, including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients, additional clinical trials as well as clinical research outsourcing and manufacturing of clinical trial material and pre-commercial and medical affairs capabilities related to vimseltinib.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that it has priced an underwritten public offering of 6.94 million shares of its common stock at a public offering price of $18.00 per share. In addition, Deciphera has granted the underwriters a 30-day option to purchase up to an additional 1.04 million shares of common stock at the public offering price of $18.00 per share, less underwriting discounts and commissions. Deciphera plans to use the net proceeds from the offering to fund its planned Phase 3 INSIGHT study of QINLOCK versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18 only; to fund the development of vimseltinib, including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients, additional clinical trials as well as clinical research outsourcing and manufacturing of clinical trial material and pre-commercial and medical affairs capabilities related to vimseltinib.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that it has priced an underwritten public offering of 6.94 million shares of its common stock at a public offering price of $18.00 per share. The company expects aggregate gross proceeds to Deciphera from the offering to be about $125 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Deciphera has granted the underwriters a 30-day option to purchase up to an additional 1.04 million shares of common stock at the public offering price of $18.00 per share, less underwriting discounts and commissions.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that it has priced an underwritten public offering of 6.94 million shares of its common stock at a public offering price of $18.00 per share. In addition, Deciphera has granted the underwriters a 30-day option to purchase up to an additional 1.04 million shares of common stock at the public offering price of $18.00 per share, less underwriting discounts and commissions. Deciphera plans to use the net proceeds from the offering to fund its planned Phase 3 INSIGHT study of QINLOCK versus sunitinib in second-line GIST patients with mutations in KIT exon 11 and 17/18 only; to fund the development of vimseltinib, including completion of its Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor patients, additional clinical trials as well as clinical research outsourcing and manufacturing of clinical trial material and pre-commercial and medical affairs capabilities related to vimseltinib.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that it has priced an underwritten public offering of 6.94 million shares of its common stock at a public offering price of $18.00 per share. In addition, Deciphera has granted the underwriters a 30-day option to purchase up to an additional 1.04 million shares of common stock at the public offering price of $18.00 per share, less underwriting discounts and commissions. The offering is expected to close on January 24, 2023.
|
3761cd81-8d95-475e-af34-c96cbc573de0
|
715441.0
|
2023-01-19 00:00:00 UTC
|
Health Care Sector Update for 01/19/2023: CNCE, SRDX, DCPH, IBB, XLV
|
DCPH
|
https://www.nasdaq.com/articles/health-care-sector-update-for-01-19-2023%3A-cnce-srdx-dcph-ibb-xlv
|
nan
|
nan
|
Health care stocks were flat to lower pre-bell Thursday. The iShares Biotechnology ETF (IBB) was inactive and the Health Care Select Sector SPDR Fund (XLV) was 0.35% lower recently.
Concert Pharmaceuticals (CNCE) was gaining over 19% in value after saying it will be acquired by Sun Pharmaceutical Industries for $576 million in equity value.
SurModics (SRDX) was down more than 13% after saying a letter from the Food and Drug Administration indicated that the company's premarket application for SurVeil drug-coated balloon is not currently approvable.
Deciphera Pharmaceuticals (DCPH) was slipping past 11% after saying it plans to sell $125 million of common shares in a public offering.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals (DCPH) was slipping past 11% after saying it plans to sell $125 million of common shares in a public offering. The iShares Biotechnology ETF (IBB) was inactive and the Health Care Select Sector SPDR Fund (XLV) was 0.35% lower recently. SurModics (SRDX) was down more than 13% after saying a letter from the Food and Drug Administration indicated that the company's premarket application for SurVeil drug-coated balloon is not currently approvable.
|
Deciphera Pharmaceuticals (DCPH) was slipping past 11% after saying it plans to sell $125 million of common shares in a public offering. Health care stocks were flat to lower pre-bell Thursday. The iShares Biotechnology ETF (IBB) was inactive and the Health Care Select Sector SPDR Fund (XLV) was 0.35% lower recently.
|
Deciphera Pharmaceuticals (DCPH) was slipping past 11% after saying it plans to sell $125 million of common shares in a public offering. The iShares Biotechnology ETF (IBB) was inactive and the Health Care Select Sector SPDR Fund (XLV) was 0.35% lower recently. Concert Pharmaceuticals (CNCE) was gaining over 19% in value after saying it will be acquired by Sun Pharmaceutical Industries for $576 million in equity value.
|
Deciphera Pharmaceuticals (DCPH) was slipping past 11% after saying it plans to sell $125 million of common shares in a public offering. Health care stocks were flat to lower pre-bell Thursday. The iShares Biotechnology ETF (IBB) was inactive and the Health Care Select Sector SPDR Fund (XLV) was 0.35% lower recently.
|
bc5cdcd7-63a0-4d37-b20d-fade15a432f5
|
715442.0
|
2023-01-04 00:00:00 UTC
|
Deciphera (DCPH) Issues Strategic & Corporate Outlook for 2023
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-dcph-issues-strategic-corporate-outlook-for-2023
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. DCPH announced an outlook and planned corporate milestones for 2023. The company outlined certain commercial, clinical and preclinical activities for the year.
Along with the same press release, DCPH announced preliminary revenues for the fourth quarter and 2022. The company expects preliminary revenues of $36 million and $134 million for the fourth quarter and 2022, respectively.
Shares of Deciphera have rallied 64.7% in the past year against the industry’s decline of 17.4%.
Image Source: Zacks Investment Research
Per the outlook for 2023, the company plans to initiate the pivotal phase III INSIGHT study evaluating its sole marketed drug, Qinlock (ripretinib), compared with sunitinib for treating patients with gastrointestinal stromal tumor (GIST) who were previously treated with Novartis’ NVS Gleevec (imatinib) in the second half of 2023.
NVS lost patent protection for Gleevec, which faces increasing generic competition in major markets.
In a separate press release, DCPH announced data from the phase III INTRIGUE study evaluating Qinlock using circulating tumor DNA (ctDNA) from a subgroup of patients with GIST previously treated with Gleevec who harbor mutations in KIT exon 11 and 17/18 only. The study compared Qinlock to sunitinib for treating second-line GIST patients with mutations in KIT exon 11 and 17/18 only.
Data from the same showed that patients treated with Qinlock had median progression-free survival of 14.2 months versus 1.5 months for patients receiving sunitinib. The objective response rate was 44.4% in the Qinlock arm versus nil in the sunitinib arm.
Qinlock is approved in the United States for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec.
Apart from this, Deciphera is evaluating its pipeline candidate vimseltinib in the phase III MOTION study to treat patients with tenosynovial giant-cell tumors, who are not amenable to surgery. Enrollment in the study is expected to be completed in the first half of 2023, with top-line data from the same expected in the fourth quarter of 2023.
DCPH plans to evaluate DCC-3116 in combination with Pfizer’s PFE Braftovi (encorafenib) and Eli Lilly’s Erbitux (cetuximab) for treating patients with colorectal cancer in the second half of 2023.
Deciphera entered a clinical trial collaboration and supply agreement with Pfizer for Braftovi.
Per the above agreement, Deciphera will sponsor the study, whereas PFE will supply Braftovi free of cost.
DCPH plans to file an investigational new drug application for DCC-3084, a potential best-in-class pan-RAF inhibitor, in the second half of 2023 with the FDA.
Zacks Rank & Stock to Consider
Deciphera currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Syndax Pharmaceuticals, Inc. SNDX, which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Loss per share estimates for Syndax Pharmaceuticals have narrowed 14.5% for 2023 in the past 60 days.
Earnings of Syndax Pharmaceuticals surpassed estimates in three of the trailing four quarters and met the same on the other occasion. SNDX witnessed an earnings surprise of 95.39%, on average.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Syndax Pharmaceuticals, Inc. (SNDX) : Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In a separate press release, DCPH announced data from the phase III INTRIGUE study evaluating Qinlock using circulating tumor DNA (ctDNA) from a subgroup of patients with GIST previously treated with Gleevec who harbor mutations in KIT exon 11 and 17/18 only. DCPH plans to evaluate DCC-3116 in combination with Pfizer’s PFE Braftovi (encorafenib) and Eli Lilly’s Erbitux (cetuximab) for treating patients with colorectal cancer in the second half of 2023. Deciphera Pharmaceuticals, Inc. DCPH announced an outlook and planned corporate milestones for 2023.
|
In a separate press release, DCPH announced data from the phase III INTRIGUE study evaluating Qinlock using circulating tumor DNA (ctDNA) from a subgroup of patients with GIST previously treated with Gleevec who harbor mutations in KIT exon 11 and 17/18 only. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. DCPH announced an outlook and planned corporate milestones for 2023.
|
In a separate press release, DCPH announced data from the phase III INTRIGUE study evaluating Qinlock using circulating tumor DNA (ctDNA) from a subgroup of patients with GIST previously treated with Gleevec who harbor mutations in KIT exon 11 and 17/18 only. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. Deciphera Pharmaceuticals, Inc. DCPH announced an outlook and planned corporate milestones for 2023.
|
Deciphera Pharmaceuticals, Inc. DCPH announced an outlook and planned corporate milestones for 2023. Along with the same press release, DCPH announced preliminary revenues for the fourth quarter and 2022. In a separate press release, DCPH announced data from the phase III INTRIGUE study evaluating Qinlock using circulating tumor DNA (ctDNA) from a subgroup of patients with GIST previously treated with Gleevec who harbor mutations in KIT exon 11 and 17/18 only.
|
2ff8e86a-1ddc-4056-82c5-61a9806ee8f6
|
715443.0
|
2022-12-06 00:00:00 UTC
|
First Week of January 2023 Options Trading For Deciphera Pharmaceuticals (DCPH)
|
DCPH
|
https://www.nasdaq.com/articles/first-week-of-january-2023-options-trading-for-deciphera-pharmaceuticals-dcph
|
nan
|
nan
|
Investors in Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw new options begin trading this week, for the January 2023 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DCPH options chain for the new January 2023 contracts and identified one put and one call contract of particular interest.
The put contract at the $12.50 strike price has a current bid of 5 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $12.50, but will also collect the premium, putting the cost basis of the shares at $12.45 (before broker commissions). To an investor already interested in purchasing shares of DCPH, that could represent an attractive alternative to paying $14.99/share today.
Because the $12.50 strike represents an approximate 17% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 80%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.40% return on the cash commitment, or 3.24% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Deciphera Pharmaceuticals Inc, and highlighting in green where the $12.50 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $22.50 strike price has a current bid of 35 cents. If an investor was to purchase shares of DCPH stock at the current price level of $14.99/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $22.50. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 52.43% if the stock gets called away at the January 2023 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if DCPH shares really soar, which is why looking at the trailing twelve month trading history for Deciphera Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DCPH's trailing twelve month trading history, with the $22.50 strike highlighted in red:
Considering the fact that the $22.50 strike represents an approximate 50% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 93%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 2.33% boost of extra return to the investor, or 18.94% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 285%, while the implied volatility in the call contract example is 115%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $14.99) to be 73%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
Also see:
Institutional Holders of CROX
AFT Insider Buying
SOI Stock Predictions
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Of course, a lot of upside could potentially be left on the table if DCPH shares really soar, which is why looking at the trailing twelve month trading history for Deciphera Pharmaceuticals Inc, as well as studying the business fundamentals becomes important. Below is a chart showing DCPH's trailing twelve month trading history, with the $22.50 strike highlighted in red: Considering the fact that the $22.50 strike represents an approximate 50% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw new options begin trading this week, for the January 2023 expiration.
|
Below is a chart showing DCPH's trailing twelve month trading history, with the $22.50 strike highlighted in red: Considering the fact that the $22.50 strike represents an approximate 50% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw new options begin trading this week, for the January 2023 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DCPH options chain for the new January 2023 contracts and identified one put and one call contract of particular interest.
|
Below is a chart showing DCPH's trailing twelve month trading history, with the $22.50 strike highlighted in red: Considering the fact that the $22.50 strike represents an approximate 50% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw new options begin trading this week, for the January 2023 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DCPH options chain for the new January 2023 contracts and identified one put and one call contract of particular interest.
|
At Stock Options Channel, our YieldBoost formula has looked up and down the DCPH options chain for the new January 2023 contracts and identified one put and one call contract of particular interest. Below is a chart showing DCPH's trailing twelve month trading history, with the $22.50 strike highlighted in red: Considering the fact that the $22.50 strike represents an approximate 50% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Deciphera Pharmaceuticals Inc (Symbol: DCPH) saw new options begin trading this week, for the January 2023 expiration.
|
ab40af7d-bc89-484a-b978-df1d801c8b56
|
715444.0
|
2022-11-04 00:00:00 UTC
|
Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues
|
DCPH
|
https://www.nasdaq.com/articles/decipheras-dcph-q3-loss-narrows-qinlock-drives-revenues
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. DCPH reported a third-quarter 2022 loss of 55 cents per share, narrower than the Zacks Consensus Estimate of a loss of 57 cents. In the year-ago quarter, DCPH had reported a loss of $1.37.
Total net revenues were $36 million in the quarter, surpassing the Zacks Consensus Estimate of $33 million. Revenues rose 55.1% year over year.
Shares of Deciphera have rallied 68.2% in the year so far against the industry’s decline of 22.3%.
Image Source: Zacks Investment Research
In May 2020, the FDA approved Deciphera’s sole marketed drug Qinlock (ripretinib) to treat adult patients with advanced gastrointestinal stromal tumors (GIST), who received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib).
Quarter in Detail
Apart from Qinlock, there is no marketable drug in Deciphera’s portfolio. Total revenues comprised net product revenues and collaboration revenues. Net product revenues from Qinlock sales were $32.3 million, up 49% year over year. Qinlock generated $24.5 million of sales in the United States and $7.8 million of sales in the ex-U.S. markets.
Collaboration revenues in the reported quarter were $3.7 million compared with $1.5 million recorded in the year-ago quarter.
Research and development expenses were $47.5 million, down 28.5% year over year owing to lower costs related to clinical studies on Qinlock.
Selling, general and administrative expenses were $30 million, down 15.5% year over year owing to lower professional and consultant fees.
Deciphera had cash, cash equivalents and investments worth $371.6 million as of Sep 30, 2022, compared with $393.1 million as of Jun 30, 2022. DCPH expects its current cash balance to fund its operating and capital expenditures into 2025.
Other Updates
Last November, the European Commission approved Qinlock for treating adult patients with advanced GIST, who already received treatment with three or more kinase inhibitors, including Novartis’ Gleevec. The nod in Europe is already generating incremental sales and should boost sales in the future quarters.
Deciphera is evaluating vimseltinib in the phase III MOTION study to treat patients with tenosynovial giant-cell tumors, who are not amenable to surgery. Enrollment in the study is currently ongoing.
This apart, DCPH treated the first patient in three-phase Ib studies, evaluating DCC-3116 in combination with the FDA-approved MEK inhibitors, namely trametinib, binimetinib and sotorasib, an FDA-approved KRASG12C inhibitor to treat patients with advanced or metastatic solid.
Deciphera Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Deciphera Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Deciphera Pharmaceuticals, Inc. Quote
Zacks Rank & Other Stocks to Consider
Deciphera currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the biotech sector are Akero Therapeutics, Inc. AKRO, Amarin Corp. plc AMRN and Atea Pharmaceuticals, Inc. AVIR, all sporting the same Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimates for Akero Therapeutics have narrowed 6.9% for 2022 and 4.8% for 2023 in the past 60 days.
Earnings of Akero Therapeutics surpassed estimates in three of the trailing four quarters and missed the mark on the remaining occasion. AKRO delivered an earnings surprise of 7.66%, on average.
Loss per share estimates for Amarin narrowed 21% for 2022 and 50% for 2023 in the past 60 days.
Earnings of Amarin surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AMRN witnessed a negative earnings surprise of 14.29%, on average.
Loss per share estimates for Atea Pharmaceuticals narrowed 10.9% for 2022 and 9.5% for 2023 in the past 60 days.
Earnings of Atea Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed the mark on the remaining occasion. AVIR witnessed a negative earnings surprise of 58.74%, on average.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amarin Corporation PLC (AMRN): Free Stock Analysis Report
Atea Pharmaceuticals, Inc. (AVIR): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Akero Therapeutics, Inc. (AKRO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. DCPH reported a third-quarter 2022 loss of 55 cents per share, narrower than the Zacks Consensus Estimate of a loss of 57 cents. In the year-ago quarter, DCPH had reported a loss of $1.37. DCPH expects its current cash balance to fund its operating and capital expenditures into 2025.
|
Deciphera Pharmaceuticals, Inc. DCPH reported a third-quarter 2022 loss of 55 cents per share, narrower than the Zacks Consensus Estimate of a loss of 57 cents. In the year-ago quarter, DCPH had reported a loss of $1.37. DCPH expects its current cash balance to fund its operating and capital expenditures into 2025.
|
Deciphera Pharmaceuticals, Inc. DCPH reported a third-quarter 2022 loss of 55 cents per share, narrower than the Zacks Consensus Estimate of a loss of 57 cents. In the year-ago quarter, DCPH had reported a loss of $1.37. DCPH expects its current cash balance to fund its operating and capital expenditures into 2025.
|
Deciphera Pharmaceuticals, Inc. DCPH reported a third-quarter 2022 loss of 55 cents per share, narrower than the Zacks Consensus Estimate of a loss of 57 cents. In the year-ago quarter, DCPH had reported a loss of $1.37. DCPH expects its current cash balance to fund its operating and capital expenditures into 2025.
|
5d2aa15f-e838-45fc-9743-ca18b8f044a7
|
715445.0
|
2022-11-03 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-reports-q3-loss-tops-revenue-estimates
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $1.37 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 3.51%. A quarter ago, it was expected that this company would post a loss of $0.65 per share when it actually produced a loss of $0.60, delivering a surprise of 7.69%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $35.97 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 8.07%. This compares to year-ago revenues of $23.22 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Deciphera Pharmaceuticals, Inc. Shares have added about 70.3% since the beginning of the year versus the S&P 500's decline of -21.1%.
What's Next for Deciphera Pharmaceuticals, Inc.
While Deciphera Pharmaceuticals, Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Deciphera Pharmaceuticals, Inc. Favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.54 on $35.53 million in revenues for the coming quarter and -$2.50 on $130.58 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 22% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Cue Biopharma, Inc. (CUE), another stock in the same industry, has yet to report results for the quarter ended September 2022.
This company is expected to post quarterly loss of $0.38 per share in its upcoming report, which represents a year-over-year change of +7.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Cue Biopharma, Inc.'s revenues are expected to be $0.65 million, down 73.1% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Cue Biopharma, Inc. (CUE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.57. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.57. Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $35.97 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 8.07%.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.57. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $35.97 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 8.07%.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.57. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $35.97 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 8.07%.
|
f50f3c33-1830-467b-98aa-fb384d00562f
|
715446.0
|
2022-10-20 00:00:00 UTC
|
Is Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year?
|
DCPH
|
https://www.nasdaq.com/articles/is-alimera-sciences-alim-stock-outpacing-its-medical-peers-this-year
|
nan
|
nan
|
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Alimera Sciences (ALIM) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Alimera Sciences is a member of our Medical group, which includes 1188 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Alimera Sciences is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ALIM's full-year earnings has moved 11.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, ALIM has returned 3.3% so far this year. Meanwhile, the Medical sector has returned an average of -22.5% on a year-to-date basis. This means that Alimera Sciences is outperforming the sector as a whole this year.
Deciphera Pharmaceuticals, Inc. (DCPH) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 70.1%.
In Deciphera Pharmaceuticals, Inc.'s case, the consensus EPS estimate for the current year increased 4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Alimera Sciences belongs to the Medical - Biomedical and Genetics industry, which includes 562 individual stocks and currently sits at #52 in the Zacks Industry Rank. On average, this group has lost an average of 26.3% so far this year, meaning that ALIM is performing better in terms of year-to-date returns. Deciphera Pharmaceuticals, Inc. is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Alimera Sciences and Deciphera Pharmaceuticals, Inc. as they could maintain their solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alimera Sciences, Inc. (ALIM): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is another Medical stock that has outperformed the sector so far this year. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Alimera Sciences is a member of our Medical group, which includes 1188 different companies and currently sits at #2 in the Zacks Sector Rank.
|
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) is another Medical stock that has outperformed the sector so far this year. Looking more specifically, Alimera Sciences belongs to the Medical - Biomedical and Genetics industry, which includes 562 individual stocks and currently sits at #52 in the Zacks Industry Rank.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is another Medical stock that has outperformed the sector so far this year. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is another Medical stock that has outperformed the sector so far this year. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Has Alimera Sciences (ALIM) been one of those stocks this year?
|
f9adcf2c-73f4-4e18-84c0-40cecfd31440
|
715447.0
|
2022-10-05 00:00:00 UTC
|
Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?
|
DCPH
|
https://www.nasdaq.com/articles/will-ayvakit-aid-blueprint-medicines-bpmc-amid-rivalry
|
nan
|
nan
|
Blueprint Medicines Corporation BPMC has made steady progress with its lead drug, Ayvakit (avapritinib), which is approved by the FDA for treating adult patients with unresectable or metastatic gastrointestinal stromal tumors (“GIST”), harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.
The European Commission has granted conditional marketing authorization to Ayvakyt (brand name of Ayvakit in Europe) as a monotherapy for the treatment of adult patients with unresectable/metastatic GIST, harboring the PDGFRA D842V mutation.
Ayvakit/Ayvakyt has also been approved for additional indications.
In June 2021, the FDA approved Ayvakit for treating advanced systemic mastocytosis (“SM”), a rare and debilitating disease.
In March, the European Commission approved Ayvakyt as a monotherapy for the treatment of adult patients with aggressive SM, including SM with an associated hematological neoplasm as well as mast cell leukemia, after at least one systemic therapy.
In August 2022, BPMC announced positive top-line data from part 2 of the PIONEER study, which evaluated Ayvakit for treating patients with non-advanced SM.
A supplemental new drug application (sNDA) seeking approval of Ayvakit for treating non-advanced SM, is expected to be submitted in the fourth quarter of 2022.
The steady performance of Ayvakit, along with encouraging pipeline progress, has maintained momentum for BPMC.
However, Ayvakit faces competition from Deciphera Pharmaceuticals' DCPH Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. The European Commission approved Qinlock for the same indication.
Deciphera’s sole-marketed drug, Qinlock, holds great potential. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST.
This apart, investors remain upbeat about Blueprint Medicines’ lucrative collaboration deals that help the company to drive its revenue stream and enhance its financial position.
Blueprint Medicines has collaborations and license agreements with Roche Holding AG RHHBY, Zai Lab Limited ZLAB and several other companies for the development/commercialization of its drugs and drug candidates.
Blueprint Medicines is co-developing a cancer drug, Gavreto (pralsetinib), with Roche for treating patients with various types of RET-altered thyroid cancers and other solid tumors.
In July 2021, Blueprint Medicines transferred the responsibilities of booking U.S. product sales of Gavreto to RHHBY.
In November 2021, Blueprint Medicines entered into a license agreement with Zai Lab for the development/commercialization of BLU-945 and BLU-701 for the treatment of patients with EGFR-driven NSCLC in Greater China.
With acute competition lingering in the targeted cancer space, such lucrative deals are likely to enable BPMC to diversify its portfolio and overcome these challenges.
Just Released: Free Report Reveals Little-Known Strategies to Help Profit from the $30 Trillion Metaverse Boom
It's undeniable. The metaverse is gaining steam every day. Just follow the money. Google. Microsoft. Adobe. Nike. Facebook even rebranded itself as Meta because Mark Zuckerberg believes the metaverse is the next iteration of the internet. The inevitable result? Many investors will get rich as the metaverse evolves. What do they know that you don't? They’re aware of the companies best poised to grow as the metaverse does. And in a new FREE report, Zacks is revealing those stocks to you. This week, you can download, The Metaverse - What is it? And How to Profit with These 5 Pioneering Stocks. It reveals specific stocks set to skyrocket as this emerging technology develops and expands. Don't miss your chance to access it for free with no obligation.
>>Show me how I could profit from the metaverse!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Blueprint Medicines Corporation (BPMC): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
However, Ayvakit faces competition from Deciphera Pharmaceuticals' DCPH Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
However, Ayvakit faces competition from Deciphera Pharmaceuticals' DCPH Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
However, Ayvakit faces competition from Deciphera Pharmaceuticals' DCPH Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
However, Ayvakit faces competition from Deciphera Pharmaceuticals' DCPH Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
e67fc740-5657-472f-afaf-6cc54c12e054
|
715448.0
|
2022-10-04 00:00:00 UTC
|
Is Deciphera Pharmaceuticals (DCPH) Stock Outpacing Its Medical Peers This Year?
|
DCPH
|
https://www.nasdaq.com/articles/is-deciphera-pharmaceuticals-dcph-stock-outpacing-its-medical-peers-this-year
|
nan
|
nan
|
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Deciphera Pharmaceuticals, Inc. (DCPH) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Deciphera Pharmaceuticals, Inc. is a member of our Medical group, which includes 1193 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Deciphera Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for DCPH's full-year earnings has moved 4.9% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that DCPH has returned about 87.3% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -22.8% on a year-to-date basis. This means that Deciphera Pharmaceuticals, Inc. is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Jazz Pharmaceuticals (JAZZ), has outperformed the sector so far this year. The stock's year-to-date return is 6.3%.
The consensus estimate for Jazz Pharmaceuticals' current year EPS has increased 4.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Deciphera Pharmaceuticals, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 564 individual stocks and currently sits at #77 in the Zacks Industry Rank. On average, this group has lost an average of 26% so far this year, meaning that DCPH is performing better in terms of year-to-date returns.
On the other hand, Jazz Pharmaceuticals belongs to the Medical - Drugs industry. This 218-stock industry is currently ranked #73. The industry has moved -28% year to date.
Investors with an interest in Medical stocks should continue to track Deciphera Pharmaceuticals, Inc. and Jazz Pharmaceuticals. These stocks will be looking to continue their solid performance.
Special Report: The Top 5 IPOs for Your Portfolio
Today, you have a chance to get in on the ground floor of one of the best investment opportunities of the year. As the world continues to benefit from an ever-evolving internet, a handful of innovative tech companies are on the brink of reaping immense rewards - and you can put yourself in a position to cash in. One is set to disrupt the online communication industry. Brilliantly designed for creating online communities, this stock is poised to explode when made public. With the strength of our economy and record amounts of cash flooding into IPOs, you don’t want to miss this opportunity.
>>See Zacks’ Hottest IPOs Now
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Is Deciphera Pharmaceuticals, Inc. (DCPH) one of those stocks right now? Over the past three months, the Zacks Consensus Estimate for DCPH's full-year earnings has moved 4.9% higher. Our latest available data shows that DCPH has returned about 87.3% since the start of the calendar year.
|
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Is Deciphera Pharmaceuticals, Inc. (DCPH) one of those stocks right now? Over the past three months, the Zacks Consensus Estimate for DCPH's full-year earnings has moved 4.9% higher.
|
Is Deciphera Pharmaceuticals, Inc. (DCPH) one of those stocks right now? Over the past three months, the Zacks Consensus Estimate for DCPH's full-year earnings has moved 4.9% higher. Our latest available data shows that DCPH has returned about 87.3% since the start of the calendar year.
|
Is Deciphera Pharmaceuticals, Inc. (DCPH) one of those stocks right now? Over the past three months, the Zacks Consensus Estimate for DCPH's full-year earnings has moved 4.9% higher. Our latest available data shows that DCPH has returned about 87.3% since the start of the calendar year.
|
5d6259d1-778a-423d-a022-dfa5ee8d3399
|
715449.0
|
2022-09-30 00:00:00 UTC
|
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-dcph-rises-90-in-the-past-6-months%3A-heres-why
|
nan
|
nan
|
Shares of Deciphera Pharmaceuticals, Inc. DCPH have rallied 90% in the past six months against the industry’s decrease of 14.4%.
The company’s sole marketed drug, Qinlock (ripretinib), is approved for the treatment of adult patients with advanced gastrointestinal stromal tumor (“GIST”), who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib).
Qinlock has also been approved in Europe for the treatment of fourth-line GIST, which is already generating incremental sales for the company.
DCPH has made steady progress with Qinlock during this time frame, with the drug witnessing solid uptake so far. Qinlock contributes the majority of Deciphera’s revenues.
Image Source: Zacks Investment Research
The initial uptake of Qinlock has been strong since its approval in May 2020. In the first six months of 2022, Qinlock generated sales worth $60.3 million, reflecting an increase of 43.5% year over year.
DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. A potential label expansion for other indications will make the drug eligible to treat a broader patient population and drive sales further in the days ahead.
This apart, Deciphera has a diverse pipeline and is advancing multiple drug candidates in various stages of clinical development.
The company is also evaluating vimseltinib in the phase III MOTION study for the treatment of patients with tenosynovial giant-cell tumors, who are not amenable to surgery.
A phase I study is evaluating DCC-3116 as a single agent and the company is also planning to initiate three phase early-stage studies on DCC-3116 in combination with the FDA-approved MEK inhibitor, trametinib, binimetinib as well as sotorasib, an FDA approved KRASG12C inhibitor, for treating patients with advanced or metastatic solid tumors later in 2022.
The successful development and potential approval of these candidates will be a big boost for the company and is likely to reduce its heavy dependence on Qinlock for revenues.
Deciphera currently has no approved product in its portfolio other than Qinlock. All of its candidates, including vimseltinib and DCC-3116, are still some time away from commercialization. As a result, the company is heavily dependent on Qinlock for growth. Any regulatory setback for the drug will hurt the company’s prospects.
Qinlock also faces competition from Blueprint Medicines’ BPMC Ayvakit, which is approved for the treatment of unresectable or metastatic GIST, harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations in adults.
Blueprint Medicines’ lead-marketed drug Ayvakit holds great potential. BPMC is also studying the drug in various label expansion studies for additional indications.
Deciphera Pharmaceuticals, Inc. Price
Deciphera Pharmaceuticals, Inc. price | Deciphera Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Deciphera currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Aptose Biosciences Inc. APTO and ORIC Pharmaceuticals, Inc. ORIC, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aptose Biosciences’ loss per share estimates narrowed 15.7% for 2022 and 15% for 2023 in the past 60 days.
Earnings of Aptose Biosciences surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. APTO delivered an earnings surprise of 2.23%, on average.
ORIC Pharmaceuticals’ loss per share estimates narrowed 8.6% for 2022 and 22% for 2023 in the past 60 days.
Earnings of ORIC Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. ORIC delivered an earnings surprise of 8.85%, on average.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Blueprint Medicines Corporation (BPMC): Free Stock Analysis Report
Aptose Biosciences, Inc. (APTO): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Oric Pharmaceuticals, Inc. (ORIC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Shares of Deciphera Pharmaceuticals, Inc. DCPH have rallied 90% in the past six months against the industry’s decrease of 14.4%. DCPH has made steady progress with Qinlock during this time frame, with the drug witnessing solid uptake so far. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST.
|
Shares of Deciphera Pharmaceuticals, Inc. DCPH have rallied 90% in the past six months against the industry’s decrease of 14.4%. DCPH has made steady progress with Qinlock during this time frame, with the drug witnessing solid uptake so far. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST.
|
Shares of Deciphera Pharmaceuticals, Inc. DCPH have rallied 90% in the past six months against the industry’s decrease of 14.4%. DCPH has made steady progress with Qinlock during this time frame, with the drug witnessing solid uptake so far. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST.
|
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Shares of Deciphera Pharmaceuticals, Inc. DCPH have rallied 90% in the past six months against the industry’s decrease of 14.4%. DCPH has made steady progress with Qinlock during this time frame, with the drug witnessing solid uptake so far.
|
1c184c1e-9030-4b55-bfe1-80b2054c99dc
|
715450.0
|
2022-09-12 00:00:00 UTC
|
Blueprint Medicines (BPMC) Rises 68.2% in 3 Months: Here's Why
|
DCPH
|
https://www.nasdaq.com/articles/blueprint-medicines-bpmc-rises-68.2-in-3-months%3A-heres-why
|
nan
|
nan
|
Shares of Blueprint Medicines Corporation BPMC have rallied 68.2% in the past three months compared with the industry’s rise of 10.2%.
The company has made steady progress with its lead drug, Ayvakit (avapritinib), approved by the FDA for treating adult patients with unresectable or metastatic gastrointestinal stromal tumors (“GIST”), harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations during this period. The European Commission has granted conditional marketing authorization to Ayvakyt (brand name of Ayvakit in Europe) as a monotherapy for the treatment of adult patients with unresectable/metastatic GIST, harboring the PDGFRA D842V mutation.
Ayvakit/Ayvakyt has witnessed strong uptake since its launch.
Image Source: Zacks Investment Research
Ayvakit was approved by the FDA for treating advanced systemic mastocytosis (“SM”), a rare and debilitating disease in June 2021.
In March 2022, the European Commission approved Ayvakyt as a monotherapy for the treatment of adult patients with aggressive SM, including SM with an associated hematological neoplasm as well as mast cell leukemia, after at least one systemic therapy.
Last month, BPMC announced top-line data from part 2 of the PIONEER study, which evaluated Ayvakit for treating patients with non-advanced SM.
Data from the registrational part 2 of the PIONEER study showed that treatment with Ayvakit led to clinically meaningful and highly significant improvements across the primary and all key secondary endpoints, including patient-reported symptoms and measures of mast cell burden.
Blueprint Medicines plans to submit a supplemental new drug application (sNDA) for Ayvakit for treating non-advanced SM in the fourth quarter of 2022.
A type II variation marketing authorization application for Ayvakit in non-advanced SM is expected to be filed with the European Medicines Agency next year.
In the first six months of 2022, Ayvakit/Ayvakyt generated sales worth $52.3 million, reflecting a significant year-over-year increase. Potential label expansion into additional indications will make Ayvakit eligible to treat a broader patient population and is likely to drive sales further in the days ahead.
This apart, the company has other promising pipeline candidates targeting various cancer indications that are progressing well.
Blueprint Medicines’ current product revenues solely comprise sales from Ayvakit. Hence, any regulatory setback for the drug could hurt the stock in the days ahead.
Moreover, Ayvakit faces competition from Deciphera Pharmaceuticals' DCPH Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. In November 2021, the European Commission approved Qinlock for the same indication.
Deciphera’s sole-marketed drug Qinlock holds great potential. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST.
Blueprint Medicines Corporation Price
Blueprint Medicines Corporation price | Blueprint Medicines Corporation Quote
Zacks Rank & Stocks to Consider
Blueprint Medicines currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Achilles Therapeutics plc ACHL and ORIC Pharmaceuticals, Inc. ORIC, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Achilles Therapeutics’ loss per share estimates narrowed 6.4% for 2022 and 9.6% for 2023 in the past 60 days.
Earnings of Achilles Therapeutics surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. ACHL delivered an earnings surprise of 12.45%, on average.
ORIC Pharmaceuticals’ loss per share estimates narrowed 8.6% for 2022 and 22% for 2023 in the past 60 days.
Earnings of ORIC Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. ORIC delivered an earnings surprise of 8.85%, on average.
This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation
Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.
>>Yes, I Want to Help Protect My Portfolio During the Recession
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Blueprint Medicines Corporation (BPMC): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Oric Pharmaceuticals, Inc. (ORIC): Free Stock Analysis Report
Achilles Therapeutics PLC Sponsored ADR (ACHL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Moreover, Ayvakit faces competition from Deciphera Pharmaceuticals' DCPH Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Moreover, Ayvakit faces competition from Deciphera Pharmaceuticals' DCPH Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Moreover, Ayvakit faces competition from Deciphera Pharmaceuticals' DCPH Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Moreover, Ayvakit faces competition from Deciphera Pharmaceuticals' DCPH Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
78b63e25-46db-49ab-a825-a1e32f734ac6
|
715451.0
|
2022-09-12 00:00:00 UTC
|
Deciphera Presents Updated Phase 1/2 Data For Vimseltinib In Tenosynovial Giant Cell Tumor AT ESMO
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-presents-updated-phase-1-2-data-for-vimseltinib-in-tenosynovial-giant-cell-tumor
|
nan
|
nan
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) presented encouraging updated results from its ongoing phase I/II trial of Vimseltinib in patients with Tenosynovial Giant Cell Tumor not amenable to surgery at the European Society for Medical Oncology Congress on Sunday.
The data from the phase I part of the trial involved 32 patients enrolled in three dose cohorts. They were administered a 30 mg, 30 mg, and 20 mg loading dose daily for 5,3,3 days followed by a maintenance dose of 30 mg twice a week, 10 mg, and 6 mg daily respectively.
Vimseltinib was well-tolerated in patients with Tenosynovial Giant Cell Tumor (TGCT), consistent with previously disclosed data, and all the patients enrolled in the study demonstrated clinical benefit.
Data from the phase II part of the trial, involved 58 patients in two cohorts - cohort A with no prior anti-CSF1/CSF1R therapy and cohort B with prior anti-CSF1/CSF1R therapy. They were administered a twice-weekly dose of 30 mg of Vimseltinib.
All patients demonstrated clinical benefit, and the Objective Response Rate was 53% in Cohort A and 46% in Cohort B, according to the company.
The results support Vimseltinib's evaluation in the ongoing Phase 3 MOTION study, noted Deciphera.
DCPH has traded in a range of $6.51 to $37.99 in the last 52 weeks. The stock closed Friday's trading at $18.08, up 0.95%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) presented encouraging updated results from its ongoing phase I/II trial of Vimseltinib in patients with Tenosynovial Giant Cell Tumor not amenable to surgery at the European Society for Medical Oncology Congress on Sunday. DCPH has traded in a range of $6.51 to $37.99 in the last 52 weeks. The data from the phase I part of the trial involved 32 patients enrolled in three dose cohorts.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) presented encouraging updated results from its ongoing phase I/II trial of Vimseltinib in patients with Tenosynovial Giant Cell Tumor not amenable to surgery at the European Society for Medical Oncology Congress on Sunday. DCPH has traded in a range of $6.51 to $37.99 in the last 52 weeks. The data from the phase I part of the trial involved 32 patients enrolled in three dose cohorts.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) presented encouraging updated results from its ongoing phase I/II trial of Vimseltinib in patients with Tenosynovial Giant Cell Tumor not amenable to surgery at the European Society for Medical Oncology Congress on Sunday. DCPH has traded in a range of $6.51 to $37.99 in the last 52 weeks. They were administered a 30 mg, 30 mg, and 20 mg loading dose daily for 5,3,3 days followed by a maintenance dose of 30 mg twice a week, 10 mg, and 6 mg daily respectively.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) presented encouraging updated results from its ongoing phase I/II trial of Vimseltinib in patients with Tenosynovial Giant Cell Tumor not amenable to surgery at the European Society for Medical Oncology Congress on Sunday. DCPH has traded in a range of $6.51 to $37.99 in the last 52 weeks. The data from the phase I part of the trial involved 32 patients enrolled in three dose cohorts.
|
f860e116-754d-44d7-87a5-5ccd5231244f
|
715452.0
|
2022-09-08 00:00:00 UTC
|
Allogene Therapeutics (ALLO) Down 10.9% Since Last Earnings Report: Can It Rebound?
|
DCPH
|
https://www.nasdaq.com/articles/allogene-therapeutics-allo-down-10.9-since-last-earnings-report%3A-can-it-rebound
|
nan
|
nan
|
It has been about a month since the last earnings report for Allogene Therapeutics (ALLO). Shares have lost about 10.9% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Allogene Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Allogene Q2 Earnings and Sales Beat Estimates
Allogene incurred a loss of 52 cents per share in second-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of 61 cents and the year-ago quarter’s loss of 53 cents.
ALLO recorded revenues of $0.09 million during the quarter, which beat the Zacks Consensus Estimate of $0.08 million. In the year-ago quarter, Allogene recorded $0.04 million of revenues.
Quarter in Detail
Research & development (R&D) expenses were $57.2 million, up 9.3% from the year-ago quarter’s level.
General and administrative (G&A) expenses increased 3.9% year over year to $19.5 million.
Allogene had $686.1 million of cash, cash equivalents and investments as of Jun 30, 2022, compared with $733.1 million as of Mar 31, 2022.
2022 Guidance
Though Allogene anticipates an increase in operating expenses in the second half of the year compared with the first half, it expects operating expenses for the full year to be at the lower end of the previously-provided guidance of $360 million-$390 million.
Cash burn for the full year is expected to be around $250 million.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month.
The consensus estimate has shifted 7.87% due to these changes.
VGM Scores
Currently, Allogene Therapeutics has a subpar Growth Score of D, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Allogene Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Allogene Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Deciphera Pharmaceuticals, Inc. (DCPH), a stock from the same industry, has gained 1.7%. The company reported its results for the quarter ended June 2022 more than a month ago.
Deciphera Pharmaceuticals, Inc. reported revenues of $32.49 million in the last reported quarter, representing a year-over-year change of +37.8%. EPS of -$0.60 for the same period compares with -$1.21 a year ago.
For the current quarter, Deciphera Pharmaceuticals, Inc. is expected to post a loss of $0.57 per share, indicating a change of +58.4% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.4% over the last 30 days.
Deciphera Pharmaceuticals, Inc. has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.
Special Report: The Top 5 IPOs for Your Portfolio
Today, you have a chance to get in on the ground floor of one of the best investment opportunities of the year. As the world continues to benefit from an ever-evolving internet, a handful of innovative tech companies are on the brink of reaping immense rewards - and you can put yourself in a position to cash in. One is set to disrupt the online communication industry. Brilliantly designed for creating online communities, this stock is poised to explode when made public. With the strength of our economy and record amounts of cash flooding into IPOs, you don’t want to miss this opportunity.
>>See Zacks’ Hottest IPOs Now
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Allogene Therapeutics, Inc. (ALLO): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Over the past month, Deciphera Pharmaceuticals, Inc. (DCPH), a stock from the same industry, has gained 1.7%. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
|
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Over the past month, Deciphera Pharmaceuticals, Inc. (DCPH), a stock from the same industry, has gained 1.7%. 2022 Guidance Though Allogene anticipates an increase in operating expenses in the second half of the year compared with the first half, it expects operating expenses for the full year to be at the lower end of the previously-provided guidance of $360 million-$390 million.
|
Over the past month, Deciphera Pharmaceuticals, Inc. (DCPH), a stock from the same industry, has gained 1.7%. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Allogene Q2 Earnings and Sales Beat Estimates Allogene incurred a loss of 52 cents per share in second-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of 61 cents and the year-ago quarter’s loss of 53 cents.
|
Over the past month, Deciphera Pharmaceuticals, Inc. (DCPH), a stock from the same industry, has gained 1.7%. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report It has been about a month since the last earnings report for Allogene Therapeutics (ALLO).
|
8be059ac-99f2-47d2-924c-813c7ff868ec
|
715453.0
|
2022-09-02 00:00:00 UTC
|
Deciphera Pharmaceuticals (NASDAQ:DCPH) adds US$97m to market cap in the past 7 days, though investors from three years ago are still down 54%
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-nasdaq%3Adcph-adds-us%2497m-to-market-cap-in-the-past-7-days-though
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shareholders will doubtless be very grateful to see the share price up 52% in the last quarter. But that is small recompense for the exasperating returns over three years. Tragically, the share price declined 54% in that time. So it is really good to see an improvement. While many would remain nervous, there could be further gains if the business can put its best foot forward.
The recent uptick of 9.3% could be a positive sign of things to come, so let's take a lot at historical fundamentals.
Because Deciphera Pharmaceuticals made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.
In the last three years, Deciphera Pharmaceuticals saw its revenue grow by 62% per year, compound. That's well above most other pre-profit companies. In contrast, the share price is down 16% compound, over three years - disappointing by most standards. This could mean hype has come out of the stock because the losses are concerning investors. When we see revenue growth, paired with a falling share price, we can't help wonder if there is an opportunity for those who are willing to dig deeper.
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
NasdaqGS:DCPH Earnings and Revenue Growth September 2nd 2022
You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.
A Different Perspective
Deciphera Pharmaceuticals shareholders are down 48% for the year, falling short of the market return. The market shed around 18%, no doubt weighing on the stock price. The three-year loss of 16% per year isn't as bad as the last twelve months, suggesting that the company has not been able to convince the market it has solved its problems. Although Baron Rothschild famously said to "buy when there's blood in the streets, even if the blood is your own", he also focusses on high quality stocks with solid prospects. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 3 warning signs for Deciphera Pharmaceuticals that you should be aware of.
We will like Deciphera Pharmaceuticals better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
NasdaqGS:DCPH Earnings and Revenue Growth September 2nd 2022 You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shareholders will doubtless be very grateful to see the share price up 52% in the last quarter. The three-year loss of 16% per year isn't as bad as the last twelve months, suggesting that the company has not been able to convince the market it has solved its problems.
|
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shareholders will doubtless be very grateful to see the share price up 52% in the last quarter. NasdaqGS:DCPH Earnings and Revenue Growth September 2nd 2022 You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic. When a company doesn't make profits, we'd generally expect to see good revenue growth.
|
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shareholders will doubtless be very grateful to see the share price up 52% in the last quarter. NasdaqGS:DCPH Earnings and Revenue Growth September 2nd 2022 You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic. Because Deciphera Pharmaceuticals made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now.
|
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shareholders will doubtless be very grateful to see the share price up 52% in the last quarter. NasdaqGS:DCPH Earnings and Revenue Growth September 2nd 2022 You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic. Because Deciphera Pharmaceuticals made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now.
|
db7fd60f-f5a7-4976-bc5b-1bc92a5f2906
|
715454.0
|
2022-08-30 00:00:00 UTC
|
Deciphera (DCPH) Thrives on Qinlock, Overdependence a Concern
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-dcph-thrives-on-qinlock-overdependence-a-concern
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc.’s DCPH sole marketed drug, Qinlock, is approved for the treatment of adult patients with advanced gastrointestinal stromal tumors (“GIST") who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib).
Qinlock has also been approved in Europe for the treatment of fourth-line GIST, which is already generating incremental sales for the company.
The initial uptake of Qinlock has been strong since its approval in May 2020. In the first six months of 2022, Qinlock generated net sales worth $60.3 million, reflecting an increase of 43.5% year over year. The drug contributes the majority of Deciphera’s revenues.
DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. A potential label expansion for other indications will make the drug eligible to treat a broader patient population and drive sales further in the days ahead.
Shares of Deciphera have rallied 61.3% this year against the industry’s decline of 23.6%.
Image Source: Zacks Investment Research
In late November 2021, Deciphera entered into a corporate restructuring, whereby the company decided to streamline its commercial operations and reduce its current workforce by approximately 35%, or almost 140 positions. The changes in the clinical development programs and restructuring efforts are expected to bring a significant reduction in the company’s operating expenses.
This apart, Deciphera has a diverse pipeline and is advancing multiple drug candidates in various stages of clinical development.
The company is evaluating vimseltinib in the phase III MOTION study for the treatment of patients with tenosynovial giant-cell tumors, who are not amenable to surgery.
A phase I study is evaluating DCC-3116 as a single agent and the company is also planning to initiate three phase early-stage studies on DCC-3116 in combination with FDA-approved MEK inhibitor, trametinib, binimetinib as well as sotorasib, an FDA- approved KRASG12C inhibitor, for treating patients with advanced or metastatic solid tumors in the second half of 2022.
The successful development and potential approval of these candidates will be a big boost for the company and is likely to reduce its heavy dependence on Qinlock for revenues.
On the flip side, Deciphera currently has no approved product in its portfolio other than Qinlock. All of its candidates, including vimseltinib and DCC-3116, are still some time away from commercialization. As a result, the company is heavily dependent on Qinlock for growth. Any regulatory setback for the drug will hurt the company’s prospects.
Qinlock also faces competition from Blueprint Medicines’ BPMC Ayvakit, which is approved for the treatment of unresectable or metastatic GIST, harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations in adults.
Blueprint Medicines’ lead-marketed drug Ayvakit holds great potential. BPMC is also studying the drug in various label expansion studies for additional indications.
Deciphera Pharmaceuticals, Inc. Price and Consensus
Deciphera Pharmaceuticals, Inc. price-consensus-chart | Deciphera Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Deciphera currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector include Achilles Therapeutics plc ACHL and Atara Biotherapeutics, Inc. ATRA, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Achilles Therapeutics’ loss per share estimates narrowed 6.4% for 2022 and 9.6% for 2023 in the past 60 days.
Earnings of Achilles Therapeutics surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. ACHL delivered an earnings surprise of 12.45%, on average.
Atara Biotherapeutics’ loss per share estimates narrowed 43.2% for 2022 and 31.8% for 2023 in the past 60 days.
Earnings of Atara Biotherapeutics surpassed estimates in three of the trailing four quarters and missed on the other occasion. ATRA delivered an earnings surprise of 4.83%, on average.
How to Profit from the Hot Electric Vehicle Industry
Global electric car sales in 2021 more than doubled their 2020 numbers. And today, the electric vehicle (EV) technology and very nature of the business is changing quickly. The next push for future technologies is happening now and investors who get in early could see exceptional profits.
See Zacks' Top Stocks to Profit from the EV Revolution >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Atara Biotherapeutics, Inc. (ATRA): Free Stock Analysis Report
Blueprint Medicines Corporation (BPMC): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Achilles Therapeutics PLC Sponsored ADR (ACHL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc.’s DCPH sole marketed drug, Qinlock, is approved for the treatment of adult patients with advanced gastrointestinal stromal tumors (“GIST") who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib). DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Deciphera Pharmaceuticals, Inc.’s DCPH sole marketed drug, Qinlock, is approved for the treatment of adult patients with advanced gastrointestinal stromal tumors (“GIST") who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib). DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Deciphera Pharmaceuticals, Inc.’s DCPH sole marketed drug, Qinlock, is approved for the treatment of adult patients with advanced gastrointestinal stromal tumors (“GIST") who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib). DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Deciphera Pharmaceuticals, Inc.’s DCPH sole marketed drug, Qinlock, is approved for the treatment of adult patients with advanced gastrointestinal stromal tumors (“GIST") who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib). DCPH is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
508288ca-8fc4-45fa-9049-754a610b0ff7
|
715455.0
|
2022-08-25 00:00:00 UTC
|
DCPH Stock Has Outperformed, Should Investors Buy?
|
DCPH
|
https://www.nasdaq.com/articles/dcph-stock-has-outperformed-should-investors-buy
|
nan
|
nan
|
The shares of Deciphera Pharmaceuticals (DCPH) have performed well in 2022, as they are up 40.4% while most healthcare stocks are down. Nevertheless, I would not buy shares of this stock due to a lack of interesting prospects for the treatments the company is developing. In fact, if I had shares in my portfolio, I would consider unloading them. As such, I am bearish on this stock for now.
So far, there has been no event that could justify such a price increase. A new equity offering was announced in late April to raise up to $150 million in cash to fund drug development. Furthermore, on June 16, the company named a former Novartis (NVS) executive as its new senior vice president and chief business officer.
However, none of this news can be classified as a strong bullish catalyst, resulting in a significant risk that this stock is being overvalued rather than reflecting the fair value of this company.
In addition, the portfolio of treatments that this specialist healthcare provider is developing does not seem attractive enough to push the share price higher.
About Deciphera Pharmaceuticals Stock and Its Treatments
Deciphera Pharmaceuticals is a biopharmaceutical developer of medication that aims to improve the effectiveness of cancer therapies and improve the quality of life of cancer patients. The company's flagship treatment is QINLOCK, which is currently being used in the therapy against gastrointestinal stromal tumors (GIST). That is, it should be used after an initial (first-line) treatment has failed or stopped producing significant results or when intolerable side effects occur.
The treatment pipeline currently under development also includes an oral therapy to inhibit the causative agent of tenosynovial giant cell tumor (TGCT) and a product to treat RAS/RAF mutant cancers. However, this is still in the clinical phase. These RAS/RAF mutations are believed to be responsible for colorectal cancer (CRC).
GIST is a disease characterized by the formation of abnormal cells in the tissues of the gastrointestinal tract. Genetic factors are not the main cause of the disease, although some of them define a higher risk of developing GIST, which is usually manifested by either blood in the stool or vomit.
At an early stage of GIST, with a 5-year survival rate of over 90%, the tumor can be cured by surgical removal through a minimally invasive laparoscopic procedure that does not damage vital organs, followed by treatment in most cases.
GIST is rare because this type of tumor accounts for less than 1% of all gastrointestinal cancers and represents between 4,000 and 6,000 new diagnoses in American adults each year.
If malignant, TGCT is a rare clinical entity consisting of a lesion of the synovial membrane (tissue connecting the joints), the tendon capsule (tissue covering the tendons), and the bursa (a fluid-filled sac located between bone, tendons, and muscles) which persists repeatedly. A malignant TGCT may also co-occur with a benign TGCT lesion.
Based on various statistics, the global incidence of TGCT accounts for 2 to 50 cases per million people belonging to the general population. Therefore, TGCT is a rare disease.
Deciphera Improves Sales but Remains Unprofitable
In the second quarter of 2022, Deciphera achieved $32.5 million in total revenue, with $31.5 million coming from the sale of QINLOCK. Total revenue grew by 38% compared to the previous year, which exceeded the median projection of analysts by $2.4 million. The company is not yet profitable and posted a net loss of -$0.60 per DCPH share. This compares to a net loss of $1.21 per share in the same quarter of last year, beating analysts' median estimate by $0.06.
Deciphera Can Fund Its Operations, for Now
The balance sheet showed a cash balance of $384 million, well in excess of total loans in operating lease liabilities of $30.58 million. This provides the financial flexibility to complete the Phase 1 drug inhibitor study in cancer patients with RAS or RAF gene mutations and the pivotal phase 3 study of a TGCT treatment agent. Given that the level of total costs and operating expenses are up 19% year-over-year to $76.3 million, the funds guarantee business continuity at best for a few more years.
After that, the company must be able to stand on its own two feet without relying solely on equity or debt, especially as the cost of capital continues to rise due to the Federal Reserve's tightening policy.
Deciphera Pharmaceuticals has an Altman Z-Score of 2.21, indicating the company is neither distressed nor safe. A company is considered distressed as soon as the value falls below 1.8. On the other hand, a value of more than 3 means a healthy financial situation. However, unless the company starts producing profits or reducing its cash burn, then it will eventually enter the distressed zone fairly quickly.
Deciphera Has an Unattractive Portfolio of Drugs Targeting Rare Diseases
The company's prospects don't look very promising to me right now. Relying on the secondary treatment of a rare disease to generate the majority of revenue doesn't exactly sound like a home run. This is especially true since DCPH is still unprofitable. In addition, the other drugs the company has in development also target rare diseases. Therefore, sales volume will ultimately be limited in the long run.
Is DCPH Stock a Buy?
In the past three months, eight Wall Street analysts have issued a 12-month price target for DCPH. The stock has a Hold consensus rating based on three Buys, three Holds, and two Sells. The average DCPH stock price target is $14.63, implying 6% downside potential.
Conclusion - DCPH Stock's Risk is Not Justified by Its Portfolio
DCPH is developing a pipeline of treatments targeting very rare diseases, which will not be used as first-line medicines. The financial position is still strong, but that could change fairly quickly if the company doesn't start producing profits. DCPH's future is very uncertain, as it faces several challenges. These include a higher cost of capital as the Federal Reserve continues to hike interest rates to deal with galloping inflation.
Disclosure
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The shares of Deciphera Pharmaceuticals (DCPH) have performed well in 2022, as they are up 40.4% while most healthcare stocks are down. The company is not yet profitable and posted a net loss of -$0.60 per DCPH share. This is especially true since DCPH is still unprofitable.
|
Conclusion - DCPH Stock's Risk is Not Justified by Its Portfolio DCPH is developing a pipeline of treatments targeting very rare diseases, which will not be used as first-line medicines. The shares of Deciphera Pharmaceuticals (DCPH) have performed well in 2022, as they are up 40.4% while most healthcare stocks are down. The company is not yet profitable and posted a net loss of -$0.60 per DCPH share.
|
Conclusion - DCPH Stock's Risk is Not Justified by Its Portfolio DCPH is developing a pipeline of treatments targeting very rare diseases, which will not be used as first-line medicines. The shares of Deciphera Pharmaceuticals (DCPH) have performed well in 2022, as they are up 40.4% while most healthcare stocks are down. The company is not yet profitable and posted a net loss of -$0.60 per DCPH share.
|
The shares of Deciphera Pharmaceuticals (DCPH) have performed well in 2022, as they are up 40.4% while most healthcare stocks are down. Is DCPH Stock a Buy? Conclusion - DCPH Stock's Risk is Not Justified by Its Portfolio DCPH is developing a pipeline of treatments targeting very rare diseases, which will not be used as first-line medicines.
|
acc53704-aa78-415b-a05a-f590fd164389
|
715456.0
|
2022-08-05 00:00:00 UTC
|
Deciphera (DCPH) Loss Narrows in Q2, Qinlock Drive Revenues
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-dcph-loss-narrows-in-q2-qinlock-drive-revenues
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. DCPH reported a second-quarter 2022 loss of 60 cents per share, narrower than the Zacks Consensus Estimate of a loss of 65 cents. In the year-ago quarter, the company had reported a loss of $1.21.
Total net revenues were $32.5 million in the quarter, which surpassed the Zacks Consensus Estimate of $30 million. Revenues rose almost 38% year over year.
Shares of Deciphera were up 23.9% on Thursday owing to the better-than-expected earnings results. The stock has skyrocketed 72% in the year against the industry’s decline of 19.7%.
Image Source: Zacks Investment Research
In May 2020, the FDA approved Deciphera’s sole marketed drug, Qinlock (ripretinib), to treat adult patients with advanced gastrointestinal stromal tumors (“GIST”), who have received prior treatment with three or more kinase inhibitors, including Gleevec (imatinib).
Quarter in Detail
Apart from Qinlock, there is no other marketable drug in the company’s portfolio. Total revenues comprised net product revenues and collaboration revenues. Net product revenues were $31.5 million, reflecting an increase of 43% year over year. Qinlock generated $23.7 million in sales in the United States and $7.8 million in sales in ex-U.S. markets.
Collaboration revenues in the reported quarter were $1 million compared to $1.5 million recorded in the year-ago quarter.
Research and development expenses were $44.9 million, down 25.2% year over year, owing to lower costs related to clinical studies on Qinlock.
Selling, general and administrative expenses were $29.6 million, down 9.7% year over year, owing to lower professional and consultant fees.
Deciphera had cash, cash equivalents and investments worth $393.1 million as of Jun 30, 2022 compared with $275.4 million as of Mar 31, 2022.
Other Updates
In November 2021, the European Commission approved Qinlock for treating adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec. The nod in Europe is already generating incremental sales and is expected to do the same in future quarters.
Per the company, Germany’s Federal Joint Committee (G-BA) has issued a “major additional benefit” rating to Qinlock. The drug has now become the first orphan oncology treatment to receive this rating in Germany. It is also the only GIST treatment to win this recognition.
Deciphera is evaluating vimseltinib in the phase III MOTION study for the treatment of patients with tenosynovial giant-cell tumors, who are not amenable to surgery.
The company is also planning to initiate three phase Ib studies on DCC-3116 in combination with FDA-approved MEK inhibitor, trametinib, binimetinib as well as sotorasib, an FDA- approved KRASG12C inhibitor, for treating patients with advanced or metastatic solid tumors in the second half of 2022.
Deciphera Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Deciphera Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Deciphera Pharmaceuticals, Inc. Quote
Zacks Rank & Other Stocks to Consider
Deciphera currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the biotech sector include Beam Therapeutics Inc. BEAM, Atara Biotherapeutics, Inc. ATRA and Precision BioSciences, Inc. DTIL, all carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Beam Therapeutics’ loss per share estimates narrowed 0.7% for 2022 and 0.8% for 2023 in the past 60 days.
Earnings of Beam Therapeutics have surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. BEAM delivered an earnings surprise of 1.80%, on average.
Atara Biotherapeutics’ loss per share estimates narrowed 0.6% for 2022 and 13.3% for 2023 in the past 60 days.
Earnings of Atara Biotherapeutics have surpassed estimates in two of the trailing four quarters and missed on the other two occasions. ATRA delivered an earnings surprise of -12.51%, on average.
Precision BioSciences’ loss per share estimates narrowed 5.8% for 2022 and 16.2% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Beam Therapeutics Inc. (BEAM): Free Stock Analysis Report
Atara Biotherapeutics, Inc. (ATRA): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Precision BioSciences, Inc. (DTIL): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. DCPH reported a second-quarter 2022 loss of 60 cents per share, narrower than the Zacks Consensus Estimate of a loss of 65 cents. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Image Source: Zacks Investment Research In May 2020, the FDA approved Deciphera’s sole marketed drug, Qinlock (ripretinib), to treat adult patients with advanced gastrointestinal stromal tumors (“GIST”), who have received prior treatment with three or more kinase inhibitors, including Gleevec (imatinib).
|
Deciphera Pharmaceuticals, Inc. DCPH reported a second-quarter 2022 loss of 60 cents per share, narrower than the Zacks Consensus Estimate of a loss of 65 cents. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Image Source: Zacks Investment Research In May 2020, the FDA approved Deciphera’s sole marketed drug, Qinlock (ripretinib), to treat adult patients with advanced gastrointestinal stromal tumors (“GIST”), who have received prior treatment with three or more kinase inhibitors, including Gleevec (imatinib).
|
Deciphera Pharmaceuticals, Inc. DCPH reported a second-quarter 2022 loss of 60 cents per share, narrower than the Zacks Consensus Estimate of a loss of 65 cents. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Total net revenues were $32.5 million in the quarter, which surpassed the Zacks Consensus Estimate of $30 million.
|
Deciphera Pharmaceuticals, Inc. DCPH reported a second-quarter 2022 loss of 60 cents per share, narrower than the Zacks Consensus Estimate of a loss of 65 cents. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report In the year-ago quarter, the company had reported a loss of $1.21.
|
31420f8d-154f-465f-af26-6e00eb898bf1
|
715457.0
|
2022-08-04 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-reports-q2-loss-tops-revenue-estimates
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $1.21 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 7.69%. A quarter ago, it was expected that this company would post a loss of $0.84 per share when it actually produced a loss of $0.80, delivering a surprise of 4.76%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $32.49 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 7.56%. This compares to year-ago revenues of $23.57 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Deciphera Pharmaceuticals, Inc. Shares have added about 38.9% since the beginning of the year versus the S&P 500's decline of -12.8%.
What's Next for Deciphera Pharmaceuticals, Inc.
While Deciphera Pharmaceuticals, Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Deciphera Pharmaceuticals, Inc. Favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.58 on $32.15 million in revenues for the coming quarter and -$2.56 on $125.28 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
LAVA Therapeutics N.V. (LVTX), another stock in the same industry, has yet to report results for the quarter ended June 2022.
This company is expected to post quarterly loss of $0.61 per share in its upcoming report, which represents a year-over-year change of -117.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
LAVA Therapeutics N.V.'s revenues are expected to be $1 million, down 7.4% from the year-ago quarter.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
LAVA Therapeutics N.V. (LVTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.65. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.65. Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $32.49 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 7.56%.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.65. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $32.49 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 7.56%.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.65. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report The company has topped consensus revenue estimates three times over the last four quarters.
|
dfbc1661-5e0c-4947-bb02-e1480459eccd
|
715458.0
|
2022-08-04 00:00:00 UTC
|
BioMarin's (BMRN) Q2 Earnings Top, Voxzogo Drives Sales
|
DCPH
|
https://www.nasdaq.com/articles/biomarins-bmrn-q2-earnings-top-voxzogo-drives-sales
|
nan
|
nan
|
BioMarin Pharmaceutical BMRN reported second-quarter 2022 adjusted earnings of 59 cents per share, beating the Zacks Consensus Estimate of 43 cents. Earnings rose 11.3% from the year-ago quarter’s figure driven by higher revenues, which offset the impact of higher marketing costs.
Total revenues were $533.8 million in the reported quarter, up 6% from the year-ago quarter’s level. The revenues beat the Zacks Consensus Estimate of $511 million.
In the year so far, BioMarin’s stock is up 0.1% against the industry’s fall of 22%.
Quarter in Detail
Product revenues (including Aldurazyme) were $517.7 million in the quarter, up 6.4% year over year. Product revenues from BioMarin's marketed brands (excluding Aldurazyme) were up 5% year over year to $480.4 million on higher revenues from the new drug, Voxzogo, which offset lower sales of Kuvan and Naglazyme. Royalty and other revenues were $16.1 million in the quarter, up 7.4%.
Vimizim sales were up 1% year over year to $173.3 million, while Naglazyme sales declined 3% to $115.8 million. Vimzim and Naglazyme sales were lower than in the first quarter due to the volume of large irregular orders placed in the first quarter. Both Naglazyme and Vimzim experience uneven quarterly revenue patterns.
Brineura generated sales of $37.7 million in the quarter, up 24% year over year, driven by 18% year-over-year growth in commercial patients.
The new drug Voxzogo, approved last year in the United States and Europe to treat achondroplasia, generated sales worth $34.4 million in the second quarter compared with $19.7 million in the first quarter. Higher sales of Voxzogo were driven by new patients initiating therapy in Europe as well as the United States. As of Jun 30, an estimated 446 children were being treated with Voxzogo, of which 164 were from the United States and 282 from international markets. Voxzogo was approved in Japan and Australia in the quarter.
In the phenylketonuria (PKU) franchise, Kuvan revenues declined 27% to $57.6 million due to generic competition as the drug lost U.S. market exclusivity in late 2020.
Palynziq injection sales grossed $61.6 million in the quarter, up 4% year over year. Sales were below management expectations. BioMarin expects Palynziq patient trends to grow at a slower pace than initial expectations. Palynziq sales continue to be hurt as PKU clinics particularly in the United States, to treat adult PKU patients with Palynziq, have not recovered their capacity lost due to the pandemic.
Product revenues from Aldurazyme totaled $37.3 million, up 33% due to the favorable timing of product fulfillment to Sanofi’s SNY subsidiary, Genzyme.
BioMarin has a collaboration agreement with Sanofi’s Genzyme for Aldurazyme. Sanofi through Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.
2022 Sales View Up Slightly
Despite ongoing economic challenges like currency fluctuations, BioMarin slightly raised its previously issued sales guidance for 2022 from a range of $2.05-$2.15 billion to $2.06-$2.16 billion, backed by the growth of Voxzogo.
BioMarin now expects to record Voxzogo sales in the range of $130-$160 million in 2022, up from the previous guidance of $100-$125 million, backed by robust demand for the drug in the United States and Europe.
Vimizim sales are expected in the range of $655-$700 million (previously $650-$700 million). Kuvan sales are anticipated in the range of $210-$235 million (previously $225-$250 million). Palynziq sales are expected in the range of $250-$275 million (previously $280-$310 million). Naglazyme sales are expected between $415 million and $450 million (previously $400 million and $440 million). Brineura sales are expected within $145-$160 million (maintained). BioMarin expects Roctavian to be a modest contributor to second-half revenues.
BioMarin maintained its adjusted net income guidance in the range of $350-$390 million.
Pipeline Update
BioMarin’s biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA in August 2020 while the marketing authorization application (MAA) in Europe was withdrawn. BioMarin resubmitted the MAA along with this one-year data to the European Medicines Agency (EMA) in June 2021. BioMarin announced two-year follow-up safety and efficacy data from the phase III GENEr8-1 study in January 2022 and submitted the same to the EMA.
In June, the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) issued a positive opinion recommending the approval of valoctocogene roxaparvovec. A final decision of the European Commission is expected in a couple of months. A BLA is expected to be re-filed with the FDA in September, delayed from the earlier timeline of June 2022. Along with the earnings release, BioMarin said that the review procedure should take nine months rather than the normal six-month review procedure as several related data-readouts are expected during that time.
Another gene therapy candidate in BioMarin’s pipeline is BMN 331 for the treatment of hereditary angioedema. A phase I/II HAERMONY study on BMN 331 is ongoing and patients have been dosed.
Zacks Rank & Stocks to Consider
Currently, BioMarin carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the same sector worth considering are Deciphera Pharmaceuticals DCPH and BioNTech BNTX, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Deciphera Pharmaceuticals’ loss per share estimates for 2022 have narrowed from $2.62 to $2.57 in the past 30 days. DCPH’s stock has risen 38.9% in the year-to-date period.
Earnings of Deciphera Pharmaceuticals missed estimates in three of the last four quarters and beat the mark once, the average negative surprise being 2.0%.
BioNTech’s stock is down 30.9% this year so far. Earnings estimates for 2022 have gone up from $33.18 per share to $34.28 per share while that for 2023 has increased from $14.28 per share to $20.17 per share over the past 30 days.
Earnings of BioNTech beat estimates in all the last four quarters, the average surprise being 56.87%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY): Free Stock Analysis Report
BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked stocks in the same sector worth considering are Deciphera Pharmaceuticals DCPH and BioNTech BNTX, both carrying a Zacks Rank #2 (Buy) at present. DCPH’s stock has risen 38.9% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Some better-ranked stocks in the same sector worth considering are Deciphera Pharmaceuticals DCPH and BioNTech BNTX, both carrying a Zacks Rank #2 (Buy) at present. DCPH’s stock has risen 38.9% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Some better-ranked stocks in the same sector worth considering are Deciphera Pharmaceuticals DCPH and BioNTech BNTX, both carrying a Zacks Rank #2 (Buy) at present. DCPH’s stock has risen 38.9% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Some better-ranked stocks in the same sector worth considering are Deciphera Pharmaceuticals DCPH and BioNTech BNTX, both carrying a Zacks Rank #2 (Buy) at present. DCPH’s stock has risen 38.9% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
8237a796-80a4-4e9f-8e57-783720655c17
|
715459.0
|
2022-07-27 00:00:00 UTC
|
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for
|
DCPH
|
https://www.nasdaq.com/articles/analysts-estimate-biomarin-pharmaceutical-bmrn-to-report-a-decline-in-earnings%3A-what-to-3
|
nan
|
nan
|
BioMarin Pharmaceutical (BMRN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2022. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The earnings report, which is expected to be released on August 3, 2022, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This rare disease biopharmaceutical is expected to post quarterly earnings of $0.43 per share in its upcoming report, which represents a year-over-year change of -18.9%.
Revenues are expected to be $514.18 million, up 2.5% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1.77% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for BioMarin?
For BioMarin, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -17.23%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination makes it difficult to conclusively predict that BioMarin will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that BioMarin would post earnings of $0.38 per share when it actually produced earnings of $0.55, delivering a surprise of +44.74%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
BioMarin doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry Player
Another stock from the Zacks Medical - Biomedical and Genetics industry, Deciphera Pharmaceuticals, Inc. (DCPH), is soon expected to post loss of $0.66 per share for the quarter ended June 2022. This estimate indicates a year-over-year change of +45.5%. Revenues for the quarter are expected to be $30.21 million, up 28.2% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for Deciphera Pharmaceuticals, Inc. has been revised 1% up to the current level. Nevertheless, the company now has an Earnings ESP of -0.51%, reflecting a lower Most Accurate Estimate.
When combined with a Zacks Rank of #2 (Buy), this Earnings ESP makes it difficult to conclusively predict that Deciphera Pharmaceuticals, Inc. will beat the consensus EPS estimate. Over the last four quarters, the company surpassed EPS estimates just once.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?
From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Expected Results of an Industry Player Another stock from the Zacks Medical - Biomedical and Genetics industry, Deciphera Pharmaceuticals, Inc. (DCPH), is soon expected to post loss of $0.66 per share for the quarter ended June 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
|
Expected Results of an Industry Player Another stock from the Zacks Medical - Biomedical and Genetics industry, Deciphera Pharmaceuticals, Inc. (DCPH), is soon expected to post loss of $0.66 per share for the quarter ended June 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate.
|
Expected Results of an Industry Player Another stock from the Zacks Medical - Biomedical and Genetics industry, Deciphera Pharmaceuticals, Inc. (DCPH), is soon expected to post loss of $0.66 per share for the quarter ended June 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate.
|
Expected Results of an Industry Player Another stock from the Zacks Medical - Biomedical and Genetics industry, Deciphera Pharmaceuticals, Inc. (DCPH), is soon expected to post loss of $0.66 per share for the quarter ended June 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Nevertheless, the company now has an Earnings ESP of -0.51%, reflecting a lower Most Accurate Estimate.
|
42de4a95-108d-4b9a-95cd-79e1063f115e
|
715460.0
|
2022-07-27 00:00:00 UTC
|
Does Deciphera Pharmaceuticals, Inc. (DCPH) Have the Potential to Rally 27% as Wall Street Analysts Expect?
|
DCPH
|
https://www.nasdaq.com/articles/does-deciphera-pharmaceuticals-inc.-dcph-have-the-potential-to-rally-27-as-wall-street
|
nan
|
nan
|
Shares of Deciphera Pharmaceuticals, Inc. (DCPH) have gained 1.7% over the past four weeks to close the last trading session at $13.57, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17.22 indicates a potential upside of 26.9%.
The average comprises nine short-term price targets ranging from a low of $6 to a high of $64, with a standard deviation of $17.81. While the lowest estimate indicates a decline of 55.8% from the current price level, the most optimistic estimate points to a 371.6% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.
But, for DCPH, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Price, Consensus and EPS Surprise
Here's What You May Not Know About Analysts' Price Targets
According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Why DCPH Could Witness a Solid Upside
There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 0.9%, as one estimate has moved higher compared to no negative revision.
Moreover, DCPH currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, while the consensus price target may not be a reliable indicator of how much DCPH could gain, the direction of price movement it implies does appear to be a good guide.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?
From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Shares of Deciphera Pharmaceuticals, Inc. (DCPH) have gained 1.7% over the past four weeks to close the last trading session at $13.57, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. But, for DCPH, an impressive average price target is not the only indicator of a potential upside. Why DCPH Could Witness a Solid Upside There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher.
|
Why DCPH Could Witness a Solid Upside There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. Shares of Deciphera Pharmaceuticals, Inc. (DCPH) have gained 1.7% over the past four weeks to close the last trading session at $13.57, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. But, for DCPH, an impressive average price target is not the only indicator of a potential upside.
|
You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much DCPH could gain, the direction of price movement it implies does appear to be a good guide. Shares of Deciphera Pharmaceuticals, Inc. (DCPH) have gained 1.7% over the past four weeks to close the last trading session at $13.57, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. But, for DCPH, an impressive average price target is not the only indicator of a potential upside.
|
Shares of Deciphera Pharmaceuticals, Inc. (DCPH) have gained 1.7% over the past four weeks to close the last trading session at $13.57, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. But, for DCPH, an impressive average price target is not the only indicator of a potential upside. Why DCPH Could Witness a Solid Upside There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher.
|
cf65c6ba-c3d1-4176-8c5e-5a61b376b79b
|
715461.0
|
2022-07-26 00:00:00 UTC
|
Will Deciphera Pharmaceuticals, Inc. (DCPH) Report Negative Q2 Earnings? What You Should Know
|
DCPH
|
https://www.nasdaq.com/articles/will-deciphera-pharmaceuticals-inc.-dcph-report-negative-q2-earnings-what-you-should-know
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2022. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This company is expected to post quarterly loss of $0.66 per share in its upcoming report, which represents a year-over-year change of +45.5%.
Revenues are expected to be $30.21 million, up 28.2% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 1.03% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Deciphera Pharmaceuticals, Inc.
For Deciphera Pharmaceuticals, Inc.The Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.51%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination makes it difficult to conclusively predict that Deciphera Pharmaceuticals, Inc. Will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Deciphera Pharmaceuticals, Inc. Would post a loss of $0.84 per share when it actually produced a loss of $0.80, delivering a surprise of +4.76%.
Over the last four quarters, the company has beaten consensus EPS estimates just once.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Deciphera Pharmaceuticals, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry Player
Another stock from the Zacks Medical - Biomedical and Genetics industry, Repligen (RGEN), is soon expected to post earnings of $0.72 per share for the quarter ended June 2022. This estimate indicates a year-over-year change of -8.9%. Revenues for the quarter are expected to be $189.06 million, up 16% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for Repligen has been revised 0.2% down to the current level. Nevertheless, the company now has an Earnings ESP of 4.79%, reflecting a higher Most Accurate Estimate.
This Earnings ESP, combined with its Zacks Rank #2 (Buy), suggests that Repligen will most likely beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
This Little-Known Semiconductor Stock Could Lead to Big Gains for Your Portfolio
The significance of semiconductors can't be overstated. Your smartphone couldn't function without it. Your personal computer would crash in minutes. Digital cameras, washing machines, refrigerators, ovens. You wouldn't be able to use any of them without semiconductors.
Disruptions in the supply chain have given semiconductors tremendous pricing power. That's why they present such a tremendous opportunity for investors.
And today, in a new free report, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most. It's yours free and with no obligation.
>>Give me access to my free special report.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Repligen Corporation (RGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Zacks Consensus Estimate This company is expected to post quarterly loss of $0.66 per share in its upcoming report, which represents a year-over-year change of +45.5%.
|
ad88e146-7dc4-4999-b113-9cbfb84aa487
|
715462.0
|
2022-07-22 00:00:00 UTC
|
Is Deciphera Pharmaceuticals (DCPH) Outperforming Other Medical Stocks This Year?
|
DCPH
|
https://www.nasdaq.com/articles/is-deciphera-pharmaceuticals-dcph-outperforming-other-medical-stocks-this-year
|
nan
|
nan
|
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Deciphera Pharmaceuticals, Inc. (DCPH) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Deciphera Pharmaceuticals, Inc. is a member of our Medical group, which includes 1190 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Deciphera Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for DCPH's full-year earnings has moved 9.8% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, DCPH has returned 38.4% so far this year. Meanwhile, the Medical sector has returned an average of -12.3% on a year-to-date basis. This shows that Deciphera Pharmaceuticals, Inc. is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Evolus, Inc. (EOLS). The stock is up 110.8% year-to-date.
The consensus estimate for Evolus, Inc.'s current year EPS has increased 15.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Deciphera Pharmaceuticals, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 558 individual companies and currently sits at #82 in the Zacks Industry Rank. On average, stocks in this group have lost 19.5% this year, meaning that DCPH is performing better in terms of year-to-date returns.
On the other hand, Evolus, Inc. belongs to the Medical - Products industry. This 100-stock industry is currently ranked #87. The industry has moved -24% year to date.
Investors with an interest in Medical stocks should continue to track Deciphera Pharmaceuticals, Inc. and Evolus, Inc. These stocks will be looking to continue their solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Evolus, Inc. (EOLS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
On average, stocks in this group have lost 19.5% this year, meaning that DCPH is performing better in terms of year-to-date returns. Has Deciphera Pharmaceuticals, Inc. (DCPH) been one of those stocks this year? Over the past 90 days, the Zacks Consensus Estimate for DCPH's full-year earnings has moved 9.8% higher.
|
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Has Deciphera Pharmaceuticals, Inc. (DCPH) been one of those stocks this year? Over the past 90 days, the Zacks Consensus Estimate for DCPH's full-year earnings has moved 9.8% higher.
|
Has Deciphera Pharmaceuticals, Inc. (DCPH) been one of those stocks this year? Over the past 90 days, the Zacks Consensus Estimate for DCPH's full-year earnings has moved 9.8% higher. Based on the most recent data, DCPH has returned 38.4% so far this year.
|
Over the past 90 days, the Zacks Consensus Estimate for DCPH's full-year earnings has moved 9.8% higher. Has Deciphera Pharmaceuticals, Inc. (DCPH) been one of those stocks this year? Based on the most recent data, DCPH has returned 38.4% so far this year.
|
470617cf-bd06-4b82-8dc7-ef5eaa007b85
|
715463.0
|
2022-06-17 00:00:00 UTC
|
Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry
|
DCPH
|
https://www.nasdaq.com/articles/blueprint-medicines-bpmc-ayvakit-aids-growth-amid-rivalry-0
|
nan
|
nan
|
Blueprint Medicines Corporation BPMC has made steady progress with its lead drug, Ayvakit (avapritinib), which is approved for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (“GIST”), harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations in the United States. The European Commission has granted conditional marketing authorization to Ayvakyt as a monotherapy for the treatment of adult patients with unresectable/metastatic GIST harboring the PDGFRA D842V mutation.
In June 2021, the FDA approved Ayvakit for a new indication — advanced systemic mastocytosis (“SM”) — a rare and debilitating disease.
In March 2022, the European Commission approved Ayvakyt as a monotherapy for the treatment of adult patients with aggressive SM, including SM with an associated hematological neoplasm as well as mast cell leukemia, after at least one systemic therapy.
Ayvakit is being evaluated in the phase II PIONEER study for treating non-advanced SM. Blueprint Medicines plans to submit a supplemental new drug application for Ayvakit in non-advanced SM to the FDA in the second half of 2022. Currently, there is no approved therapy for non-advanced SM.
Per the company, Ayvakit has the potential to be the first and only treatment approved for non-advanced SM.
Shares of Blueprint Medicines have plunged 56.4% so far this year compared with the industry’s decrease of 28.8%.
Image Source: Zacks Investment Research
Blueprint Medicines is co-developing another cancer drug, Gavreto (pralsetinib), with Roche RHHBY for treating patients with various types of RET-altered thyroid cancers and other solid tumors.
In July 2021, Blueprint Medicines transferred the responsibilities of booking U.S. product sales of Gavreto to RHHBY. The company only records the share of profit and loss for Gavreto in its financial results and does not record any net product revenues from Gavreto sales.
Gavreto is approved in the United States for treating advanced/metastatic RET-mutant and RET fusion-positive thyroid cancer. The drug is also approved for the treatment of adults with metastatic RET fusion-positive non-small-cell lung cancer.
This apart, Blueprint Medicines has other promising pipeline candidates that are currently being evaluated in various early-to-mid-stage studies, targeting various cancer indications.
Successful development and potential approval of the candidates will boost the company’s growth prospects in the future ahead.
Blueprint Medicines is riding on the success of Ayvakit. The company’s current product revenues solely comprise sales from Ayvakit, which narrows its revenue stream. Hence, any regulatory setback for Ayvakit could hurt the stock in the days ahead.
Moreover, Ayvakit faces competition from Deciphera Pharmaceuticals' DCPH Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. In November 2021, the European Commission approved Qinlock for the same indication.
Deciphera is also working to expand the label of Qinlock for the larger commercial opportunity in GIST.
Blueprint Medicines Corporation Price and Consensus
Blueprint Medicines Corporation price-consensus-chart | Blueprint Medicines Corporation Quote
Zacks Rank & Stock to Consider
Blueprint Medicines currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Leap Therapeutics, Inc. LPTX, which has a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Blueprint Medicines Corporation (BPMC): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Leap Therapeutics, Inc. (LPTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Moreover, Ayvakit faces competition from Deciphera Pharmaceuticals' DCPH Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Blueprint Medicines Corporation BPMC has made steady progress with its lead drug, Ayvakit (avapritinib), which is approved for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (“GIST”), harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations in the United States.
|
Moreover, Ayvakit faces competition from Deciphera Pharmaceuticals' DCPH Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Blueprint Medicines Corporation BPMC has made steady progress with its lead drug, Ayvakit (avapritinib), which is approved for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (“GIST”), harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations in the United States.
|
Moreover, Ayvakit faces competition from Deciphera Pharmaceuticals' DCPH Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Blueprint Medicines Corporation BPMC has made steady progress with its lead drug, Ayvakit (avapritinib), which is approved for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (“GIST”), harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations in the United States.
|
Moreover, Ayvakit faces competition from Deciphera Pharmaceuticals' DCPH Qinlock (ripretinib), which is approved for the treatment of fourth-line GIST. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Per the company, Ayvakit has the potential to be the first and only treatment approved for non-advanced SM.
|
ac062067-ff1c-4279-afff-425d2642ce0c
|
715464.0
|
2022-06-15 00:00:00 UTC
|
Deciphera (DCPH) Up More Than 30% in Past 3 Months: Here's Why
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-dcph-up-more-than-30-in-past-3-months%3A-heres-why
|
nan
|
nan
|
Shares of Deciphera Pharmaceuticals, Inc. DCPH have rallied 31.5% in the past three months against the industry’s decrease of 17%.
Image Source: Zacks Investment Research
Deciphera's sole marketed drug, Qinlock (ripretinib), is approved for the treatment of adult patients with advanced gastrointestinal stromal tumor (“GIST”) who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib). Qinlock has also been approved in Europe for the treatment of fourth-line GIST.
The company has made steady progress with Qinlock during this time frame, with the drug witnessing solid uptake so far. Qinlock contributes the majority of Deciphera’s revenues.
In first-quarter 2022, Qinlock generated sales worth $28.8 million, reflecting a sequential increase of 21.5%. Qinlock generated $23.4 million in sales in the United States and $5.4 million in sales in ex-U.S. markets.
Deciphera is also working to expand the label of Qinlock for the larger commercial opportunity in GIST. A potential label expansion for other indications will make the drug eligible to treat a broader patient population and drive sales further in the days ahead.
In late November 2021, Deciphera entered into a corporate restructuring, whereby the company decided to streamline its commercial operations and reduce its current workforce by approximately 35% or almost 140 positions. The changes in the clinical development programs and restructuring efforts are expected to bring a significant reduction in the company’s operating expenses and extend the cash runway into 2024.
This apart, Deciphera has a diverse pipeline and is advancing multiple drug candidates in various stages of clinical development.
The company is evaluating vimseltinib in the phase III MOTION study for the treatment of tenosynovial giant-cell tumor.
A phase I study is evaluating DCC-3116 as a single agent and in combination with FDA-approved MEK inhibitors, trametinib and binimetinib as well as assotorasib, an FDA- approved KRASG12C inhibitor, for treating patients with various advanced/metastatic tumors, driven by mutations in RAS/RAF genes.
A successful development and potential approval of these candidates will be a big boost for the company.
Deciphera currently has no approved product in its portfolio other than Qinlock. All of its drug candidates, including vimseltinib and DCC-3116, are still some time away from commercialization. As a result, the company is heavily dependent on Qinlock for growth. Any regulatory setback for the drug will hurt the company’s prospects.
Deciphera Pharmaceuticals, Inc. Price
Deciphera Pharmaceuticals, Inc. price | Deciphera Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Deciphera currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Leap Therapeutics, Inc. LPTX, Aeglea BioTherapeutics, Inc. AGLE and Precision BioSciences, Inc. DTIL, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Aeglea BioTherapeutics’ loss per share estimates narrowed 19.4% for 2022 and 37.6% for 2023 in the past 60 days.
Earnings of Aeglea BioTherapeutics have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AGLE delivered an earnings surprise of 9.47%, on average.
Precision BioSciences’ loss per share estimates narrowed 21.7% for 2022 and 31.4% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.
Zacks' Top Picks to Cash in on Electric Vehicles
Big money has already been made in the Electric Vehicle (EV) industry. But, the EV revolution has not hit full throttle yet. There is a lot of money to be made as the next push for future technologies ramps up. Zacks’ Special Report reveals 5 picks investors
See 5 EV Stocks With Extreme Upside Potential >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aeglea BioTherapeutics, Inc. (AGLE): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Leap Therapeutics, Inc. (LPTX): Free Stock Analysis Report
Precision BioSciences, Inc. (DTIL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Shares of Deciphera Pharmaceuticals, Inc. DCPH have rallied 31.5% in the past three months against the industry’s decrease of 17%. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report A potential label expansion for other indications will make the drug eligible to treat a broader patient population and drive sales further in the days ahead.
|
Shares of Deciphera Pharmaceuticals, Inc. DCPH have rallied 31.5% in the past three months against the industry’s decrease of 17%. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Image Source: Zacks Investment Research Deciphera's sole marketed drug, Qinlock (ripretinib), is approved for the treatment of adult patients with advanced gastrointestinal stromal tumor (“GIST”) who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib).
|
Shares of Deciphera Pharmaceuticals, Inc. DCPH have rallied 31.5% in the past three months against the industry’s decrease of 17%. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Image Source: Zacks Investment Research Deciphera's sole marketed drug, Qinlock (ripretinib), is approved for the treatment of adult patients with advanced gastrointestinal stromal tumor (“GIST”) who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib).
|
Shares of Deciphera Pharmaceuticals, Inc. DCPH have rallied 31.5% in the past three months against the industry’s decrease of 17%. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Image Source: Zacks Investment Research Deciphera's sole marketed drug, Qinlock (ripretinib), is approved for the treatment of adult patients with advanced gastrointestinal stromal tumor (“GIST”) who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib).
|
954de2b3-4891-43e2-91d4-353f4d13ef30
|
715465.0
|
2022-06-03 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Up 4.3% Since Last Earnings Report: Can It Continue?
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-up-4.3-since-last-earnings-report%3A-can-it-continue
|
nan
|
nan
|
A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). Shares have added about 4.3% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Deciphera Pharmaceuticals, Inc. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Deciphera’s Q1 Loss Narrower-Than-Expected, Revenues Rise Y/Y
Deciphera reported first-quarter 2022 loss of 80 cents per share, narrower than the Zacks Consensus Estimate of a loss of 84 cents. In the year-ago quarter, the company had reported a loss of $1.06.
Total net revenues were $29.2 million in the quarter, which surpassed the Zacks Consensus Estimate of $27 million. Revenues rose 15.8% year over year.
Quarter in Detail
Qinlock net product revenues were $28.8 million, reflecting a sequential increase of 21.5%. Qinlock generated $23.4 million in sales in the United States and $5.4 million in sales in ex-U.S. markets.
Collaboration revenues of $0.4 million comprised commercial supply and royalty revenues under the company’s license agreement with Zai Lab.
Research and development expenses were $47.4 million, down 14.9% year over year, owing to lower costs related to clinical studies on Qinlock.
Selling, general and administrative expenses were $28.3 million, down 7.8% year over year, owing to a decrease in professional and consultant fees.
Deciphera had cash, cash equivalents and investments worth $275.4 million as of Mar 31, 2022, down from $327.6 million as of Dec 31, 2021.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended upward during the past month.
VGM Scores
Currently, Deciphera Pharmaceuticals, Inc. has an average Growth Score of C, however its Momentum Score is doing a bit better with a B. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Deciphera Pharmaceuticals, Inc. has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Deciphera Pharmaceuticals, Inc. is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Emergent Biosolutions (EBS), a stock from the same industry, has gained 1.5%. The company reported its results for the quarter ended March 2022 more than a month ago.
Emergent Biosolutions reported revenues of $307.5 million in the last reported quarter, representing a year-over-year change of -10.4%. EPS of $0.18 for the same period compares with $1.53 a year ago.
Emergent Biosolutions is expected to post earnings of $0.63 per share for the current quarter, representing a year-over-year change of +90.9%. Over the last 30 days, the Zacks Consensus Estimate has changed +2.5%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #5 (Strong Sell) for Emergent Biosolutions. Also, the stock has a VGM Score of C.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Emergent Biosolutions Inc. (EBS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Will the recent positive trend continue leading up to its next earnings release, or is Deciphera Pharmaceuticals, Inc. due for a pullback?
|
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). Deciphera’s Q1 Loss Narrower-Than-Expected, Revenues Rise Y/Y Deciphera reported first-quarter 2022 loss of 80 cents per share, narrower than the Zacks Consensus Estimate of a loss of 84 cents.
|
A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Deciphera’s Q1 Loss Narrower-Than-Expected, Revenues Rise Y/Y Deciphera reported first-quarter 2022 loss of 80 cents per share, narrower than the Zacks Consensus Estimate of a loss of 84 cents.
|
A month has gone by since the last earnings report for Deciphera Pharmaceuticals, Inc. (DCPH). Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Total net revenues were $29.2 million in the quarter, which surpassed the Zacks Consensus Estimate of $27 million.
|
b6eef644-5897-4907-9e62-f028da6f78e0
|
715466.0
|
2022-05-06 00:00:00 UTC
|
Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View Tweaked
|
DCPH
|
https://www.nasdaq.com/articles/vertex-vrtx-q1-earnings-lag-sales-top-expense-view-tweaked
|
nan
|
nan
|
Vertex Pharmaceuticals Incorporated VRTX reported first-quarter 2022 adjusted earnings per share of $3.52, which missed the Zacks Consensus Estimate of $3.60. Earnings rose 18% year over year. Strong cystic fibrosis (“CF”) product revenues led to higher earnings for the reported quarter.
Revenues of $2.10 billion, which surpassed the Zacks Consensus Estimate of $2.08 billion, comprised fully of CF product revenues. Total product revenues rose 22% year over year, primarily driven by higher sales of Trikafta (marketed as Kaftrio in Europe).
Shares were down almost 3% in after-hours trading on May 5 after the results were announced. This year so far, shares of Vertex have risen 21.3% in contrast to the industry’s 19.8% decline.
Image Source: Zacks Investment Research
Quarter in Detail
The company markets four CF products — Trikafta/Kaftrio, Symdeko (marketed as Symkevi in Europe), Orkambi and Kalydeco.
CF product sales rose 9% year over year in the United States to $1.37 billion while sales outside the United States surged 55% to $729 million.
Trikafta generated sales worth $1.76 billion, up 47.7% year over year, driven by additional patients starting treatment with Trikafta, most notably pediatric patients (6-11 years of age- approval received in mid-2021) in the United States and strong launches in several countries in Europe. Vertex has now secured reimbursement agreements for Kaftrio in more than 25 countries.
Symdeko/Symkevi registered sales of $65 million in the quarter, down 48% year over year.
Kalydeco recorded sales of $139 million in the quarter, down 25.3% year over year. Orkambi generated sales of $132 million in the reported quarter, down 39.7% from the prior-year quarter. Sales of Kalydeco, Symdeko/ Symkevi and Orkambi were hurt by patients switching to Trikafta.
Costs Rise
Adjusted operating income rose 16% year over year to $1.17 billion in the quarter, driven by higher revenues. Adjusted research and development (R&D) expenses rose 36.8% from the year-ago quarter to $520 million due to the expansion of the CF and non-CF pipelines.
Adjusted selling, general and administrative (SG&A) expenses increased 10.6% to $167 million for the reported quarter.
2022 Guidance
The company maintained its previously issued product sales guidance in the range of $8.4-$8.6 billion for 2022.
Combined adjusted R&D and SG&A expense guidance for 2022 was raised from a range of $2.70-$2.75 billion to $2.82 to $2.92 billion. The change in the combined adjusted R&D and SG&A expense guidance was to reflect the change in industry-wide reporting of upfront and milestone expenses. The adjusted tax rate is expected in the range of 21-22%.
Pipeline & Other Updates
While Vertex’s main focus is on the development and strengthening of its CF franchise, the company also has a rapidly advancing mid- and late-stage clinical pipeline across six disease areas.
Vertex is co-developing a gene-editing treatment, CTX001 in partnership with CRISPR Therapeutics CRSP in two devastating diseases — sickle cell disease and thalassemia. Phase I/II studies of CTX001 in adult transfusion-dependent b-thalassemia in Europe and sickle cell disease in the United States are ongoing. The preliminary safety and efficacy data from the studies were positive. Vertex and CRISPR Therapeutics plan to file regulatory applications for CTX001 for both indications in late 2022. Vertex expects CTX001 to be its next commercial launch. Vertex and CRISPR Therapeutics have also initiated two new phase III studies in pediatric patients with TDT and SCD.
In March, Vertex announced that it is moving VX-147, its first oral small molecule medicine for APOL1-mediated kidney disease, into pivotal development. A pivotal phase III study on VX-147 targeting a patient population with proteinuric kidney disease mediated by two mutations in the APOL1 gene began enrollment.
VX-548, a novel first-in-class, non-opioid NaV1.8 inhibitor, is being evaluated in two phase II acute pain studies, one following bunionectomy surgery and the other following abdominoplasty surgery. In March 2022, Vertex announced positive data from the two phase II studies on VX-548. The studies met their primary endpoint and established proof of concept for VX-548. Based on this data, the company plans to advance VX-548 into pivotal development for acute pain in second-half 2022.
A phase I/II study is ongoing on VX-880, Vertex’s stem cell-derived, fully differentiated islet replacement therapy that could offer a functional cure for type 1 diabetes (T1D) patients. Data from the first three patients treated to date in the phase I/II study were announced last week. The first patient, who received VX-880 at half the target dose, achieved insulin independence at day 270, with a HbA1c of 5.2%. The second patient who also received a half dose of VX-880, showed robust increases in fasting and stimulated C-peptide and reductions in exogenous insulin requirements through day 150. Overall, the results from the two patients demonstrated proof of concept for VX-880. The third patient, who received a full dose of VX-880, reached the day 29 milestone, which encouraged early indications of efficacy, with increasing C-peptide levels and improving glycemic control.
The Independent Data Monitoring Committee reviewed the totality of the safety and efficacy data from the first two patients dosed in part A of the study and recommended advancement to part B, where patients receive the full target dose of VX-880. However, the FDA placed a clinical hold on the study due to a determination that there is insufficient information to support dose escalation with the product.
Zacks Rank & Other Stocks to Consider
Vertex currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the biotech sector include Alkermes ALKS and Deciphera Pharmaceuticals DCPH. While Alkermes sports a Zacks Rank #1 (Strong Buy), Deciphera Pharmaceuticals carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Vertex Pharmaceuticals Incorporated Price and Consensus
Vertex Pharmaceuticals Incorporated price-consensus-chart | Vertex Pharmaceuticals Incorporated Quote
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents over the past 30 days. Shares of Alkermes have risen 20% this year so far.
Earnings of Alkermes beat estimates in all the last four quarters, delivering a surprise of 350.5%, on average.
Deciphera Pharmaceuticals’ loss per share estimates for 2022 have narrowed from $2.94 to $2.77 while that for 2023 have gone down from $2.38 to $1.84 in the past 30 days.
Earnings of Deciphera Pharmaceuticals missed estimates in three of the last four quarters while beating the mark on one occasion, delivering a negative surprise of 2.0%, on average. The stock is up 8.8% this year so far.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some other top-ranked stocks in the biotech sector include Alkermes ALKS and Deciphera Pharmaceuticals DCPH. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report A phase I/II study is ongoing on VX-880, Vertex’s stem cell-derived, fully differentiated islet replacement therapy that could offer a functional cure for type 1 diabetes (T1D) patients.
|
Some other top-ranked stocks in the biotech sector include Alkermes ALKS and Deciphera Pharmaceuticals DCPH. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Total product revenues rose 22% year over year, primarily driven by higher sales of Trikafta (marketed as Kaftrio in Europe).
|
Some other top-ranked stocks in the biotech sector include Alkermes ALKS and Deciphera Pharmaceuticals DCPH. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report CF product sales rose 9% year over year in the United States to $1.37 billion while sales outside the United States surged 55% to $729 million.
|
Some other top-ranked stocks in the biotech sector include Alkermes ALKS and Deciphera Pharmaceuticals DCPH. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated VRTX reported first-quarter 2022 adjusted earnings per share of $3.52, which missed the Zacks Consensus Estimate of $3.60.
|
ecbb1b10-f24f-46cf-b140-adcf0fa40571
|
715467.0
|
2022-05-06 00:00:00 UTC
|
Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-dcph-down-despite-narrower-than-expected-q1-loss
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. DCPH reported first-quarter 2022 loss of 80 cents per share, narrower than the Zacks Consensus Estimate of a loss of 84 cents. In the year-ago quarter, the company had reported a loss of $1.06.
Total net revenues were $29.2 million in the quarter, which surpassed the Zacks Consensus Estimate of $27 million. Revenues rose 15.8% year over year.
Shares of Deciphera were down 1.5% on May 5 despite the better-than-expected earnings result. The stock has rallied 8.8% in the year so far against the industry’s decline of 20.1%.
Image Source: Zacks Investment Research
In May 2020, the FDA approved Deciphera’s sole marketed drug, Qinlock (ripretinib), to treat adult patients with advanced gastrointestinal stromal tumors (“GIST”) who have received prior treatment with three or more kinase inhibitors, including Novartis’ NVS Gleevec (imatinib).
NVS has lost the patent protection for Gleevec, which faces increasing generic competition in major markets.
Quarter in Detail
Apart from Qinlock, there is no other marketable drug in the company’s portfolio. Total revenues comprised net product revenues and collaboration revenues. Net product revenues were $28.8 million, reflecting a sequential increase of 21.5%. Qinlock generated $23.4 million in sales in the United States and $5.4 million in sales in ex-U.S. markets.
Collaboration revenues of $0.4 million comprised commercial supply and royalty revenues under the company’s license agreement with Zai Lab.
Research and development expenses were $47.4 million, down 14.9% year over year, owing to lower costs related to clinical studies on Qinlock.
Selling, general and administrative expenses were $28.3 million, down 7.8% year over year, owing to a decrease in professional and consultant fees.
Deciphera had cash, cash equivalents and investments worth $275.4 million as of Mar 31, 2022, down from $327.6 million as of Dec 31, 2021.
Other Updates
In November 2021, the European Commission approved Qinlock for treating adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec. The nod in Europe should boost sales in 2022 and beyond.
Deciphera is evaluating vimseltinib in the phase III MOTION study for the treatment of tenosynovial giant-cell tumor.
The company is also planning to initiate three phase Ib studies on DCC-3116 in combination with FDA-approved MEK inhibitor, trametinib, and binimetinib as well assotorasib, an FDA- approved KRASG12C inhibitor, for treating patients with advanced or metastatic solid tumors.
In November 2021, Deciphera announced a corporate restructuring plan to prioritize the development of select clinical programs, streamline commercial operations, reduce expenses and extend its cash runway. The company reduced its current workforce by approximately 35% or almost 140 positions.
Deciphera Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Deciphera Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Deciphera Pharmaceuticals, Inc. Quote
Zacks Rank & Other Stocks to Consider
Deciphera currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the biotech sector are Vertex Pharmaceuticals Incorporated VRTX and Applied Therapeutics, Inc. APLT, both carrying the same Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Vertex’s earnings estimates have been revised 0.3% upward for 2022 and 0.1% upward for 2023 over the past 60 days. The VRTX stock has rallied 21.3% year to date.
Earnings of Vertex have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
Applied Therapeutics’ loss per share estimates have improved 34.1% for 2022 and 20.2% for 2023 over the past 60 days.
Earnings of Applied Therapeutics surpassed estimates in two of the trailing four quarters, met the same once and missed the same on the other occasion.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Applied Therapeutics Inc. (APLT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. DCPH reported first-quarter 2022 loss of 80 cents per share, narrower than the Zacks Consensus Estimate of a loss of 84 cents. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Image Source: Zacks Investment Research In May 2020, the FDA approved Deciphera’s sole marketed drug, Qinlock (ripretinib), to treat adult patients with advanced gastrointestinal stromal tumors (“GIST”) who have received prior treatment with three or more kinase inhibitors, including Novartis’ NVS Gleevec (imatinib).
|
Deciphera Pharmaceuticals, Inc. DCPH reported first-quarter 2022 loss of 80 cents per share, narrower than the Zacks Consensus Estimate of a loss of 84 cents. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Image Source: Zacks Investment Research In May 2020, the FDA approved Deciphera’s sole marketed drug, Qinlock (ripretinib), to treat adult patients with advanced gastrointestinal stromal tumors (“GIST”) who have received prior treatment with three or more kinase inhibitors, including Novartis’ NVS Gleevec (imatinib).
|
Deciphera Pharmaceuticals, Inc. DCPH reported first-quarter 2022 loss of 80 cents per share, narrower than the Zacks Consensus Estimate of a loss of 84 cents. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Total net revenues were $29.2 million in the quarter, which surpassed the Zacks Consensus Estimate of $27 million.
|
Deciphera Pharmaceuticals, Inc. DCPH reported first-quarter 2022 loss of 80 cents per share, narrower than the Zacks Consensus Estimate of a loss of 84 cents. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Total net revenues were $29.2 million in the quarter, which surpassed the Zacks Consensus Estimate of $27 million.
|
12a23c3e-9333-4bce-bb6f-a43d023f72b5
|
715468.0
|
2022-05-06 00:00:00 UTC
|
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y
|
DCPH
|
https://www.nasdaq.com/articles/puma-biotech-pbyi-q1-earnings-beat-nerlynx-sales-fall-y-y
|
nan
|
nan
|
Puma Biotechnology PBYI reported first-quarter 2022 loss of 8 cents per share, narrower than the Zacks Consensus Estimate of a loss of 13 cents per share. In the year-ago quarter, the company had reported earnings of 40 cents per share.
Adjusted earnings (excluding stock-based compensation expense) were 1 cent per share for first-quarter 2022 compared with 55 cents in the year-ago quarter.
In the first quarter, total revenues were $45.7 million, down 53.5% year over year due to lower product sales and the absence of license revenues. Sales were in line with the Zacks Consensus Estimate.
Total revenues consisted of net product sales of Nerlynx (neratinib), Puma Biotech's only marketed drug in the United States, and license fees and royalty revenues from PBYI’s sub-licensees.
Quarter in Detail
Nerlynx is indicated for extended adjuvant treatment of HER2-positive early-stage breast cancer in patients previously treated with Roche’s RHHBY Herceptin-based adjuvant therapy. In 2020, the FDA expanded Nerlynx’s label to allow its use in combination with Roche’s Xeloda for third-line HER2-positive metastatic breast cancer.
Product revenues from Nerlynx were $40.7 million in the first, down 11.1% year over year and 20% sequentially due to inventory drawdown at specialty pharmacies/distributors.
Shares were down almost 9% in after-hours trading, following the earnings release probably due to unimpressive Nerlynx product sales. Puma Biotech’s shares have declined 26.3% this year so far compared with the industry’s 19.8% decrease.
Image Source: Zacks Investment Research
Nerlynx’s product revenues were slightly better than management’s guidance of $35 million - $39 million.
In the first quarter, Nerlynx’s new prescriptions were up approximately 17% from the fourth quarter of 2021, while total prescriptions were down approximately 1.7%.
Royalty revenues were $5.0 million in the quarter compared with $2.4 million in the year-ago quarter. Puma Biotech did not record any license revenues in the first quarter compared with $50 million in the first quarter of 2021.
Total operating costs in the quarter were $46.4 million, down 40.5% year over year. Research and development expenses were $15.2 million in the quarter, down 24.8% year over year. Selling, general and administrative expenses declined 27.7% year over year to $20.4 million due to lower professional fees and expenses.
2022 Guidance
For 2022, Puma Biotech maintained Nerlynx’s net sales guidance range of $180-$190 million. Royalty revenues are expected in the range of $27-$34 million. However, pandemic-related disruptions may continue to hurt PBYI’s revenues in 2022. Operating expenses are expected to be lower in 2022 compared with 2021. SG&A expenses are expected to decline in the range of approximately 15% to 20% and R&D expenses are expected to be down 10% to 15% year over year.
Nerlynx’s net revenues are expected in the range of $44-$47 million in the second quarter of 2022 while royalty revenues are expected to be in the range of $7 million to $9 million.
Pipeline Update
Several additional studies on Nerlynx targeting different types of breast cancer patient populations and other types of cancers are currently underway.
A key analysis of Nerlynx is the phase II SUMMIT basket study for treating solid tumors in patients with activating EGFR, HER2 or HER4 mutated cancers.
The company plans to report data from a cohort of the SUMMIT study evaluating Nerlynx in HER2-mutated HR-positive breast cancer in the first half of the year and hold a pre-NDA meeting with the FDA to discuss the potential for an accelerated approval pathway for this indication in the second half.
The company plans to report data from another cohort of the SUMMIT study in second-half 2022, evaluating Nerlynx in non-small cell lung cancer patients with EGFR exon 18 mutations. The company also expects to report phase II data from the SUMMIT study from a cohort of patients with HER2-mutated biliary tract cancer in the first half and from another cohort of cervical cancer patients with HER2 mutations in second-half 2022.
Meanwhile, Puma Biotech plans to release results from the phase II TBCRC-022 study on Nerlynx in combination with Roche’s Kadcyla in patients with HER2-positive breast cancer with brain metastases who have previously been treated with Kadcyla in second-half 2022.
Zacks Rank & Stocks to Consider
Puma Biotech currently has a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector include Alkermes ALKS and Deciphera Pharmaceuticals DCPH. While Alkermes sports a Zacks Rank #1 (Strong Buy), Deciphera Pharmaceuticals carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Puma Biotechnology, Inc. Price, Consensus and EPS Surprise
Puma Biotechnology, Inc. price-consensus-eps-surprise-chart | Puma Biotechnology, Inc. Quote
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents over the past 30 days. Shares of Alkermes have risen 20% this year so far.
Earnings of Alkermes beat estimates in all the last four quarters, delivering a surprise of 350.5%, on average.
Deciphera Pharmaceuticals’ loss per share estimates for 2022 have narrowed from $2.94 to $2.77 while those for 2023 have gone down from $2.38 to $1.84 in the past 30 days.
Earnings of Deciphera Pharmaceuticals missed estimates in three of the last four quarters while beating the mark on one occasion, delivering a negative surprise of 2.0%, on average. The stock is up 8.8% this year so far.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Alkermes plc (ALKS): Free Stock Analysis Report
Puma Biotechnology, Inc. (PBYI): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked stocks in the biotech sector include Alkermes ALKS and Deciphera Pharmaceuticals DCPH. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report A key analysis of Nerlynx is the phase II SUMMIT basket study for treating solid tumors in patients with activating EGFR, HER2 or HER4 mutated cancers.
|
Some better-ranked stocks in the biotech sector include Alkermes ALKS and Deciphera Pharmaceuticals DCPH. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Puma Biotechnology PBYI reported first-quarter 2022 loss of 8 cents per share, narrower than the Zacks Consensus Estimate of a loss of 13 cents per share.
|
Some better-ranked stocks in the biotech sector include Alkermes ALKS and Deciphera Pharmaceuticals DCPH. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Puma Biotechnology PBYI reported first-quarter 2022 loss of 8 cents per share, narrower than the Zacks Consensus Estimate of a loss of 13 cents per share.
|
Some better-ranked stocks in the biotech sector include Alkermes ALKS and Deciphera Pharmaceuticals DCPH. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report In the year-ago quarter, the company had reported earnings of 40 cents per share.
|
35c83a2c-50fa-4d78-b663-e19074b8d9b2
|
715469.0
|
2022-05-05 00:00:00 UTC
|
Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics
|
DCPH
|
https://www.nasdaq.com/articles/amarin-amrn-q1-earnings-sales-hurt-by-vascepa-generics
|
nan
|
nan
|
Amarin Corporation PLC AMRN reported first-quarter 2022 adjusted loss of 6 cents (excluding stock-based compensation) per American depositary share against adjusted earnings of 3 cents in the year-ago period. The Zacks Consensus Estimate was pegged at earnings of 2 cents.
Revenues, primarily from its cardiovascular drug, Vascepa, were down almost 33% year over year to approximately $94.6 million in the quarter, missing the Zacks Consensus Estimate of $127.91 million. Sales were hurt due to rising generic competition in the United States as well as lower net prices in certain countries.
The company continues to avoid revenue guidance for 2022 due to the uncertainty related to the COVID-19 pandemic and generic competition for its sole marketed drug, Vascepa, in the United States.
Shares of Amarin crashed 43.1% on May 4 on lackluster first-quarter results and also most probably on the increasing unfavorable impact of generics on Vascepa sales in the United States. The stock has declined 53.7% so far this year compared with the industry’s 21.2% decrease.
Image Source: Zacks Investment Research
Quarter in Details
Product revenues, entirely from Vascepa, were $94 million, down approximately 34% year over year due to lower volumes in the United States amid rising generic competition for Vascepa’s reduction of triglyceride levels indication. The company stated that a new generic version entered the U.S. market during the first quarter, taking the total to three generics versions of Vascepa. Moreover, Vascepa sales were also hurt due to ongoing challenges related to COVID-19 disruptions.
Licensing revenues were $0.6 million in the first quarter compared with $0.8 million in the year-ago period. The royalty revenues were primarily from sales of Vascepa recorded by its partners in Canada, the China region and the Middle East. Initial sales of the drug in Germany were unfavorably impacted during the first quarter due to a significant surge in COVID-19 cases in the country.
The company ended the quarter with $389.3 million in cash and investments, compared with $489.1 million as of Dec 31, 2021.
Vascepa Update
In October 2021, Amarin initiated a new Go-To-Market strategy in the United States that focuses on enhancing awareness and expanding the company’s reach to healthcare providers, increasing managed care access for Vascepa, and prioritizing cardiovascular risk reduction indication. The company continues to progress with its strategy and focuses on stabilizing Vascepa revenues. It also expanded coverage for Vascepa to approximately 45% of total commercial and Medicare Part D lives.
Amarin launched Vazkepa (U.S. tradename Vascepa) in Germany in September last year. The company received reimbursement decisions in up to eight European countries and plans to launch the drug in six of them in 2022.
Apart from Europe, Amarin is also focusing on expanding in other international countries. The company’s partners are expected to gain approval for Vascepa and launch it in up to six new countries this year.
The company’s partner gained approval for Vascepa in Hong Kong recently and is planning to launch the drug later this year. A regulatory application seeking approval for Vascepa is under review in China.
Amarin Corporation PLC Price, Consensus and EPS Surprise
Amarin Corporation PLC price-consensus-eps-surprise-chart | Amarin Corporation PLC Quote
Zacks Rank & Stock to Consider
Amarin currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the pharma/biotech sector include Alkermes ALKS, Deciphera Pharmaceuticals DCPH and BeiGeneBGNE. While Alkermes sports a Zacks Rank #1 (Strong Buy), Deciphera and BeiGene carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates have improved from 14 cents to 3 cents for 2022 in the past 60 days. ALKS has gained 24.4% so far this year.
Alkermes delivered an earnings surprise of 350.48%, on average, in the last four quarters.
Estimates for Deciphera have narrowed from a loss of $2.94 to $2.77 for 2022 in the past 60 days. DCPH has risen 10.2% so far this year.
Deciphera delivered a negative earnings surprise of 2.73%, on average, in the last four quarters.
BeiGene’s loss per share estimates have narrowed from $15.79 to $15.66 for 2022 in the past 60 days. BGNE has declined 39.8% so far this year.
BeiGene delivered an earnings surprise of 14.63%, on average, in the last four quarters.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?
From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis Report
Amarin Corporation PLC (AMRN): Free Stock Analysis Report
BeiGene, Ltd. (BGNE): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Some better-ranked stocks from the pharma/biotech sector include Alkermes ALKS, Deciphera Pharmaceuticals DCPH and BeiGeneBGNE. DCPH has risen 10.2% so far this year. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Some better-ranked stocks from the pharma/biotech sector include Alkermes ALKS, Deciphera Pharmaceuticals DCPH and BeiGeneBGNE. DCPH has risen 10.2% so far this year. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Some better-ranked stocks from the pharma/biotech sector include Alkermes ALKS, Deciphera Pharmaceuticals DCPH and BeiGeneBGNE. DCPH has risen 10.2% so far this year. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Some better-ranked stocks from the pharma/biotech sector include Alkermes ALKS, Deciphera Pharmaceuticals DCPH and BeiGeneBGNE. DCPH has risen 10.2% so far this year. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
6b9ec184-1730-460d-8063-58c59283a5d4
|
715470.0
|
2022-05-04 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Tops Revenue Estimates
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-reports-q1-loss-tops-revenue-estimates
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $1.06 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 4.76%. A quarter ago, it was expected that this company would post a loss of $1.49 per share when it actually produced a loss of $1.51, delivering a surprise of -1.34%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $29.22 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 7.47%. This compares to year-ago revenues of $25.16 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Deciphera Pharmaceuticals, Inc. Shares have added about 8% since the beginning of the year versus the S&P 500's decline of -12.4%.
What's Next for Deciphera Pharmaceuticals, Inc.
While Deciphera Pharmaceuticals, Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Deciphera Pharmaceuticals, Inc. Favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.68 on $30.07 million in revenues for the coming quarter and -$2.77 on $123.88 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, NGM Biopharmaceuticals (NGM), has yet to report results for the quarter ended March 2022.
This biotechnology company is expected to post quarterly loss of $0.42 per share in its upcoming report, which represents a year-over-year change of -16.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
NGM Biopharmaceuticals' revenues are expected to be $22.35 million, up 3.6% from the year-ago quarter.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
NGM Biopharmaceuticals, Inc. (NGM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.84. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.84. Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $29.22 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 7.47%.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.84. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $29.22 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 7.47%.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.84. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report While Deciphera Pharmaceuticals, Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
|
4181193a-0b3d-454e-a321-1883ad9673c8
|
715471.0
|
2022-05-03 00:00:00 UTC
|
Why Axsome (AXSM) is Up 7% Despite Wider-Than-Expected Q1 Loss
|
DCPH
|
https://www.nasdaq.com/articles/why-axsome-axsm-is-up-7-despite-wider-than-expected-q1-loss
|
nan
|
nan
|
Axsome Therapeutics, Inc. AXSM incurred a loss of $1.03 per share for first-quarter 2022, wider than the Zacks Consensus Estimate of a loss of $1.02. AXSM had reported a loss of 78 cents per share in the year-ago period.
Axsome does not have any approved product in its portfolio, currently. As a result, revenues are yet to be generated from the same.
Quarter in Detail
Research and development expenses were $12.6 million for the quarter, down 24.2% from the year-ago period’s level owing to NDA filing expenses incurred in the year-ago period.
General and administrative expenses were $25.7 million, up 128.5% year over year. The significant increase was due to higher pre-commercialization activities related to the potential launch of AXS-05 and AXS-07.
As of Mar 31, 2022, Axsome had cash worth $84.7 million compared with $86.5 million on Dec 31, 2021.
2022 Guidance
Management believes that its cash balance as of March 2022 end and its $300 million term-loan facility will be enough to fund operations into 2024.
Axsome expects an increase in operating expenses on account of pipeline development and commercialization activities.
Pipeline Update
Axsome’s key pipeline candidates, including AXS-05, AXS-07, AXS-12 and AXS-14, target multiple central nervous system indications.
AXS-05
AXS-05, one of Axsome’s lead candidates, is developed for treating a major depressive disorder (MDD), treatment-resistant depression (TRD), smoking cessation and agitation associated with Alzheimer's disease (AD).
Axsome’s new drug application (NDA) seeking approval for AXS-05 to treat MDD is under a priority review with the FDA. After a positive interaction with the regulatory agency’s officials on post-marketing requirements, AXSM anticipates a potential approval for the drug in second-quarter 2022.
Shares of AXSM gained 7.2% on May 2, probably due to the above announcement. In the year so far, the stock has declined 9.9% compared with the industry’s 21.4% fall.
Image Source: Zacks Investment Research
Others
Another lead candidate, AXS-07, is developed for the acute treatment of migraine. In a separate press release issued alongside the first-quarter earnings report, Axsome announced that it received a complete response letter (CRL) from the FDA about the NDA, seeking approval for AXS-07 to address the given indication.
Per management, the FDA seeks additional chemistry, manufacturing and controls (CMC) data related to drug product and manufacturing process. The CRL was expected as Axsome had previously notified about this issue in an SEC filing last month. While AXSM believes that the FDA’s queries can be resolved, it intends to consult with the regulatory body before providing any timeline for refiling the NDA.
The CRL did not raise any concerns about the clinical efficacy or safety issues of AXS-07 nor did the FDA request any new clinical study to support the approval of the candidate.
Axsome’s AXS-12 is being developed to treat narcolepsy, a sleep disorder characterized by excessive sleepiness. AXSM is currently enrolling patients in the phase III SYMPHONY study for the given indication. Top-line data from this study is expected in first-half 2023.
AXS-14 is Axsome’s candidate for the treatment of fibromyalgia. An NDA is expected to be filed in 2023, following the successful completion of manufacturing and other activities related to the candidate.
Axsome Therapeutics, Inc. Price
Axsome Therapeutics, Inc. price | Axsome Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Currently, Axsome Therapeutics has a Zacks Rank #3 (Hold). Better-ranked stocks in the same sector include Angion Biomedica ANGN, Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX. While Angion Biomedica sports a Zacks Rank #1 (Strong Buy), both Deciphera Pharmaceuticals and Vertex Pharmaceuticals carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, estimates for Angion Biomedica’s 2022 loss per share have narrowed from $2.38 to $1.79. The same for 2023 has narrowed from $2.95 to $2.19 in the same time frame.
Earnings of Angion Biomedica beat estimates in three of the last four quarters and missed the mark on one occasion, witnessing a negative surprise of 47.5%, on average.
Deciphera Pharmaceuticals’ loss per share estimates for 2022 have narrowed from $2.94 to $2.73 in the past 30 days. The same for 2023 has narrowed from $2.38 to $2.23 in the same time period. DCPH has risen 11.7% in the year-to-date period.
Earnings of Deciphera Pharmaceuticals missed estimates in three of the last four quarters and beat the mark once, the average negative surprise being 2.7%.
Vertex Pharmaceuticals’ earnings per share estimates for 2022 have increased from $14.52 to $14.56 in the past 30 days. The same for 2023 has risen from $15.31 to $15.35 during the same period. VRTX has rallied 19.3% in the year so far.
Earnings of Vertex Pharmaceuticals beat estimates in each of the last four quarters, the average being 10%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Angion Biomedica Corp. (ANGN): Free Stock Analysis Report
Axsome Therapeutics, Inc. (AXSM): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Better-ranked stocks in the same sector include Angion Biomedica ANGN, Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX. DCPH has risen 11.7% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Better-ranked stocks in the same sector include Angion Biomedica ANGN, Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX. DCPH has risen 11.7% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Better-ranked stocks in the same sector include Angion Biomedica ANGN, Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX. DCPH has risen 11.7% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Better-ranked stocks in the same sector include Angion Biomedica ANGN, Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX. DCPH has risen 11.7% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
4a3a6e5b-d755-4a06-9728-18d591c3f15c
|
715472.0
|
2022-05-02 00:00:00 UTC
|
Can Deciphera Pharmaceuticals, Inc. (DCPH) Climb 79% to Reach the Level Wall Street Analysts Expect?
|
DCPH
|
https://www.nasdaq.com/articles/can-deciphera-pharmaceuticals-inc.-dcph-climb-79-to-reach-the-level-wall-street-analysts
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. (DCPH) closed the last trading session at $10.12, gaining 2.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $18.10 indicates a 78.9% upside potential.
The average comprises 10 short-term price targets ranging from a low of $10 to a high of $64, with a standard deviation of $16.68. While the lowest estimate indicates a decline of 1.2% from the current price level, the most optimistic estimate points to a 532.4% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.
But, for DCPH, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Price, Consensus and EPS Surprise
Here's What You May Not Know About Analysts' Price Targets
According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Why DCPH Could Witness a Solid Upside
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 7.1%, as two estimates have moved higher compared to no negative revision.
Moreover, DCPH currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, while the consensus price target may not be a reliable indicator of how much DCPH could gain, the direction of price movement it implies does appear to be a good guide.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) closed the last trading session at $10.12, gaining 2.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. But, for DCPH, an impressive average price target is not the only indicator of a potential upside. Why DCPH Could Witness a Solid Upside Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock.
|
Deciphera Pharmaceuticals, Inc. (DCPH) closed the last trading session at $10.12, gaining 2.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. But, for DCPH, an impressive average price target is not the only indicator of a potential upside. Why DCPH Could Witness a Solid Upside Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock.
|
You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much DCPH could gain, the direction of price movement it implies does appear to be a good guide. Deciphera Pharmaceuticals, Inc. (DCPH) closed the last trading session at $10.12, gaining 2.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. But, for DCPH, an impressive average price target is not the only indicator of a potential upside.
|
You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much DCPH could gain, the direction of price movement it implies does appear to be a good guide. Deciphera Pharmaceuticals, Inc. (DCPH) closed the last trading session at $10.12, gaining 2.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. But, for DCPH, an impressive average price target is not the only indicator of a potential upside.
|
45e2fd1e-6f2f-46cb-b52e-78eab75e6678
|
715473.0
|
2022-04-29 00:00:00 UTC
|
AstraZeneca (AZN) Q1 Earnings and Revenues Beat Estimates
|
DCPH
|
https://www.nasdaq.com/articles/astrazeneca-azn-q1-earnings-and-revenues-beat-estimates
|
nan
|
nan
|
AstraZeneca’s AZN first-quarter 2022 core earnings of 95 cents per American depositary share (ADS) beat the Zacks Consensus Estimate of 85 cents. Core earnings of $1.89 per share rose 16% year over year on a reported basis and 20% at constant exchange rates (CER).
Total revenues, including sales of the rare disease drugmaker Alexion acquired in July 2021, were up 56% on a reported basis and 60% at CER to $11.39 billion in the quarter, driven by higher product sales and a contribution from AstraZeneca’s COVID-19 vaccine. Revenues beat the Zacks Consensus Estimate of $11.14 billion.
All growth rates mentioned below are on a year-over-year basis and at CER.
Product Sales Rise
Product sales rose 56% at CER to $10.98 billion. Collaboration revenues were $410 million. Collaboration revenues included a $175-million sales milestone payment for Lynparza, $75 million for Enhertu (from partner Daiichi Sankyo) and $70 million for tralokinumab (as part of the license agreement with Leo Pharma).
Among AstraZeneca’s various therapeutic areas, Oncology product sales were up 25%. CVRM product sales were up 18%, while the Respiratory & Immunology segment gained 4%. Rare disease product sales were up 7%. Sales of other medicines declined 15%.
Sales in Detail
In Vaccines & Immune Therapies (V&I), AstraZeneca’s COVID-19 vaccine Vaxzevria, generated $1.09 billion of revenues. AZN’s new COVID-19 antibody cocktail medicine Evusheld generated $469 million worth of sales, of which $307 million came from the United States, $89 million from the Emerging Markets and $66 million from Europe.
In Oncology, Lynparza product revenues rose 17% year over year to $617 million owing to its higher adoption in ovarian, breast and prostate cancer treatments in the United States. Additional reimbursements, increasing BRCAm-testing rates and a successful launch for addressing the first-line ovarian cancer in Europe also boosted sales. The drug is the leading PARP-inhibitor in the United States.
AstraZeneca markets Lynparza in partnership with Merck MRK. The profit-sharing deal between AstraZeneca and Merck was inked in 2017. In addition to Lynparza, the deal included Koselugo.
AstraZeneca & Merck’s Lynparza is approved for four cancer types, namely ovarian, breast, prostate and pancreatic. Lynparza is also being evaluated in an earlier-line setting for the approved cancer indications as well as some other cancer types.
Tagrisso recorded sales of $1.30 billion, up 17% year over year on strong demand for use as a first-line and adjuvant treatment, partially offset by lower rates of new patient diagnosis due to the new wave of Omicron-related infections in the United States.
Imfinzi generated sales of $599 million in the quarter, up 11% year over year, driven by increased demand for an extensive stage non-small cell lung cancer (ES-SCLC) indication. COVID-19 continued to hurt lung cancer diagnosis rates, mainly in the United States.
Calquence generated $414 million in the quarter, up 100% year over year, benefiting from the new patients initiating treatment.
Sales of AstraZeneca’s legacy cancer drugs, such as Iressa, Arimidex, Faslodex and Casodex declined during the quarter. However, sales of Zoladex were up 12%.
In CVRM, Brilinta/Brilique sales were $325 million in the reported quarter, down 10% year over year, primarily due to the impact of COVID-19 (reflecting fewer elective procedures) in the United States and the EU and pricing pressures from the VBP (volume-based procurement) program in China.
Farxiga recorded product sales of $1.0 billion in the quarter, up 67% year over year, reflecting volume growth across all regions and growth of the SGLT2 inhibitor class in general. The recent label expansion approvals for heart failure with a reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) indications contributed to Farxiga’s sales growth in the United States and Europe. The inclusion of Farxiga in the NRDL in China boosted sales in the Emerging Markets.
Bydureon sales declined 33% to $68 million. Sales of older CVRM medicine Crestor were flat year over year while product sales of another old CVRM drug Seloken/Toprol-XL declined 1% in the quarter.
In Respiratory & Immunology, Symbicort sales were flat in the quarter at $674 million. Pulmicort sales declined 34% to $217 million.
Fasenra recorded sales of $308 million in the quarter, up 22% year over year, driven by sustainable growth in volume in the United States and an increased volume from sustained leadership in new to brand prescriptions in Europe.
AstraZeneca’s new triple combo COPD treatment Breztri recorded sales of $87 million in the quarter compared with $73 million in the previous quarter.
In the Rare Disease portfolio, which added with Alexion post acquisition, Soliris recorded sales of $990 million, in line with the year-ago quarter’s figure. The performance in the United States was driven by its growing uptake in neurology indications, generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD), offset by the patient conversion to Ultomiris for paroxysmalnocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) indications. Ultomiris and Strensiq sales were $419 million and $208 million each, up 25% and 7%, respectively. Koselugo, a new drug which was recently moved to AstraZeneca’s Rare Disease Portfolio, generated sales of $39 million in the quarter.
Profit Discussion
AstraZeneca’s core gross margin of 79.3% was up 4 percentage points at CER. Core selling, general and administrative (SG&A) expenses increased 25% to $2.95 billion.
Core research and development (R&D) expenses rose 36% to $2.19 billion. Core operating profit rose 60% to $3.96 billion in the quarter. The core operating margin was 34.8% in the quarter, which was stable year over year.
2022 Guidance Intact
AstraZeneca reiterated its financial guidance for 2022. AZN expects total revenues to increase in high-teens percentage in 2022. The guidance includes the full-year contribution from the COVID-19 vaccine.
Management expects a decline in total revenues from COVID-19 medicines in 2022 by a low-to-mid-twenties percentage, with an expected decline in the sales of COVID-19 vaccine being partially offset by growth in Evusheld sales. Shares of AstraZeneca were down 1.2% in pre-market trading on Apr 29, attributable to this factor most likely.
So far this year, the stock has gained 15.4% compared with an increase of 5.1% for the industry.
Image Source: Zacks Investment Research
Core earnings are expected to increase in mid-to-high twenties’ percentage in 2022.
Our Take
AstraZeneca’s first-quarter results were encouraging as it beat on both earnings and sales Product sales growth was driven by its V&I unit, COVID products and higher sales of key medicines across the Oncology and CVRM units like Tagrisso and Farxiga, which offset some negative impacts from the pandemic. The rare disease drugs were added to AZN’s portfolio following the Alexion acquisition, which in turn, aided sales growth.
On a region-wise analysis, AstraZeneca witnessed double-digit growth in all major regions, including the Emerging Markets except China. Sales in China were hurt by pricing pressure associated with the National Reimbursement Drug List (NRDL) and VBP programs.
AstraZeneca PLC Price
AstraZeneca PLC price | AstraZeneca PLC Quote
Zacks Rank & Stocks to Consider
Currently, AstraZeneca has a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX, each of which has a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Deciphera Pharmaceuticals’ loss per share estimates for 2022 have narrowed from $2.94 to $2.84 in the past 30 days. The same for 2023 has narrowed from $2.38 to $2.27 in the past 30 days. DCPH has risen 10.9% in the year-to-date period.
Earnings of Deciphera Pharmaceuticals missed estimates in three of the last four quarters and beat the mark once, the average surprise being 2.7%.
Vertex Pharmaceuticals’ earnings per share estimates for 2022 have increased from $14.52 to $14.56 in the past 30 days. The same for 2023 has risen from $15.31 to $15.35 in the past 30 days. VRTX has risen 22.3% in the year so far.
Earnings of Vertex Pharmaceuticals beat estimates in each of the last four quarters, the average being 10%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Better-ranked stocks in the biotech sector include Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX, each of which has a Zacks Rank #2 (Buy) at present. DCPH has risen 10.9% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Better-ranked stocks in the biotech sector include Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX, each of which has a Zacks Rank #2 (Buy) at present. DCPH has risen 10.9% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Better-ranked stocks in the biotech sector include Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX, each of which has a Zacks Rank #2 (Buy) at present. DCPH has risen 10.9% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Better-ranked stocks in the biotech sector include Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX, each of which has a Zacks Rank #2 (Buy) at present. DCPH has risen 10.9% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
b33a690c-da4c-40e1-aa28-c7b980f9240b
|
715474.0
|
2022-04-29 00:00:00 UTC
|
Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates
|
DCPH
|
https://www.nasdaq.com/articles/emergents-ebs-q1-earnings-miss-revenues-beat-estimates
|
nan
|
nan
|
Emergent BioSolutions Inc. EBS reported first-quarter 2022 adjusted earnings of 18 cents per share, which missed the Zacks Consensus Estimate of 24 cents. In the year-ago quarter, EBS had reported earnings of $1.53 per share.
Revenues in the reported quarter were $307.5 million, down 10% from the prior-year period’s level. Although Emergent reported higher product sales, the same was largely offset by lower contract development and manufacturing (CDMO) revenues in the quarter. Revenues beat the Zacks Consensus Estimate of $292.3 million.
Shares of Emergent BioSolutions have declined 15.8% in the year so far compared with the industry’s 20.6% decrease.
Image Source: Zacks Investment Research
Quarter in Detail
Total product sales increased 72% from the year-ago quarter’s level to $237.1 million, driven by strong sales of the anthrax vaccine, the Narcan nasal spray and smallpox vaccine.
Sales of anthrax vaccines (BioThrax and AV7909) were $103.6 million in the reported quarter, up 88% year over year. The increase in sales of anthrax vaccines was owing to a rise in deliveries of AV7909 for the strategic national stockpile.
Narcan (naloxone HCl) nasal spray added $93.1 million to product sales, up 25% year over year, driven primarily by growth in the U.S. and Canadian markets.
Emergent reported sales of $14.4 million for its smallpox vaccine ACAM2000, driven by international sales.
Other product sales were $26 million compared with $8.7 million in the year-ago period.
Revenues from contracts and grants declined 55% year over year to $9.6 million. This substantial decline was on account of lower revenues from the Biomedical Advanced Research and Development Authority (BARDA) due to termination of a development and manufacturing agreement last November.
Total CDMO revenues were down 67% year over year to $60.8 million. While CDMO services revenues declined 23% year over year to $51.8 million, the CDMO leases revenues fell 92% to $9 million. The decline in CDMO services revenues was due to maintenance-related work carried out at one of Emergent’s facilities, which reduced manufacturing activities. Revenues from the CDMO leases fell due to completion of a public-private partnership between EBS and BARDA
Emergent reported adjusted EBITDA of $36 million for the first quarter, down 71% from the prior-year quarter’s level.
Recent Updates
Emergent completed the rolling submission of the biologic license application (BLA) for its new anthrax vaccine candidate AV7909 in the last week.
Update on 2022 Guidance
Alongside its first-quarter results, Emergent announced that it is temporarily suspending its CDMO financial guidance. The decision was taken after Johnson & Johnson JNJ announced the suspension of its previously issued 2022 financial guidance for its COVID-19 vaccine on its first-quarter conference call earlier this month.
J&J took this step in the wake of global surplus supply and demand uncertainty. The manufacturing of J&J’s COVID-19 vaccine is one of Emergent’s key CDMO contracts. Hence, until EBS gets a better understanding of J&J’s COVID-19 vaccine requirements, it is also temporarily suspending guidances on other metrics, including total revenues, adjusted net income, adjusted EBITDA and gross margin.
However, EBS maintained its previous guidance for all other business segments. Management continues to expect sales of $280-$300 million from anthrax vaccines, $190-$210 million from smallpox vaccine and $240-$310 million from the Narcan nasal spray. The projection for revenues from other products, and Contracts and Grants was reaffirmed in the range of $200-$260 million.
Emergent Biosolutions Inc. Price
Emergent Biosolutions Inc. price | Emergent Biosolutions Inc. Quote
Zacks Rank & Stocks to Consider
Currently, Emergent BioSolutions has a Zacks Rank #5 (Strong Sell).
Better-ranked stocks in the same sector include Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX, each holding a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Deciphera Pharmaceuticals’ loss per share estimates for 2022 have narrowed from $2.94 to $2.84 in the past 30 days. The same for 2023 has narrowed from $2.38 to $2.27 in the past 30 days. DCPH has risen 10.9% in the year-to-date period.
Earnings of Deciphera Pharmaceuticals missed estimates in three of the last four quarters and beat the mark once, the average surprise being 2.7%.
Vertex Pharmaceuticals’ earnings per share estimates for 2022 have increased from $14.52 to $14.56 in the past 30 days. The same for 2023 has risen from $15.31 to $15.35 in the past 30 days. VRTX has rallied 22.3% in the year so far.
Earnings of Vertex Pharmaceuticals beat estimates in each of the last four quarters, the average being 10%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Emergent Biosolutions Inc. (EBS): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Better-ranked stocks in the same sector include Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX, each holding a Zacks Rank #2 (Buy) at present. DCPH has risen 10.9% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Better-ranked stocks in the same sector include Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX, each holding a Zacks Rank #2 (Buy) at present. DCPH has risen 10.9% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Better-ranked stocks in the same sector include Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX, each holding a Zacks Rank #2 (Buy) at present. DCPH has risen 10.9% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Better-ranked stocks in the same sector include Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX, each holding a Zacks Rank #2 (Buy) at present. DCPH has risen 10.9% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
19554ae5-746f-4c81-9430-34f242832716
|
715475.0
|
2022-04-28 00:00:00 UTC
|
Repligen (RGEN) Q1 Earnings and Sales Beat Estimates, Stock Up
|
DCPH
|
https://www.nasdaq.com/articles/repligen-rgen-q1-earnings-and-sales-beat-estimates-stock-up
|
nan
|
nan
|
Repligen Corporation RGEN announced first-quarter 2022 adjusted earnings per share of 92 cents, beating the Zacks Consensus Estimate of 72 cents. Earnings also rose 35.3% year over year.
Total revenues of $206.4 million also surpassed the Zacks Consensus Estimate of $183.6 million. Sales rose 45% year over year (48% in constant currency) on robust demand across the filtration, chromatography and process analytics franchises.
Excluding the impact of currency and acquisitions/divestitures, Repligen’s organic revenues grew 44% year over year for first-quarter 2022.
Shares of Repligen rose 10.5% on Apr 27, following the encouraging earnings results. Yet, the stock has plunged 40.5% in the year so far compared with the industry’s 20.4% decline.
Image Source: Zacks Investment Research
Quarter in Detail
During the quarter, Repligen’s base business accounted for 71% of revenues while COVID-related sales constituted 26%. Remaining growth was on account of inorganic revenues from the acquisitions made during 2021.
We note that Repligen’s base business can be categorized mainly under four franchises, namely filtration, chromatography, protein and process analytics.
Sales of the company’s overall base business registered growth of 37% year over year. While revenue growth from the filtration, chromatography and process analytics franchises was up over 30% year over year. Revenue growth of the protein franchise was in line with the year-ago quarter’s level.
The gene-therapy business was up more than 100% during the quarter.
Adjusted gross margin was 60.4% in the first quarter, up 100 basis points (bps) year over year.
For the reported quarter, adjusted research and development expenses were $11.8 million, up 60.1% from the year-ago quarter’s figure.
Adjusted selling, general and administrative expenses were $45.4 million, surging 43.2% year over year.
Adjusted operating income was $67.4 million, increasing 47% year over year. Adjusted operating margin was 32.6%, up 70 bps year over year.
As of Mar 31, 2022, Repligen had cash and cash equivalents worth $584.6 million compared with $603.8 million on Dec 31, 2021.
Updated 2022 Guidance
Repligen revised its financial guidance for 2022.
RGEN expects revenues in the range of $770-$800 million, reflecting a 4% reduction from the earlier projected levels of $800-$830 million. The new revenue guidance indicates overall revenue growth of 15-19% year over year on a reported basis while 17-21% growth on constant-currency basis. Organic growth is now expected in the range of 14-18%, down from the earlier projected growth band of 18-22%.
Repligen now expects base business revenues in the $598-$628 million range, up from the previously issued guided range of $578-$587 million.
The updated guidance lowers Repligen’s expectations from COVID-related sales due to slowing vaccination rates. However, RGEN expects a rise in demand for products sold under its base business.
Adjusted net income is now projected in the $177-$182 million band, down from the earlier guidance of $185-$190 million. Adjusted operating income is now anticipated within $225-$231 million, down from the earlier projected $234-$240 million band.
Adjusted EPS is anticipated within $3.07-$3.15, reflecting a decline from the earlier guidance range of $3.21-$3.30.
Repligen Corporation Price
Repligen Corporation price | Repligen Corporation Quote
Zacks Rank & Stocks to Consider
Currently, Repligen has a Zacks Rank #3 (Hold). Better-ranked stocks in the same sector include Angion Biomedica ANGN, Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX. While Angion Biomedica sports a Zacks Rank #1 (Strong Buy), both Deciphera Pharmaceuticals and Vertex Pharmaceuticals carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Angion Biomedica’s loss per share estimates for 2022 have narrowed from $2.59 to $1.79 in the past 30 days. The same for 2023 has narrowed from $3.11 to $2.19 in the past 30 days.
Earnings of Angion Biomedica beat estimates in three of the last four quarters and missed the mark once, the average surprise being 47.5%.
Deciphera Pharmaceuticals’ loss per share estimates for 2022 have narrowed from $2.94 to $2.84 in the past 30 days. The same for 2023 has narrowed from $2.38 to $2.27 in the past 30 days. The stock has risen 10.1% in the year-to-date period.
Earnings of Deciphera Pharmaceuticalsmissed estimates in three of the last four quarters and beat the mark once, the average surprise being 2.7%.
Vertex Pharmaceuticals’ earnings per share estimates for 2022 have increased from $14.52 to $14.56 in the past 30 days. The same for 2023 has risen from $15.31 to $15.35 in the past 30 days. VRTX has risen 21.7% in the year so far.
Earnings of Vertex Pharmaceuticals beat estimates in each of the last four quarters, the average being 10%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Angion Biomedica Corp. (ANGN): Free Stock Analysis Report
Repligen Corporation (RGEN): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Better-ranked stocks in the same sector include Angion Biomedica ANGN, Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report We note that Repligen’s base business can be categorized mainly under four franchises, namely filtration, chromatography, protein and process analytics.
|
Better-ranked stocks in the same sector include Angion Biomedica ANGN, Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Repligen Corporation RGEN announced first-quarter 2022 adjusted earnings per share of 92 cents, beating the Zacks Consensus Estimate of 72 cents.
|
Better-ranked stocks in the same sector include Angion Biomedica ANGN, Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report The new revenue guidance indicates overall revenue growth of 15-19% year over year on a reported basis while 17-21% growth on constant-currency basis.
|
Better-ranked stocks in the same sector include Angion Biomedica ANGN, Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Image Source: Zacks Investment Research Quarter in Detail During the quarter, Repligen’s base business accounted for 71% of revenues while COVID-related sales constituted 26%.
|
0f7f33af-43af-45cb-b2ae-633b17a8dbe6
|
715476.0
|
2022-04-28 00:00:00 UTC
|
BioMarin (BMRN) Q1 Earnings and Revenues Beat Estimates
|
DCPH
|
https://www.nasdaq.com/articles/biomarin-bmrn-q1-earnings-and-revenues-beat-estimates
|
nan
|
nan
|
BioMarin Pharmaceutical Inc. BMRN reported first-quarter 2022 adjusted earnings of 55 cents per share, beating the Zacks Consensus Estimate of 38 cents. However, earnings slid 1.8% from the year-ago quarter’s figure.
Total revenues were $519.4 million in the reported quarter, up 7% from the year-ago quarter’s level. The revenues beat the Zacks Consensus Estimate of $505 million.
Quarter in Detail
Product revenues (including Aldurazyme) were $505.5 million in the quarter, up 8.1% year over year. Product revenues from BioMarin's marketed brands (excluding Aldurazyme) were up 15% year over year to $481.1 million on higher revenues from Vimzim, Naglazyme, Voxzogo and Brineura. Royalty and other revenues were $13.8 million in the quarter, down 24.2%.
Vimizim sales were up 16% year over year to $183 million while Naglazyme sales were up 19% to $128 million. The rise in sales was driven by the new patients initiating therapy as well as the favorable timing of orders in the Middle East and Europe. On the conference call, management said that both Naglazyme and Vimzim achieved record quarterly sales in first-quarter 2022.
Brineura generated sales of $36.2 million in the quarter, up 33% year over year, driven by 18% growth in new patients starting treatment in Europe.
The new drug Voxzogo, approved last year in United Sates and Europe to treat achondroplasia, generated sales worth $19.7 million in the first quarter with the majority of sales coming from Europe. During the previous quarter, the drug generated $5.2 million of revenues. Per management, an estimated 284 children are being treated with Voxzogo, of which 83 reside in the United States.
Palynziq injection sales grossed $54.9 million in the quarter, up 2% year over year. Sales continued to be hurt by the pandemic impact as PKU clinics were not operating at full capacity.
In the phenylketonuria (PKU) franchise, Kuvan revenues declined 16% to $59.3 million due to generic competition as the drug lost U.S. market exclusivity in late 2020.
Product revenues from Aldurazyme totaled $24.4 million, down 51% due to the unfavorable timing of product fulfillment to Sanofi’s SNY subsidiary Genzyme.
BioMarin has a collaboration agreement with Sanofi’s Genzyme for Aldurazyme. SNY through Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.
Pipeline Update
BioMarin’s biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA in August 2020 while the marketing authorization application (MAA) in Europe was withdrawn. BioMarin resubmitted the MAA along with this one-year data to the European Medicines Agency (EMA) in June 2021. BioMarin announced two-year follow-up safety and efficacy data from the phase III GENEr8-1 study in January 2022 and submitted the same to the EMA. A BLA is expected to be re-filed with the FDA later this year in June. BMRN scheduled a pre-submission interaction with the regulatory agency during the second quarter to discuss its resubmission efforts.
In first-quarter 2022, BioMarin announced that a study participant who was treated in a phase II study evaluating Roctavian in 2016 had reported a salivary gland tumor. Alongside its first quarter earnings, BMRN announced that it had completed a genomic analysis of the tissue sample from the tumor mass, which did not show any evidence of vector integration contributing to the tumor. BMRN already submitted this information to the EMA.
An important candidate in BioMarin’s pipeline is BMN 307, an investigational gene-therapy for PKU. Its phase I/II PHEarless study has beenplaced under clinical hold by the FDA since September 2021. In February 2022, BMRN reported that it received a request from the regulatory body to submit data from additional non-clinical studies to assess the theoretical oncogenic risk to human study participants to resolve the clinical hold. Management believes that this data will take several quarters to be available.
Another gene therapy candidate in BioMarin’s pipeline is BMN 331 for the treatment of hereditary angioedema. A phase I/II HAERMONY study on BMN 331 is now open for enrolment.
2022 Guidance Revision
BioMarin now expects to record Voxzogo sales in the range of $100-$125 million in 2022, up from the previously affirmed guidance of $90-$115 million. On the conference call, management said that it expects Voxzogo to be a meaningful contributor to BMRN’s total revenues. BMRN expects robust prescription demand to continue driving the drug’s growth, including approval in the new markets.
Shares of BioMarin were up 3.4% in after-hours trading on Wednesday as investors were most likely impressed with the raised financial guidance for 2022 revenues from Voxzogo. In the year so far, the stock has declined 9.1% compared with the industry’s fall of 20%.
Image Source: Zacks Investment Research
Apart from Voxzogo sales, BioMarin maintained its previously issued guidance for 2022. BMRN reiterated total 2022 revenues in the range of $2.05-$2.15 billion, indicating growth of 14% at the midpoint.
Vimizim sales are expected in the range of $650-$700 million in 2022. Kuvan sales are anticipated in the range of $225-$250 million. Palynziq sales are expected in the range of $280-$310 million. Naglazyme sales are expected between $400 million and $440 million. Brineura sales are expected within $145-$160 million. BioMarin expects Roctavian to be a modest contributor to its current-year revenues.
BioMarin expects adjusted net income in the range of $350-$390 million, indicating more than 50% growth from the 2021 actuals.
BioMarin Pharmaceutical Inc. Price
BioMarin Pharmaceutical Inc. price | BioMarin Pharmaceutical Inc. Quote
Zacks Rank & Other Stocks to Consider
Currently, BioMarin sports a Zacks Rank #1 (Strong Buy). Other top-ranked stocks in the same sector include Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Deciphera Pharmaceuticals’ loss per share estimates for 2022 have narrowed from $2.94 to $2.84 in the past 30 days. The same for 2023 has narrowed from $2.38 to $2.27 in the past 30 days. DCPH’s stock has risen 10.1% in the year-to-date period.
Earnings of Deciphera Pharmaceuticals missed estimates in three of the last four quarters and beat the mark once, the average surprise being 2.7%.
Vertex Pharmaceuticals’ earnings per share estimates for 2022 have increased from $14.52 to $14.56 in the past 30 days. The same for 2023 has risen from $15.31 to $15.35 in the past 30 days. VRTX’s stock has rallied 21.7% in the year so far.
Earnings of Vertex Pharmaceuticals beat estimates in each of the last four quarters, the average being 10%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY): Free Stock Analysis Report
BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Other top-ranked stocks in the same sector include Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX, both carrying a Zacks Rank #2 (Buy) at present. DCPH’s stock has risen 10.1% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Other top-ranked stocks in the same sector include Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX, both carrying a Zacks Rank #2 (Buy) at present. DCPH’s stock has risen 10.1% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Other top-ranked stocks in the same sector include Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX, both carrying a Zacks Rank #2 (Buy) at present. DCPH’s stock has risen 10.1% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
Other top-ranked stocks in the same sector include Deciphera Pharmaceuticals DCPH and Vertex Pharmaceuticals VRTX, both carrying a Zacks Rank #2 (Buy) at present. DCPH’s stock has risen 10.1% in the year-to-date period. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
c179a8e9-60ef-4586-8c3c-3e1d6a3ebf03
|
715477.0
|
2022-04-27 00:00:00 UTC
|
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
|
DCPH
|
https://www.nasdaq.com/articles/neogenomics-neo-reports-q1-loss-tops-revenue-estimates
|
nan
|
nan
|
NeoGenomics (NEO) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 13.04%. A quarter ago, it was expected that this operator of cancer-focused testing laboratories would post a loss of $0.13 per share when it actually produced a loss of $0.14, delivering a surprise of -7.69%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
NeoGenomics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $117.17 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 0.90%. This compares to year-ago revenues of $115.53 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
NeoGenomics shares have lost about 68.2% since the beginning of the year versus the S&P 500's decline of -12.4%.
What's Next for NeoGenomics?
While NeoGenomics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for NeoGenomics: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.20 on $127.73 million in revenues for the coming quarter and -$0.72 on $518.82 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 46% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has yet to report results for the quarter ended March 2022.
This company is expected to post quarterly loss of $0.84 per share in its upcoming report, which represents a year-over-year change of +20.8%. The consensus EPS estimate for the quarter has been revised 2.8% higher over the last 30 days to the current level.
Deciphera Pharmaceuticals, Inc.'s revenues are expected to be $26.68 million, up 6% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NeoGenomics, Inc. (NEO): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has yet to report results for the quarter ended March 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.
|
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has yet to report results for the quarter ended March 2022. NeoGenomics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $117.17 million for the quarter ended March 2022, surpassing the Zacks Consensus Estimate by 0.90%.
|
Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has yet to report results for the quarter ended March 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report NeoGenomics (NEO) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.23.
|
Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has yet to report results for the quarter ended March 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report The company has topped consensus revenue estimates three times over the last four quarters.
|
e93749ad-3164-4627-8f9c-f86aebaddc7a
|
715478.0
|
2022-04-26 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-expected-to-beat-earnings-estimates%3A-can-the-stock-0
|
nan
|
nan
|
Wall Street expects a year-over-year increase in earnings on higher revenues when Deciphera Pharmaceuticals, Inc. (DCPH) reports results for the quarter ended March 2022. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This company is expected to post quarterly loss of $0.84 per share in its upcoming report, which represents a year-over-year change of +20.8%.
Revenues are expected to be $26.68 million, up 6% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 2.75% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Deciphera Pharmaceuticals, Inc.
For Deciphera Pharmaceuticals, Inc.The Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +27.26%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination indicates that Deciphera Pharmaceuticals, Inc. Will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Deciphera Pharmaceuticals, Inc. Would post a loss of $1.49 per share when it actually produced a loss of $1.51, delivering a surprise of -1.34%.
Over the last four quarters, the company has beaten consensus EPS estimates just once.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Deciphera Pharmaceuticals, Inc. Appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Wall Street expects a year-over-year increase in earnings on higher revenues when Deciphera Pharmaceuticals, Inc. (DCPH) reports results for the quarter ended March 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
|
Wall Street expects a year-over-year increase in earnings on higher revenues when Deciphera Pharmaceuticals, Inc. (DCPH) reports results for the quarter ended March 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out.
|
Wall Street expects a year-over-year increase in earnings on higher revenues when Deciphera Pharmaceuticals, Inc. (DCPH) reports results for the quarter ended March 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate.
|
Wall Street expects a year-over-year increase in earnings on higher revenues when Deciphera Pharmaceuticals, Inc. (DCPH) reports results for the quarter ended March 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report The stock might move higher if these key numbers top expectations in the upcoming earnings report.
|
33fecac9-26a9-41c5-9246-30476aeaad1c
|
715479.0
|
2022-04-26 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-expected-to-beat-earnings-estimates%3A-can-the-stock
|
nan
|
nan
|
Wall Street expects a year-over-year increase in earnings on higher revenues when Deciphera Pharmaceuticals, Inc. (DCPH) reports results for the quarter ended March 2022. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This company is expected to post quarterly loss of $0.84 per share in its upcoming report, which represents a year-over-year change of +20.8%.
Revenues are expected to be $26.68 million, up 6% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 2.75% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Deciphera Pharmaceuticals, Inc.
For Deciphera Pharmaceuticals, Inc.The Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +27.26%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination indicates that Deciphera Pharmaceuticals, Inc. Will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Deciphera Pharmaceuticals, Inc. Would post a loss of $1.49 per share when it actually produced a loss of $1.51, delivering a surprise of -1.34%.
Over the last four quarters, the company has beaten consensus EPS estimates just once.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Deciphera Pharmaceuticals, Inc. Appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Wall Street expects a year-over-year increase in earnings on higher revenues when Deciphera Pharmaceuticals, Inc. (DCPH) reports results for the quarter ended March 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
|
Wall Street expects a year-over-year increase in earnings on higher revenues when Deciphera Pharmaceuticals, Inc. (DCPH) reports results for the quarter ended March 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out.
|
Wall Street expects a year-over-year increase in earnings on higher revenues when Deciphera Pharmaceuticals, Inc. (DCPH) reports results for the quarter ended March 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate.
|
Wall Street expects a year-over-year increase in earnings on higher revenues when Deciphera Pharmaceuticals, Inc. (DCPH) reports results for the quarter ended March 2022. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report The stock might move higher if these key numbers top expectations in the upcoming earnings report.
|
a6a5cdc2-33b8-4e65-b9e8-a5e36ca367f5
|
715480.0
|
2022-04-22 00:00:00 UTC
|
4 Reasons to Add Deciphera (DCPH) Stock to Your Portfolio
|
DCPH
|
https://www.nasdaq.com/articles/4-reasons-to-add-deciphera-dcph-stock-to-your-portfolio
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. DCPH currently looks like a good stock from the biotech sector to invest in. Though smaller biotech companies are riskier as their product pipelines are several years away from commercialization, an investor looking to invest in a relatively safe yet prospective stock can consider Deciphera at the moment.
Deciphera's sole marketed drug, Qinlock (ripretinib), is approved for the treatment of adult patients with advanced gastrointestinal stromal tumor (“GIST”) who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib).
Let’s delve deeper:
Good Rank and Rising Estimates: Deciphera currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Deciphera’s loss estimates have narrowed from $2.94 per share to $2.84 per share for 2022 over the past 60 days. The Deciphera stock have gained 5.1% so far this year against the industry’s decline of 14.8%.
Image Source: Zacks Investment Research
Qinlock Approval a Big Boost: Qinlock’s sales are being driven by high demand in the advanced GIST market. The initial uptake of the drug has been strong. Apart from Qinlock, there is no other marketable drug in the company’s portfolio. The drug contributes the majority of Deciphera’s revenues.
In November 2021, the European Commission approved Qinlock for the treatment of fourth-line GIST. The nod in Europe should fuel sales further.
Deciphera is also working to expand the label of Qinlock in second-line GIST. A potential label expansion for other indications will make the drug eligible to treat a broader patient population and drive sales further in 2022 and beyond.
Restructuring Initiatives Saving Costs: Deciphera, in November 2021, entered into a corporate restructuring operation, whereby the company decided to streamline its commercial operations and reduce its current workforce by approximately 35% or almost 140 positions.
The changes in clinical development programs, along with restructuring efforts, are expected to significantly reduce the company’s operating expenses and extend the cash runway into 2024, which is a positive.
Promising Pipeline: Deciphera is rapidly advancing its portfolio of innovative pipeline candidates that are in various stages of clinical development.
The company initiated the phase III MOTION study, which is evaluating vimseltinib for the treatment of tenosynovial giant cell tumor (“TGCT”). The company plans to present updated data from a phase I/II study in TGCT patients in the second half of 2022.
A phase I study is evaluating DCC-3116 as a single agent and in combination with FDA-approved MEK inhibitor, trametinib, for the treatment of patients with various advanced/metastatic tumors resulting from mutations in RAS/RAF genes.
A successful development and potential approval of these candidates will be a big boost for the company.
Other Stocks to Consider
Other stocks worth considering in the biotech sector include Aligos Therapeutics, Inc. ALGS, Vertex Pharmaceuticals Incorporated VRTX and Voyager Therapeutics, Inc. VYGR, all carrying the same Zacks Rank #2 at present.
The Zacks Consensus Estimate for Aligos Therapeutics’ loss per share has narrowed 14.3% for 2022 and 43.7% for 2023 over the past 60 days.
Earnings of ALGS surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
Vertex’s earnings estimates have been revised 1.7% upward for 2022 and 0.4% upward for 2023 over the past 60 days. The VRTX stock has rallied 28.2% year to date.
Earnings of Vertex surpassed estimates in each of the trailing four quarters.
Voyager Therapeutics’ loss per share estimates have narrowed 38.6% for 2022 and 29% for 2023 over the past 60 days. The VYGR stock has skyrocketed 167.5% year to date.
Earnings of Voyager Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Voyager Therapeutics, Inc. (VYGR): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Aligos Therapeutics, Inc. (ALGS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. DCPH currently looks like a good stock from the biotech sector to invest in. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Though smaller biotech companies are riskier as their product pipelines are several years away from commercialization, an investor looking to invest in a relatively safe yet prospective stock can consider Deciphera at the moment.
|
Deciphera Pharmaceuticals, Inc. DCPH currently looks like a good stock from the biotech sector to invest in. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Image Source: Zacks Investment Research Qinlock Approval a Big Boost: Qinlock’s sales are being driven by high demand in the advanced GIST market.
|
Deciphera Pharmaceuticals, Inc. DCPH currently looks like a good stock from the biotech sector to invest in. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Deciphera's sole marketed drug, Qinlock (ripretinib), is approved for the treatment of adult patients with advanced gastrointestinal stromal tumor (“GIST”) who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec (imatinib).
|
Deciphera Pharmaceuticals, Inc. DCPH currently looks like a good stock from the biotech sector to invest in. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Apart from Qinlock, there is no other marketable drug in the company’s portfolio.
|
58f66f0f-3e8d-4f78-9af7-4d0cdda1cc60
|
715481.0
|
2022-04-22 00:00:00 UTC
|
The Zacks Analyst Blog Highlights Johnson & Johnson, Eli Lilly, Vertex Pharmaceuticals and Deciphera Pharmaceuticals
|
DCPH
|
https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-johnson-johnson-eli-lilly-vertex-pharmaceuticals-and
|
nan
|
nan
|
For Immediate Release
Chicago, IL – April 22, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson JNJ, Eli Lilly LLY, Vertex Pharmaceuticals VRTX and Deciphera Pharmaceuticals DCPH.
Here are highlights from Thursday’s Analyst Blog:
J&J Sets in Motion Q1 Earnings for Drugs/Biotech: 3 Stocks to Buy
Johnson & Johnson is usually the first pharma company to report quarterly earnings. On Tuesday, J&J reported mixed first-quarter results, beating estimates for earnings but missing the same for sales. The company, however, cut its guidance for the year.
Mixed Performance of J&J's Segments
J&J's Pharmaceuticals unit's adjusted operational sales growth remained above-market levels though its sales fell short of market expectations, mainly because of lower-than-expected sales of J&J's single-shot COVID-19 vaccine.
Key products, such as Darzalex and Stelara, and other core products like Invega Sustenna and new drugs, Erleada and Tremfya, contributed significantly to sales growth. The sales growth was, however, dampened by lower sales of key medicines, Imbruvica and Xarelto and generic/biosimilar competition to drugs like Zytiga and Remicade as well as lower COVID-19 vaccine sales.
Nonetheless, J&J continues to expect its Pharmaceutical business to deliver market-leading adjusted operational sales growth in 2022 driven by drugs like Darzalex, Tremfya, Stelara, Erleada and the newly launched Rybrevant.
Sales in the J&J's MedTech (previously Medical Devices) segment improved, driven by a faster-than-expected market recovery, better commercial execution and new product launches. J&J saw a steady uptick in surgical procedures in the first quarter with the easing of COVID restrictions in several countries.
In the MedTech unit, J&J expects continued market recovery and uptake from the products launched in 2022. Second-half sales of the MedTech unit are expected to be stronger than the first half.
In the Consumer segment, higher sales of over-the-counter (OTC) products were partially offset by external supply constraints (due to raw material availability and labor shortages), which hurt sales of the skin health and beauty franchise.
In the Consumer segment, J&J expects supply constraints and inflationary pressure to continue to linger throughout the remainder of 2022. However, the impact is expected to be more pronounced in the first half of the year. Second-half sales are expected to be stronger than the first half.
Lowers Financial Outlook
J&J lowered its earnings and sales expectations for 2022, mainly citing the greater-than-expected negative impact from currency movements. However, the negative impact of lower COVID vaccine sales might have contributed to the lowered sales outlook for the year.
Excluding revenues from the COVID-19 vaccine, J&J expects to generate revenues from its base business in the range of $94.8 billion to $95.8 billion, lower than $95.9 billion to $96.9 billion guided previously. The adjusted earnings per share guidance was lowered from a range of $10.40-$10.60 per share to $10.15-$10.35.
What Does J&J's Results Mean for Others?
J&J is usually the first of the big drugmakers to report earnings in any quarter. Investors typically look at J&J's results to get an idea about how the rest of the drug/biotech companies as well as some medical device makers will fare.
Importantly, the faster-than-expected recovery and improved sales of J&J's MedTech segment caught investors' attention. It clearly suggests that the recovery of the Medical Devices industry is underway with an improvement in procedure volume. The MedTech segment's better-than-expected sales are seen as a positive sign for other Medical device companies.
On the first-quarter conference call, J&J said that the market demand for all COVID-19 vaccines is currently challenged by the global supply surplus and vaccine hesitancy in developing markets. The fact that sales of its COVID-19 vaccine were much below expectations due to lower demand suggests that other COVID vaccine makers, Pfizer/BioNTech, Moderna and AstraZeneca may also see slightly lower-than-expected sales of their vaccines.
Overall, despite mixed results, a guidance cut and softer Pharmaceuticals sales, J&J'searnings callleft investors feeling encouraged about a positive 2022, especially the second half, both for J&J as well as for the drug, biotech and medical devices industry.
3 Stocks to Buy
Here we have highlighted three drug/biotech stocks that may prove to be good buys. All the three stocks have a Zacks Rank #2 (Buy) and have seen their estimates and stock price rise. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Eli Lilly
Lilly's stock has risen 6.5% this year so far compared with an increase of 6.6% for the industry.
Estimates for Lilly's 2022 earnings have gone up from $8.71 to $8.78 while those for 2023 have increased from $9.78 to $9.92 per share over the past 30 days.
Lilly boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer. Lilly's revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, and others. It is regularly adding promising new pipeline assets through business development deals. It has an exciting pipeline of potential new medicines including tirzepatide for type II diabetes and donanemab for early Alzheimer's disease. Both candidates have multibillion dollar sales potential.
Vertex Pharmaceuticals
Vertex Pharmaceuticals' stock has risen 29.9% this year against the industry's decline of 14.7%.
Estimates for Vertex Pharmaceuticals' 2022 earnings have gone up from $14.52 to $14.58 per share, while the same for 2023 have increased from $15.31 to $15.37 per share over the past 30 days.
Vertex's cystic franchise sales continue to grow despite the impact of the pandemic. Triple therapy, Trikafta/Kaftrio's launch was a significant milestone for Vertex as it addresses 90% of CF patients. New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups in the United States are driving Trikafta/Kaftrio sales higher.
Meanwhile, Vertex has a broad clinical non-CF pipeline across six disease areas, which are progressing rapidly with data from multiple programs expected in 2022. Vertex faces only minimal competition in its core CF franchise.
Deciphera Pharmaceuticals
Deciphera's stock has risen 5% this year so far against the industry's decline of 14.6%.
Loss estimates for Deciphera have narrowed from $2.94 to $2.84 per share for 2022, while the same for 2023 have narrowed from $2.38 to $2.27 per share over the past 30 days.
Deciphera got a significant boost with the FDA approval for Qinlock in treating advanced gastrointestinal stromal tumors (GIST) in 2020. This is the first commercial product for the company The drug has witnessed solid uptake so far. Qinlock has also been approved in Europe for the treatment of fourth-line GIST. The nod in the EU should boost sales in the future quarters. The company is rapidly advancing its portfolio of innovative pipeline candidates. The recent restructuring initiative is also cutting costs, which is a positive.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Stocks recently featured in the blog include: Johnson & Johnson JNJ, Eli Lilly LLY, Vertex Pharmaceuticals VRTX and Deciphera Pharmaceuticals DCPH. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Nonetheless, J&J continues to expect its Pharmaceutical business to deliver market-leading adjusted operational sales growth in 2022 driven by drugs like Darzalex, Tremfya, Stelara, Erleada and the newly launched Rybrevant.
|
Stocks recently featured in the blog include: Johnson & Johnson JNJ, Eli Lilly LLY, Vertex Pharmaceuticals VRTX and Deciphera Pharmaceuticals DCPH. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Nonetheless, J&J continues to expect its Pharmaceutical business to deliver market-leading adjusted operational sales growth in 2022 driven by drugs like Darzalex, Tremfya, Stelara, Erleada and the newly launched Rybrevant.
|
Stocks recently featured in the blog include: Johnson & Johnson JNJ, Eli Lilly LLY, Vertex Pharmaceuticals VRTX and Deciphera Pharmaceuticals DCPH. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Mixed Performance of J&J's Segments J&J's Pharmaceuticals unit's adjusted operational sales growth remained above-market levels though its sales fell short of market expectations, mainly because of lower-than-expected sales of J&J's single-shot COVID-19 vaccine.
|
Stocks recently featured in the blog include: Johnson & Johnson JNJ, Eli Lilly LLY, Vertex Pharmaceuticals VRTX and Deciphera Pharmaceuticals DCPH. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Mixed Performance of J&J's Segments J&J's Pharmaceuticals unit's adjusted operational sales growth remained above-market levels though its sales fell short of market expectations, mainly because of lower-than-expected sales of J&J's single-shot COVID-19 vaccine.
|
5dd6002d-e70b-425f-8857-0e5aacc407da
|
715482.0
|
2022-04-21 00:00:00 UTC
|
J&J Sets in Motion Drug/Biotech Q1 Earnings: 3 Stocks to Buy
|
DCPH
|
https://www.nasdaq.com/articles/jj-sets-in-motion-drug-biotech-q1-earnings%3A-3-stocks-to-buy
|
nan
|
nan
|
Johnson & Johnson JNJ is usually the first pharma company to report quarterly earnings. On Tuesday, J&J reported mixed first-quarter results, beating estimates for earnings but missing the same for sales. The company, however, cut its guidance for the year.
Mixed Performance of J&J’s Segments
J&J’s Pharmaceuticals unit’s adjusted operational sales growth remained above-market levels though its sales fell short of market expectations, mainly because of lower-than-expected sales of J&J’s single-shot COVID-19 vaccine.
Key products, such as Darzalex and Stelara, and other core products like Invega Sustenna and new drugs, Erleada and Tremfya, contributed significantly to sales growth. The sales growth was, however, dampened by lower sales of key medicines, Imbruvica and Xarelto and generic/biosimilar competition to drugs like Zytiga and Remicade as well as lower COVID-19 vaccine sales.
Nonetheless, J&J continues to expect its Pharmaceutical business to deliver market-leading adjusted operational sales growth in 2022 driven by drugs like Darzalex, Tremfya, Stelara, Erleada and the newly launched Rybrevant.
Sales in the J&J’s MedTech (previously Medical Devices) segment improved, driven by a faster-than-expected market recovery, better commercial execution and new product launches. J&J saw a steady uptick in surgical procedures in the first quarter with the easing of COVID restrictions in several countries.
In the MedTech unit, J&J expects continued market recovery and uptake from the products launched in 2022. Second-half sales of the MedTech unit are expected to be stronger than the first half.
In the Consumer segment, higher sales of over-the-counter (OTC) products were partially offset by external supply constraints (due to raw material availability and labor shortages), which hurt sales of the skin health and beauty franchise.
In the Consumer segment, J&J expects supply constraints and inflationary pressure to continue to linger throughout the remainder of 2022. However, the impact is expected to be more pronounced in the first half of the year. Second-half sales are expected to be stronger than the first half.
Lowers Financial Outlook
J&J lowered its earnings and sales expectations for 2022, mainly citing the greater-than-expected negative impact from currency movements. However, the negative impact of lower COVID vaccine sales might have contributed to the lowered sales outlook for the year.
Excluding revenues from the COVID-19 vaccine, J&J expects to generate revenues from its base business in the range of $94.8 billion to $95.8 billion, lower than $95.9 billion to $96.9 billion guided previously. The adjusted earnings per share guidance was lowered from a range of $10.40-$10.60 per share to $10.15-$10.35.
What Does J&J’s Results Mean for Others?
J&J is usually the first of the big drugmakers to report earnings in any quarter. Investors typically look at J&J’s results to get an idea about how the rest of the drug/biotech companies as well as some medical device makers will fare.
Importantly, the faster-than-expected recovery and improved sales of J&J’s MedTech segment caught investors’ attention. It clearly suggests that the recovery of the Medical Devices industry is underway with an improvement in procedure volume. The MedTech segment’s better-than-expected sales are seen as a positive sign for other Medical device companies.
On the first-quarter conference call, J&J said that the market demand for all COVID-19 vaccines is currently challenged by the global supply surplus and vaccine hesitancy in developing markets. The fact that sales of its COVID-19 vaccine were much below expectations due to lower demand suggests that other COVID vaccine makers, Pfizer/BioNTech, Moderna and AstraZeneca may also see slightly lower-than-expected sales of their vaccines.
Overall, despite mixed results, a guidance cut and softer Pharmaceuticals sales, J&J’searnings callleft investors feeling encouraged about a positive 2022, especially the second half, both for J&J as well as for the drug, biotech and medical devices industry.
3 Stocks to Buy
Here we have highlighted three drug/biotech stocks that may prove to be good buys. All the three stocks have a Zacks Rank #2 (Buy) and have seen their estimates and stock price rise. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Eli Lilly LLY
Lilly’s stock has risen 6.5% this year so far compared with an increase of 6.6% for the industry.
Image Source: Zacks Investment Research
Estimates for Lilly’s 2022 earnings have gone up from $8.71 to $8.78 while those for 2023 have increased from $9.78 to $9.92 per share over the past 30 days.
Lilly boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer. Lilly’s revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, and others. It is regularly adding promising new pipeline assets through business development deals. It has an exciting pipeline of potential new medicines including tirzepatide for type II diabetes and donanemab for early Alzheimer's disease. Both candidates have multibillion dollar sales potential.
Vertex Pharmaceuticals VRTX
Vertex Pharmaceuticals’ stock has risen 29.9% this year against the industry’s decline of 14.7%.
Image Source: Zacks Investment Research
Estimates for Vertex Pharmaceuticals’ 2022 earnings have gone up from $14.52 to $14.58 per share, while the same for 2023 have increased from $15.31 to $15.37 per share over the past 30 days.
Vertex’s cystic franchise sales continue to grow despite the impact of the pandemic. Triple therapy, Trikafta/Kaftrio’s launch was a significant milestone for Vertex as it addresses 90% of CF patients. New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups in the United States are driving Trikafta/Kaftrio sales higher. Meanwhile, Vertex has a broad clinical non-CF pipeline across six disease areas, which are progressing rapidly with data from multiple programs expected in 2022. Vertex faces only minimal competition in its core CF franchise.
Deciphera Pharmaceuticals DCPH
Deciphera’s stock has risen 5% this year so far against the industry’s decline of 14.6%.
Image Source: Zacks Investment Research
Loss estimates for Deciphera have narrowed from $2.94 to $2.84 per share for 2022, while the same for 2023 have narrowed from $2.38 to $2.27 per share over the past 30 days.
Deciphera got a significant boost with the FDA approval for Qinlock in treating advanced gastrointestinal stromal tumors (GIST) in 2020. This is the first commercial product for the company The drug has witnessed solid uptake so far. Qinlock has also been approved in Europe for the treatment of fourth-line GIST. The nod in the EU should boost sales in the future quarters. The company is rapidly advancing its portfolio of innovative pipeline candidates. The recent restructuring initiative is also cutting costs, which is a positive.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals DCPH Deciphera’s stock has risen 5% this year so far against the industry’s decline of 14.6%. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Nonetheless, J&J continues to expect its Pharmaceutical business to deliver market-leading adjusted operational sales growth in 2022 driven by drugs like Darzalex, Tremfya, Stelara, Erleada and the newly launched Rybrevant.
|
Deciphera Pharmaceuticals DCPH Deciphera’s stock has risen 5% this year so far against the industry’s decline of 14.6%. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Nonetheless, J&J continues to expect its Pharmaceutical business to deliver market-leading adjusted operational sales growth in 2022 driven by drugs like Darzalex, Tremfya, Stelara, Erleada and the newly launched Rybrevant.
|
Deciphera Pharmaceuticals DCPH Deciphera’s stock has risen 5% this year so far against the industry’s decline of 14.6%. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Mixed Performance of J&J’s Segments J&J’s Pharmaceuticals unit’s adjusted operational sales growth remained above-market levels though its sales fell short of market expectations, mainly because of lower-than-expected sales of J&J’s single-shot COVID-19 vaccine.
|
Deciphera Pharmaceuticals DCPH Deciphera’s stock has risen 5% this year so far against the industry’s decline of 14.6%. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Mixed Performance of J&J’s Segments J&J’s Pharmaceuticals unit’s adjusted operational sales growth remained above-market levels though its sales fell short of market expectations, mainly because of lower-than-expected sales of J&J’s single-shot COVID-19 vaccine.
|
c673e3c6-5bfc-4e06-b258-b5cb3902df64
|
715483.0
|
2022-04-15 00:00:00 UTC
|
Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 73%: Read This Before Placing a Bet
|
DCPH
|
https://www.nasdaq.com/articles/wall-street-analysts-think-deciphera-pharmaceuticals-inc.-dcph-could-surge-73%3A-read-this
|
nan
|
nan
|
Shares of Deciphera Pharmaceuticals, Inc. (DCPH) have gained 15.5% over the past four weeks to close the last trading session at $10.45, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18.10 indicates a potential upside of 73.2%.
The average comprises 10 short-term price targets ranging from a low of $10 to a high of $64, with a standard deviation of $16.68. While the lowest estimate indicates a decline of 4.3% from the current price level, the most optimistic estimate points to a 512.4% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.
But, for DCPH, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Here's What You Should Know About Analysts' Price Targets
According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Here's Why There Could be Plenty of Upside Left in DCPH
There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. And that could be a legitimate reason to expect an upside in the stock. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 3.3%, as one estimate has moved higher compared to no negative revision.
Moreover, DCPH currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, while the consensus price target may not be a reliable indicator of how much DCPH could gain, the direction of price movement it implies does appear to be a good guide.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Shares of Deciphera Pharmaceuticals, Inc. (DCPH) have gained 15.5% over the past four weeks to close the last trading session at $10.45, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. But, for DCPH, an impressive average price target is not the only indicator of a potential upside. Here's Why There Could be Plenty of Upside Left in DCPH There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher.
|
Shares of Deciphera Pharmaceuticals, Inc. (DCPH) have gained 15.5% over the past four weeks to close the last trading session at $10.45, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. But, for DCPH, an impressive average price target is not the only indicator of a potential upside. Here's Why There Could be Plenty of Upside Left in DCPH There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher.
|
You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much DCPH could gain, the direction of price movement it implies does appear to be a good guide. Shares of Deciphera Pharmaceuticals, Inc. (DCPH) have gained 15.5% over the past four weeks to close the last trading session at $10.45, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. But, for DCPH, an impressive average price target is not the only indicator of a potential upside.
|
You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much DCPH could gain, the direction of price movement it implies does appear to be a good guide. Shares of Deciphera Pharmaceuticals, Inc. (DCPH) have gained 15.5% over the past four weeks to close the last trading session at $10.45, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. But, for DCPH, an impressive average price target is not the only indicator of a potential upside.
|
dfbc3091-4401-4a76-ae10-4b27fe36fecc
|
715484.0
|
2022-02-09 00:00:00 UTC
|
Deciphera (DCPH) Q4 Loss Wider Than Expected, Revenues Beat
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-dcph-q4-loss-wider-than-expected-revenues-beat
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. DCPH reported fourth-quarter 2021 loss of $1.51 per share, wider than the Zacks Consensus Estimate of a loss of $1.49 and the year-ago quarter’s loss of $1.10.
Total net revenues were $24.2 million in the quarter, which surpassed the Zacks Consensus Estimate of $23 million. Revenues rose 24.1% year over year.
Shares of Deciphera were down 3.8% in after-hours trading on Tuesday following the earnings announcement. The stock has plunged 83.7% in the past year compared with the industry’s decline of 39.7%.
Image Source: Zacks Investment Research
In May 2020, the FDA approved Deciphera’s sole marketed drug, Qinlock (ripretinib), to treat adult patients with advanced gastrointestinal stromal tumors (“GIST”) who have received prior treatment with three or more kinase inhibitors, including Novartis’ NVS Gleevec (imatinib).
Novartis has lost the patent protection for Gleevec, which faces increasing generic competition in major markets.
Full-Year Results
For 2021, Deciphera generated total revenues of $96.1 million compared with $42.1 million recorded in 2020.
For full-year 2021, the company reported a loss of $5.16 per share compared with net loss of $4.78 per share in 2020.
Quarter in Detail
Apart from Qinlock, there are no other marketable drugs in the company’s portfolio. Total revenues comprised net product revenues and collaboration revenues. Net product revenues were $23.7 million, including $21.5 million in U.S. sales and $2.2 million in ex-U.S. sales.
Collaboration revenues of $0.5 million comprised commercial supply and royalty revenues under the company’s license agreement with Zai Lab Limited ZLAB.
In March 2021, Deciphera collaborated with Zai Lab to commercially launch Qinlock in China to treat adult patients with fourth-line GIST.
Research and development expenses were $74.9 million, up 43.2% year over year. The increase was primarily attributed to the one-time restructuring charge of $22.2 million related to employee termination costs and study discontinuation costs.
In November 2021, Deciphera announced a corporate restructuring plan to prioritize the development of select clinical programs, streamline commercial operations, reduce expenses and extend its cash runway. The company reduced its current workforce by approximately 35% or almost 140 positions.
Selling, general and administrative expenses were $37.2 million, up from $30.1 million in the year-ago quarter due to the one-time restructuring charge of $4 million related to employee termination costs as well as higher external costs to support the launch of Qinlock in Europe.
Deciphera had cash, cash equivalents and investments worth $327.6 million as of Dec 31, 2021, down from $392.2 million as of Sep 30, 2021.
Pipeline Updates
In November 2021, the European Commission approved Qinlock for treating adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including Novartis’ Gleevec.
In November 2021, Deciphera announced top-line data from the phase III INTRIGUE study evaluating the efficacy and safety of Qinlock compared to sunitinib for treating patients with GIST who were previously treated with imatinib. The study did not meet the primary endpoint of improved progression-free survival versus standard-of-care sunitinib in patients with second-line GIST. Deciphera shares plunged heavily on this news.
During the same time, Deciphera stopped a phase Ib/II study of Qinlock in combination with Mektovi (binimetinib), an approved MEK inhibitor, in patients with post-imatinib GIST.
Deciphera initiated the phase III MOTION study evaluating vimseltinib for the treatment of tenosynovial giant cell tumor (“TGCT”). The company plans to present updated data from a phase I/II study in TGCT patients in the second half of 2022.
The company is also planning to study DCC-3116 in combination with FDA-approved MEK inhibitor, trametinib, for treating patients with selected mutations in advanced or metastatic pancreatic ductal adenocarcinoma, non-small-cell lung cancer, colorectal cancer and melanoma in the second half of 2022.
Deciphera Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Deciphera Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Deciphera Pharmaceuticals, Inc. Quote
Zacks Rank & Stock to Consider
Deciphera currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Axsome Therapeutics, Inc. AXSM, which has a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Axsome Therapeutics’ loss per share estimates have narrowed 0.8% for 2022 over the past 60 days.
Earnings of Axsome Therapeutics have surpassed estimates in three of the trailing four quarters, and missed the same on the other occasion.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Axsome Therapeutics, Inc. (AXSM): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. DCPH reported fourth-quarter 2021 loss of $1.51 per share, wider than the Zacks Consensus Estimate of a loss of $1.49 and the year-ago quarter’s loss of $1.10. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Image Source: Zacks Investment Research In May 2020, the FDA approved Deciphera’s sole marketed drug, Qinlock (ripretinib), to treat adult patients with advanced gastrointestinal stromal tumors (“GIST”) who have received prior treatment with three or more kinase inhibitors, including Novartis’ NVS Gleevec (imatinib).
|
Deciphera Pharmaceuticals, Inc. DCPH reported fourth-quarter 2021 loss of $1.51 per share, wider than the Zacks Consensus Estimate of a loss of $1.49 and the year-ago quarter’s loss of $1.10. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Image Source: Zacks Investment Research In May 2020, the FDA approved Deciphera’s sole marketed drug, Qinlock (ripretinib), to treat adult patients with advanced gastrointestinal stromal tumors (“GIST”) who have received prior treatment with three or more kinase inhibitors, including Novartis’ NVS Gleevec (imatinib).
|
Deciphera Pharmaceuticals, Inc. DCPH reported fourth-quarter 2021 loss of $1.51 per share, wider than the Zacks Consensus Estimate of a loss of $1.49 and the year-ago quarter’s loss of $1.10. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Image Source: Zacks Investment Research In May 2020, the FDA approved Deciphera’s sole marketed drug, Qinlock (ripretinib), to treat adult patients with advanced gastrointestinal stromal tumors (“GIST”) who have received prior treatment with three or more kinase inhibitors, including Novartis’ NVS Gleevec (imatinib).
|
Deciphera Pharmaceuticals, Inc. DCPH reported fourth-quarter 2021 loss of $1.51 per share, wider than the Zacks Consensus Estimate of a loss of $1.49 and the year-ago quarter’s loss of $1.10. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Image Source: Zacks Investment Research In May 2020, the FDA approved Deciphera’s sole marketed drug, Qinlock (ripretinib), to treat adult patients with advanced gastrointestinal stromal tumors (“GIST”) who have received prior treatment with three or more kinase inhibitors, including Novartis’ NVS Gleevec (imatinib).
|
c4cb3e3b-7187-4ec2-9438-14476d958cfb
|
715485.0
|
2022-02-08 00:00:00 UTC
|
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc.-dcph-reports-q4-loss-tops-revenue-estimates
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $1.51 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.10 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -1.34%. A quarter ago, it was expected that this company would post a loss of $1.29 per share when it actually produced a loss of $1.37, delivering a surprise of -6.20%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $24.2 million for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 3.26%. This compares to year-ago revenues of $19.49 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Deciphera Pharmaceuticals, Inc. Shares have lost about 16% since the beginning of the year versus the S&P 500's decline of -5.9%.
What's Next for Deciphera Pharmaceuticals, Inc.
While Deciphera Pharmaceuticals, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Deciphera Pharmaceuticals, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.61 on $26.8 million in revenues for the coming quarter and -$2.55 on $123.57 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2021.
This biopharmaceutical company is expected to post quarterly loss of $0.16 per share in its upcoming report, which represents a year-over-year change of +30.4%. The consensus EPS estimate for the quarter has been revised 3.2% higher over the last 30 days to the current level.
Arbutus Biopharma's revenues are expected to be $3.39 million, up 41.6% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $1.51 per share versus the Zacks Consensus Estimate of a loss of $1.49. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock.
|
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $1.51 per share versus the Zacks Consensus Estimate of a loss of $1.49. Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $24.2 million for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 3.26%.
|
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $1.51 per share versus the Zacks Consensus Estimate of a loss of $1.49. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $24.2 million for the quarter ended December 2021, surpassing the Zacks Consensus Estimate by 3.26%.
|
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $1.51 per share versus the Zacks Consensus Estimate of a loss of $1.49. The company has topped consensus revenue estimates three times over the last four quarters.
|
410ca907-8767-4a34-a6b6-13b87ebae54a
|
715486.0
|
2022-02-07 00:00:00 UTC
|
Drug/Biotech Stock Q4 Earnings Due Feb 8: PFE, INCY & DCPH
|
DCPH
|
https://www.nasdaq.com/articles/drug-biotech-stock-q4-earnings-due-feb-8%3A-pfe-incy-dcph
|
nan
|
nan
|
It has been an interesting earnings season for the Medical sector so far. The sector mainly comprises pharma/biotech and medical device companies.
Per the Earnings Trends report, as of Feb 2, 33.9% of the companies in the Medical sector — which represent nearly 53.7% of the sector’s market capitalization — have reported their quarterly earnings. While 63.2% beat earnings estimates, 57.9% beat the same for revenues. Earnings and revenues increased 10% and 12.1% year over year, respectively. Overall, fourth-quarter earnings and sales of the Medical sector are expected to rise 18.4% and 12.8% year over year, respectively.
With quite a large number of pharma and biotech bigwigs having already reported results, the earnings picture is looking reasonably well. Last week, a number of big pharma and biotech companies reported solid earnings for the fourth quarter. Merck MRK beat estimates on both counts, driven by additional sales of oral COVID-19 drug molnupiravir. Similar to Merck, Biogen, Novo Nordisk and Regeneron also beat on both earnings and sales. Roche also boasted a solid sales performance for 2021, which was primarily driven by strong demand for COVID-19 tests and recovery in pharma sales.
With regard to other pharma/biotech companies, Pfizer PFE, Incyte INCY and Deciphera Pharmaceuticals DCPH are scheduled to release Q4 earnings on Feb 8.
Let’s analyze the performance of the above three biotech/pharma companies.
Pfizer
Pfizer, which has a decent earnings track record so far, is scheduled to report quarterly results before market open.
Pfizer beat earnings estimates in three of the last four quarters and missed in one, with the average surprise being 10.9%. In the last reported quarter, PFE beat earnings estimates by 24.1%.
Per our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Our model predicts an earnings beat for Pfizer this time around. For the quarter to be reported, Pfizer has an Earnings ESP of +1.18% and a Zacks Rank #1 (Strong Buy).
The Zacks Consensus Estimate for earnings stands at 85 cents per share. You can see the complete list of today’s Zacks #1 Rank stocks here.
A key contributor to Pfizer’s fourth-quarter sales is likely to have been its partner BioNTech’s COVID-19 vaccine, Comirnaty. We expect sales to be higher than third-quarter sales of $13.0 billion.
Pfizer Inc. Price and EPS Surprise
Pfizer Inc. price-eps-surprise | Pfizer Inc. Quote
Incyte
Incyte, which has an impressive earnings track record so far, is also scheduled to report quarterly results before market open.
Incyte beat earnings estimates in each of the trailing four quarters, with the average being 20.7%. In the last reported quarter, the company’s earnings beat estimates by 55.3%.
Incyte has an Earnings ESP of -11.98% and a Zacks Rank #4 (Sell). The Zacks Consensus Estimate for earnings stands at 84 cents per share.
Jakafi sales and royalties are likely to have been key catalysts for Incyte’s revenue growth. Iclusig sales and Olumiant royalties from Eli Lilly may have also contributed to the top line. The trend is most likely to have continued in the to-be-reported quarter.
Incyte Corporation Price and EPS Surprise
Incyte Corporation price-eps-surprise | Incyte Corporation Quote
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, which has a mixed earnings track record so far, is scheduled to report quarterly results after the closing bell.
Deciphera beat earnings estimates in two of the trailing four quarters and missed the mark on the other two occasions, with the average negative surprise being 1.1%. In the last reported quarter, the company’s earnings missed estimates by 6.2%.
Deciphera has an Earnings ESP of 0.00% and a Zacks Rank #3. The Zacks Consensus Estimate for earnings stands at a loss of $1.49 per share.
Qinlock, Deciphera’s sole marketed drug, received approval for use in the European Union last November. We expect this approval to have contributed to DCPH’s top line in the quarter.
Deciphera Pharmaceuticals, Inc. Price and EPS Surprise
Deciphera Pharmaceuticals, Inc. price-eps-surprise | Deciphera Pharmaceuticals, Inc. Quote
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022?
Last year's 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys
Access Zacks Top 10 Stocks for 2022 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Incyte Corporation (INCY): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
With regard to other pharma/biotech companies, Pfizer PFE, Incyte INCY and Deciphera Pharmaceuticals DCPH are scheduled to release Q4 earnings on Feb 8. We expect this approval to have contributed to DCPH’s top line in the quarter. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
With regard to other pharma/biotech companies, Pfizer PFE, Incyte INCY and Deciphera Pharmaceuticals DCPH are scheduled to release Q4 earnings on Feb 8. We expect this approval to have contributed to DCPH’s top line in the quarter. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
With regard to other pharma/biotech companies, Pfizer PFE, Incyte INCY and Deciphera Pharmaceuticals DCPH are scheduled to release Q4 earnings on Feb 8. We expect this approval to have contributed to DCPH’s top line in the quarter. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
With regard to other pharma/biotech companies, Pfizer PFE, Incyte INCY and Deciphera Pharmaceuticals DCPH are scheduled to release Q4 earnings on Feb 8. We expect this approval to have contributed to DCPH’s top line in the quarter. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
|
8bedcc89-d9c9-4c54-bbb6-6928a37c240e
|
715487.0
|
2022-02-01 00:00:00 UTC
|
Analysts Estimate Deciphera Pharmaceuticals, Inc. (DCPH) to Report a Decline in Earnings: What to Look Out for
|
DCPH
|
https://www.nasdaq.com/articles/analysts-estimate-deciphera-pharmaceuticals-inc.-dcph-to-report-a-decline-in-earnings%3A
|
nan
|
nan
|
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2021. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on theearnings callwill mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This company is expected to post quarterly loss of $1.49 per share in its upcoming report, which represents a year-over-year change of -35.5%.
Revenues are expected to be $23.44 million, up 20.3% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Deciphera Pharmaceuticals, Inc.
For Deciphera Pharmaceuticals, Inc.The Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination makes it difficult to conclusively predict that Deciphera Pharmaceuticals, Inc. Will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Deciphera Pharmaceuticals, Inc. Would post a loss of $1.29 per share when it actually produced a loss of $1.37, delivering a surprise of -6.20%.
Over the last four quarters, the company has beaten consensus EPS estimates two times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Deciphera Pharmaceuticals, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.3% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2021. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2021. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
|
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2021. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2021. Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report The earnings report might help the stock move higher if these key numbers are better than expectations.
|
bdede14a-c1e6-453a-a858-1a7bd487dc64
|
715488.0
|
2021-12-22 00:00:00 UTC
|
MHRA Authorizes Deciphera’s QINLOCK in the U.K.
|
DCPH
|
https://www.nasdaq.com/articles/mhra-authorizes-decipheras-qinlock-in-the-u.k.
|
nan
|
nan
|
Deciphera Pharmaceuticals (NASDAQ: DCPH) has received marketing authorization for QINLOCK (ripretinib) in the U.K. from the Medicines and Healthcare products Regulatory Agency (MHRA). Following the news, shares of the commercial-stage biopharmaceutical company rose 5.1% on Tuesday to close at $10.32.
QINLOCK, a switch-control tyrosine kinase inhibitor, is designed to treat adult patients with advanced gastrointestinal stromal tumors (GIST). These patients include individuals who have received prior treatment with three or more kinase inhibitors, including imatinib.
Supporting Data
The regulator’s decision followed the efficacy results from the primary analysis of the pivotal Phase 3 INVICTUS study in patients with advanced GIST and the combined safety results from INVICTUS and the Phase 1 study of QINLOCK.
Notably, in the Phase 3 INVICTUS study, QINLOCK demonstrated a significant reduction in the risk of disease progression or death by 85% and reflected clinically meaningful overall survival.
Official Comments
Deciphera CEO Steve Hoerter commented, “The approval of QINLOCK in the UK is an important milestone for patients with advanced GIST who have been waiting for a new treatment option. The results from the INVICTUS study underscore the potential for QINLOCK to transform the treatment of advanced GIST and establish a new standard of care in the UK for fourth-line GIST.”
Wall Street’s Take
Recently, JMP Securities analyst Reni Benjamin maintained a Hold rating on the stock.
Overall, the stock has a Hold consensus rating based on 2 Buys, 8 Holds, and 1 Sell. The average Deciphera price target of $12.25 implies 18.7% upside potential from current levels. Shares have lost 83.1% over the past year.
Risk Analysis
According to the new TipRanks Risk Factors tool, Deciphera stock is at risk mainly from three factors: Tech and Innovation, Finance and Corporate, and Legal and Regulatory, which contribute 32%, 28%, and 18%, respectively to the total 78 risks identified for the stock.
Related News:
Novavax Receives Second EUL from WHO for Nuvaxovid
Pfizer & BioNTech SE to Supply Over 200 Additional Doses of COMIRNATY
McKesson to Vend Austrian Business
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals (NASDAQ: DCPH) has received marketing authorization for QINLOCK (ripretinib) in the U.K. from the Medicines and Healthcare products Regulatory Agency (MHRA). Notably, in the Phase 3 INVICTUS study, QINLOCK demonstrated a significant reduction in the risk of disease progression or death by 85% and reflected clinically meaningful overall survival. The results from the INVICTUS study underscore the potential for QINLOCK to transform the treatment of advanced GIST and establish a new standard of care in the UK for fourth-line GIST.” Wall Street’s Take Recently, JMP Securities analyst Reni Benjamin maintained a Hold rating on the stock.
|
Deciphera Pharmaceuticals (NASDAQ: DCPH) has received marketing authorization for QINLOCK (ripretinib) in the U.K. from the Medicines and Healthcare products Regulatory Agency (MHRA). Supporting Data The regulator’s decision followed the efficacy results from the primary analysis of the pivotal Phase 3 INVICTUS study in patients with advanced GIST and the combined safety results from INVICTUS and the Phase 1 study of QINLOCK. Notably, in the Phase 3 INVICTUS study, QINLOCK demonstrated a significant reduction in the risk of disease progression or death by 85% and reflected clinically meaningful overall survival.
|
Deciphera Pharmaceuticals (NASDAQ: DCPH) has received marketing authorization for QINLOCK (ripretinib) in the U.K. from the Medicines and Healthcare products Regulatory Agency (MHRA). Supporting Data The regulator’s decision followed the efficacy results from the primary analysis of the pivotal Phase 3 INVICTUS study in patients with advanced GIST and the combined safety results from INVICTUS and the Phase 1 study of QINLOCK. The results from the INVICTUS study underscore the potential for QINLOCK to transform the treatment of advanced GIST and establish a new standard of care in the UK for fourth-line GIST.” Wall Street’s Take Recently, JMP Securities analyst Reni Benjamin maintained a Hold rating on the stock.
|
Deciphera Pharmaceuticals (NASDAQ: DCPH) has received marketing authorization for QINLOCK (ripretinib) in the U.K. from the Medicines and Healthcare products Regulatory Agency (MHRA). Notably, in the Phase 3 INVICTUS study, QINLOCK demonstrated a significant reduction in the risk of disease progression or death by 85% and reflected clinically meaningful overall survival. The results from the INVICTUS study underscore the potential for QINLOCK to transform the treatment of advanced GIST and establish a new standard of care in the UK for fourth-line GIST.” Wall Street’s Take Recently, JMP Securities analyst Reni Benjamin maintained a Hold rating on the stock.
|
f287edc3-102a-4a33-b4e8-5810359f5ae8
|
715489.0
|
2021-12-21 00:00:00 UTC
|
Deciphera Pharma Reports Approval Of QINLOCK In The UK - Quick Facts
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharma-reports-approval-of-qinlock-in-the-uk-quick-facts
|
nan
|
nan
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) announced the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorization for QINLOCK in the UK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib.
The company said the QINLOCK approval was supported by efficacy results from the primary analysis of the pivotal phase 3 INVICTUS study in patients with advanced gastrointestinal stromal tumor and combined safety results from INVICTUS and the phase 1 study of QINLOCK.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) announced the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorization for QINLOCK in the UK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. The company said the QINLOCK approval was supported by efficacy results from the primary analysis of the pivotal phase 3 INVICTUS study in patients with advanced gastrointestinal stromal tumor and combined safety results from INVICTUS and the phase 1 study of QINLOCK. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) announced the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorization for QINLOCK in the UK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. The company said the QINLOCK approval was supported by efficacy results from the primary analysis of the pivotal phase 3 INVICTUS study in patients with advanced gastrointestinal stromal tumor and combined safety results from INVICTUS and the phase 1 study of QINLOCK. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) announced the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorization for QINLOCK in the UK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. The company said the QINLOCK approval was supported by efficacy results from the primary analysis of the pivotal phase 3 INVICTUS study in patients with advanced gastrointestinal stromal tumor and combined safety results from INVICTUS and the phase 1 study of QINLOCK. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH) announced the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorization for QINLOCK in the UK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. The company said the QINLOCK approval was supported by efficacy results from the primary analysis of the pivotal phase 3 INVICTUS study in patients with advanced gastrointestinal stromal tumor and combined safety results from INVICTUS and the phase 1 study of QINLOCK. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
aa90b6ad-b3a5-4e68-87e8-40f0526d023f
|
715490.0
|
2021-12-09 00:00:00 UTC
|
Deciphera: Why There Won’t Be a Quick Recovery
|
DCPH
|
https://www.nasdaq.com/articles/deciphera%3A-why-there-wont-be-a-quick-recovery
|
nan
|
nan
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Deciphera Pharmaceuticals (NASDAQ:DCPH) stock absolutely imploded in November. Shares lost more than two-thirds of their value virtually overnight.
Source: Iryna Imago / Shutterstock.com
DCPH stock plunged after the company released surprising trial results. The company’s phase 3 trial was supposed to affirm that its ripretinib drug was more effective than the current standard of care. Instead, it failed to meet that, and DCPH stock collapsed. So, is there a path forward for the company?
The Trial Failure: A Big Surprise
In November, Deciphera presented its clinical results for ripretinib compared to the current standard of care drug, sunitinib. Deciphera’s drug failed to show statistically significant improvement compared to the existing benchmark.
7 Stocks to Buy as Biden Picks Powell For Fed Chair
Investors hadn’t expected such a negative response out of this clinical readout. After all, ripretinib had already secured Food and Drug Administration (FDA) approval last year for advanced gastrointestinal stromal tumor. The drug had a commercial name, Qinlock, and started to generate revenues.
Most biotech companies never make it to generating commercial revenue. So Deciphera already appeared to be a winner in the fraught field of young biotech firms. However, ripretinib wasn’t able to stand up to the scrutiny of another trial. What changed?
Previously, ripretinib was up against a placebo in patients that had exhausted other clinical options, and showed strong comparative results. However, ripretinib wasn’t able to pull off a repeat performance in a more challenging trial against another active drug. Management acknowledged the setback, and didn’t try to spin the results. Instead, Deciphera will be reducing its focus on ripretinib and turning to other more promising early-stage projects in its clinical pipeline.
Has Cash To Keep Going
As of the September quarter end, Deciphera had $392 million in cash on hand. That’s a sizable sum. It will have to spend roughly $32 million to wind down its clinical research program for ripretinib and pay compensation to the 35% of its workforce that it is terminating. Still, it will have a lot left over in the treasury.
Given Deciphera’s old levels of corporate overhead, that cash still would have run out fairly quickly. The company an operating loss of $274 million over the past 12 months, primarily tied to its large research & development budget. Now though, management projects that with the new leaner corporate layout, its cash will last through 2024.
That should give the company enough time to potentially generate interesting results from its upcoming early phase trials on its newer drug candidates. Of course, that’s nowhere near as good as having its drugs producing strong revenues or being near a potential FDA decision. Deciphera has taken a massive setback here, and that’s why the stock price isn’t coming back anytime soon. But Deciphera isn’t out of the ballgame entirely, either.
DCPH Stock Verdict
So, how to decipher the current situation with DCPH stock? There’s two ways of looking at a company like this one.
First, there’s the trading reaction. DCPH stock just plummeted from $35 to $8. Is there a chance of it making a rapid bounce back up to $20 or $30? Almost certainly not. With a busted biotech company such as this one, if the drug doesn’t live up to expectations, the stock simply isn’t going to return to prosperity in the near-term. Rather, the company will have to come up with a new clinical program that will generate new shareholder interest.
So, if you’re looking at DCPH stock simply for a quick flip, you’ll probably be disappointed. This isn’t the sort of stock that will make a V-shaped recovery.
On the other hand, if you’re a long-term investor, perhaps there is some value in DCPH stock. Given the company’s change in strategic direction, it has the cash to carry on operations until 2024. And this management team achieved a significant degree of success; it got a drug approved by the FDA in 2020 after all. So this isn’t the worst biotech on which to bet. Just don’t expect that second act to be an overnight success.
On the date of publication, Ian Bezek did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
Ian Bezek has written more than 1,000 articles for InvestorPlace.com and Seeking Alpha. He also worked as a Junior Analyst for Kerrisdale Capital, a $300 million New York City-based hedge fund. You can reach him on Twitter at @irbezek.
The post Deciphera: Why There Won’t Be a Quick Recovery appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Deciphera Pharmaceuticals (NASDAQ:DCPH) stock absolutely imploded in November. Source: Iryna Imago / Shutterstock.com DCPH stock plunged after the company released surprising trial results. Instead, it failed to meet that, and DCPH stock collapsed.
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Deciphera Pharmaceuticals (NASDAQ:DCPH) stock absolutely imploded in November. Source: Iryna Imago / Shutterstock.com DCPH stock plunged after the company released surprising trial results. Instead, it failed to meet that, and DCPH stock collapsed.
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Deciphera Pharmaceuticals (NASDAQ:DCPH) stock absolutely imploded in November. Source: Iryna Imago / Shutterstock.com DCPH stock plunged after the company released surprising trial results. Instead, it failed to meet that, and DCPH stock collapsed.
|
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Deciphera Pharmaceuticals (NASDAQ:DCPH) stock absolutely imploded in November. Source: Iryna Imago / Shutterstock.com DCPH stock plunged after the company released surprising trial results. Instead, it failed to meet that, and DCPH stock collapsed.
|
ecf28f18-b250-4a19-93c3-f6de4bc16d49
|
715491.0
|
2021-11-30 00:00:00 UTC
|
Deciphera Pharma Announces Corporate Restructuring; To Cut About 140 Positions - Quick Facts
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharma-announces-corporate-restructuring-to-cut-about-140-positions-quick-facts
|
nan
|
nan
|
(RTTNews) - Biopharmaceutical company Deciphera Pharmaceuticals, Inc. (DCPH) announced Tuesday a corporate restructuring intended to prioritize clinical development of select programs, streamline commercial operations, maintain a focus on discovery research and extend the Company's cash runway.
Following a detailed review of its portfolio and growth opportunities, Deciphera will focus its resources on the continued advancement of vimseltinib and DCC-3116, while discontinuing the rebastinib program.
The Company will streamline commercial operations for QINLOCK in the U.S. and focus commercialization efforts on a select number of key European markets. These changes are expected to result in a significant reduction in operating expenses, including personnel-related costs and external expenses, and extend the Company's cash runway into 2024.
The Company will implement an organizational restructuring that will result in a workforce reduction of approximately 35%, or approximately 140 positions. The restructuring is expected to affect U.S. employees across all areas of the organization.
Deciphera will remain focused on the commercialization of QINLOCK for the treatment of fourth-line GIST in the U.S. with a reduced commercial team.
Deciphera expects to recognize a one-time cash charge in the fourth quarter of approximately $32 million associated principally with the workforce reduction and discontinuation of continued clinical development of rebastinib and ripretinib.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Biopharmaceutical company Deciphera Pharmaceuticals, Inc. (DCPH) announced Tuesday a corporate restructuring intended to prioritize clinical development of select programs, streamline commercial operations, maintain a focus on discovery research and extend the Company's cash runway. Following a detailed review of its portfolio and growth opportunities, Deciphera will focus its resources on the continued advancement of vimseltinib and DCC-3116, while discontinuing the rebastinib program. Deciphera expects to recognize a one-time cash charge in the fourth quarter of approximately $32 million associated principally with the workforce reduction and discontinuation of continued clinical development of rebastinib and ripretinib.
|
(RTTNews) - Biopharmaceutical company Deciphera Pharmaceuticals, Inc. (DCPH) announced Tuesday a corporate restructuring intended to prioritize clinical development of select programs, streamline commercial operations, maintain a focus on discovery research and extend the Company's cash runway. The Company will streamline commercial operations for QINLOCK in the U.S. and focus commercialization efforts on a select number of key European markets. Deciphera expects to recognize a one-time cash charge in the fourth quarter of approximately $32 million associated principally with the workforce reduction and discontinuation of continued clinical development of rebastinib and ripretinib.
|
(RTTNews) - Biopharmaceutical company Deciphera Pharmaceuticals, Inc. (DCPH) announced Tuesday a corporate restructuring intended to prioritize clinical development of select programs, streamline commercial operations, maintain a focus on discovery research and extend the Company's cash runway. The Company will streamline commercial operations for QINLOCK in the U.S. and focus commercialization efforts on a select number of key European markets. Deciphera expects to recognize a one-time cash charge in the fourth quarter of approximately $32 million associated principally with the workforce reduction and discontinuation of continued clinical development of rebastinib and ripretinib.
|
(RTTNews) - Biopharmaceutical company Deciphera Pharmaceuticals, Inc. (DCPH) announced Tuesday a corporate restructuring intended to prioritize clinical development of select programs, streamline commercial operations, maintain a focus on discovery research and extend the Company's cash runway. The Company will streamline commercial operations for QINLOCK in the U.S. and focus commercialization efforts on a select number of key European markets. Deciphera expects to recognize a one-time cash charge in the fourth quarter of approximately $32 million associated principally with the workforce reduction and discontinuation of continued clinical development of rebastinib and ripretinib.
|
2f76c923-24c2-4fc8-b5ac-31df07b63822
|
715492.0
|
2021-11-26 00:00:00 UTC
|
After Hours Most Active for Nov 26, 2021 : UBER, AAPL, CVE, FB, BMY, QQQ, DCPH, PFF, PFE, TMUS, BSX, ATUS
|
DCPH
|
https://www.nasdaq.com/articles/after-hours-most-active-for-nov-26-2021-%3A-uber-aapl-cve-fb-bmy-qqq-dcph-pff-pfe-tmus-bsx
|
nan
|
nan
|
The NASDAQ 100 After Hours Indicator is up 2.44 to 16,028.02. The total After hours volume is currently 67,404,081 shares traded.
The following are the most active stocks for the after hours session:
Uber Technologies, Inc. (UBER) is -0.23 at $40.29, with 7,480,824 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2021. The consensus EPS forecast is $-0.33. As reported by Zacks, the current mean recommendation for UBER is in the "buy range".
Apple Inc. (AAPL) is +0.47 at $157.28, with 4,775,337 shares traded. Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2022. The consensus EPS forecast is $1.37. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
Cenovus Energy Inc (CVE) is unchanged at $12.39, with 2,979,273 shares traded. As reported by Zacks, the current mean recommendation for CVE is in the "buy range".
Meta Platforms, Inc. (FB) is +0.23 at $333.35, with 2,801,175 shares traded. As reported by Zacks, the current mean recommendation for FB is in the "buy range".
Bristol-Myers Squibb Company (BMY) is +0.07 at $56.60, with 2,399,134 shares traded. As reported by Zacks, the current mean recommendation for BMY is in the "buy range".
Invesco QQQ Trust, Series 1 (QQQ) is -0.31 at $390.89, with 2,354,113 shares traded. This represents a 32.69% increase from its 52 Week Low.
Deciphera Pharmaceuticals, Inc. (DCPH) is +0.13 at $8.20, with 2,209,737 shares traded., following a 52-week high recorded in today's regular session.
iShares Preferred and Income Securities ETF (PFF) is unchanged at $38.37, with 1,982,715 shares traded. This represents a 3.59% increase from its 52 Week Low.
Pfizer, Inc. (PFE) is unchanged at $54.00, with 1,664,192 shares traded., following a 52-week high recorded in today's regular session.
T-Mobile US, Inc. (TMUS) is -0.62 at $112.91, with 1,657,738 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2022. The consensus EPS forecast is $0.94. As reported by Zacks, the current mean recommendation for TMUS is in the "buy range".
Boston Scientific Corporation (BSX) is unchanged at $38.57, with 1,646,972 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2022. The consensus EPS forecast is $0.41. As reported by Zacks, the current mean recommendation for BSX is in the "buy range".
Altice USA, Inc. (ATUS) is +0.11 at $16.13, with 1,449,453 shares traded., following a 52-week high recorded in today's regular session.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is +0.13 at $8.20, with 2,209,737 shares traded., following a 52-week high recorded in today's regular session. Pfizer, Inc. (PFE) is unchanged at $54.00, with 1,664,192 shares traded., following a 52-week high recorded in today's regular session. Altice USA, Inc. (ATUS) is +0.11 at $16.13, with 1,449,453 shares traded., following a 52-week high recorded in today's regular session.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is +0.13 at $8.20, with 2,209,737 shares traded., following a 52-week high recorded in today's regular session. Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2022. Pfizer, Inc. (PFE) is unchanged at $54.00, with 1,664,192 shares traded., following a 52-week high recorded in today's regular session.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is +0.13 at $8.20, with 2,209,737 shares traded., following a 52-week high recorded in today's regular session. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2021. Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2022.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is +0.13 at $8.20, with 2,209,737 shares traded., following a 52-week high recorded in today's regular session. As reported by Zacks, the current mean recommendation for UBER is in the "buy range". Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2022.
|
5576fde1-8b54-4759-94fd-14cc162e3d92
|
715493.0
|
2021-11-24 00:00:00 UTC
|
After Hours Most Active for Nov 24, 2021 : ATUS, EDU, ZNGA, SBGI, DCPH, INTC, BMY, IQ, MSFT, XOM, ZYME, JNPR
|
DCPH
|
https://www.nasdaq.com/articles/after-hours-most-active-for-nov-24-2021-%3A-atus-edu-znga-sbgi-dcph-intc-bmy-iq-msft-xom
|
nan
|
nan
|
The NASDAQ 100 After Hours Indicator is down -.03 to 16,367.78. The total After hours volume is currently 115,021,089 shares traded.
The following are the most active stocks for the after hours session:
Altice USA, Inc. (ATUS) is +0.34 at $16.65, with 9,849,434 shares traded. ATUS's current last sale is 59.46% of the target price of $28.
New Oriental Education & Technology Group, Inc. (EDU) is -0.01 at $2.28, with 8,076,752 shares traded.EDU is scheduled to provide an earnings report on 11/30/2021, for the fiscal quarter ending Aug2021.
Zynga Inc. (ZNGA) is unchanged at $6.31, with 6,542,514 shares traded. ZNGA's current last sale is 54.87% of the target price of $11.5.
Sinclair Broadcast Group, Inc. (SBGI) is unchanged at $24.64, with 4,563,370 shares traded. As reported in the last short interest update the days to cover for SBGI is 8.705533; this calculation is based on the average trading volume of the stock.
Deciphera Pharmaceuticals, Inc. (DCPH) is unchanged at $8.35, with 4,015,293 shares traded. DCPH's current last sale is 64.23% of the target price of $13.
Intel Corporation (INTC) is unchanged at $49.76, with 3,262,574 shares traded. INTC's current last sale is 90.47% of the target price of $55.
Bristol-Myers Squibb Company (BMY) is unchanged at $56.81, with 3,163,283 shares traded. As reported by Zacks, the current mean recommendation for BMY is in the "buy range".
iQIYI, Inc. (IQ) is unchanged at $6.79, with 3,075,304 shares traded. As reported in the last short interest update the days to cover for IQ is 8.103769; this calculation is based on the average trading volume of the stock.
Microsoft Corporation (MSFT) is -0.1 at $337.81, with 3,019,224 shares traded. Over the last four weeks they have had 8 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2021. The consensus EPS forecast is $2.28. MSFT's current last sale is 93.84% of the target price of $360.
Exxon Mobil Corporation (XOM) is -0.03 at $63.45, with 2,691,296 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2021. The consensus EPS forecast is $1.73. XOM's current last sale is 101.93% of the target price of $62.25.
Zymeworks Inc. (ZYME) is unchanged at $19.66, with 2,126,247 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2021. The consensus EPS forecast is $-1.1. ZYME's current last sale is 41.39% of the target price of $47.5.
Juniper Networks, Inc. (JNPR) is unchanged at $32.42, with 1,990,595 shares traded. JNPR's current last sale is 108.07% of the target price of $30.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is unchanged at $8.35, with 4,015,293 shares traded. DCPH's current last sale is 64.23% of the target price of $13. New Oriental Education & Technology Group, Inc. (EDU) is -0.01 at $2.28, with 8,076,752 shares traded.EDU is scheduled to provide an earnings report on 11/30/2021, for the fiscal quarter ending Aug2021.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is unchanged at $8.35, with 4,015,293 shares traded. DCPH's current last sale is 64.23% of the target price of $13. As reported in the last short interest update the days to cover for SBGI is 8.705533; this calculation is based on the average trading volume of the stock.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is unchanged at $8.35, with 4,015,293 shares traded. DCPH's current last sale is 64.23% of the target price of $13. Zynga Inc. (ZNGA) is unchanged at $6.31, with 6,542,514 shares traded.
|
Deciphera Pharmaceuticals, Inc. (DCPH) is unchanged at $8.35, with 4,015,293 shares traded. DCPH's current last sale is 64.23% of the target price of $13. ATUS's current last sale is 59.46% of the target price of $28.
|
10b6effe-5c4b-47a5-a1cd-5235a8fb996d
|
715494.0
|
2021-11-22 00:00:00 UTC
|
EU Approves Deciphera's Qinlock For Advanced Gastrointestinal Stromal Tumor Treatment
|
DCPH
|
https://www.nasdaq.com/articles/eu-approves-decipheras-qinlock-for-advanced-gastrointestinal-stromal-tumor-treatment
|
nan
|
nan
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that the European Commission has approved Qinlock or ripretinib in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
The approval is applicable to all 27 European Union member states plus Iceland, Norway, and Liechtenstein. In September 2021, Qinlock was added as a fourth-line treatment for GIST patients progressing or intolerant to imatinib, sunitinib, and regorafenib to the ESMO-EURACAN-GENTURIS clinical practice guidelines for GIST.
The company noted that Qinlock significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in the INVICTUS phase 3 study.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that the European Commission has approved Qinlock or ripretinib in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. The approval is applicable to all 27 European Union member states plus Iceland, Norway, and Liechtenstein. The company noted that Qinlock significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in the INVICTUS phase 3 study.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that the European Commission has approved Qinlock or ripretinib in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. The approval is applicable to all 27 European Union member states plus Iceland, Norway, and Liechtenstein. In September 2021, Qinlock was added as a fourth-line treatment for GIST patients progressing or intolerant to imatinib, sunitinib, and regorafenib to the ESMO-EURACAN-GENTURIS clinical practice guidelines for GIST.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that the European Commission has approved Qinlock or ripretinib in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. In September 2021, Qinlock was added as a fourth-line treatment for GIST patients progressing or intolerant to imatinib, sunitinib, and regorafenib to the ESMO-EURACAN-GENTURIS clinical practice guidelines for GIST. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that the European Commission has approved Qinlock or ripretinib in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. The company noted that Qinlock significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in the INVICTUS phase 3 study. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
1deb831b-6e76-494d-8ae4-dff097e70f66
|
715495.0
|
2021-11-08 00:00:00 UTC
|
Deciphera Reveals Topline Results of INTRIGUE Phase 3 Clinical Study; Shares Crash
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-reveals-topline-results-of-intrigue-phase-3-clinical-study-shares-crash
|
nan
|
nan
|
Shares of Deciphera Pharmaceuticals (DCPH) plunged 75.5% on Friday to close at $8.82 after the commercial-stage biopharmaceutical company provided update and topline results of the INTRIGUE Phase 3 clinical study of QINLOCK.
The study was evaluating QINLOCK in patients with gastrointestinal stromal tumor (GIST), who were previously treated with imatinib. The INTRIGUE Phase 3 clinical study, a randomized, global, multi-center, open-label study, was evaluating the efficacy and safety of QINLOCK compared to sunitinib.
As per the topline analysis update, treatment with QINLOCK did not meet the primary endpoint of progression-free survival (PFS), demonstrated by independent radiologic review, which used modified Response Evaluation Criteria in Solid Tumors (RECIST).
The CEO of Deciphera, Steve Hoerter, said, "While we are disappointed with these results, which we learned yesterday, we believe this was a robust, well-designed, and well-executed study. The full results from the INTRIGUE Phase 3 clinical study are expected to be presented at an upcoming medical meeting...QINLOCK remains the standard of care and only approved therapy in patients with fourth-line GIST, and we are committed to ensuring that patients around the world in the fourth-line GIST treatment setting have access to QINLOCK." (See Deciphera stock charts on TipRanks)
Wall Street’s Take
Following the news, JMP Securities analyst Reni Benjamin downgraded the stock to Hold from Buy and decreased the price target to $64 (625.62% upside potential) from $70.
Benjamin expects the company to decrease R&D expenses significantly to conserve cash in the near term, given that 4L GIST QINLOCK revenues have already peaked. "While the company did not update R&D guidance, we expect expenses to decrease in the near term by approximately $15 MM,” the analyst said.
The rest of the Street is cautiously optimistic about the stock and has a Moderate Buy consensus rating based on 3 Buys and 3 Holds. The average Deciphera price target of $51.80 implies 487.3% upside potential from current levels. Shares have lost 86.4% over the past year.
Smart Score
According to TipRanks’ Smart Score rating system, Deciphera gets a 5 out of 10, which indicates that the stock is likely to perform in line with market averages. (See Top Smart Score Stocks on TipRanks >>)
Related News:
Roku’s Q3 Revenues & Q4 Outlook Disappoint
Qualcomm Posts a Blowout Quarter; Shares Jump 7.5%
Skillz Drops 10% on Quarterly Loss
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Shares of Deciphera Pharmaceuticals (DCPH) plunged 75.5% on Friday to close at $8.82 after the commercial-stage biopharmaceutical company provided update and topline results of the INTRIGUE Phase 3 clinical study of QINLOCK. As per the topline analysis update, treatment with QINLOCK did not meet the primary endpoint of progression-free survival (PFS), demonstrated by independent radiologic review, which used modified Response Evaluation Criteria in Solid Tumors (RECIST). Benjamin expects the company to decrease R&D expenses significantly to conserve cash in the near term, given that 4L GIST QINLOCK revenues have already peaked.
|
Shares of Deciphera Pharmaceuticals (DCPH) plunged 75.5% on Friday to close at $8.82 after the commercial-stage biopharmaceutical company provided update and topline results of the INTRIGUE Phase 3 clinical study of QINLOCK. (See Deciphera stock charts on TipRanks) Wall Street’s Take Following the news, JMP Securities analyst Reni Benjamin downgraded the stock to Hold from Buy and decreased the price target to $64 (625.62% upside potential) from $70. Smart Score According to TipRanks’ Smart Score rating system, Deciphera gets a 5 out of 10, which indicates that the stock is likely to perform in line with market averages.
|
Shares of Deciphera Pharmaceuticals (DCPH) plunged 75.5% on Friday to close at $8.82 after the commercial-stage biopharmaceutical company provided update and topline results of the INTRIGUE Phase 3 clinical study of QINLOCK. The full results from the INTRIGUE Phase 3 clinical study are expected to be presented at an upcoming medical meeting...QINLOCK remains the standard of care and only approved therapy in patients with fourth-line GIST, and we are committed to ensuring that patients around the world in the fourth-line GIST treatment setting have access to QINLOCK." (See Deciphera stock charts on TipRanks) Wall Street’s Take Following the news, JMP Securities analyst Reni Benjamin downgraded the stock to Hold from Buy and decreased the price target to $64 (625.62% upside potential) from $70.
|
Shares of Deciphera Pharmaceuticals (DCPH) plunged 75.5% on Friday to close at $8.82 after the commercial-stage biopharmaceutical company provided update and topline results of the INTRIGUE Phase 3 clinical study of QINLOCK. The INTRIGUE Phase 3 clinical study, a randomized, global, multi-center, open-label study, was evaluating the efficacy and safety of QINLOCK compared to sunitinib. The full results from the INTRIGUE Phase 3 clinical study are expected to be presented at an upcoming medical meeting...QINLOCK remains the standard of care and only approved therapy in patients with fourth-line GIST, and we are committed to ensuring that patients around the world in the fourth-line GIST treatment setting have access to QINLOCK."
|
bb16e0a6-6461-4873-bf71-cd5dcaad6d2b
|
715496.0
|
2021-11-05 00:00:00 UTC
|
Health Care Sector Update for 11/05/2021: NRXP,DCPH,RWLK,ASRT
|
DCPH
|
https://www.nasdaq.com/articles/health-care-sector-update-for-11-05-2021%3A-nrxpdcphrwlkasrt-2021-11-05
|
nan
|
nan
|
Health care stocks were market laggards Friday, with the NYSE Health Care Index falling 0.9% while the Health Care Select Sector SPDR ETF (XLV) was down 1.1% shortly before the closing bell.
The Nasdaq Biotechnology index sank 2.9%.
In company news, NRX Pharmaceuticals (NRXP) was down almost 29% after the US Food and Drug Administration declined to issue an emergency use authorization for the company's Zyesami drug candidate as a potential treatment for respiratory failure in patients with severe COVID-19, citing the lack of sufficient data showing its likely benefits and risks.
Deciphera (DCPH) shares plunged almost 36% to a record low of $8.70 a share after the company said its Qinlock drug candidate missed its primary efficacy endpoint of improving progression-free survival compared with Pfizer's (PFE) Sutent chemotherapy during phase 3 testing in patients with gastrointestinal stromal cancer.
To the upside, ReWalk Robotics (RWLK) shares jumped more than 27% after the company's ReBoot battery-powered orthotic exo-suit received breakthrough device designation from the US FDA to assist movement in people with reduced ankle function due to neurological injuries like stroke.
Assertio Holdings (ASRT) shares added nearly 32% after the drug maker reported a surprise Q3 profit of $0.08 per share on around $26 million in sales, topping a lone analyst's forecast for a net loss of $0.16 per share on $22 million in sales.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera (DCPH) shares plunged almost 36% to a record low of $8.70 a share after the company said its Qinlock drug candidate missed its primary efficacy endpoint of improving progression-free survival compared with Pfizer's (PFE) Sutent chemotherapy during phase 3 testing in patients with gastrointestinal stromal cancer. In company news, NRX Pharmaceuticals (NRXP) was down almost 29% after the US Food and Drug Administration declined to issue an emergency use authorization for the company's Zyesami drug candidate as a potential treatment for respiratory failure in patients with severe COVID-19, citing the lack of sufficient data showing its likely benefits and risks. To the upside, ReWalk Robotics (RWLK) shares jumped more than 27% after the company's ReBoot battery-powered orthotic exo-suit received breakthrough device designation from the US FDA to assist movement in people with reduced ankle function due to neurological injuries like stroke.
|
Deciphera (DCPH) shares plunged almost 36% to a record low of $8.70 a share after the company said its Qinlock drug candidate missed its primary efficacy endpoint of improving progression-free survival compared with Pfizer's (PFE) Sutent chemotherapy during phase 3 testing in patients with gastrointestinal stromal cancer. Health care stocks were market laggards Friday, with the NYSE Health Care Index falling 0.9% while the Health Care Select Sector SPDR ETF (XLV) was down 1.1% shortly before the closing bell. In company news, NRX Pharmaceuticals (NRXP) was down almost 29% after the US Food and Drug Administration declined to issue an emergency use authorization for the company's Zyesami drug candidate as a potential treatment for respiratory failure in patients with severe COVID-19, citing the lack of sufficient data showing its likely benefits and risks.
|
Deciphera (DCPH) shares plunged almost 36% to a record low of $8.70 a share after the company said its Qinlock drug candidate missed its primary efficacy endpoint of improving progression-free survival compared with Pfizer's (PFE) Sutent chemotherapy during phase 3 testing in patients with gastrointestinal stromal cancer. Health care stocks were market laggards Friday, with the NYSE Health Care Index falling 0.9% while the Health Care Select Sector SPDR ETF (XLV) was down 1.1% shortly before the closing bell. Assertio Holdings (ASRT) shares added nearly 32% after the drug maker reported a surprise Q3 profit of $0.08 per share on around $26 million in sales, topping a lone analyst's forecast for a net loss of $0.16 per share on $22 million in sales.
|
Deciphera (DCPH) shares plunged almost 36% to a record low of $8.70 a share after the company said its Qinlock drug candidate missed its primary efficacy endpoint of improving progression-free survival compared with Pfizer's (PFE) Sutent chemotherapy during phase 3 testing in patients with gastrointestinal stromal cancer. Health care stocks were market laggards Friday, with the NYSE Health Care Index falling 0.9% while the Health Care Select Sector SPDR ETF (XLV) was down 1.1% shortly before the closing bell. The Nasdaq Biotechnology index sank 2.9%.
|
faf94913-4cfd-4650-ad7e-862c1cd09e43
|
715497.0
|
2021-11-05 00:00:00 UTC
|
Health Care Sector Update for 11/05/2021: DCPH, RWLK, ASRT
|
DCPH
|
https://www.nasdaq.com/articles/health-care-sector-update-for-11-05-2021%3A-dcph-rwlk-asrt-2021-11-05
|
nan
|
nan
|
Health care stocks were retreating this afternoon, with the NYSE Health Care Index falling 1.0% while the SPDR Health Care Select Sector ETF (XLV) was down 1.7%.
The Nasdaq Biotechnology index also was sinking 3.9%.
In company news, Deciphera (DCPH) shares plunged more than 75% to a record low of $8.92 a share after saying its Qinlock drug candidate missed its primary efficacy endpoint of improving progression-free survival compared with Pfizer's (PFE) Sutent chemotherapy during phase III testing in patients with gastrointestinal stromal cancer.
ReWalk Robotics (RWLK) jumped more than 27% higher after the company's ReBoot battery-powered orthotic exo-suit received breakthrough device designation from the US Food and Drug Administration to assist movement in people with reduced ankle function due to neurological injuries like stroke.
Assertio Holdings (ASRT) shares added nearly 22% after reporting a surprise Q3 profit of $0.08 per share on around $26 million in sales, topping the forecast of the lone analyst tracking the drug maker expecting a $0.16 per share net loss on $22 million in sales.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
In company news, Deciphera (DCPH) shares plunged more than 75% to a record low of $8.92 a share after saying its Qinlock drug candidate missed its primary efficacy endpoint of improving progression-free survival compared with Pfizer's (PFE) Sutent chemotherapy during phase III testing in patients with gastrointestinal stromal cancer. ReWalk Robotics (RWLK) jumped more than 27% higher after the company's ReBoot battery-powered orthotic exo-suit received breakthrough device designation from the US Food and Drug Administration to assist movement in people with reduced ankle function due to neurological injuries like stroke. Assertio Holdings (ASRT) shares added nearly 22% after reporting a surprise Q3 profit of $0.08 per share on around $26 million in sales, topping the forecast of the lone analyst tracking the drug maker expecting a $0.16 per share net loss on $22 million in sales.
|
In company news, Deciphera (DCPH) shares plunged more than 75% to a record low of $8.92 a share after saying its Qinlock drug candidate missed its primary efficacy endpoint of improving progression-free survival compared with Pfizer's (PFE) Sutent chemotherapy during phase III testing in patients with gastrointestinal stromal cancer. Health care stocks were retreating this afternoon, with the NYSE Health Care Index falling 1.0% while the SPDR Health Care Select Sector ETF (XLV) was down 1.7%. The Nasdaq Biotechnology index also was sinking 3.9%.
|
In company news, Deciphera (DCPH) shares plunged more than 75% to a record low of $8.92 a share after saying its Qinlock drug candidate missed its primary efficacy endpoint of improving progression-free survival compared with Pfizer's (PFE) Sutent chemotherapy during phase III testing in patients with gastrointestinal stromal cancer. Health care stocks were retreating this afternoon, with the NYSE Health Care Index falling 1.0% while the SPDR Health Care Select Sector ETF (XLV) was down 1.7%. Assertio Holdings (ASRT) shares added nearly 22% after reporting a surprise Q3 profit of $0.08 per share on around $26 million in sales, topping the forecast of the lone analyst tracking the drug maker expecting a $0.16 per share net loss on $22 million in sales.
|
In company news, Deciphera (DCPH) shares plunged more than 75% to a record low of $8.92 a share after saying its Qinlock drug candidate missed its primary efficacy endpoint of improving progression-free survival compared with Pfizer's (PFE) Sutent chemotherapy during phase III testing in patients with gastrointestinal stromal cancer. Health care stocks were retreating this afternoon, with the NYSE Health Care Index falling 1.0% while the SPDR Health Care Select Sector ETF (XLV) was down 1.7%. The Nasdaq Biotechnology index also was sinking 3.9%.
|
59caa199-7256-44ea-b0f4-0dd1fa71952a
|
715498.0
|
2021-11-03 00:00:00 UTC
|
Deciphera Pharmaceuticals, inc (DCPH) Q3 2021 Earnings Call Transcript
|
DCPH
|
https://www.nasdaq.com/articles/deciphera-pharmaceuticals-inc-dcph-q3-2021-earnings-call-transcript-2021-11-03
|
nan
|
nan
|
Image source: The Motley Fool.
Deciphera Pharmaceuticals, inc (NASDAQ: DCPH)
Q3 2021 Earnings Call
Nov 2, 2021, 4:30 p.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good afternoon, everyone, and welcome to the Deciphera Pharmaceuticals Third Quarter 2021 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Jen Robinson, Vice President of Investor Relations, Jen?
10 stocks we like better than Deciphera Pharmaceuticals, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of October 20, 2021
Jen Robinson -- Vice President, Investor Relations
Thank you operator. Welcome, and thank you for joining us today to discuss Deciphera's third quarter 2021 financial results. I am Jen Robinson, Vice President, Investor Relations at Deciphera. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Dan Martin, Chief Commercial Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
Before we begin, I would like to remind you that any statements we make on this call that are not historical facts are forward-looking statements reflecting the current beliefs and expectations of management, made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements made during this conference call include our expectations for our preclinical and clinical programs, our commercialization of QINLOCK and 2021 and 2022 guidance.
Forward-looking statements made on this call involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we cannot assure you that our expectations will be achieved. Such risks and uncertainties include those set forth in our most recent quarterly report on Form 10-Q as well as our other SEC filings. We assume no obligation to update or revise any forward-looking statements.
Following this call, a replay will be made available on the company's website, www.deciphera.com.
With that, I will now turn the call over to Steve Hoerter, President and Chief Executive Officer of Deciphera. Steve?
Steve Hoerter -- President and Chief Executive Officer
Thank you, Jen, and good afternoon, everyone. During the third quarter, we made significant progress against our strategic priorities, including both expanding the reach of QINLOCK for patients with just around the world and providing important new data updates for the next two product candidates advancing through the pipeline and moving toward registration directed studies.
In the US, we have rapidly established QINLOCK as the clear standard of care and fourth-line GIST, providing a strong foundation as we prepare to report top-line results from the Phase three INTRIGUE study in second line GIST later this quarter. At ASCO, we presented long-term follow-up from the Phase three INVICTUS study, showing that QINLOCK nearly tripled the overall survival benefit for patients in this setting.
Based on the totality of the clinical data we have generated with QINLOCK so far, we remain confident in the potential for QINLOCK to fundamentally transform the treatment of this disease.
Outside of the US, we continue our work to broaden the geographic reach of QINLOCK. In September, we received a positive opinion from the EMAs, CHMP. And we expect EU approval for QINLOCK in fourth-line GIST later this quarter.
In October, we were also pleased to announce the approval of QINLOCK by Swissmedic, Switzerland's regulatory agency. This marks the seventh approval worldwide for QINLOCK and our first approval in Continental Europe. We are excited to bring this important new medicines specifically designed for GIST to patients in Europe who are in need of a new treatment option.
Beyond Europe, our partner, Zai Lab continues to execute on its launch of QINLOCK in fourth-line GIST in the China market, where an estimated 30,000 new patients are diagnosed with this disease each year. Building on the recent regulatory approvals in China and Hong Kong, Zai received approval for QINLOCK in Taiwan last quarter. We look forward to working with Zai to provide QINLOCK to just patients throughout Greater China. Later on today's call, Matt Sherman, our Chief Medical Officer will review the highly encouraging data updates we provided for Vimseltinib and Rebastinib at the ESMO meeting in September.
We were excited to present these new data updates and disclose our plans to move forward with pivotal Phase three studies for these novel product candidates. For Vimseltinib our potential best in class CSF one receptor inhibitor, we expect to initiate the Phase three motion study in patients with tennis synovial giant cell tumour this quarter. And for Rebastinib our potential first-in-class type two inhibitor, we expect to initiate a registration study next year.
We are leaders in targeting autophagy in cancer and our ULK inhibitor DCC-3116 is the first to enter the clinic in this important area of cancer research. In June, we initiated the Phase one study of DCC-3116 and we expect to present data from the dose escalation portion of this study next year.
In October at the triple meeting, we highlighted exciting new preclinical data with 3116 in combination with EGFR inhibitors. For the first time, we described the upregulation of autophagy and non-small cell lung cancer preclinical models with osimertinib, the current standard of care for mutant EGFR, non-small cell lung cancer, and the significant anti-tumour synergy seen with the combination of DCC-3116 and osimertinib.
These data and the growing literature underscore the broad applicability of targeting autophagy in cancer and the potential for DCC-3116 to be combined with a number of targeted agents across a spectrum of solid and haematological malignancies.
I'll now turn the call over to Dan Martin, our Chief Commercial Officer to discuss the QINLOCK commercial results from Q3. Dan?
Dan Martin -- Chief Commercial Officer
Thank you, Steve. In Q3, we continue to execute on our commercial goals for QINLOCK, reinforcing its position as the standard of care in fourth-line GIST and further strengthening the excellent foundation we have established ahead of our planned launch into the significantly larger second line setting.
In Q3, we achieved 21.7 million in total net Product Revenue globally, including 20 million in the US. The core drivers of QINLOCK demand remained consistent, including new patient acquisition, payer access and persistency.
During the quarter, we increased our prescriber footprint by nearly 20% to approximately 530 prescribers since launch with most of this growth again coming from the community setting. Other key performance metrics again demonstrated strong commercial execution and positive physician perceptions of QINLOCK.
As in prior quarters, we achieved high levels of prescriber reach, share voice and product awareness. And prescribers again gave QINLOCK high marks for efficacy, safety, convenience and ease of access.
Consistent with our guidance during our Q2earnings call the percentage of patients receiving free drug under our patient assistance program or PAP was slightly higher than our 20% to 30% estimated range due to increased patient affordability challenges within the Medicare Part D patient population.
Additionally, as expected, the Q3 gross net adjustment increased significantly versus Q2 and was in line with our projected annual average of 15%. In Q4, we expect the core drivers of QINLOCK demand to remain consistent, and we expect the PAP percentage in gross to net adjustment to be in line with Q3.
Looking ahead, our team is hard at work preparing for the second line launch where we expect to benefit from the clinical experience and positive product perceptions we have already established. Since launch in addition to the approximately 530 GIST treaters who have prescribed QINLOCK, we have reached almost 3,000 additional physicians mostly in the community setting, who are potential traders of earlier line GIST patients.
Recent market research has also been very encouraging. In a recent market research survey, GIST treaters rated QINLOCK higher than sunitinib across all product attributes tested based on their experience with the two agents. We believe QINLOCK has the potential to establish a new standard of care in the second line setting, and we look forward to helping even more patients gain access to this important medicine.
I will now turn the call over to Matt.
Matt Sherman -- Chief Medical Officer
Thank you, Dan. We've made tremendous progress advancing our clinical stage pipeline this year, and I'm pleased to share the encouraging results we have in each of our programs. Importantly, working toward our mission to discover, develop and deliver important new medicines to patients for the treatment of cancer. We are rapidly advancing our clinical development programs forward.
I'd like to start with QINLOCK in the Phase three line INTRIGUE study comparing QINLOCK to sunitinib in patients with second-line GIST. We expect to report top line results this quarter and remain confident in the likelihood of success in this pivotal study. We're also excited to move forward with our next pivotal development program Vimseltinib, our potential best-in-class inhibitor of CSF1R. This quarter, we expect to treat the first patient in the motion study. The global randomized, placebo controlled Phase three study and approximately patients with symptomatic TGCT non-amenable to surgical resection.
In the double-blind period of the study, eligible patients will be randomized to 2:1 to receive either Vimseltinib 30 milligrams twice weekly or placebo for 24 weeks. Following the evaluation of the primary endpoint of objective response rate of week 25, patients will have the option to continue or crossover to Vimseltinib during the open-label period of the study.
I'm extremely proud of our team for getting this pivotal study up and running so quickly. There's a great unmet medical need in TGCT and Vimseltinib may offer a new best-in-class treatment option for these patients. Today, there is only one approved product for this indication pexidartinib, which has a black boxed warning and subject to a REMS program to the potentially fatal hepatotoxicity, an adverse event that is thought to be an off target effect.
Interestingly, most patients are using off late imatinib to treat their disease. Imatinib is a weak CSF1R inhibitor which is not approved for TGCT and was listed in the NCCN guidelines based on limited data from a retrospective study that showed a low response rate. We are excited to announce today that we have received Fast Track Designation for Vimseltinib from the FDA for treatment of patients with symptomatic TGCT who are not amenable to surgery. This designation is designed to get important drugs to patients and need faster, and is intended to help facilitate the development of themselves to them and expedite this regulatory review.
The motion study was designed based on the exciting safety and efficacy results from the Phase one, two Study we recently presented at ESMO this year. We reported a 47% objective response rate across all cohorts in the Phase one dose escalation portion of the study and from patients without CSF1R treatment exposure Cohort A of the Phase two expansion portion of the study. The encouraging preliminary data from CT is still early, and we're looking forward to longer follow up.
Treatment with Vimseltinib it was generally well tolerated in patients with TGCT, the majority of the common treatment emergent as adverse events 15% or greater, for Grade 2 or lower.
Now turning to our other late stage clinical program rebastinib, our potential best-in-class class TIE2 inhibitor, planning is ongoing for Phase three pivotal study rebastinib and Rebastinib in platinum-resistant ovarian cancer or PROC. We expect to initiate this study next year following feedback from health authorities.
Earlier this year, we presented exciting preliminary data ESMO from the ongoing Phase one two study of Rebastinib, the combination of Paclitaxel in heavily pretreated PROC patients. The combination demonstrated the promising median progression-free survival with 9.1 months. In addition, the confirmed and unconfirmed objective response rate was 38% and the confirmed objective response rate was 29%. Based on the published literature, the median progression-free survival of single agent Paclitaxel is expected to be three to four months, while its objective response rate is expected to be 15% to 25%. The combination was also generally well tolerated and most treatment emergent adverse events were grade one or two.
We recently received Orphan Drug Designation in the EU for the treatment of ovarian cancer based on a positive opinion issued by the EMA, underscoring the significant unmet patient need that Rebastinib has potential to address. In addition to our late-stage programs, we are very excited about our next generation of product candidates led by DCC-3116, our first-in-class ULK kinase inhibitor that entered clinical development a few months ago. The ULK kinase is an initiating factor in the autophagy pathway, the key survival mechanism in which cells recycle components to generate energy. There's substantial and growing body of evidence showing that autophagy is upregulated in cancer cells to the stress of damage caused by anticancer treatments.
And then, in addition of autophagy, in combination with a variety of anticancer agents may provide a novel approach to treatment by directly addressing one of the important escape mechanisms that plague many types of cancer therapy. Deciphera continue to generate preclinical evidence on the role of autophagy in cancer. At the recent triple meeting, we presented new data demonstrating synergy with 3116 in EGFR inhibitors osimertinib and afatinib in non-small cell lung cancer preclinical models.
In Vitro data show that 3116 reduce autophagy that develops the resistance mechanism after treatment with EGFR inhibitors in lung cancer cell lines. In addition, the in vivo data demonstrated that the combination of 3116 with EGFR inhibitors resulted in significant greater tumor responses, non-lung cancer xenograft model compared to single agent treatment. Researchers outside of Deciphera have also continued to add the strong case for a potential role of a tough gene in addition, in the treatment of solid and haematological malignancies. When recently published study in Nature cancer showed that non-small cell lung cancers with an LKB 1 mutation, which is frequently co mutated with KRAS are resistant to immune checkpoint inhibition, that can be resensitize the PD-1 checkpoint inhibition after blocking both kinase and autophagy.
Another recent study in Science Translational Medicine show the treatment of CML cell lines with an autophagy inhibitor in a matter of decreased growth. In addition, co-treatment on eliminated persistent leukemic stem cells, which drive TKI resistance and patient relapse. Once again, our leadership role in the field of autophagy in cancer, including old kinase and VPS34 kinase positions Deciphera to make significant contributions to cancer patients in the near future. These data provide additional support for the potential graph of the DCC-3116 program adding to the preclinical evidence supporting combination strategies with other cancer treatments, including MEK, ERK, RAF, and direct KRAS G12C inhibitors, as well as PD-1, PDL-1 checkpoint inhibitors, and a wide range of cancers. We're actively pursuing preclinical combinations of 3116 with a with a variety of standard of care therapies and drugs acting by novel cancer mechanisms and look forward to reporting further on these studies next year. Our first area of focus for clinical development in 3116 is for the treatment of RAS/RAF mutated solid tumors in combination with MEK inhibitor. The ongoing Phase oneudy is two parts, dose escalation phase and an expansion phase. Enrolling for the dose escalation phase of the study started in the second quarter of this year and will provide important single agent data for 3116 including safety, tolerability, pharmacokinetics and pharmacodynamics. Data from this phase will also determine the go forward dose and the expansion phase of the study with 3116 will be used in combination with trametinib in multiple tumor types. We look forward to presenting data from the dose escalation phase next year. We are strongly encouraged by the progress across each of our innovative programs and believe that these will make a meaningful difference in the treatment of patients with cancer.
I will now turn the call over to Tucker Kelly, our Chief Financial Officer to review the financial results. Tucker.
Tucker Kelly -- Chief Financial Officer
Thanks, Matt. I'd like to give the highlights from our third quarter financial results. Total revenues in the third quarter was $23.2 million, which includes $21.7 million in net product revenue QINLOCK. Net product revenues for the third quarter of 2021 includes US sales of QINLOCK of $20 million and ex-US sales of QINLOCK of $1.7 million. The gross to net adjustment in the third quarter was in line with our estimate of 15%. Collaboration revenue in the quarter was $1.5 million, which includes QINLOCK supply and royalty revenue under our agreements with Zai Lab for Greater China.
Cost of Sales for the three months ended September 30, 2021 was $0.9 million, which included $0.2 million in cost of net product revenue for QINLOCK product sales and $0.7 million in cost of collaboration efforts. We do not expect that the cost of sales as a percentage of net product sales of QINLOCK will increase significantly after we have sold all zero cost inventories and commence the sales of inventories which will reflect the full cost of manufacturing. We expect to continue to sell the zero cost inventories of QINLOCK in US during the remainder of this year and into 2022.
Total operating expenses were $102 million in the third quarter of 2021 compared to total operating expenses of $79.4 million in the same period in 2020. Research and Development expenses in the third quarter were $66.4 million compared to $49.2 million in the same period in 2020. Selling, general and administrative expenses in the third quarter with $35.5 million compared to $30.1 million in the same period in 2020.
We expect that operating expenses will increase as we continue to invest in the development of our clinical pipeline, execute on the commercialization of QINLOCK in US and prepare for potential commercial launch in Europe. We ended the third quarter in a strong financial position and remain well capitalized with cash, cash equivalents and marketable securities of approximately $392 million, which together with our anticipated product and supply revenues, we expect will be sufficient to fund our operations into the first half of 2023.
With that I'm now turn the call back over to Steve.
Steve Hoerter -- President and Chief Executive Officer
Thank you, Tucker. As we enter the last quarter of 2021, I'm excited about what we've accomplished so far this year and the progress we've made across the company. We are well positioned for long term success as we prepare to launch QINLOCK in Europe and report the results from the Phase threeIGUE study. In addition, we continue to advance the rest of our pipeline as first in class and best in class product candidates. And we look forward to updating you on our future progress.
Operator. I'd now like to open the call for Q&A.
Questions and Answers:
Operator
Thank you [Operator Instructions] And our first question comes from Chris Raymond from Piper Sandler. Your line is now open.
Chris Raymond -- Piper Sandler -- Analyst
Hey, thanks for taking the question. Just a couple quick ones commercial questions here. Dan, I heard you talk about a lot of the metrics, but I'm not sure, I heard you talk about this. Last quarter, I think you were indicating there was some intra patient dose escalation that was going on past progression. Just wonder if you can talk directionally. Are you seeing that pick up? Is it the same? Is there any sort of dynamic to that especially since you had that data at ASCO? It was published, I think, in July?
And then maybe just sort of another sort of broader question, I guess. And I get this question -- this is probably the most asked question I hear from investors is, just thinking about, how quickly QINLOCK became standard of care in fourth line just, really maxing out the opportunity in three quarters. How should we be thinking about the dynamic in the second line setting? Obviously, it's a different sort of dynamic, given that there's an established option in second line, but just kind of talk about, the sort of velocity of penetration between fourth and second that you might be anticipating, assuming, obviously, positive data this quarter? Thanks.
Steve Hoerter -- President and Chief Executive Officer
Hey Chris, it's Steve. So let me take the first part of that, and then I'll turn it over to Dan to address the other part of your question. So you reference the IPDE data from both INVICTUS randomized phase three study, the fourth line study, as well as from the phase one. And we were really pleased to see both of those datasets published in the peer reviewed literature as manuscripts over the course of the summer months. And as you know, from the data and certainly the feedback that we've heard from thought leaders, they view the PFS2 to data that we generated upon dose escalation, as being very meaningful clinically for patients, especially when you look at the data as a fraction of the benefit that patients received as measured by PFS1. So we're really encouraged by the data.
As you might remember, in the Phase one udy, the dose escalation part of the study, we didn't actually reach a maximum tolerated dose with ripretinib, and we dose patients up to 400 milligrams daily. So, we feel as if we have ample headroom for dose escalation, and I think that's been now evidenced by the data from INVICTUS and from the phase one, and certainly even at that higher dose, the drug remains well tolerated. So, we're encouraged by the data, and that underscores the efficacy of the product interests. Dan, do you want to address the rest of Chris's question with respect to what you're seeing in the actual market in terms of utilization of IPDE
Dan Martin -- Chief Commercial Officer
Sure, absolutely. Thanks Chris for the questions. So on the IPDE front, as Steve said, the data has been really well received by the KOL in particular, who view this as a really meaningful benefit for patients. And so there's certainly been interest there. The challenge though is that, of course, this is an off label, so we're not able to promote that. We only, of course, promote consistent with our label dose. And so, what we see in the marketplace is relatively consistent use, which is a smaller portion of our overall dosing, the vast majority of doses are at the labeled dose.
And a couple thoughts on this. From a payer perspective, what we see is sort of inconsistent. We see some claims are approved for the IPDE dose and others are not. And, you know, it has not been added to the NCCN Guidelines, thus far remains to be seen, if and when that will happen. If it is, and if we think that could provide some momentum with respect to not only demand for use of that dosing regimen, but also the access side of the equation. So we'll just have to see how that plays out. But thus far, it's been pretty consistent as a relatively small overall portion of our dosing.
With respect to your second question about uptake in the second line, yes, we've been incredibly pleased with the rapid uptake that we've seen in the fourth line. And we just continue to see, as I underscored in the prepared remarks, just tremendous support, and belief in QINLOCK and really high scores across the board, not just by users but even more broadly, as we've made more and more progress in reaching the community setting, so we're really pleased with the progress thus far. And we think it bodes extremely well for our second line plan second line launch.
As I mentioned, we've reached an additional 3,000 physicians who are likely to be treaters of earlier line patients beyond the 530 or so that have prescribed it, you know, today. And we reached, of course we only message our fourth line indication to those physicians to be clear, because you never know where a fourth line patients going to appear. But the awareness that we've developed in that broader set of potential future prescribers, we think sets us up extremely well.
And as I mentioned in the prepared remarks, the market research that we're seeing now suggests that just based on general experience and perceptions of the two drugs that actually many just treaters rate QINLOCK significantly higher than students. So for all of these reasons, we think that we're really well set up for second line, we think a relatively rapid uptake is certainly possible.
The only other things I'll mention, that will be things we work through, of course, is as you mentioned, there isn't established therapy. And we think that, you know, we'll need to continue to reach, and continue to impact the community more and more, because we think that earlier line setting will be that much more, you know, the domain of the community physician. So those are things that will be very focused on driving at launch. But we think for all the reasons listed, we've got a great opportunity for a rapid penetration is a second line tending data from INTRIGUE.
Chris Raymond -- Piper Sandler -- Analyst
Okay, thank you.
Operator
And thank you. And our next question comes from Jessica Fye from JPMorgan. Your line is now open.
Jessica Fye -- JPMorgan -- Analyst
Hey, guys. Good evening. Thanks for taking my question. A couple from me. Where do you estimate your penetration rate stands in fourth line just at this point? And separately, can you talk about the next steps following the top line results for INTRIGUE? So how soon could you file? And appreciate those earlier kind of comments about the reaching more community physicians, but how much additional SG&A if any, do you envision would be needed to support a second line launch?
Steve Hoerter -- President and Chief Executive Officer
Hey, It's Steve, Jess. Thanks for your questions. But let's try and work our way through these in turn. So I think that I'll take the part of the last two here, and then I'll turn it over to Dan to talk a little bit about what we're seeing in the market in terms of penetration and how we view that.
With respect to the top line, once we report out the INTRIGUE results, you know, our next step, of course, would be to prepare a filing both in the US as well as in Europe. And our goal would be to, of course, get those filings in over the course of the subsequent months. And I think probably looking back to the timeline that we experienced with INVICTUS for the initial fourth line filings, probably a good proxy to use with respect to the US filing. And we would, of course, hope to make the European filing shortly thereafter.
With respect to SG&A and what to expect in terms of additional investment for a second line launch. We don't expect at all and don't plan to increase the size of our footprint from a commercial or medical affairs perspective. We are right size for the opportunity already. And as Dan has noted, we're already calling on the physicians in the community to treat patients Jess's, who would see both fourth line patients as well as second line patients. So we wouldn't expect to see any increase in terms of headcount. Of course, there'll be additional investment in terms of marketing and promotional dollars as we start that launch process in the second line, post data from INTRIGUE. Dan, do you want to cover off on the penetration question?
Dan Martin -- Chief Commercial Officer
Sure. Absolutely. Thanks, Jess, for the question. So we, continue all fronts continuing to point to being very highly penetrated within a fourth line opportunity. We do any number of surveys, -- I've mentioned before that the data to derive the shares and perfect in the space. So we leverage any number of surveys, position surveys, but we also will go out and do what are called chart audit surveys will actually have positions pull their charts and show us, who's getting what in the fourth line setting and by all accounts, it continues to be very highly penetrated, clearly viewed as the standard of care and fourth line. And one physician even told us lately, recently, excuse me, that he'd use it as a quote, must use agent in the fourth line setting.
Jessica Fye -- JPMorgan -- Analyst
Okay. Thanks. I just had a couple follow-ups the comment on the proportion of your patients who are on free drug right now. Seems like it's running a little high this quarter, and you talked about the same Q4 -- fourth quarter, should we expect that dynamic to persist through 2022? Or to come back down to the range that you've talked about that 20 to 30% range? And then one R&D question, how long do you project it will take to enroll the motion trial.
Steve Hoerter -- President and Chief Executive Officer
Yeah. Thanks for the questions. Just Dan, do you want to take Jess's first question about PAP percentage and persistency of that. And then Matt, if you'd like to take the motion question.
Dan Martin -- Chief Commercial Officer
Yeah, absolutely. Thank you. So good question, Jess. Thanks. So as we mentioned, on the Q2earnings call we did expect that PAP would continue to be at or perhaps slightly above our -- the top end of our 20 to 30% range and in Q3 and then likely in Q4 as well. And the reason for that is the way the Medicare Part D drug benefit or drug program works is that if a patient goes on free drug -- free drug program, they need to remain on free drugs for the balance of the calendar year. So there is that? I don't know if seasonality is the best term for it. But there is that dynamic to the program that you know once you're into Q3, you have a sense for where you're likely to wind up, in as you round out the year. So that's why we've been able to provide the guidance that we have. And it's played out pretty much exactly as we anticipated thus far. In terms going forward though, there it does as we've said all along. It does we do expect it to vary somewhat quarter-to-quarter; these are that along with gross to matter things that can vary quarter-to-quarter. We think that overall our 20% to 30% estimated range is still very much the guidance that we would give over the whole of the year.
Matt Sherman -- Chief Medical Officer
Hi, Jess. Yeah, this is Matt. So regards to your question about the MOTION study, we're very excited about the Phase one and two data that we recently presented at ESMO showing a combined 47% response rate across all cohorts and both the escalation and the cohort expansion things without planning the 120 patient MOTION study will be a randomized study in about 40 countries.
Just as a benchmark, we were able to enroll about 40 patients in approximately six months in the Part one of the core of the Phase one and two study. So really excited about the interest from the investigators the high response rate, and now opening this up in multiple countries around the world, we expect that this enrollment should be very good enrollment rates.
Jessica Fye -- JPMorgan -- Analyst
Thank you.
Operator
And thank you. And our next question comes from Michael Schmidt from Guggenheim. Your line is now open.
Paul -- Guggenheim Securities -- Analyst
Hi. This is Paul on from Michael. Thanks for taking our questions. Just a couple on INTRIGUE from us ahead of the readout. First, maybe your current thoughts on the expected genetic breakdown of second line patients in the study in terms of primary or secondary mutations. And then as a follow on, any additional color on how you view the exon 13/14 population, in terms of patent share and potential performance of QINLOCK would be really helpful. Thank you.
Steve Hoerter -- President and Chief Executive Officer
Great. Hi, Paul. It's Steve. Thanks. Thanks for the question with respect to genetic profile ingest, and what we'd expect to see in the second line population. I'll ask Matt to just kind of follow-up on this, but what will we expect to see in the second line population in the INTRIGUE studies. INTRIGUE is a 450 patients study. So we would expect the patient population to be very representative of what a second line patient population would look like generally, and as reported in the literature. And so in terms of primary mutations, we would expect to see about 70% of patients with a KIT exon 11, maybe up to 15% of patients with a kit exon nine, and then you'd expect to see 5% to 6% of PDGFRA-alpha mutated patients, and then the balance would be wild type patients. So that's generally when you look at the literature references, what you what you see in the literature in terms of expectations for a population, and just in terms of distribution of primary mutations. Matt, is there anything else you would add to that in terms of secondary mutations?
Matt Sherman -- Chief Medical Officer
I think we would just also highlight the recent publication we had on the INVICTUS Phase three four points study that was published in Global Cancer Research just back in September. And what that highlights is the distribution of both primary and secondary mutations in the fourth line setting. And really, there's a quite extensive mutational heterogeneity in the fourth line setting and that's also been seen in the Phase one study we had an earlier look at some of the second line, third line, fourth line patients, also showing that many of these patients harbor up to five knee mutations. So it's interesting to note that broad spectrum regions such as QINLOCK will be necessary to recover this broad spectrum of mutational burden that these patients harbor.
Paul -- Guggenheim Securities -- Analyst
Great, Thank you.
Operator
And thank you. And our next question comes from Eun Yang from Jefferies. Your line is now open.
Eun Yang -- Jefferies -- Analyst
Thank you. So Steve, in your prepared remark, you said Phase three and trigger data on late this quarter. So should we assume that the data is going to be in December?
Steve Hoerter -- President and Chief Executive Officer
Yeah. Hi, Eun. Good afternoon and thanks, thanks for joining the call.
So, with respect to our guidance on intrigued topline results, what we said very consistently as quarter four. So, we have not refined that guidance to be any specific time within Q4. We just said quarter four this year. So, what you may have heard me say was later this quarter, given that we're already in Q4.
Eun Yang -- Jefferies -- Analyst
Okay. Thank you. And then in the study, in terms of tumor imaging scan. So, in INTRIGUE Phase three, imaging scans are done every six weeks cycle for the first six cycles than every other cycle later -- every other cycle. But in Pfizer's SUTENT Phase three trial, I think a scan was done on day 28 of all treatment cycles. And could it be done more frequently? So, just want to ask you, your rationale for you choosing every six week cycles scanning in your trial aside from patient convenience?
Steve Hoerter -- President and Chief Executive Officer
Yes, thanks for the question.
Eun Yang -- Jefferies -- Analyst
Yes, -- sorry for interruption. And then do you think that every six weeks cycle versus every 28-day cycle would potentially impact PFS? Thank you. Sorry for interruption.
Steve Hoerter -- President and Chief Executive Officer
No, that's all right Eun. Thank thanks for completing the thought and the question. Matt, would you like to take that?
Matt Sherman -- Chief Medical Officer
Sure Steven. Hi Eun. Yes, you're right in the INTRIGUE Phase three study, what we have is a scanning cycle of every other cycle with a six week cycle. And that's related to the dosing of sunitinib that patients are being administered.
So, this dosing is 12 weeks of drug and two weeks of rest period and that constitutes one cycle. So, it's very typical for companies to use that type of cycle for follow-up scans for patients.
But what's probably most important is that's the same for both arms of the study. Even though we're -- is a continuous dosing drug, the interval for scanning will be the same across the two arms of the study and that prevents any bias in terms of the time to be move-in, such as a progression-free survival event.
Eun Yang -- Jefferies -- Analyst
And if I remember, maybe I'm mistaken, but I thought the Pfizer's trial -- in Pfizer's Phase three trial for SUTENT, tumor imaging was done on day 28 of all treatment cycles. So, does that mean it's every six weeks as well because two weeks off?
Matt Sherman -- Chief Medical Officer
Yes, that I don't know. We'd have to go back and look at their protocol design, look at the FDA documents about -- for their actual schedule. But it's -- for our sites, probably more important, just recognize that -- it's a pretty every six weeks is a frequent interval for measuring tumor progression, like many standards -- like many standard protocols, that's a four-week cycle, measure every other cycle. So, that's in every eight week basis. So, every cycle -- very -- pretty reasonable or aggressive interval to measure for those first six cycles.
Eun Yang -- Jefferies -- Analyst
Okay. Thank you. Thank you for the clarification. And the last question is on Vimseltinib. So, the Phase three MOTION trial, you are enrolling patients who are not amenable to surgery. So, can you actually quantify what percent of diffused -- form of a patient are not amenable to surgery in general? Thank you.
Steve Hoerter -- President and Chief Executive Officer
Yes, hi Eun, its Steve, thanks for the question. So, at our ESMO Investor Event, once we -- after we presented the data at ESMO from the Phase one two study with Vimseltinib and then Matt references this earlier during the Q&A and also in the prepared remarks, we were really pleased to see that high 47% response rate we saw in that patient population across the Phase one and Phase two portions of the study. So really encouraging activity that we saw. Dan Martin also spend some time talking a little bit about what we see today in the market in terms of how these patients are being treated, and talked a little bit about patient journey and how these patients who are not amenable to surgery flow through, so maybe I'll ask Dan to comment on that in just a second.
But before I do, I think the one point that I would make, and I think that Matt mentioned this in his prepared remarks is surprisingly in TGCT despite having an approved treatment for these patients pexidartinib this -- that drug, when we look at claims analysis in the US, actually isn't the market share leader that's not the standard treatment that's used for these patients, it's actually a imatinib Gleevec, despite the fact that imatinib is not approved for this use. And the data to support its use actually shows a very low response rate in these patients.
So we think that speaks to the unmet medical need in TGCT. And I think that was really reinforced by the FDA granting themselves in a fast track designation. So we were pleased to announce that as well today. Dan, would you like to comment just on patient journey?
Dan Martin -- Chief Commercial Officer
Sure. Absolutely. Thank you. And thanks Eun for the question. So overview that was a lot of work that we've done, not only with KOLs, but also as Steve mentioned with a lot of US claims work to really try to understand the patient journey. And also to try to size the both the incident and the prevalent populations that we think are likely to be eligible for our drug upon launch.
And so we what we laid out was that we think there are about 14,000 to 18,000 patients who are diagnosed annually in US with TGCT now that's both localized and diffuse. And as you mentioned, it is true that diffuse patients tend to have a higher recurrence rate and localized, but there are a lot more localized patients and so both contribute to a population that would be recurrent after surgery. We think there's somewhere in the order of 2,000 to 2,400 a year, who would recur after their first surgery.
Now, some of those patients may go on to get additional surgeries and receive some benefit. But ultimately, this population as they progress were systemic therapy becomes a focus, systemic therapy delivered by medical oncologists. And so we've estimated that the incident RX treated population within the US is about 1,300 to 1,400 patients annually. And then given that this is a non-lethal disease, therefore, we believe that there is a meaningful prevalent population. And we estimate that to be about 8,000 patients, 8,000 patients that around the time that we would be launching, and that's consists of patients who are on systemic therapy currently, and those who were recently on in the prior several years.
So that's kind of a summary of how that -- how it flows. And a little bit about, we think the market opportunity size wise. And as Steve mentioned, while pexidartinib is really important consideration from sort of a regulatory and development point of view, it really has struggled with uptake. And we think about, a lot of patients out there actually receive imatinib and other TKIs because of the issues that imatinib and pexidartinib profile presents.
Eun Yang -- Jefferies -- Analyst
So in your trial, when you say patients who are not amenable to surgery, that's not really a first timer for surgery, or is it the patients who had the surgery previously, and relapsed, so that they are not eligible for surgery anymore?
Steve Hoerter -- President and Chief Executive Officer
So, it could be Eun, it's Steve, it could be either, right, so it could be patients who present with a tumor and based on tumor location, or based on other maybe medical history of the patient, the patient's not eligible for surgery anymore? So it could be -- Eun, it's Steve. It could be either, right.
Eun Yang -- Jefferies -- Analyst
Okay.
Steve Hoerter -- President and Chief Executive Officer
So it could be a patient who's pushed out with a tumor and based on tumor location or based on other -- maybe medical history of the patient, the patient's not eligible for a surgical intervention, and so therefore, they become eligible for systemic treatment, or it could be patients that have had a lengthy journey with the disease and have undergone multiple surgeries who then become eligible.
And we've shared previously some vignettes from the Phase one experience and we have both of those types of patients, in fact, in the Phase one-two to study. There's a vignette of a woman who was diagnosed some years ago that had undergone multiple surgeries, I think, including a total joint replacement. And then we had another patient who was newly diagnosed, but not amenable to surgery. So that's the spectrum.
Eun Yang -- Jefferies -- Analyst
Okay. Thank you very much.
Operator
Eun, thank you. And our next question comes from Ren Benjamin from JMP Security. Your line is now open.
Reni Benjamin -- JMP Securities -- Analyst
Hey. Good afternoon, guys. Thanks for taking the questions. Just to piggyback off of what just asked. Regarding next steps for the INTRIGUE study, I guess, not after the data is reported, I'm pretty confident as the next steps at that point, but kind of between now and call at the end of the year.
Can you just kind of take us through, I guess, how you're getting the data? Is this something that's coming in daily or weekly? Do you just wait for an email from the DSMB that says, hey, this is what the results are? How long database clean up might be? Just any sort of color in regards to that.
Steve Hoerter -- President and Chief Executive Officer
Hi, Ren, it's Steve. Thanks for the question. So let me try and answer that in general terms. So with any study of this nature there's a time to event end point. And, of course, the sponsor needs to wait for the number of events to accumulate in the study before proceeding with data cleaning, and then being able to lock the database and do the statistical analysis and then report out the top line.
And the timelines associated with each of those steps, of course, can vary, just based on complexity of the study, number of subjects in the study, and the like. So those are the key steps that are taken before any sponsor would be prepared to report out top line results.
Reni Benjamin -- JMP Securities -- Analyst
Okay. And just, I don't know when is the last time you guys get the data, but I guess based on the last time you feel very confident that this can't slip into the first quarter or second quarter, just because of a delay of events. You feel you feel pretty confident about this fourth quarter bookends that you've created.
Steve Hoerter -- President and Chief Executive Officer
Thanks for the question Ren. That's exactly why we reiterated today our guidance of reporting our top line results for INTRIGUE in Q4 of this year.
Reni Benjamin -- JMP Securities -- Analyst
Got it. And then just switching gears to the EU preparedness and the launch activities. I know, we've talked about this in the in the past, but can you just remind us kind of what those are, the key EU markets that you're targeting.
And as we think about kind of the EU launch? Should we be using maybe the U.S. ramp in fourth line as a good proxy? Or should we be kind of looking more at the rest of the world revenues as kind of more of a proxy?
Steve Hoerter -- President and Chief Executive Officer
Yes. Thanks for the question, Ren. So let me let me try and address each of those components. So, for us, our focus is on the five largest markets in Europe. So by five largest I'm including the UK, despite the fact that the UK, of course, is no longer part of the European Union. But those are the five markets principally that we will be targeting with our team.
As we've spoken about previously, our goal always has been to put in place a nimble focus team in Europe to address the fourth line launch in that territory. And we would expect to see that launch cascade over time across markets from early launch markets to later launch markets. And what really drives the timing is achieving market access. So in some markets, like Germany, we're able to price freely, so that allows us to launch very quickly.
In other markets, if you think about Southern European markets, as an example, Italy and Spain, the pricing and reimbursement negotiations can take longer. And so that those launches would occur at some later period in time, once we achieve market access in those territories.
And so the way that we think about our build is in a very efficient way or organizational build, is in a very efficient way to ensure that we're only adding the human resources that we need at the time when we expect to get market access in a key territory.
Now with respect to uptake, it's a great question. And I think, touching on, I think was a question that Chris may have asked earlier. One of the reasons that we think that we've seen such rapid uptake of repetitive of QINLOCK in the fourth line setting in the U.S, is based on the strength of the data.
So as you know, we reported long-term follow-up recently at ESMO, which showed with longer term follow-up and overall survival benefit in the QINLOCK arm of 18 months versus about six months in the placebo arm so I think tripling in the overall survival benefit for patients.
So I think the strength of the data certainly helps us in terms of being a compelling factor for physicians, as they think about treatment options for their patients. And as we know, in the fourth line setting there, there are no good options aside from QINLOCK for these patients.
So when you combine the unmet need with the strength of the data, we think that's a key factor or key set of factors that's driving rapid uptake of the drug in that setting. So in Europe, I think it's premature for us to comment on what we might see in European markets, I think each market will be slightly different.
So as we get into the markets will be in a better position to talk about, what we're seeing, what we see in terms of rapidity of uptake, and how physicians are viewing the drug as they get hands on experience with it.
Reni Benjamin -- JMP Securities -- Analyst
Great, I guess one final one for me. Can you talk? Is there any thought from your end regarding a biomarker strategy? For the inhibitors cover the autophagy or targeting autophagy inhibition? So there are there -- is there a tumor selection or patient selection model where you can look for enhanced levels of autophagy that would result in a patient selection for preclinical studies?
That's a great question,. I mean, we certainly are evaluating that, I think, however, pre-clinically, we certainly haven't seen any indication that there would be a selection strategy that seems to be a fairly widespread, sort of up-regulation of autophagy in solid tumors, as well as now in CML based on what's been reported in the literature.
And I think what what's changing for us and what's evolving for us with this program specifically is we're starting to see not only in the data that we're generating internally, but also the data in the literature, as Matt spoke to in his prepared remarks, we're seeing that this, this mechanism of escape, seems to be very common when tumors are treated with targeted therapies.
So we reported our own preclinical data, looking at Osimertinib and in afatinib and meeting EGFR lung cancer models. At the triple meeting, as we referenced in the prepared remarks, there have been other groups that have published now in the literature looking at LKB 1 mutant non-small cell lung cancer, separate group published on data looking at autophagy in CML and in the effect of afatinib on an upregulation of autophagy.
So we're encouraged by what we see as broad confirmation of the mechanism and the role that this plays is an escape mechanism in both, solid and liquid tumors. And so for us, I think the challenge now is continuing, of course, to progress with the Phase one dose escalation study. But also thinking about what this potential broad applicability tells us in terms of how our clinical program may evolve over time. So we're really encouraged by what we're seeing, and certainly very pleased to be the leader in this space and to have the leading program first into the clinic. Great. Thanks for taking the questions.
Operator
And thank you. And our next question comes from Robyn Karnauskas from Truist Security. Your line is now open.
Alex -- Truist Securities -- Analyst
Hi. This is Alex on for Robyn. Thanks for taking the question. Can you walk us through any market research that you've done that touches upon how physician use for QINLOCK in the second-line setting would be affected by price? And Sutent going generic and is there any indication that a generic Sutent affects the bar so to speak for QINLOCK at all?
Steve Hoerter -- President and Chief Executive Officer
Yes. Thanks for the questions. We, of course, and Dan referenced this earlier, we've done quite a bit of market research with physicians in the US to understand their perception of QINLOCK relative to Sutent, even based on the data that we've generated so far in the fourth-line, and of course, from the Phase one study in the second-line cohort. And as Dan referenced earlier, we're quite encouraged by what we see in terms of physician response there. Dan, are there some details that you'd like to offer in terms of how we're thinking about Sutent into next profile relative to QINLOCK.
Dan Martin -- Chief Commercial Officer
Sure, just a little bit extra color. As Steve mentioned, we have done quite a bit of research thus far. Of course, the outcome of intrigue will be a really important part of understanding exactly how it will stack up with Sutent in the eyes of treaters. And of course, we'll do additional research after we have those results. But we've done quite a bit of work thus far. And what comes back really consistently is that, you know, there are concerns with Sutent a profile and it's a drug that, can be hard to give and hard to take for patients.
And so physicians, both academic and community are really rooting for QINLOCK and intrigue and they really want to use it in the second-line. In fact, we just did some research, as I mentioned in my prepared remarks, where we asked physicians, just treaters, you know, for their basically to rate the product attributes of QINLOCK and Sutent side by side. And what we saw was that QINLOCK came out on top, on every attribute we tested, and by a fair amount, in fact, nearly all of the attributes scoring was statistically significantly higher for QINLOCK.
So I think what that tells us is that, you know, clinicians are really eager to use QINLOCK in the second line. And, you know, I think that's why there's so much anticipation and looking forward to the intrigue results.
As it relates to generic Sutent, you know, we think that at the end of the day, most clinicians, make their decisions based on the clinical evidence. And so a positive head to head study will put us in great position with treaters. And we think also with payers, while obviously payers look to different factors, value and cost and such, at the end of the day, the gold standard for demonstrating, head to head value, head to head clinical trial. And that's what we have. So we look forward to the readout of intrigue, and we believe, you know, pending positive results will be in a really good position for a successful launch in the second line.
Alex -- Truist Securities -- Analyst
Sounds good. Thanks. And one more if I can. I think we've touched on this before, but it's been another quarter. And you know, when you interact with doctors, what are you seeing with how doctors use student in the second mind? And is it hasn't been different from label at all?
Steve Hoerter -- President and Chief Executive Officer
Yes. Thanks for the question. So I'd be happy to take that. So, we've done quite a lot of work looking at how physicians use Sutent. And I assume your question really relates to dosing schedule. Is that correct?
Alex -- Truist Securities -- Analyst
Yeah. Exactly.
Steve Hoerter -- President and Chief Executive Officer
Yeah. So what we see is really a mixed bag. So there isn't any one standard dosing schedule that's used of Sutent. So you see everything from the labeled dosing schedule of 50 milligrams four weeks on, two weeks off, all the way to down to patients who are getting 25 milligrams per day, and we think that's probably just reflective of the tolerability challenges that are often seen with Sutent.
Alex -- Truist Securities -- Analyst
All right. Thanks for taking my question.
Operator
Thank you. And our next question comes from Brad Canino from Stifel. Your line is now open.
Brad Canino -- Stifel -- Analyst
Good afternoon, and congrats on the additional approvals for QINLOCK. One on INTRIGUE and then one on the pipeline, as I've been having my conversations heading into the INTRIGUE data, one of the sticking points remains the high rate of censoring you announced back in early 2020. So I just like to ask, what is your level of confidence that you have that this censoring will not add bias to the PFS measure for either drug arm?
Steve Hoerter -- President and Chief Executive Officer
Well, thanks for the question, Brad. So this isn't something that we spend a lot of time thinking about. So we announced the addition of patients at the beginning of last year. We're really pleased with the conduct of the study, and how the team has navigated INTRIGUE during the pandemic in particular, and following regulatory guidance from regulators around the world. So we're pleased with how things have been conducted and looking forward to reporting out the top line.
Brad Canino -- Stifel -- Analyst
Okay, I appreciate that. And then, on the call, you spoke at length about the ULK inhibitor. Sounds like you have pretty grand ambitions for multiple combination therapy trials. So Steve, how are you thinking about value creation for shareholders with this asset, given that you've already in three Phase three programs and spending on those? Is the ULK inhibitor program that would be better to out license and co develop, and if so, at what stage? Or do you think you can establish some R&D collaborations for free drug where you share data but retain the cost and the value for the asset? Thanks.
Steve Hoerter -- President and Chief Executive Officer
Yeah, thanks for the question, Brad. So as we mentioned in the prepared remarks, we're really excited about the ULK program and the potential broad applicability. And Matt spoke to this in some detail based on the data we reported at the triple meeting, and of course, what's been reported in the literature. So we do believe that the program has the potential to have very broad applicability and a range of solid and liquid tumors, potentially in combination with a variety of different targeted agents.
So we're looking forward to continuing to follow the science here and to prioritize where we want to take the ULK inhibitor in combination with other agents and you'll be hearing more from us, I'm sure in the in the coming months in terms of how we might decide to prosecute that. But with respect to partnering specifically, it would just be premature for me to comment on that. But we're excited about the program and the opportunity to build long term value.
Brad Canino -- Stifel -- Analyst
Okay. Thank you.
Operator
And thank you. And I am showing no further questions. I would now like to turn the call back over to Steve Hoerter for closing remarks.
Steve Hoerter -- President and Chief Executive Officer
Thanks very much. Thanks, everyone, for joining us on today's call and thank you for your continued support. We look forward to keeping you updated on our continued progress. I hope you all have a great evening.
Operator
[Operator Closing Remarks]
Duration: 60 minutes
Call participants:
Jen Robinson -- Vice President, Investor Relations
Steve Hoerter -- President and Chief Executive Officer
Dan Martin -- Chief Commercial Officer
Matt Sherman -- Chief Medical Officer
Tucker Kelly -- Chief Financial Officer
Chris Raymond -- Piper Sandler -- Analyst
Jessica Fye -- JPMorgan -- Analyst
Paul -- Guggenheim Securities -- Analyst
Eun Yang -- Jefferies -- Analyst
Reni Benjamin -- JMP Securities -- Analyst
Alex -- Truist Securities -- Analyst
Brad Canino -- Stifel -- Analyst
More DCPH analysis
All earnings call transcripts
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Deciphera Pharmaceuticals, inc (NASDAQ: DCPH) Q3 2021 Earnings Call Nov 2, 2021, 4:30 p.m. Operator [Operator Closing Remarks] Duration: 60 minutes Call participants: Jen Robinson -- Vice President, Investor Relations Steve Hoerter -- President and Chief Executive Officer Dan Martin -- Chief Commercial Officer Matt Sherman -- Chief Medical Officer Tucker Kelly -- Chief Financial Officer Chris Raymond -- Piper Sandler -- Analyst Jessica Fye -- JPMorgan -- Analyst Paul -- Guggenheim Securities -- Analyst Eun Yang -- Jefferies -- Analyst Reni Benjamin -- JMP Securities -- Analyst Alex -- Truist Securities -- Analyst Brad Canino -- Stifel -- Analyst More DCPH analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. During the third quarter, we made significant progress against our strategic priorities, including both expanding the reach of QINLOCK for patients with just around the world and providing important new data updates for the next two product candidates advancing through the pipeline and moving toward registration directed studies.
|
Operator [Operator Closing Remarks] Duration: 60 minutes Call participants: Jen Robinson -- Vice President, Investor Relations Steve Hoerter -- President and Chief Executive Officer Dan Martin -- Chief Commercial Officer Matt Sherman -- Chief Medical Officer Tucker Kelly -- Chief Financial Officer Chris Raymond -- Piper Sandler -- Analyst Jessica Fye -- JPMorgan -- Analyst Paul -- Guggenheim Securities -- Analyst Eun Yang -- Jefferies -- Analyst Reni Benjamin -- JMP Securities -- Analyst Alex -- Truist Securities -- Analyst Brad Canino -- Stifel -- Analyst More DCPH analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Deciphera Pharmaceuticals, inc (NASDAQ: DCPH) Q3 2021 Earnings Call Nov 2, 2021, 4:30 p.m. With me this afternoon to discuss the financial results and provide a general corporate update are Steve Hoerter, President and Chief Executive Officer; Dan Martin, Chief Commercial Officer; Matt Sherman, Chief Medical Officer; and Tucker Kelly, Chief Financial Officer.
|
Operator [Operator Closing Remarks] Duration: 60 minutes Call participants: Jen Robinson -- Vice President, Investor Relations Steve Hoerter -- President and Chief Executive Officer Dan Martin -- Chief Commercial Officer Matt Sherman -- Chief Medical Officer Tucker Kelly -- Chief Financial Officer Chris Raymond -- Piper Sandler -- Analyst Jessica Fye -- JPMorgan -- Analyst Paul -- Guggenheim Securities -- Analyst Eun Yang -- Jefferies -- Analyst Reni Benjamin -- JMP Securities -- Analyst Alex -- Truist Securities -- Analyst Brad Canino -- Stifel -- Analyst More DCPH analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Deciphera Pharmaceuticals, inc (NASDAQ: DCPH) Q3 2021 Earnings Call Nov 2, 2021, 4:30 p.m. And really, there's a quite extensive mutational heterogeneity in the fourth line setting and that's also been seen in the Phase one study we had an earlier look at some of the second line, third line, fourth line patients, also showing that many of these patients harbor up to five knee mutations.
|
Operator [Operator Closing Remarks] Duration: 60 minutes Call participants: Jen Robinson -- Vice President, Investor Relations Steve Hoerter -- President and Chief Executive Officer Dan Martin -- Chief Commercial Officer Matt Sherman -- Chief Medical Officer Tucker Kelly -- Chief Financial Officer Chris Raymond -- Piper Sandler -- Analyst Jessica Fye -- JPMorgan -- Analyst Paul -- Guggenheim Securities -- Analyst Eun Yang -- Jefferies -- Analyst Reni Benjamin -- JMP Securities -- Analyst Alex -- Truist Securities -- Analyst Brad Canino -- Stifel -- Analyst More DCPH analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Deciphera Pharmaceuticals, inc (NASDAQ: DCPH) Q3 2021 Earnings Call Nov 2, 2021, 4:30 p.m. I'll ask Matt to just kind of follow-up on this, but what will we expect to see in the second line population in the INTRIGUE studies.
|
bfaa0ba2-bab5-4357-bfd9-2beccdb9fd4a
|
715499.0
|
2021-10-22 00:00:00 UTC
|
3 Biotech Stocks With Huge Catalysts Incoming
|
DCPH
|
https://www.nasdaq.com/articles/3-biotech-stocks-with-huge-catalysts-incoming-2021-10-22
|
nan
|
nan
|
If you're looking for stocks that can make big moves on a relatively predictable timeline, the biotechnology space has you covered. Hardly a day goes by where you don't see at least one stock from this industry rocket higher, or crash and burn.
Right now, investors are waiting for news from BeyondSpring (NASDAQ: BYSI), Allakos (NASDAQ: ALLK), and Deciphera Pharmaceuticals (NASDAQ: DCPH) that could send their stock prices screaming higher, or lower, overnight. Here's why.
Image source: Getty Images.
1. BeyondSpring
Shares of BeyondSpring more than tripled in August after the clinical-stage biotech's lead candidate, plinabulin, produced positive results. During a clinical trial with lung cancer patients called Dublin-3, adding plinabulin to standard chemotherapy significantly reduced patients' risk of death.
In September, BeyondSpring tanked after the company gave investors a closer look at Dublin-3 data. In a nutshell, the treatment might not be any more effective than existing options.
Recent lung cancer data was a little disappointing, but investors may be missing the point here. Plinabulin isn't intended to fight cancer directly. It's meant to stop toxic chemotherapy from destroying white blood cells. A lack of white blood cells, or neutropenia, is a dangerous complication that frequently interrupts chemotherapy treatment.
On or before Nov. 30, 2021, the FDA is expected to issue an approval decision for BeyondSpring's lead candidate plinabulin. If given a green light to treat chemotherapy-induced neutropenia, it could become an important new treatment for lots of different cancer patients.
Image source: Getty Images.
2. Allakos
Shares of this clinical-stage biotech stock soared in late 2020 when the company published compelling results of a phase 2 trial with its lead candidate, lirentelimab. Since then, attention has waned along with a stock price that's about 32% below its all-time high.
Before the end of 2021, Allakos stock could soar to new heights all over again. The company expects to report topline data from a phase 3 trial with lirentelimab and patients with severe cases of stomach inflammation.
Lirentelimab reduces circulating eosinophils, the heavy artillery squad of your immune system. Eosinophilic gastroenteritis (EoG), or stomach inflammation led by eosinophil activity, is a rare disorder that probably isn't nearly as rare as once thought. Without any available treatments that can address the issue directly, physicians haven't been eager to test for the presence of eosinophils when patients complain about chronic stomach irritation.
Lirentelimab has been proven to reduce the presence of eosinophils in the stomach lining. When the company reads out the results of its ongoing phase 3 trial, we'll find out if this translates to significantly improved outcomes.
Image source: Getty Images.
3. Deciphera
Shares of Deciphera have fallen around 49% since they reached a peak last year. This is because sales of its lead product, a stomach cancer drug called Qinlock, have been somewhat disappointing since it launched in 2020.
At the moment, Qinlock's addressable patient population is limited to patients with tumors that keep coming back after at least three previous lines of treatment. Before the end of the year, we could find out if Deciphera's drug can move up to the second-line setting.
Topline results from the phase 3 Intrigue study of Qinlock with stomach cancer patients who progressed after their first line of treatment are due in the fourth quarter. If Qinlock does a better job at fighting tumors and preventing disease progression than standard care, its annual sales potential will skyrocket from roughly $100 million at the moment to more than $1 billion.
At recent prices, Deciphera's market cap is just $1.95 billion. That makes it an attractive takeout target for deep-pocketed pharmaceutical giants eager to expand their product lines with new drugs.
10 stocks we like better than Deciphera Pharmaceuticals, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Deciphera Pharmaceuticals, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of September 17, 2021
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Right now, investors are waiting for news from BeyondSpring (NASDAQ: BYSI), Allakos (NASDAQ: ALLK), and Deciphera Pharmaceuticals (NASDAQ: DCPH) that could send their stock prices screaming higher, or lower, overnight. Allakos Shares of this clinical-stage biotech stock soared in late 2020 when the company published compelling results of a phase 2 trial with its lead candidate, lirentelimab. Without any available treatments that can address the issue directly, physicians haven't been eager to test for the presence of eosinophils when patients complain about chronic stomach irritation.
|
Right now, investors are waiting for news from BeyondSpring (NASDAQ: BYSI), Allakos (NASDAQ: ALLK), and Deciphera Pharmaceuticals (NASDAQ: DCPH) that could send their stock prices screaming higher, or lower, overnight. BeyondSpring Shares of BeyondSpring more than tripled in August after the clinical-stage biotech's lead candidate, plinabulin, produced positive results. During a clinical trial with lung cancer patients called Dublin-3, adding plinabulin to standard chemotherapy significantly reduced patients' risk of death.
|
Right now, investors are waiting for news from BeyondSpring (NASDAQ: BYSI), Allakos (NASDAQ: ALLK), and Deciphera Pharmaceuticals (NASDAQ: DCPH) that could send their stock prices screaming higher, or lower, overnight. Allakos Shares of this clinical-stage biotech stock soared in late 2020 when the company published compelling results of a phase 2 trial with its lead candidate, lirentelimab. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Cory Renauer has no position in any of the stocks mentioned.
|
Right now, investors are waiting for news from BeyondSpring (NASDAQ: BYSI), Allakos (NASDAQ: ALLK), and Deciphera Pharmaceuticals (NASDAQ: DCPH) that could send their stock prices screaming higher, or lower, overnight. Topline results from the phase 3 Intrigue study of Qinlock with stomach cancer patients who progressed after their first line of treatment are due in the fourth quarter. 10 stocks we like better than Deciphera Pharmaceuticals, Inc.
|
d1e0b38a-5eaa-4464-99ce-a26910c735fd
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.